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Abstract 
Observational studies suggest there is an independent relationship between obesity and 
chronic kidney disease (CKD).  The mechanisms of this relationship remain unclear, 
although contributing factors include inflammation, insulin resistance, and hypertension.  
The aim of this thesis was to investigate the relationship between obesity and CKD using a 
range of study methodologies, deploying established and novel weight loss interventions. 
Participation in a structured multidisciplinary weight loss intervention may be associated 
with a longer event-free period for the combined outcome of all cause mortality and 
cardiovascular morbidity in obese patients with CKD, compared to those referred to, but 
not participating in the intervention.  Estimated kidney function significantly under-
predicted measured glomerular filtration rate in obese patients with stages 3-4 CKD.  
Laparoscopic sleeve gastrectomy weight loss surgery was effective for weight loss in obese 
patients with CKD, although, in the small samples studied in this thesis, the risk for 
complications and adverse events, including mortality, may be greater in patients 
undergoing haemodialysis than in obese patients with earlier stages of CKD. Sleeve 
gastrectomy resulted in significantly greater weight loss than best medical care in obese 
patients with CKD, and may improve kidney function by reducing hyperfiltration.  Quality 
of life, adiponectin and insulin resistance improved following sleeve gastrectomy, 
compared to best medical care in obese patients with moderate CKD.  The odds ratio for 
CKD increases with overweight and obesity in the Health Survey for England 2010, 
compared to healthy weight participants.   Evidence of a relationship between obesity and 
risk of CKD in a national sample of the United Kingdom population confirms the 
perceived need for safe and effective weight loss interventions for obese patients with 
CKD in a national context.    
3 
In summary, these results cautiously support the overarching hypothesis that weight loss is 
beneficial in obese patients with CKD, yet the risks of weight loss surgery in patients 
undergoing haemodialysis must be carefully considered against the perceived benefits.  
Further studies validating measures of kidney function in obese patients with CKD, and 
examining the safety and effectiveness of surgical and non-surgical weight loss 
interventions, are warranted. 
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This thesis explores weight loss interventions in obese patients with chronic kidney disease.  
The studies reported in this thesis address specific research aims designed to explore 
different weight loss methods and to study the effect of weight loss interventions on 
specific outcomes including kidney function, survival, and quality of life, and to establish 
whether a relationship is apparent between obesity and the prevalence of chronic kidney 
disease in the United Kingdom.  The studies are exploratory in nature, and set out to 
establish the safety and effectiveness of weight loss interventions in obese patients with 
chronic kidney disease.  This thesis does not set out to establish the mechanisms of the 
effect of weight loss on kidney function or cardiovascular risk factors in this population. 
 
Thesis aim  
The overarching purpose of this thesis was to examine the relationship between obesity 
and chronic kidney disease using a range of study methodologies.  This broad approach 
included a retrospective observational study to examine of the effect of participation in a 
structured lifestyle weight loss intervention on morbidity and mortality outcomes.  An in-
depth exploration of a surgical weight loss technique, the laparoscopic sleeve gastrectomy, 
reported for the first time in obese patients with chronic kidney disease, encompassed three 
studies, a case series, an observational cohort study and a randomised controlled pilot 
study.  Finally, an epidemiological approach was used to determine the risk of chronic 
kidney disease with obesity in two large United Kingdom population databases, to establish 




Each study is presented in complete form as a distinct chapter, with the introduction to the 
topic preceding the studies and the concluding discussion culminating in an in-depth 
examination of the implications of the research findings, with a forward projection 
focussing on future studies. 
 
The structure of the thesis is as follows: 
	  
Chapter 1: Introduction 
This chapter considers the literature on the relationship between obesity and chronic 
kidney disease.  In particular, how obesity contributes to the development of chronic 
kidney disease is examined, and the effect of weight loss interventions on delaying or 
preventing progression of chronic kidney disease or improving other patient focused 
outcomes is explored, with the aim of identifying significant gaps in the evidence and to 
inform the subsequent study designs featured in this thesis. 
 
Chapter 2: Participation in a structured weight loss programme and all-cause 
mortality and cardiovascular morbidity in obese patients with chronic kidney 
disease 
This study describes the participants and non-participants who self-selected to attend, or 
not attend, a structured, multidisciplinary weight management programme and aims to 
determine if participation in a weight loss programme impacts upon all-cause mortality and 
cardiovascular morbidity in obese patients with chronic kidney disease, over up to 6 years 




Chapter 3: Laparoscopic sleeve gastrectomy  - a novel technique for weight loss in  
obese patients with chronic kidney disease 
This study describes the first case-series of obese patients with chronic kidney disease 
undergoing sleeve gastrectomy, performed in a single centre in the United Kingdom.  The 
study reports on the extent of weight loss achieved, and documents the surgical 
complications and post-operative adverse events over the observation period.    
 
Chapter 4: A prospective cohort study of laparoscopic sleeve gastrectomy for weight 
loss in obese patients on haemodialysis - pilot study 
This study aims to evaluate the effectiveness of the sleeve gastrectomy procedure to elicit 
sufficient weight loss to enable kidney transplantation in obese patients with kidney failure 
currently undergoing haemodialysis.   Additionally, the effectiveness of the procedure for 
improving quality of life, reducing insulin resistance, hypertension and dyslipidaemia was 
studied, and adverse effects were monitored.   
 
Chapter 5: The effect of weight loss surgery on preservation of kidney function and 
cardiovascular disease risk factors in obese patients with chronic kidney disease: a 
randomised controlled pilot study 
This randomised controlled parallel-design pilot study aims to evaluate the effect of weight 
loss surgery on kidney function, compared to best medical treatment, including a structured 
multidisciplinary weight management programme, in obese patients with chronic kidney 
disease.  Additionally the effects of the two different weight loss treatments on 
adipocytokines and quality of life will be examined in this patient population. 
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Chapter 6: Prevalence of Chronic Kidney Disease by Body Mass Index in the 
Health Survey for England and in Patients with Acute Coronary Syndromes in 
England and Wales 
This study aims to determine if the relationship evident between body mass index and 
prevalence of chronic kidney disease in European and North American populations is also 
apparent in two United Kingdom populations: the Health Survey for England 2010 
randomly sampled population, and the Myocardial Infarction National Audit Project 
(MINAP) selectively sampled population with existing cardiovascular disease.    
 
Chapter 7: Discussion 
The final chapter presents a summary of the findings of the 5 studies included in this thesis 
and discusses some of the strengths and weakness of the different weight loss intervention 
methodologies explored in this body of work.  A detailed discussion is presented on 
developing future studies of weight loss surgery interventions in obese patients with 
chronic kidney disease, using a structured framework for research in surgical innovation.   
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Chapter 1: Introduction 
 
Chronic kidney disease (CKD) is becoming increasingly prolific, and now significantly 
contributes to the national and global burden of disease, affecting nearly 1 in 10 adults in 
the United States and 1 in 20 in the United Kingdom (UK) (Coresh, Astor et al. 2003; 
John, Webb et al. 2004; Schoolwerth, Engelgau et al. 2006).  CKD is defined as structural 
or functional abnormalities of the kidney, present for at least 3 months, which impact upon 
health (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 2013).  
The following chapter will explain how kidney function is defined and measured, introduce 
the definition and classification of the stages of CKD, and consider the literature on the 
relationship between obesity and CKD, in particular, how obesity contributes to the 
development of CKD, and the effect of weight loss interventions on delaying or preventing 
progression of CKD or improving other patient focused outcomes, with the aim of 
identifying significant gaps in the evidence and to inform the subsequent study designs 
featured in this thesis. 
 
Role of the kidney and glomerular filtration rate 
The role of the kidney is to retain adequate fluid, protein, electrolytes and hormones for 
optimal body function and facilitate the excretion of the excess, including the by-products 
of protein metabolism, urea and creatinine, by filtering the blood through the glomeruli.  
Regardless of the cause, as kidney function declines with a reduction in the glomerular 
filtration rate (GFR), or kidney filtration capacity, the ability to perform these functions is 
progressively reduced and the urea and creatinine, plus other substances, accumulate in the 
plasma, and proteins that are normally retained for re-use in the body, may be excreted in 
urine (Mitch and Klahr 2005).     
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GFR is measured by determining the rate of clearance, in millilitres per minute (ml/min), 
of a exogenous marker that meets the requirements of an ideal filtration substance 
(Gaspari, Perico et al. 1995).  The substance must be freely filtered by the glomeruli and 
not taken up by the renal tubules, must not be made or broken down by the body and 
should be physiologically inert (Gaspari, Perico et al. 1995).  Classically, inulin, a fructose 
polymer, has been the gold standard marker for measurement of GFR, but it requires a 
continuous intravenous infusion of inulin and patients must be bed rested (Gaspari, Perico 
et al. 1995).  Therefore, other endogenous markers that can be administered with a single 
injection, such as radioactive [51Cr] ethylene diamine tetraacetic acid (EDTA), or the non-
ionic, low-osmolar radiological contrast medium, iohexol, have been studied and are now 
considered to be highly correlated to inulin clearance (Gaspari, Perico et al. 1995; 
Brandstrom, Grzegorczyk et al. 1998).  Clinically, even iohexol measured GFR is difficult 
to implement into practice, due to the time and expertise required to measure it, and 
estimations of GFR, based on serum creatinine levels, are typically calculated.  Presently, 
the most common prediction equation for estimated GFR (eGFR) is the 4-variable 
Modification in Diet and Renal Disease study equation, which requires serum creatinine, 
sex, age and ethnicity, and correlates well with measured GFR when kidney function is 
impaired, but is less representative of GFR when kidney function is normal (Levey, Bosch 
et al. 1999; Levey, Greene et al. 2000).  More recently, the CKD Epidemiology 
Collaboration (CKD-EPI) have addressed this issue, with the development and validation 
of the CKD-EPI equation to estimate GFR, however, this estimation equation is not yet in 
widespread use, as validation studies in broader population groups, are still being carried 
out (Levey, Stevens et al. 2009; Matsushita, Mahmoodi et al. 2012). 
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Definition of Chronic Kidney Disease (CKD) 
CKD is defined by both degree of damage and time.  Structural or functional kidney 
damage must be evident on at least 2 occasions over a period of at least 3 months, and is 
further classified into 5 stages by the National Kidney Foundation – Kidney Disease 
Outcomes Quality Initiative (NKF-KDOQI) (Levey, Coresh et al. 2003).  Table 1 lists the 
stages from mild disease at stage 1 with kidney damage (proteinuria, haematuria or an 
anatomical abnormality) and normal kidney function to the most severe form at stage 5, in 
which kidney function is less than 15% of normal level and/or life-saving renal 
replacement therapy such as dialysis or kidney transplantation is required (Levey, Coresh et 
al. 2003).    
Table 1: NKF-KDOQI stages of chronic kidney disease (adapted from Levey, Coresh et al 2003) 
Stage Description Glomerular Filtration Rate 
(GFR) (ml/min/1.73m2) 
1 Kidney damage with normal or increased GFR ≥ 90 
2 Kidney damage with mild reduction in GFR 60-89 
3 Moderate reduction in GFR 30-59 
4 Severe reduction in GFR 15-29 
5 Kidney failure <15 (or dialysis) 
 
Kidney function is predictive of mortality in the general population, with risk increasing 
once eGFR falls below 60 ml/minute with even trace amounts of albuminuria (Chronic 
Kidney Disease Prognosis Consortium, 2010).   These classifications are based on eGFR 
measurement, which is most often used in practice to identify the stage of CKD, and 
monitor kidney disease progression.   
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In patients with kidney failure requiring dialysis, 50% of the mortality is due to 
cardiovascular causes, with the risk of death from a cardiovascular cause, on average, 15-30 
times higher than the age-adjusted mortality in the general population (Schiffrin, Lipman et 
al. 2007), and 500 times higher in young patients aged 25-34 years (Sarnak, Levey et al. 
2003) .  This relationship is also evident in earlier stages of CKD, with a 3 fold greater 
adjusted hazard ratio for the risk of all cause mortality and cardiovascular morbidity in 
those with impaired kidney function compared to those with normal kidney function, after 
adjustment for age, sex, race, socio-economic status and co-existing illness (Go, Chertow et 
al. 2004).   
 
Three recent meta-analyses examined the additional effect of age, hypertension or diabetes 
on the relationship between eGFR and mortality, and found that whilst diabetes and age 
were associated with increased absolute mortality risk across the ranges of eGFR, neither 
age, nor diabetes, or hypertension increased the relative risk for mortality for any given 
level of eGFR (Fox, Matsushita et al. 2012; Hallan, Matsushita et al. 2012; Mahmoodi, 
Matsushita et al. 2012).  These findings indicate that eGFR is a stronger predictor of 
outcome, and points towards aggressive management of all cardiovascular risk factors, such 
as glycaemic control, lipids, and obesity in all patients with, or at risk of developing, CKD. 
 
Prevention of progression of CKD 
Over the last 10 years, emphasis has been placed on the implementation of national 
secondary prevention measures to prevent the progression of CKD in the United 
Kingdom.  These measures include the expansion of the National Renal Service 
Framework to include identification and management of CKD prior to end stage disease, 
improved detection of CKD, and the inclusion of renal indicators within the Quality 
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Outcomes Framework incentive scheme for General Practitioners (The Health and Social 
Care Information Centre 2009) .    
 
The second stage of the National Renal Service Framework (Figure 1), published by the 
Department of Health in 2005, contains two key quality requirements pertaining to 
screening, assessment and management of CKD (Department of Health 2005).  
 
Figure 1: Renal National Service Framework quality requirements relating to prevention of CKD 
(Department of Health 2005) 
 
 
In 2006, reporting of estimated GFR (eGFR) – an estimate of kidney function – was 
incorporated into standard biochemistry practice, which led to increases in the known 
prevalence of CKD and referral of patients with CKD to specialist services in the United 
Kingdom (Zoccali, Kramer et al. 2009).  Additionally, the NHS Quality Outcomes 
Framework for General Practice recognises the importance of screening and management 
of CKD, with the introduction of CKD indicators in 2006/2007, and most Practices now 
hold a CKD register (The Health and Social Care Information Centre 2009).  Furthermore, 
National Institute of Health and Clinical Excellence (NICE) guidelines for the 
identification, management and referral of adults with CKD were produced in 2008 
(National Institute for Health and Clinical Excellence 2008).  These guidelines recommend 
targeting of patients with CKD risk factors, such as hypertension, diabetes, cardiovascular 
disease, or a family history of kidney failure for CKD screening and optimising treatment.  
The Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group have just 
Quality	  requirement	  1	  –	  “People	  at	  increased	  risk	  of	  developing	  or	  having	  
undiagnosed	  CKD,	  especially	  people	  with	  diabetes	  or	  hypertension,	  are	  
identified,	  assessed,	  and	  their	  condition	  managed	  to	  preserve	  their	  kidney	  
function.”	  
	  
Quality	  requirement	  2	  –	  “People	  with	  a	  diagnosis	  of	  CKD	  receive	  timely,	  
appropriate	  and	  effective	  investigation,	  treatment	  and	  follow-­‐up	  to	  reduce	  
risk	  of	  progression	  and	  complications.”	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published an internationally agreed clinical practice guideline for the evaluation and 
management of CKD, which recommend addressing risk factors to improve cardiovascular 
health, including blood pressure (BP), blood sugar, dyslipidaemia, exercise and achieving a 
healthy weight (body mass index (BMI) 20-25 kg/m2, according to country specific 
demographics) (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work 
Group 2013). 
 
This strategic emphasis on the prevention, and management of CKD and its associated risk 
factors highlights the enormity of the consequences of failing to halt progression of CKD 
towards end stage kidney disease.  These strategies share a common theme of focusing on 
the detection and management of CKD and its most common contributing aetiologies, 
diabetes and hypertension, to ensure that patients diagnosed with CKD receive treatment 
and long term follow up to reduce the risk of progression of CKD, which is associated, not 
only with high economic cost, but also increased mortality.   
 
Early and aggressive treatment of the major risk factors, such as hypertension, proteinuria 
and diabetes, may prevent progression of CKD to end stage kidney failure (Hallan, Coresh 
et al. 2006).  Intensive treatment of patients with type 1 diabetes to elicit near-normal 
glycaemic control in resulted in a reduction in the long-term risk of the development of 
CKD (de Boer, Sun et al. 2011).  Patients enrolled in the study had type 1 diabetes for 1-5 
years plus no, or very mild, microvascular complications at baseline.  The reduction in 
incidence of CKD was attenuated by glycaemic control and albuminuria, indicating that it 
is via these mechanisms that intensive treatment of diabetes can reduce the risk of the 
development of CKD.  Similarly, incident patients with type 2 diabetes randomised to 
intensive glycaemic control in the United Kingdom Prospective Diabetes Study 
experienced a 24% lower relative risk of developing microvascular complications (which 
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included CKD) after 10 years, however, there was no protective effect in overweight 
patients (Holman, Paul et al. 2008). 
 
Recent evidence from the 4th National Health and Nutrition Examination Survey 
(NHANES IV) suggests that the rising prevalence of obesity is an additional contributing 
factor to early kidney damage (Coresh, Selvin et al. 2007), although evidence of a causal 
link is lacking.  A systematic review and meta-analysis in 2008 demonstrated a 4-fold 
increased risk of end-stage kidney failure with obesity (Wang, Chen et al. 2008) and 
population studies have also established an association between obesity and prevalent 
CKD (Kramer, Luke et al. 2005; Hallan, de Mutsert et al. 2006; Burton, Gray et al. 2012).  
Nutritional treatment remains the cornerstone of obesity management when using both 
lifestyle and surgical interventions.  Current practice guidelines for nutritional intervention 
in CKD (2000; Fouque, Vennegoor et al. 2007; Renal Association 2007) provide very little 
guidance on the management of obesity in patients with CKD, and the majority of 
evidence is gleaned from epidemiological studies rather than clinical intervention trials.    
 
Further research on the contribution of obesity to the development and progression of 
CKD may provide additional information upon which to base future preventative strategies 
targeting treatment of obesity alongside diabetes and hypertension, to reduce the societal 
burden of CKD. 
 
Chronic Kidney Disease and Cardiovascular Disease Risk 
Patients with CKD are more likely to die of cardiovascular causes than reach end stage 
kidney disease, and cardiovascular disease accounts for one-third of deaths in 
haemodialysis patients in the United Kingdom (Shulman, Ford et al. 1989; Ansell 2008).  A 
systematic review of 85 studies and over 550 000 patients provides strong evidence that 
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CKD is associated with cardiovascular risk from an early stage and the risk increases 
progressively with declining kidney function (Vanholder, Massy et al. 2005).  As traditional 
risk factors for cardiovascular disease, such as diabetes and hypertension, are also common 
causes of kidney disease, the relationship between CKD and cardiovascular disease is likely 
to be bidirectional, and early stage CKD may be a marker of cardiovascular damage 
(Stenvinkel, Carrero et al. 2008).  The presence of hypertension, diabetes and 
hyperlipidaemia, all worsened in the presence of CKD, may lead to endothelial 
dysfunction, causing changes to the media of blood vessel walls resulting in thickening and 
reduced vascular elasticity (Schiffrin, Lipman et al. 2007), which is an early phase of 
atherosclerosis (Dogra, Irish et al. 2006).  However, the mortality rate due to cardiovascular 
causes in haemodialysis patients is higher than can be accounted for due to these traditional 
cardiovascular risk factors alone (Stenvinkel, Carrero et al. 2008), indicating that other 
parallel processes are also contributing to the increased cardiovascular disease risk.  
 
Hypertension and cardiovascular disease are associated not only with lifestyle risk factors 
but also with low birth weight; a relationship first proposed by Barker, based on research 
conducted in the 1980s and 1990s (Barker 1990; Barker, Bull et al. 1990).  Low birth weight 
is also associated with reduced nephron number and increased prevalence of albuminuria, a 
manifestation of hyperfiltration (an absolute increase in glomerular filtration rate (Helal, 
Fick-Brosnahan et al. 2012)), which leads to glomerular damage (Brenner, Garcia et al. 
1988; Hoy, Rees et al. 1999).  Whilst it is tempting to conclude that low birth weight may 
be directly associated with the development of CKD, there remains a lack of direct 
evidence supporting a link between reduced nephron number, glomerular hyperfiltration 
and an increased risk of the development of CKD (Schreuder and Nauta 2007), and the 
relationship may be mediated by a concurrent process with diabetes or cardiovascular 
disease (Zandi-Nejad, Luyckx et al. 2006; Franco, Oliveira et al. 2012).   
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Reduced kidney function causes changes in endothelial structure and function that may 
trigger the inflammatory response evident in CKD (Schiffrin, Lipman et al. 2007), which is 
associated with mortality in haemodialysis patients (Pecoits-Filho, Barany et al. 2002).  
Populations of endothelial progenitor cells (EPC), which are bone marrow derived 
circulating progenitor cells required for regeneration and repair of injured and inflamed 
endothelium (Hill, Zalos et al. 2003; Muller-Ehmsen, Braun et al. 2008), are reduced in 
patients with CKD (Bahlmann, Speer et al. 2010), possibly due to uraemic toxicity (de 
Groot, Bahlmann et al. 2004).  Measurement of circulating EPC is performed with either 
flow cytometry to count the number of cells, or by culturing cells into colonies, which 
provide a functional measure of EPC capacity to assist in vascular repair and regeneration, 
and both indices of EPC correlate inversely with cardiovascular risk in those without CKD 
(Hill, Zalos et al. 2003; Maruyama, Taguchi et al. 2008; Lorenzen, David et al. 2010).   In 
haemodialysis patients, a reduction in the number of active EPC was associated with 
cardiovascular events, but did not correlate with traditional cardiovascular risk factors such 
as hypertension and hypercholesterolaemia, indicating that the reduction in repair and 
regeneration capacity brought about by the reduction in EPC may play a role in the 
increased cardiovascular disease risk in this population group (Lorenzen, David et al. 2010).   
 
Other contributing factors to endothelial dysfunction in patients with CKD include insulin 
resistance (Shinohara, Shoji et al. 2002), increased activation of the renin-angiotensin 
system, increased oxidative stress, and impaired bone mineral metabolism (Schiffrin, 
Lipman et al. 2007).  In a cross sectional study of patients with stages 3-5 CKD and healthy 
age, gender, and BMI matched control healthy subjects, exploring the effect of both novel 
and traditional cardiovascular risk factors on vascular dysfunction, patients with stages 3-5 
CKD had higher waist circumference, systolic blood pressure, insulin resistance, 
triglycerides and raised makers of inflammation, compared to healthy controls (Dogra, 
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Irish et al. 2006).  Insulin resistance is related to cardiovascular mortality but not all cause 
mortality in end stage kidney disease patients, independently of BMI, hypertension and 
dyslipidaemia (Shinohara, Shoji et al. 2002), indicating that insulin resistance may cause 
vascular damage via a pathway not directly associated with the atherosclerotic processes 
associated with traditional cardiovascular risk factors.   
 
Insulin resistance, measured by the Homeostasis Method Assessment of Insulin Resistance 
(HOMA-IR) (Matthews, Hosker et al. 1985) - a valid measure of insulin resistance in 
patients with CKD (Shoji, Emoto et al. 2001) - was associated with CKD in a sub-analysis 
of the 3rd National Health and Nutrition Examination Survey (Chen, Muntner et al. 2003).  
The relationship was maintained after adjustment for multiple confounders, and this was 
the first study to demonstrate a link between insulin resistance and CKD in a population 
without diabetes.  Furthermore, in a prospective study of over 10 000 subjects without 
diabetes or CKD at baseline, the odds ratio of developing CKD after 9 years of follow up 
was 1.7 (95% CI 1.26 to 2.30) for the highest quintile of insulin resistance, compared to the 
lowest (Kurella, Lo et al. 2005).  Insulin resistance is known to be associated with 
albuminuria (a risk factor for both cardiovascular disease and CKD), which occurs due to 
increased permeability of the glomerular filtration membrane via structural damage to the 
intricate foot processes of the podocytes, possibly through several mechanisms including a 
deficiency of insulin receptors on the podocyte, regulation by adipose tissue cytokines, and 
activation of the renin-angiotensin-aldosterone system (Fornoni 2010; Kalaitzidis and 
Siamopoulos 2011; Nistala and Whaley-Connell 2013).  
 
The inflammation, insulin resistance, and hypertension associated with both obesity and 
CKD result in changes to the structural organisation of collagen and elastin, which 
determine the stiffness of the arterial wall, and to the haemodynamics of blood flow due to 
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increased pressure (Laurent, Cockcroft et al. 2006).    Arterial stiffness can be measured 
directly, and non-invasively, using the gold standard method of carotid to femoral pulse 
wave velocity measurement, by dividing the distance the pulse wave travels by the time 
taken (Boutouyrie, Briet et al. 2009).  Pulse wave velocity has been demonstrated to be 
predictive of cardiovascular events in patients with CKD.  In a prospective observational 
study of 317 patients followed up for 3.6 years, pulse wave velocity was an independent 
predictor of combined fatal and non fatal cardiovascular events in patients with stages 4-5 
CKD, and remained so after adjustment for established cardiovascular risk factors - age, 
gender, blood pressure, diabetes, past cardiovascular disease, cholesterol level, and smoking 
(Zoungas, Cameron et al. 2007).  Reductions in arterial stiffness with therapeutic 
interventions represent a true reduction in arterial wall damage, rather than simply a change 
in cardiovascular risk scores achieved with reductions in hypertension, lipid lowering and 
improvement in glycaemic control (Laurent, Cockcroft et al. 2006).  In haemodialysis 
patients, a reduction in arterial stiffness achieved through blood pressure control 
independently predicted a reduction in mortality, whereas a reduction in blood pressure, 
without a concomitant improvement in arterial stiffness, was related to increased mortality 
(Guerin, Blacher et al. 2001).  These findings indicate that vascular remodelling, or a 
capacity for vascular remodelling, rather than a reduction in blood pressure per se, impact 
upon mortality and can reduce cardiovascular risk in the end stage kidney disease 
population. 
 
In summary, both traditional cardiovascular risk factors, such as hypertension and 
hypercholesterolaemia, and non-traditional risk factors, including insulin resistance, 
inflammation, elevated waist circumference, increased vascular stiffness, and a reduction in 
the number and/or function of EPC contribute to the elevated cardiovascular risk evident 
in patients with CKD. 
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Role of obesity in the development and progression of CKD 
Overweight and obesity may be best defined as an excess of adipose tissue in the body that 
may impair health.  However, for both individuals and populations, body weight, classified 
with reference to height, using the body mass index (BMI; weight in kg/height in (m)2) is 
used to classify obesity, largely due to its ease of measurement, and close association with 
adiposity in population studies.  Overweight is a BMI ≥ 25kg/m2 and obesity is classified 
as a BMI ≥ 30 kg/m2 (World Health Organisation 2006).  The prevalence of obesity, 
measured by BMI, has reached epidemic proportions across the developed and developing 
world, and it is rapidly becoming a greater public health problem than malnutrition or 
infectious diseases (World Health Organisation 1997).   
 
The prevalence of CKD is increasing worldwide (Zhang and Rothenbacher 2008; Zoccali, 
Kramer et al. 2009), and hypertension and diabetes are well established precursors to the 
development of CKD (Cooper, Rotimi et al. 1997; Kearney, Whelton et al. 2004; Gonzalez, 
Johansson et al. 2009).  In observational studies, obesity has been identified as an 
independent risk factor for the development of CKD and progression to kidney failure 
(Fox, Larson et al. 2004; Kramer, Luke et al. 2005; Munkhaugen, Lydersen et al. 2009; 
Othman, Kawar et al. 2009; Rossi, Nicolucci et al. 2010), and remains so, after adjustment 
for hypertension and diabetes in some studies (Gelber, Kurth et al. 2005; Hallan, de 
Mutsert et al. 2006; Hsu, McCulloch et al. 2006; Kawamoto, Kohara et al. 2008; Satirapoj, 
Supasyndh et al. 2012), but not all (Foster, Hwang et al. 2008). Evidence relating to obesity 
as a risk factor for the progression of earlier stages of CKD is equivocal (Othman, Kawar 
et al. 2009; Brown, Mohsen et al. 2012; Mohsen, Brown et al. 2012), and differences may 
relate to the number of repeated measures of kidney function, the length of follow up and 
the inaccuracy of indexed estimated measures of kidney function in obesity, particularly 
over time (Delanaye, Radermecker et al. 2005; Chang and Kramer 2012).  
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In a large population based cross-sectional study of over 65 000 Norwegian men and 
women enrolled in the Health Survey of Nord-Trondelag County (HUNT II), the 
relationships between CKD, defined as an eGFR < 45 ml/min/1.73m2 using the MDRD 
equation, and obesity, physical inactivity and smoking were studied (Hallan, de Mutsert et 
al. 2006).  After adjustment for age and sex, the relative risk of CKD with a BMI ≥ 30 
kg/m2 was 1.77 (95% CI 1.47-2.14).  Obesity remained an independent risk factor for 
CKD after further adjustment for diabetes, hypertension, blood lipids and cardiovascular 
disease (adjusted relative risk 1.44, 95% CI 1.18-1.75).  The results of this study are 
supported by a smaller, more recent study in a Japanese community based population, with 
the risk of CKD, defined as eGFR<60 ml/min/1.73m2 using the MDRD equation, 
doubling with overweight and obesity, after multivariable adjustment (Kawamoto, Kohara 
et al. 2008).   
 
Furthermore, the relationship between obesity and CKD is also evident in patients with 
known hypertension.  The prevalence of CKD increased with obesity at baseline in the 
Hypertension Detection and Follow Up Program patient population, and in patients 
without CKD at baseline the risk of developing CKD after 5 years increased with 
increasing BMI (Kramer, Luke et al. 2005).  In 9 585 patients with hypertension (diastolic 
BP > 90 mm Hg) at baseline, the prevalence of CKD, again defined as eGFR <60 
ml/min/1.73m2 using the MDRD equation, was 18% in the normal BMI group and 22% 
in the obese group (p <0.001).  Using logistic regression modelling, after adjustment for 
age, sex and race, the risk of CKD with BMI ≥ 30 kg/m2 was increased (odds ratio 1.32, 
95% CI 1.15 – 1.54).  The relationship remained statistically significant after further 
adjustment for diabetes and blood pressure (OR 1.23, 95% CI 1.07 – 1.40) (Kramer, Luke 
et al. 2005).  The authors went on to explore the development of incident CKD in 5 897 
hypertensive patients without evidence of CKD at baseline.   After 5 years, the OR of 
 34 
developing CKD in patients with a baseline BMI of ≥ 30 kg/m2 was 1.40 (95% CI 1.20 – 
1.63), after adjustment for age, sex, race, diabetes and hypertension variables.  The risk of 
developing CKD after 5 years was also increased in overweight patients in this study, 
demonstrating a link between increasing BMI and the development of CKD after 
controlling for established risk factors including diabetes and hypertension (Kramer, Luke 
et al. 2005). 
	  
Two further longitudinal studies, in apparently healthy cohorts at baseline, also studied the 
development of CKD with increasing BMI.  Using information collected in the Physicians’ 
Health Study, in 11 000 men with a mean follow up period of 14 years, the risk of 
developing CKD, defined as an eGFR <60ml/min using the MDRD study equation, was 
increased (OR 1.45, 95% CI 1.19-1.76), in the highest BMI quintile (BMI > 26.6 kg/m2), 
compared with lowest BMI quintile (< 22.7 kg/m2) after adjustment for age, smoking, 
alcohol, exercise and parenteral history of myocardial infarction at < 60 years of age.  
Further adjustment for diabetes, cardiovascular disease, hypertension and cholesterol, 
attenuated the relationship, but it remained significant (adjusted OR 1.26, 95% CI 1.03 – 
1.54) (Gelber, Kurth et al. 2005).  This increased risk of developing CKD was also evident 
in obese participants in the Framingham Offspring Study cohort (Fox, Larson et al. 2004), 
but became non-significant after adjustment for diabetes, hypertension, smoking status and 
baseline HDL-cholesterol (adjusted OR 1.09, 95% CI 0.69 – 1.73) (Foster, Hwang et al. 
2008).   
 
In a recent study examining the relationship between baseline BMI and progression of 
CKD over at least 5 years in 125 patients without diabetes, younger age and greater 
baseline BMI predicted worsening of kidney function (R2 = 0.12, p <0.001), whilst blood 
pressure and proteinuria did not (Othman, Kawar et al. 2009).   Obese patients also had 
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higher follow-up blood pressure and triglycerides than normal weight patients, both of 
which are known modifiable CKD risk factors (National Institute for Health and Clinical 
Excellence 2008).   
 
Metabolic syndrome is defined by the National Cholesterol Education Program (NCEP) 
Revised Adult Treatment Panel (ATP) III criteria as the presence of at least 3 of the 
following metabolic disturbances: hypertension, impaired glucose metabolism, 
dyslipidaemia and abdominal obesity, and contributes to cardiovascular disease risk 
(Grundy, Cleeman et al. 2005).   Some, or all, of the key elements of metabolic syndrome 
are evident in patients with CKD (Ross and McGill 2006), and metabolic syndrome has 
also been identified as a precursor to CKD in a large cross sectional study of over 6 000 
adults (Chen, Muntner et al. 2004).  A recent meta-analysis of prospective cohort studies 
examined the relationship between metabolic syndrome, its components, and development 
of CKD (eGFR < 60 ml/min/1.73m2) (Thomas, Sehgal et al. 2011).  Fully adjusted risk 
estimates were pooled for the 10 studies meeting the inclusion criteria.  The pooled OR for 
the development of CKD in patients with metabolic syndrome was 1.55 (95% CI 1.34 – 
1.80) with mean follow up of 5.8 years (Thomas, Sehgal et al. 2011).  Furthermore, the 
impact of each of the individual components of metabolic syndrome on the development 
of CKD was evaluated, and the OR of CKD with obesity was 1.19 (95% CI 1.05 – 1.34), 
which is a similar level of risk evident in other studies examining this relationship (Gelber, 
Kurth et al. 2005; Kramer, Luke et al. 2005; Othman, Kawar et al. 2009). 
 
There is strong evidence for a relationship between obesity and the development of end 
stage kidney disease in 2 large longitudinal studies.  This relationship was first evident in an 
analysis of over 320 000 health screening records in the Kaiser Permanente Health System 
database, against the United States Renal Data System records for patients commencing 
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haemodialysis, peritoneal dialysis or undergoing kidney transplantation (Hsu, McCulloch et 
al. 2006).  1 471 cases of end stage kidney disease occurred in the 15-35 year follow-up 
period.  The risk for the development of end stage kidney disease increased incrementally 
with increasing BMI over 25 kg/m2 (Figure 2), after adjustment for baseline age, race, sex, 
education, smoking status, previous myocardial infarction, proteinuria, blood lipids, 
haematuria and serum creatinine.   
 
Figure 2: Increasing risk of end stage kidney disease by BMI category (Hsu, McCulloch et al. 2006) 
 
These results were supported by a more recent longitudinal study of the HUNT 
participants in Norway.  After 21 years of follow up of almost 75 000 participants, 
participants with a baseline BMI of 30 kg/m2 had a greater combined risk of CKD related 
death or commencing renal replacement therapy, and the effect remained after adjustment 
for sex, age, physical activity, smoking status, socioeconomic status, diabetes, 
cardiovascular disease and hypertension (Munkhaugen, Lydersen et al. 2009).   The risk 
increased markedly in patients with blood pressure greater than 120/80 mm Hg, and the 
interaction of the 2 risk factors indicated that the effect of elevated blood pressure 
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combined with elevated BMI exerted an effect almost 6 times greater than that expected 
based on the addition of the 2 risk factors (Munkhaugen, Lydersen et al. 2009). 
 
These studies demonstrate an independent relationship between obesity and the 
development of both moderate CKD and end stage kidney failure.  In moderate CKD the 
risk is attenuated by other known CKD risk factors, indicating that whilst obesity does 
increase the risk of CKD development and progression, the relationship is multifactorial 
and there are likely to be several mechanisms associated with the reduction in kidney 
function evident over time with the increased metabolic demands of the obese state, 
commonly evident as a cluster of risk factors in metabolic syndrome.   However, the level 
of increased risk is much higher for end stage kidney failure, than for moderate CKD, 
which may possibly be related to the longer follow up period in these studies, particularly if 
obesity related kidney disease manifests slowly.  Understanding the mechanisms linking 
obesity and CKD is important, considering the concomitant rise in both obesity and CKD 
prevalence, to generate insights that may lead to potential therapeutic strategies to treat or 
prevent CKD and its associated co-morbidities (Ix and Sharma 2010). 
 
Mechanisms of obesity related kidney damage 
Obesity is associated with CKD progression and kidney failure, and whilst the exact 
mechanisms remain unknown, inflammation, dyslipidaemia, insulin resistance, and 
hypertension contribute to obesity related kidney damage (Becker, Kronenberg et al. 2005; 
Kramer, Luke et al. 2005; Hsu, McCulloch et al. 2006; Axelsson 2008; Teplan, Vyhnanek et 
al. 2010).  Kidney damage associated with obesity was first recognised with the 
classification of obesity related focal segmental glomerular sclerosis in 1974 (Serra, Romero 
et al. 2008).  Microalbuminuria, one of the first indicators of kidney damage, worsens with 
increasing adiposity, although the mechanisms relating obesity and albuminura are not 
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completely known, but are likely to be haemodynamic and/or metabolic (Gilardini, Zulian 
et al. 2010).  Obesity related albuminuria is associated with increased renal blood flow and 
glomerular pressure, resulting in glomerular hyperfiltration which may increase albumin 
losses, but is reversed with weight loss (Chagnac, Weinstein et al. 2003).   There is no 
widely accepted definition of hyperfiltration, other than an absolute increase in glomerular 
filtration rate, and the mechanisms of hyperfiltration in chronic disease states are not clear, 
although the renin-angiotensin-aldosterone system is thought to be involved, and increased 
glomerular capillary pressure and glomerular hypertrophy is evident in obesity (Helal, Fick-
Brosnahan et al. 2012).  With glomerular hyperfiltration, morphological changes occur, 
including increased glomerular size, basement membrane thickening and podocyte 
hypertrophy, which result in kidney damage, and ultimately reduced kidney function (Serra, 
Romero et al. 2008; Kato, Nazneen et al. 2009).   
 
From a series of 6 818 kidney biopsies performed between 1986 to 2000, the prevalence of 
obesity related glomerulopathy (ORG) was first defined, as focal segmental 
glomerulosclerosis with glomerulomegaly or glomerulomegaly alone in patients with a BMI 
> 30 kg/m2 (Kambham, Markowitz et al. 2001).  A total of 103 cases of ORG were 
detected in the series (1.5%), and the prevalence increased from 0.2% between 1986 – 1990 
to 2.0% from 1996 – 2000.  71 cases, with adequate clinical information (57 with focal 
segmental glomerulosclerosis with glomerulomegaly, and 14 cases with glomerulomegaly 
alone), were compared to 50 cases of idiopathic focal segmental glomerulosclerosis (I-
FSGS), and those with ORG had more glomerulomegaly, less podocyte damage and fewer 
lesions of segmental sclerosis that those with I-FSGS (Kambham, Markowitz et al. 2001).   
Additionally, even though proteinuria was present in nearly 50% of the patients with ORG, 
these patients had lower incidence of oedema and nephrotic syndrome, indicating that 
ORG is a condition associated with proteinuria, but without the hypoalbuminuria and full 
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nephrotic syndrome seen more commonly in the I-FSGS group.  Progression to end stage 
kidney disease or doubling of serum creatinine occurred less frequently in the ORG group 
than in the I-FSGS group, indicating that ORG may be a slowly progressive disease.   
 
In a smaller case series studying the clinical outcomes of 15 patients with ORG and 15 
patients with I-FSGS, patients with ORG developed worsening proteinuria and the 10-year 
renal survival was poor, with almost 50% of patients with ORG experiencing a doubling of 
serum creatinine, including 5 patients who reached end stage kidney disease requiring 
dialysis (Praga, Hernandez et al. 2001).  A third series of kidney biopsies from 95 obese 
patients with normal kidney function and 40 normal weight controls was published in 2008 
(Serra, Romero et al. 2008).  60 patients showed evidence of glomerulomegaly or FSGS in 
the obese group, compared to 1 patient in the control group.  The obese group also 
displayed higher levels of globally sclerosed glomeruli, increased mesangial matrix and 
mesangial cell proliferation and greater podocyte hypertrophy than the control group 
(Serra, Romero et al. 2008).  Additionally, BMI was the only factor predictive of glomerular 
lesions in the obese patients, compared to controls, after multivariate adjustment (Serra, 
Romero et al. 2008), indicating that obesity related changes in the kidney prior to any 
clinical manifestation of CKD, may increase the risk of developing CKD over time.  These 
3 clinical studies, demonstrating structural changes in the kidneys of obese patients, 
support the epidemiological findings linking obesity to the development and progression of 
CKD. 
 
In addition to structural and functional adaptations contributing to obesity related kidney 
damage, inflammatory and metabolic effects have also been identified (Wu, Liu et al. 2006; 
Wahba and Mak 2007; Deji, Kume et al. 2009).  Mice fed a high-fat, high-energy diet for 12 
weeks gained weight and developed metabolic syndrome, with increased systolic blood 
 40 
pressure, triglycerides and insulin resistance, when compared to mice fed either a standard 
diet, or an energy-reduced high fat diet.  After 12 weeks, structural and functional kidney 
changes including lipid and macrophage infiltration in kidney tissue were evident in mice 
on the hypercaloric high energy, high fat diet, but not in mice on either the standard diet or 
the energy-reduced high fat diet (Deji, Kume et al. 2009), indicating that excess energy 
intake, rather than a high fat diet itself, induces changes in kidney tissue.  These structural 
changes may be related to alterations in adipokines (signalling peptides secreted almost 
exclusively by adipose tissue), insulin resistance, and/or increased intra-abdominal pressure 
accompanying the weight gain leading to obesity (Kato, Nazneen et al. 2009).  Therefore it 
is possible that obesity-related kidney damage occurs during weight gain, and may be 
related to altered production of adipokines and exhaustion of insulin homeostasis leading 
to insulin resistance.   
 
In order to examine multiple factors related to the pathogenesis of ORG, gene expression 
profiles of biopsy-derived glomeruli from obese patients with ORG were studied (Wu, Liu 
et al. 2006).   In 6 patients with obesity, proteinuria and biopsy proven ORG (Kambham, 
Markowitz et al. 2001), microarray analysis and real-time quantitative polymerase chain 
reaction (RT-qPCR) revealed a distinct up-regulation of gene expression for the 
inflammatory cytokines tumour necrosis factor-alpha (TNF-α) and its receptors and 
interleukin-6 (IL-6) signal transducer in the glomeruli of patients with ORG, compared to 
normal weight healthy controls.  There was also abnormal regulation of the LDL-
cholesterol receptor gene and increased expression of vascular endothelial growth factor 
(VEGF), transforming growth factor beta (TGF-β), glucose transporter 1 (GLUT-1) and 
the leptin receptor, which are involved in lipid metabolism and insulin resistance 
(Kambham, Markowitz et al. 2001).  This study provided the first evidence that 
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inflammatory cytokines and their downstream pathways were likely to play a role in obesity 
related glomerular injuries. 
 
Figure 3 outlines the possible relationships and pathways between increased weight gain, 
obesity and the mechanisms resulting in kidney damage and cardiovascular complications.  
 
 
Figure 3: Mechanisms of obesity induced kidney injury 
FFA – free fatty acids; IL-6 – interleukin 6; TNF-α – tumour necrosis factor-α; RAAS – renin angiotensin aldosterone 
system  
Hepatic production of fetuin-A increases with obesity, and suppresses adipocyte adiponectin mRNA expression, 
induces insulin resistance in muscle and liver and increases IL-6 and TNF-α expression (Ix and Sharma 2010); low 
adiponectin levels and insulin resistance compromise protective mechanisms on podocytes and renal tubular cells 
leading to microalbuminuria (Fornoni 2010; Fang, Liu et al. 2013), inappropriate up-regulation of the RAAS system, 
increased reactive oxygen species and vascular endothelial dysfunction and kidney damage (Nistala and Whaley-Connell 
2013); leptin increases due to a feedback inhibition mechanism which inhibits activation of leptin receptors (Myers, 
Leibel et al. 2010), increases sympathetic nervous system activity, inflammation, and increases TGF-β in the kidney 
(Wolf, Hamann et al. 1999). 
 
ORG is not the only manifestation of obesity related kidney damage, and obesity 
accelerates the loss of renal function with other primary causes of CKD.  There are several 
major, potentially reversible, mechanisms by which obesity may result in kidney damage 
leading to a reduction in kidney function over time; increased intra-abdominal pressure and 
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increased glomerular filtration, increased inflammation, and alterations in adipose tissue 
hormones (Ritz, Koleganova et al. 2011).  Increased physical compression caused by excess 
adipose tissue surrounding the kidneys, and sympathetic activation of the renin-angiotensin 
aldosterone system (RAAS), resulting in increased renal blood flow leading to excess 
tubular sodium resorption, which, in turn, signals to increase vasodilation of the afferent 
arterioles (Kambham, Markowitz et al. 2001) and increased vasoconstriction of efferent 
arterioles, due to increased angiotensin II, leading to increased renal perfusion pressure, 
volume expansion, hypertension, hyperfiltration, glomerulomegaly, and eventually loss of 
nephrons and fibrosis (Wahba and Mak 2007; Sarafidis 2008).   
 
The increase in gene expression of inflammatory factors and lipid dysmetabolism evident 
in ORG (Wu, Liu et al. 2006), together with the reduction in clearance of uraemic toxins in 
patients with CKD (Stenvinkel, Carrero et al. 2008), due to the reduced glomerular 
filtration rate, may lead to nephrotoxicity due to an amplified cytokine response from both 
increased production and decreased clearance of pro-inflammatory factors.  
 
Adipose tissue is not simply a storage repository, but the largest endocrine organ in the 
body, secreting pleiotropic adipocytokines such as leptin, adiponectin and the inflammatory 
factors IL-6 and TNF-α (Axelsson, Qureshi et al. 2004).  An increase in circulating leptin, 
which occurs with obesity due to leptin resistance, increases insulin resistance, promoting 
glomerular hypertrophy and glomeruloscerosis through up-regulation of TGF-β and 
insulin-like growth factors (Wolf, Hamann et al. 1999).  Altered adipokines and the 
inflammatory state present in both obesity and CKD may be the link between metabolic 
syndrome, insulin resistance and vascular damage, culminating in atherosclerotic 
cardiovascular disease (CVD) in both chronic disease states (Pecoits-Filho, Barany et al. 
2002; Addabbo, Mallamaci et al. 2007). Mechanisms of the cardiovascular complications in 
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CKD are related to endothelial dysfunction, inflammation, activation of the renin-
angiotensin system, increased circulation of cytokines, and impaired bone mineral 
metabolism (Schiffrin, Lipman et al. 2007), although many of the specific pathways and 
mechanisms in obesity related kidney disease remain unknown.  
 
Insulin has anti-inflammatory, anti-oxidant and anti-thrombotic effects alongside 
modulation of blood glucose levels.  The insulin resistance evident in obesity is likely 
related to reduced insulin signal transduction caused by activation of inhibitory pathways 
by elevated pro-inflammatory cytokines IL-6, C-reactive protein (CRP) and TNF-α 
produced by adipose tissue and macrophages (Dadona, Chaudhuri et al. 2008).  In CKD, 
peripheral insulin resistance is strongly and inversely correlated to kidney function - 
independent of diabetes (Crutchlow, Robinson et al. 2007) and body weight - and 
positively correlated with TNF-α and IL-6, and is known to reflect atherosclerosis in 
patients with CKD (Addabbo, Mallamaci et al. 2007).  Additionally, insulin stimulates the 
production of TGF-β from renal mesangial and tubular cells, which is known to be 
involved in pathways leading to renal fibrosis (Sarafidis 2008). 
 
Adipose tissue secretes adipokines, including leptin and adiponectin, which have pro- and 
anti-inflammatory properties and may be involved in insulin resistance, metabolic 
syndrome and atherosclerosis (Bobbert and Spranger 2008).  Leptin functions as a chronic 
satiety signal, and modulates fatty acid oxidation and utilisation, enhancing insulin 
sensitivity (Stenvinkel, Lindholm et al. 2000).  Paradoxically, circulating leptin 
concentrations increase with obesity, a mechanism often referred to as leptin resistance 
(Munzberg and Myers 2005). Leptin resistance is not fully understood, but occurs in part, 
due to a reduction in leptin receptor activation as a result the feedback inhibition signalling 
from the accumulation of signal transducer and activator of transcription – 3 (STAT-3) 
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induced suppressor of cytokine signalling – 3 (SOCS-3), and other mechanisms such as 
endoplasmic reticulum stress and inflammation, which lead to insulin resistance are 
thought to also contribute to leptin resistance (Myers, Leibel et al. 2010).  Leptin has also 
been observed to exert pro-atherogenic effects (Dadona, Chaudhuri et al. 2008).  Leptin 
levels also increase in CKD without increased body fat in patients with mild to moderate 
CKD, likely due to reduced leptin clearance (Guebre-Egziabher, Bernhard et al. 2005), and 
may be involved in several metabolic processes, including uremic anorexia, protein energy 
wasting (Fouque, Kalantar-Zadeh et al. 2007), and vascular calcification (Stenvinkel, 
Lindholm et al. 2000; Parhami, Tintut et al. 2001). 
 
Adiponectin is a circulating adipokine produced by adipocytes (Goldstein and Scalia 2004).  
It has protective metabolic and vascular effects in non-CKD subjects and may work in 
anti-inflammatory pathways (Rabin, Kamari et al. 2005) by suppressing early events in the 
atherosclerotic process (Ouchi, Kihara et al. 1999).  Adiponectin levels are reduced in 
obesity, negatively correlate with leptin and insulin resistance (Wiecek, Adamczak et al. 
2007).  Low adiponectin levels related to compromised endothelial function, which can 
result in accelerated atherosclerosis (Heber 2008).  Reduced renal function obscures these 
relationships as adiponectin levels increase as kidney function declines.  This largely reflects 
reduced adiponectin clearance, although uraemia and inflammation may also contribute 
(Barazzoni, Bernardi et al. 2007; Neiszporek, Witkowicz et al. 2007), possibly with 
adiponectin levels rising as a protective anti-inflammatory mechanism, concomitantly with 
an overwhelming inflammatory response.  Therefore, in CKD, both high (Menon, Li et al. 
2006) and low (Zoccali, Mallamaci et al. 2002; Iwashima, Horio et al. 2006) levels of 
adiponectin have been associated with increased CVD risk.  Recent research indicates that 
adiponectin is a likely regulator of albuminuria, with a reduction in adiponectin related to 
increased albuminuria, reversible with adiponectin administration and normalisation of 
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podocyte foot process structure (Ix and Sharma 2010).  These findings identified 
adiponectin as a possible link between adipose tissue and kidney cross-talk (Ix and Sharma 
2010).  
 
Fetuin-A, a peptide produced exclusively in the liver, is increased with obesity, and is 
associated with increased truncal obesity, and dyslipidaemia in haemodialysis patients 
(Axelsson, Wang et al. 2008; Chen, Chiu et al. 2009).   Fetuin-A is known to play an 
important role in the inhibition of vascular calcification, and low fetuin-A levels are related 
to mortality in haemodialysis patients (Stenvinkel, Wang et al. 2005).  Fetuin-A may also be 
involved in insulin resistance by suppressing adiponectin in adipose tissue (Ix and Sharma 
2010).   This reduction in adiponectin inactivates 5' adenosine monophosphate-activated 
protein kinase (AMPK), and the increased fetuin-A induces insulin resistance by blocking 
the insulin receptor tyrosine kinase, the net effect of which may be kidney damage through 
podocyte effacement and albuminuria (Ix and Sharma 2010).  In a 1-year weight loss 
intervention study in obese children, fetuin-A levels were associated with insulin resistance 
and components of metabolic syndrome prior to weight loss, and both fetuin-A and insulin 
resistance decreased with weight loss (Reinehr, Roth et al. 2008).  The relationships 
between fetuin-A, adiponectin and leptin in adipose tissue and the kidney offer some 
insight into the possible mechanisms of obesity related glomerulopathy, particularly 
podocyte damage, which warrant further study through weight loss interventions in obese 
patients with CKD.  
 
Weight loss, inflammation and adipokines 
As it became established that obesity was an inflammatory condition, the effects of weight 
loss interventions on the levels of inflammatory cytokines and adipokines began to be 
investigated. Early studies indicated that weight loss, achieved with energy reduced diets 
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and increased physical activity, is associated with reductions in IL-6, CRP, leptin, and 
increased adiponectin (Gallistl, Sudi et al. 2001; Esposito, Pontillo et al. 2003; de Luis, Aller 
et al. 2008; de Luis, Aller et al. 2009).  The addition of orlistat, a lipase inhibitor that 
reduces fat absorption in the gastrointestinal tract by 30% (Guerciolini 1997), may enhance 
the effects of weight loss on reducing inflammation.  In a randomised controlled trial of an 
energy-reduced diet, with or without Orlistat, the diet plus orlistat group demonstrated 
greater weight loss and body fat loss, as well as greater reductions in CRP and TNF-α than 
the diet alone group, after correcting for weight loss (Bougoulia, Triantos et al. 2006).   
This implies that either the greater reduction in fat mass, or another factor related to the 
use of orlistat itself, also contributes to reducing obesity-associated inflammation.   
 
A review of the evidence relating to changes in adipokines and inflammatory markers with 
dietary based weight loss interventions was published in 2010 (Klimcakova, Kovacikova et 
al. 2010).  Overall, the only adipokine consistently associated with weight loss is a decrease 
in leptin, which reflects a reduction in body fat mass.  Total plasma adiponectin was not as 
sensitive to changes in body weight, and this may be related to the presence of different 
isoforms of adiponectin, with the high molecular weight isoform the most physiologically 
active in humans, which may be more sensitive indicator of active adiponectin in obesity.  
Studies of inflammatory markers such as IL-6 and TNF-α with weight loss were equivocal, 
with either no change or a decrease in these inflammatory markers, however, as these 
markers are not specific to adipose tissue, total serum levels do not necessarily reflect 
changes mediated by a reduction in adipose tissue with weight loss (Klimcakova, 
Kovacikova et al. 2010). 
 
The effect of weight loss on inflammation and adipokines, via weight loss surgery, is 
addressed later in this chapter. 
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Obesity in Haemodialysis Patients 
The prevalence of obesity in patients with end stage kidney disease requiring dialysis is now 
consistent with that in the general population (Kramer, Saranathan et al. 2006).  Between 
1994 and 2002 in the United States, the mean BMI at initiation of dialysis rose from 25.7 
kg/m2 to 27.5 kg/m2 and now almost one third of incident dialysis patients are obese 
(Kramer, Saranathan et al. 2006).   Similar data is not accessible in the United Kingdom as 
data on BMI at initiation of dialysis is incomplete in the Renal Registry (United Kingdom 
Renal Registry).  However, it is likely that the pattern in the United States is indicative of 
the situation in the United Kingdom also, and the increase in the number of obese patients 
with end stage kidney disease requiring dialysis has implications for planning and providing 
dialysis services. (Zoccali, Kramer et al. 2009). 
 
Increasing body size in the CKD population has resulted in an unexpected association 
between greater body mass index and improved survival in haemodialysis patients (Abbott, 
Glanton et al. 2004; Kalantar-Zadeh, Kopple et al. 2005; Chazot, Gassia et al. 2009), in 
contrast to that evident in the general “healthy” population (Rogers 2003), and in patients 
with non-dialysis CKD (Elsayed, Sarnak et al. 2008).  However, not all studies show on-
going improvement in survival with increasing BMI in obese patients.  There may be a limit 
to the protective capacity of BMI, as no significantly greater survival advantage was evident 
for BMI between 31-37 kg/m2 than for BMI of 29-31 kg/m2 in patients followed up for 2 
years (Johansen, Young et al. 2004), or with percentage body fat > 36% compared to 12 – 
24% body fat, which was also associated with lower quality of life (Kalantar-Zadeh, Kuwae 
et al. 2006).   
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Yet the emerging relationship between obesity and its impact on CKD is complex.  Further 
exploration of the observation that obesity is protective in haemodialysis patients failed to 
find this survival advantage in older haemodialysis patients followed for 7 years compared 
to obese controls followed for the same time period (de Mutsert, Snijder et al. 2007).  
Similarly, in a cohort of patients in the Netherlands Cooperative Study on the Adequacy of 
Dialysis-2 (NECOSAD) Study also followed up for 7 years, there was no relationship 
between BMI and mortality in patients older than 65 years, yet in obese dialysis patients 
less than 65 years, the age standardised adjusted mortality rate was 1.57 times higher than 
in dialysis patients with a normal BMI (Hoogeveen, Halbesma et al. 2012).  Therefore, in 
contrast to older dialysis patients, younger obese dialysis patients have a higher risk of 
death than dialysis patients of normal BMI, and the relationship between BMI and 
mortality in older dialysis patients appears to be attenuated with longer follow up.   
 
BMI is a surrogate marker of body composition, but is actually more reflective of total 
body size than total body fat or body fat distribution.  The observation that higher BMI is 
more protective that normal BMI against mortality in haemodialysis patients may reflect 
the importance of lean body mass or nutritional status rather than body adipose tissues 
stores, in the context of BMI.  Indeed, when other measures of adiposity are used to define 
obesity, the relationship becomes clearer.  In a population of 537 Italian haemodialysis 
patients, both waist circumference and BMI were measured at baseline and patients were 
followed up for 2 years to determine the relationship between all-cause and cardiovascular 
mortality and obesity (Postorino, Marino et al. 2009).  Whilst an inverse association 
between BMI and mortality was also found in this population, a direct relationship was 
evident between waist circumference and all cause mortality, indicating that excess 
abdominal adipose tissue increases mortality risk in haemodialysis patients.   
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Studies that have included surrogate measures of muscle mass in the survival analysis have 
found improved survival in those with greater estimated muscle mass. High pre-dialysis 
urinary creatinine plus high BMI was linked to reduced mortality risk when compared to 
normal BMI and higher creatinine, indicating that higher muscle mass, regardless of BMI 
was protective against mortality in haemodialysis patients (Beddhu, Pappas et al. 2003).  
Low mid-arm muscle circumference was associated with reduced 10-year survival in 
incident haemodialysis patients, even when BMI was > 25 kg/m2 (Araujo, Kamimura et al. 
2006). Protein energy wasting, often evident in obese and overweight patients, predicted 
mortality in overweight haemodialysis patients but BMI did not (Honda, Qureshi et al. 
2007), again indicating that muscle is protective against mortality in this population.  Whilst 
the literature lacks direct evidence that high muscle mass is the protective component of 
BMI against mortality in haemodialysis patients, these data suggest that good muscle mass 
is advantageous for survival (Mafra, Guebre-Egziabher et al. 2008) and that greater BMI 
above a certain threshold may not provide any further advantage due to the negative effects 
of excess abdominal adiposity. 
 
Obesity and kidney transplantation 
Obesity may limit treatment options in kidney failure as access to kidney transplantation is 
reduced once BMI > 35 kg/m2 (Segev, Simpkins et al. 2008).  In kidney transplant 
recipients with BMI > 35 kg/m2 mortality increases and graft survival decreases when 
compared to patients with BMI 30 - 35 kg/m2 (Cacciola, Pujar et al. 2008).  Obese kidney 
transplant recipients have higher rates of surgical wound infections, delayed graft 
functioning and acute rejection, and longer than average length of hospital stay than non-
obese kidney transplant recipients (Meier-Kriesche, Arndorfer et al. 2002; Gore, Pham et 
al. 2006).  In a study that sought to distinguish between obese and morbidly obese patients 
to determine the effect on mortality and graft survival, obese patients with BMI > 35 kg 
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/m2 had greater mortality and lower kidney graft survival after 1 and 5 years than obese 
patients with BMI 30-34.9 kg/m2, but there was no difference in wound infection rates 
between the 2 groups (Cacciola, Pujar et al. 2008).  The results indicated that patients with 
BMI > 35 kg/m2 are a high-risk group for transplantation, with the highest risk period 
being the first year post-transplantation.  The authors recommended that all obese patients 
be considered for transplantation based on individual cardiovascular risk factors rather than 
simply by BMI.  Post-kidney transplant risk of cardiovascular morbidity also increases with 
increasing BMI.  In a study of 1 105 post-kidney transplant patients categorised by BMI 
quartiles, increased incidence of congestive heart failure and atrial fibrillation occurred with 
increasing BMI, yet there was no difference in the myocardial infarction event rate by BMI 
quartile (Lentine, Rocca-Rey et al. 2008). 
 
Weight loss interventions in obese patients with chronic kidney disease 
Management of obesity is now an important consideration in patients with CKD, yet it 
may be even more complex than within the general population, given the additional 
limitations on dietary and fluid intake and reduced clearance of excess metabolites due to 
diminished or absent kidney function.  Current practice guidelines for nutritional 
intervention in CKD provide very little guidance on the management of obesity in patients 
with CKD and the evidence is gleaned from epidemiological studies rather than clinical 
intervention trials (Fouque, Vennegoor et al. 2007; Wright and Jones 2010; Masoomi, Kim 
et al. 2011).   There are very few studies investigating weight loss interventions for obesity 
in CKD.  A recent systematic review and meta analysis reported on 12 studies in patients 
with CKD, proteinuria and glomerular hyperfiltration; 6 with exercise and/or dietary 
interventions and 6 investigating weight loss surgery (Navaneethan, Yehnert et al. 2009).   
Nine observational cohort studies, one retrospective analysis, 1 non-randomised trial and 2 
randomised controlled trials were included in the analysis.    The pooled results of these 
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studies demonstrated significant reductions in systolic blood pressure, proteinuria and 
glomerular hyperfiltration with weight loss.  In patients with CKD, there was no change in 
kidney function with weight loss, although some studies reported a decline in kidney 
function in the control groups which may indicate that weight loss in obese patients with 
CKD may halt disease progression (Navaneethan, Yehnert et al. 2009). 
 
A similar systematic review of the effect of intentional weight loss on proteinuria, reported 
on 5 randomised controlled trials and 8 uncontrolled trials (Afshinnia, Wilt et al. 2010).   
Weight loss was associated with significant reductions in microalbuminuria and proteinuria 
using meta-regression analysis, and weight loss with surgery was associated with a reduction 
in hyperfiltration.  The authors commented on the limitations of the primary data sources 
which were of small sample size, many lacked control groups and most were conducted 
over relatively short time periods (Afshinnia, Wilt et al. 2010).  Therefore, well-designed 
randomised controlled trials of intentional weight loss in obese patients across the 
spectrum of CKD are still required, to determine the effect on markers of kidney damage 
and measures of kidney function. 
	  
Lifestyle Interventions 
Successful lifestyle-based interventions for weight loss in chronic kidney disease include 
energy restrictions ranging from 500 kilocalories (kcal) less than usual intake/day (Morales, 
Valero et al. 2003) , through 1 000-1 400 kcal/day meal plans (Solerte, Fioravanti et al. 
1989; Praga, Hernandez et al. 1995), to low energy intakes of 700-900 kcal/day (Vasquez, 
Flock et al. 1984; Saiki, Nagayama et al. 2005) and a combination of 500 kcal less than 
usual intake/day, exercise and orlistat (Roche, Basel, Switzerland) therapy (Cook, 
MacLaughlin et al. 2008).   The duration of these interventions ranges from 4 to 52 weeks, 
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however, detailed information on the dietary prescription and how it is monitored is often 
lacking in published reports. 
 
Weight loss achieved is related to the level of energy restriction imposed.  Over 4 weeks, 
balanced very low kcal meal replacements were utilised for 1-2 meals per day, to induce a 6 
kg weight loss, which reduced proteinuria (Saiki, Nagayama et al. 2005).  The study did not 
follow up patients after the 4-week intervention to determine whether weight was regained 
once the intervention ceased.  Work by our group and others has found that moderate 
energy restriction of 500 kcal per day resulted in a similar level of weight loss over 12 
months (Morales, Valero et al. 2003; Cook, MacLaughlin et al. 2008), and our follow up 
study demonstrated this level of weight loss was maintained for a further 12 months, in 
conjunction with exercise and orlistat (MacLaughlin, Cook et al. 2010). 
 
In a cohort of obese non-diabetic women, improvements in glucose metabolism, but not 
blood pressure reduction or weight loss, were associated with a reduction in 
microalbuminuria following a 3 month lifestyle based weight loss intervention, suggesting 
that metabolic alterations such as insulin resistance - rather than altered glomerular 
dynamics - contribute to impaired kidney function in obesity (Gilardini, Zulian et al. 2010). 
One, small uncontrolled, study attempted to address the effects of a 20% energy reduction 
on adipokines, insulin resistance and inflammation in obese patients with diabetic 
nephropathy.  After two months, minimal, non significant, weight loss occurred, and there 
was no change in leptin, adiponectin, insulin resistance or CRP (Kozlowska, Rydzewski et 
al. 2010).  The dietary energy deficit did not appear sufficient to induce weight loss and 
there was no intervention in increase physical activity to increase energy expenditure.  
Further study of weight loss is warranted to determine the impact on novel cardiovascular 
risk factors such as leptin, adiponectin, IL-6, TNF-α, CRP, and endothelial function in 
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obese patients with CKD.  However, levels of these signalling factors are influenced by 
reduced renal clearance and insulin resistance, metabolic syndrome with and without overt 
obesity in CKD, so defining mechanistic relationships between these factors and weight 
loss remains difficult. 
 
A meta analysis of the effect of weight loss (surgical and non surgical) on kidney function 
demonstrated a pooled reduction in hyperfiltration of 23.7 ml/min (95% CI, 11.4 to 36.2), 
a 17% decrease from baseline (95% CI, 8% to 26%) (Afshinnia, Wilt et al. 2010), indicating 
that weight loss may reduce obesity-associated glomerular hyperfiltration, which can be a 
precursor to reduction in kidney function (Hostetter, Olson et al. 1981) and may delay or 
prevent progression towards overt, irreversible, kidney damage.  However, in patients with 
BMI >35 kg/m2, weight loss achieved with lifestyle interventions may remain inadequate 
for kidney transplantation access, and the factors associated with obesity related kidney 
function decline are likely to persist.   
 
Weight loss surgery  
Weight loss surgery leads to sustained weight loss, resolution of diabetes, and a reduction 
in traditional cardiovascular risk factors (Sjostrom 2000), and may provide a practical 
solution to increasing eligibility for kidney transplantation in obese patients with CKD.  A 
recent Health Technology Assessment of weight loss surgery for obesity reported weight 
loss surgery as a more effective intervention for weight loss than non-surgical options; and 
is cost effective, particularly over the longer term (Picot, Jones et al. 2009).  
 
Weight loss surgery is a more effective intervention for weight loss than medical treatments 
and is either purely restrictive to reduce the size of the stomach and limit food intake, or 




Figure 4: Weight loss surgery techniques A – Roux–en Y Gastric bypass, B – Adjustable Gastric Band, C – 
Sleeve Gastrectomy, D – Biliopancreatic Diversion, E – Biliopancreatic Diversion with Duodenal Switch 
(Adapted from (Bradley, Magkos et al. 2012)) 
 
procedures include adjustable gastric banding, vertical banded gastroplasty (no longer 
performed routinely) and sleeve gastrectomy.  Laparoscopic sleeve gastrectomy is a novel 
form of restrictive weight loss surgery to create a long tube-like stomach after subtotal 
gastric resection of the fundus and body, and has recently been accepted as an approved 
bariatric surgery procedure by the American Society for Metabolic and Bariatric Surgery 
(ASMBS Clinical Issues Committee 2009).  Restrictive and malabsorptive procedures,  
bypassing part of the small intestine to reduce nutrient absorption, are the Roux-en-Y 
gastric bypass, biliopancreatic diversion and biliopancreatic diversion with duodenal switch 
(Picot, Jones et al. 2009).   In the Roux-en Y bypass, a small stomach is created and 
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anastamosed to the proximal jejunum, with the biliopancreatic limb reinserted into the 
distal jejunum, leaving a considerable length of common limb for digestion.  The 
biliopancreatic diversion consists of a horizontal gastrectomy anastamosed to the ilium, 
with a short common limb after rejoining the proximal end of the dissected ilium 50cm 
before the terminal ilium.  A modification of this procedure, with duodenal switch, has a 
vertical sleeve gastrectomy with a duodenal-ileal anastomosis and ileal to ileal resection 
100cm from the terminal ilium (Bradley, Magkos et al. 2012). 
 
A 2004 systematic review and meta analysis of all forms of weight loss surgery, except 
sleeve gastrectomy, included 22 094 patients in 136 studies, and reported a mean excess 
weight loss of 61.2% (95% CI 58.1%-64.4%) for all patients, with drastic improvements in 
sleep apnoea, hypertension, hyperlipidaemia and diabetes (Buchwald, Avidor et al. 2004).  
Weight loss surgery has been associated with a reduction in mortality in patients who had 
undergone weight loss surgery when compared to age, gender and weight matched controls 
in three large observational cohort studies (Christou, Sampalis et al. 2004; Adams, Gress et 
al. 2007; Sjostrom, Narbro et al. 2007).  Yet one study also reported an increase in deaths 
from accidents and suicide in the surgery group, compared to the control group (Adams, 
Gress et al. 2007).   
 
The Swedish Obese Subjects study is the largest, prospective, controlled study of mortality 
following weight loss surgery.  After a mean follow up period of 10.9 years, the multi-
variable adjusted risk of death was lower in the surgery group compared to the control 
group (adjusted hazard ratio 0.71; 95% confidence interval (CI) 0.54, 0.92; p = 0.01) 
(Sjostrom, Narbro et al. 2007).   Additionally, the incidence of stroke and myocardial 
infarction were also reduced after weight loss surgery (adjusted hazard ratio 0.67; 95% CI 
0.54, 0.83; p < 0.001) (Sjostrom, Peltonen et al. 2012).  The effect of weight loss surgery on 
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blood glucose control in obese patients with type-2 diabetes has recently been investigated 
in 2 randomised controlled trials of weight loss surgery compared to best medical care 
(Mingrone, Panunzi et al. 2012; Schauer, Kashyap et al. 2012).  Resolution of diabetes 
occurred in 37 - 42% of patients 12 months after weight loss surgery in one study (Schauer, 
Kashyap et al. 2012) and after 2 years, there was a 75 - 95% reduction in diabetes post 
bariatric surgery in the second study (Mingrone, Panunzi et al. 2012).  Therefore, weight 
loss surgery appears an effective treatment for obesity, which may reduce mortality, 
cardiovascular events and diabetes in obese patients, when compared to no surgical 
treatment.     
 
Several studies have examined the effect of weight loss surgery on markers of 
inflammation, adipokines and insulin resistance.  Weight loss surgery using either the Roux-
en-Y bypass or sleeve gastrectomy is associated with improvements in insulin resistance 
and adiponectin, and reductions in leptin, CRP, IL-6 and metabolic syndrome after twelve 
months (Vilarrasa, Vendrell et al. 2007; Hofso, Nordstrand et al. 2010; Woelnerhanssen, 
Peterli et al. 2011; Illan Gomez 2012; Illan-Gomez, Gonzalvez-Ortega et al. 2012).  A 
reduction in the inflammatory cytokine IL-18 was associated with a decrease in insulin 
resistance and triglycerides 12 months after gastric bypass surgery, and adiponectin levels 
increased (Vilarrasa, Vendrell et al. 2007).  No association was reported between 
adiponectin and inflammatory markers 12 months post surgery (Vilarrasa, Vendrell et al. 
2007; Illan Gomez 2012; Illan-Gomez, Gonzalvez-Ortega et al. 2012), although 
relationships between the changes in variables with weight loss were not examined.  
Furthermore, one of these studies also included a comprehensive lifestyle programme 
study arm, and reported that improvements in glycaemic control and decreased diastolic 
blood pressure were related to weight loss of > 10% regardless of treatment group (Hofso, 
Nordstrand et al. 2010).  
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Weight loss surgery in obese patients with CKD is sparsely reported in the literature.  
There are 11 intervention studies (excluding individual case reports) reporting on the effect 
of weight loss surgery on renal outcomes.  Five studies report on obese patients with 
normal or elevated kidney function and 6 studies include patients with defined CKD.  
 
Observational studies of gastric bypass and gastric banding in obese patients with CKD 
suggest that weight loss surgery can induce significant weight loss and reduction in 
glomerular hyperfiltration and proteinuria (Chagnac, Weinstein et al. 2003; Navarro-Diaz, 
Serra et al. 2006; Agrawal, Khan et al. 2008), may improve or stabilise estimated kidney 
function (Alexander and Goodman 2007; Alexander, Goodman et al. 2009; Navaneethan 
and Yehnert 2009), urinary inflammatory markers (Bueter, Dubb et al. 2010) or serum 
creatinine (Schuster, Teodorescu et al. 2011), and improve candidacy for kidney 
transplantation (Newcombe, Blanch et al. 2005; Koshy, Coombes et al. 2008; Takata, 
Campos et al. 2008).   However, these studies have either been conducted in obese patients 
without overt CKD or have reported retrospectively on small numbers of selected patients 
with varying stages of CKD and without comparison to matched controls not undergoing 
weight loss surgery.   
 
Observational studies of gastric bypass surgery in obese and super-obese patients with early 
signs of kidney disease demonstrated significant weight loss and reduction in proteinuria, 
especially in patients with diabetes and metabolic syndrome (Chagnac, Weinstein et al. 
2003; Navarro-Diaz, Serra et al. 2006; Agrawal, Khan et al. 2008).  In a case series analysis 
of 45 obese patients with varying severity of CKD undergoing gastric bypass surgery, 14 
patients then underwent kidney transplantation and 31 did not. Of these remaining 31 
patients, 9 patients (29%) demonstrated an improvement or stabilisation in either 
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proteinuria or serum creatinine, including the cessation of dialysis in 2 patients for some 
time after gastric bypass surgery (Alexander, Goodman et al. 2009).  This study reported 
positive outcomes of transplantation, or improvement or stabilisation of kidney function 
for half the study population, but did not comment on the outcomes in the rest of the 
studied population.  Gastric bypass surgery in an uncontrolled retrospective analysis of 25 
obese patients with stage 3 CKD improved estimated kidney function from 47.9 
ml/min/1.73m2 at baseline to 61.6 ml/min/1.73m2 after 12 months, with a reduction in 
BMI from 49.8 kg/m2 to 34.5 kg/m2 over the same time period (Navaneethan and Yehnert 
2009).  Whilst this data is encouraging, this study used an estimate, rather than a direct 
measurement, of kidney function indexed to standardised body surface area, which 
underestimates kidney function in obese patients and introduces bias when longitudinal 
data is compared without accounting for the changes in body weight and body surface area 
over time (Delanaye, Radermecker et al. 2005), so the results must be interpreted 
cautiously.   
 
There is emerging evidence that both the gastric bypass and adjustable gastric banding 
procedures may lead to kidney related complications in a minority of patients.  A sub-
population of obese patients develops hyperoxaluric nephrolithiasis after gastric bypass, 
which increases the risk of formation of calcium oxalate crystals within the kidney tissue 
and can cause chronic oxalate nephropathy and deterioration in kidney function (Nelson, 
Houghton et al. 2005; Sinha, Collazo-Clavell et al. 2007; Nasr, D'Agati et al. 2008; Matlaga, 
Shore et al. 2009).  Gastric bypass was associated with an increased likelihood of diagnosis 
and treatment of kidney and upper urinary tract stone formation (nephrolithiasis) in 4 693 
obese subjects when compared 4 693 BMI, age, gender, diabetes status and 
antihypertensive treatment matched controls who did not undergoing gastric bypass 
surgery (OR for diagnosis of urinary calculus 1.71; 95% CI 1.44, 2.04; and OR for any 
 59 
urological procedure 3.65; 95% CI 2.60, 5.14) (Matlaga, Shore et al. 2009).   A case series of 
60 patients with nephrolithiasis after gastric bypass was identified at the Mayo Clinic-
Rochester between 1985 and 2004, with approximately 30% of patients identified as having 
pre-existing nephrolithiasis prior to gastric bypass surgery (Sinha, Collazo-Clavell et al. 
2007).   
 
A more serious complication in a small minority of patients has been reported.  Thirteen 
cases of chronic oxalate nephropathy, developed as a result of gastric bypass surgery, have 
been reported in the literature - including two cases from the Mayo Clinic-Rochester series 
- with 10 of these 13 cases progressing to stage 5 kidney disease requiring dialysis (Nelson, 
Houghton et al. 2005; Nasr, D'Agati et al. 2008).  In many of these cases patients also had 
long standing diabetes and hypertension, which whilst unlikely to be the catalyst for the 
sudden deterioration in kidney function in this sub-group, may have contributed to the 
rapidity of the decline. 
 
Several factors known to be associated with nephrolithiasis and oxalate nephropathy have 
been identified in patients after gastric bypass, including increased urinary oxalate and 
calcium-oxalate supersaturation, reduced urine volume and decreased urinary citrate (Sinha, 
Collazo-Clavell et al. 2007; Park, Storm et al. 2009).  However, restrictive weight loss 
surgery procedures (gastric banding and sleeve gastrectomy) are not associated with 
increased urinary stone risk factors, including urinary oxalate, when compared to gastric 
bypass in obese patients (Semins, Asplin et al. 2010).  This indicates that the surgery 
induced malabsorption and increase in bile salts production, secondary to the reduction in 
the length of small intestine, rather than weight loss itself leads to hyperoxaluria and 
calcium oxalate supersaturation.   
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Gastric banding may be complicated by the combination of CKD and post kidney 
transplantation immunosuppression, and may require further investigation, as two cases of 
complications with gastric banding post kidney transplantation have been reported (Buch, 
El-Sabrout et al. 2006).  In one case, a gastric band inserted prior to kidney transplantation 
subsequently became eroded after kidney transplantation and was removed.  The second 
case report relates to gastric banding performed secondary to weight gain post kidney 
transplantation; two months after insertion, the band migrated downwards, causing gastric 
obstruction, and also required subsequent removal (Buch, El-Sabrout et al. 2006).  Both 
band erosion and migration may have been related to immunosuppression treatment 
associated with organ transplantation (Buch, El-Sabrout et al. 2006).    
 
Therefore, whilst gastric bypass and gastric banding procedures are effective in inducing 
weight loss and may improve kidney function and increase the likelihood of patients 
undergoing kidney transplant, they may worsen kidney function in a small minority of 
patients.   
 
There remains a distinct lack of well-designed studies on the treatment of obesity in 
patients with CKD and as yet, no studies have reported on the use of sleeve gastrectomy in 
this patient population.  Sleeve gastrectomy is a relatively novel form of restrictive weight 
loss surgery in which a tube-like stomach is created after two-thirds subtotal gastric 
resection of the fundus and body, and is usually performed laparoscopically (ASMBS 
Clinical Issues Committee 2009).  Functional stomach integrity is maintained with a 
reduced stomach volume and as it is a purely restrictive procedure there is no 
malabsorption; nor is a foreign object introduced into the body.  As these characteristics 
prohibit the occurrence of the aforementioned side effects of other weight loss surgery 
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procedure, sleeve gastrectomy has the potential to be a promising solution for morbidly 
obese patients with CKD.  
 
A 2009 systematic review of 36 studies of 2 570 patients undergoing sleeve gastrectomy 
reported weight loss of 36-85% of excess body weight loss with follow up from 3 to 60 
months (Brethauer, Hammel et al. 2009).   Reported complication rates ranged between 0-
24% for all studies and between 0-15% for studies including more than 100 patients; 30-
day mortality was 0.19% and incidence of gastric leak was 2.2%, bleeding 1.2% and post 
operative strictures 0.6% (Brethauer, Hammel et al. 2009).   Weight loss after sleeve 
gastrectomy is attributed to both the reduction in stomach volume and to a post surgical 
reduction in plasma ghrelin levels - a hormone produced in the stomach that is associated 
with hunger signalling (Langer, Hoda et al. 2005; Karamanakos, Vagenas et al. 2008). 
 
The safety and effectiveness of laparoscopic sleeve gastrectomy was compared to 
laparoscopic Roux-en-Y gastric bypass and laparoscopic gastric banding using data from 
the American College of Surgeons Bariatric Surgery Centre Network Accreditation 
Program (Hutter, Schirmer et al. 2011).   Data from 28 616 patients in 109 hospitals were 
collected from 2007 to 2011, and 12-month outcomes were reported in 2011.  Of the 944 
patients who underwent sleeve gastrectomy surgery, there were 8 patients (0.74%) with 
renal insufficiency and 8 patients (0.74%) on dialysis.  Sleeve gastrectomy had a 30-day 
complication rate of 5.6%, which was similar gastric bypass (5.9%), and both procedures 
had a higher complication rate than gastric banding (1.4%).  There was no difference in 30-
day or 12-month mortality between the three procedures, with a combined 30-day 
mortality rate of 0.12%.   The effectiveness of sleeve gastrectomy lay between gastric 
bypass and gastric banding.  The mean decrease in BMI at 12 months was 11.9 kg/m2 for 
sleeve gastrectomy, compared to 7.1 kg/m2 for gastric banding and 15.3 kg/m2 for gastric 
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bypass (Hutter, Schirmer et al. 2011).  Similar data has recently been reported in the first 
report from the UK National Bariatric Surgery Registry (Welbourn, Fiennes et al. 2011).     
 
As the sleeve gastrectomy procedure is a relatively quick, effective weight loss procedure 
that does not involve insertion of a foreign body or require adjustments, immediately 
restricts food intake and is not associated with increased risk of nephrolithiasis, it may be 
seen as advantageous over adjustable gastric banding and gastric bypass procedures 
(Himpens, Dapri et al. 2006; Karamanakos, Vagenas et al. 2008; Semins, Asplin et al. 2010; 
Brethauer, Hammel et al. 2009).  Disadvantages may include irreversibility of gastric 
resection, possible longer term gastric dilation which may lead to weight re-gain, and an 
increased short term risk of leak and bleeding compared to gastric banding (Himpens, 
Dapri et al. 2006).  However, long-term data on the safety and efficacy of weight loss with 
sleeve gastrectomy over more than 2 years remains limited and the safety and efficacy of 
the sleeve gastrectomy has yet to be established in obese patients with CKD. 
 
Well-designed prospective studies with matched surgical intervention and non-surgical 
intervention treatment groups are still lacking, particularly in obese patients with stages 2-5 
CKD, and there are no published studies examining the use of the relatively novel sleeve 
gastrectomy procedure in obese patients with CKD.  Calls for interventional studies on 
obese patients with CKD have been expressed repeatedly in the literature, in order to 
determine both the effects of weight loss on kidney function, and the benefits of weight 
loss to this patient group (Locatelli, Pozzoni et al. 2006; Cignarelli and Lamacchia 2007; 
Wang, Chen et al. 2008; Navaneethan, Yehnert et al. 2009; Othman, Kawar et al. 2009; 
Afshinnia, Wilt et al. 2010; Chang and Kramer 2012). 
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Furthermore, since the intervention studies in this thesis were commenced, 2 recently 
published papers have quantified the risk associated with weight loss surgery in patients 
with kidney disease or renal failure.  In a retrospective review of the American College of 
Surgeons National Surgical Quality Improvement Program Participant Use File, 6 930 
patients with CKD stages 2-5 were identified among 27 736 patients undergoing weight 
loss surgery between 2006 and 2008 (Turgeon, Perez et al. 2012).   Risk of complications 
increased as stage of CKD increased with an increase in the odds ratio of 1.3 for each stage 
of CKD.  Overall, the risk remained <10% in patients with stage 5 CKD, which given the 
high morbidity and mortality in patients with stage 5 CKD, is still an acceptable risk, but 
one which patients should be informed of (Turgeon, Perez et al. 2012).   Similarly, in a 
study of in-patient mortality post weight loss surgery using information from the United 
States Nationwide Inpatient Sample, chronic renal failure was associated with increased risk 
of death post weight loss surgery (adjusted odds ratio 2.7) (Caterson, Finer et al. 2012).  
The studies reporting increased risk of complications in patients with CKD (Caterson, 
Finer et al. 2012; Turgeon, Perez et al. 2012), did not include the sleeve gastrectomy 
procedure, so the mortality risk and complication rate in obese patients with CKD 
undergoing sleeve gastrectomy remains unknown.  These retrospective analyses, and those 
studies reporting on oxalate nephropathy, nephrolithiasis and gastric band migration and 
erosion, are based on gastric bypass and gastric banding procedures, and provide new 
evidence that weight loss surgery in patients with CKD carries an increased risk of 
complications and mortality, than in patients without kidney disease.   
 
Summary 
Whilst evidence is accumulating for the contribution of obesity to the development and 
progression of CKD, there remains a lack of evidence on the mechanisms contributing to 
kidney damage and there are few interventional studies of the effects of significant weight 
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loss on CKD parameters.  It is known that weight loss can improve albuminuria, 
proteinuria and hyperfiltration.  One retrospective study demonstrated an improvement in 
estimated kidney function with weight loss surgery (Navaneethan and Yehnert 2009).  No 
prospective, controlled studies have been identified with measured kidney function, or 
kidney transplantation listing as a primary outcome following a weight loss intervention in 
obese patients with CKD.  Relationships between adipokines, obesity, inflammation, 
insulin resistance, CKD and mortality have been identified, although there are no studies 
examining the effect of weight loss on mortality, and just one small uncontrolled study 
addressing inflammation, insulin resistance and adipokines in obese patients with 
established CKD (Kozlowska, Rydzewski et al. 2010).   
 
Intervention studies examining changes in levels of adipokines and inflammatory cytokines 
known to be modified in both obesity and CKD may add to the body of knowledge of the 
mechanisms involved in obesity related kidney changes and might prove useful in 
identifying targets for therapeutic agents in the future.  Weight loss with weight loss surgery 
may be a useful model for determining the effects of obesity on the kidney over a relatively 
short period of time.  Sleeve gastrectomy has not yet been studied in obese patients with 
CKD, yet it appears to be a suitable procedure to utilise, as it should not expose patients to 
the known risks of bypass surgery or gastric band placement in patients with CKD.  
Carefully designed and diligently controlled investigations are required into the effect of 
planned weight loss in obese patients with CKD, in order to determine to effect of weight 
loss on kidney function, inflammatory signalling markers and cardiovascular risk markers, 




Intervention studies aiming to demonstrate a relationship between weight loss and a 
reduction in morbidity associated with CKD, such as a reduction in cardiovascular events, 
have yet to be published.  There are several factors related to CKD such as dyslipiaemia, 
accumulation of waste products and a chronic inflammatory state that may be detrimental 
to vascular function and perhaps these may counteract the beneficial effects of weight loss.  
It is crucial that the effect of weight loss on cardiovascular disease risk factors in patients 
with CKD is understood, in order to determine whether or not pursuing weight loss 
treatments is beneficial for patients.   Major benefits would be improvement in kidney 
function or acceptance for kidney transplantation, and secondary benefits would likely 
include reduction in inflammation and improvement in vascular functional measures.  Long 
term outcomes, such as cardiovascular events and mortality should also be studied, but are 
beyond the scope of this PhD project. 
 
Whilst we understand that weight loss in patients with, or approaching, kidney failure, is 
likely to assist patients to become eligible for kidney transplantation, the effect on kidney 
function, and morbidity and mortality is unknown.  The timeframe of this clinical 
intervention based research limits its focus on major clinical outcomes, but it may have 
implications for the prevention of obesity related progression of CKD, creating greater 
access to kidney transplantation, improving quality of life and contributing to the 
knowledge of the mechanistic effects of obesity on the kidney through its reversal with 
weight loss.   
 
Exploration of the literature in the area revealed information on indicators of early kidney 
disease and novel cardiovascular risk markers derived from epidemiological and 
observational studies.  Yet, very few interventions studies on weight loss in obese patients 
with CKD exist.  As the candidate’s clinical group has expertise in delivering an effective 
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intervention treatment for obesity in patients with CKD, it was a natural progression to 
study the mechanisms involved by examining changes in markers of cardiovascular risk and 
kidney function with weight loss over time.  Weight loss surgery provides a useful model 
for rapid weight loss in order to investigate the resultant changes in metabolic and 
functional measures relating to kidney function, inflammation, adipose tissue signalling 
peptides and vascular function, as well as quality of life. 
 
Overall Aim  
The overall aim of this research is to determine the effect of weight loss interventions on 
cardiovascular and all cause mortality, kidney function, quality of life and access to kidney 
transplantation in obese patients with chronic kidney disease.  Additionally, weight loss 
surgery is being used to explore the effects of significant weight loss on novel 
cardiovascular risk factors, such as inflammation, adipose tissue hormones, insulin 
resistance and vascular function, and the complications and adverse events associated with 
sleeve gastrectomy in obese patients with chronic kidney disease will be monitored.   
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Chapter 2: Participation in a structured weight loss 
programme and all-cause mortality and cardiovascular 
morbidity in obese patients with chronic kidney disease 
 
Chapter Summary 
Obesity is associated with higher all-cause mortality.  Whilst weight loss of 5 to 10 % of 
body weight in overweight and obese populations is associated with favourable changes in 
blood pressure, blood lipids and glycaemic control, the relationship between weight loss 
and mortality in overweight and obese populations is less clear.  Intentional weight loss in 
obese patients with established cardiovascular risk factors may concur a survival advantage.  
Obesity, cardiovascular disease and diabetes are all risk factors for the development and 
progression of chronic kidney disease (CKD), and weight loss interventions are 
recommended for obese patients with CKD, yet studies on the long term outcomes of 
weight loss interventions in obese patients with CKD are lacking. 
 
A retrospective cohort study was conducted to determine if participation in a weight loss 
programme impacts upon all-cause mortality and cardiovascular morbidity in obese 
patients with CKD.  All patients with a body mass index (BMI) of > 30 kg/m2 or >28 
kg/m2 with at least one co-morbidity (hypertension, diabetes or dyslipidemia) referred to 
an established weight management programme (WMP) from 2005-2009 were eligible for 
inclusion in the study cohort.   
 
The WMP is a structured weight loss programme of a low-fat, energy reduced renal diet, 
exercise and pharmacotherapy delivered by a renal dietitian and renal physiotherapist.  The 
primary outcome was time to a combined event of all cause mortality, myocardial 
infarction, stroke, or hospitalisation for congestive heart failure, in patients who chose to 
participate in the WMP, compared to those who did not participate.  Univariate analysis 
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was performed with Kaplan Meier curves with log rank test and a multivariable adjusted 
Cox regression analysis was undertaken to adjust for potential confounding factors for the 
combined outcome.   Additionally, factors contributing to kidney transplant waitlisting in 
obese patients with chronic kidney disease were explored using multiple logistic regression 
analysis.   169 obese patients with CKD commenced the WMP and 169 did not - becoming 
the observational control group (CON).  There were no significant differences between 
groups for age, body mass index (BMI), gender, ethnicity, hypertension status, or kidney 
function at baseline, although CON included more patients with diabetes than WMP (49% 
vs 38%, p=0.03).  Kaplan Meier survival analysis with log rank test for time to the primary 
combined outcome of cardiovascular morbidity and all cause mortality differed between 
groups (p=0.03).  Cox regression analysis with adjustment for baseline BMI, diabetes, age, 
kidney function, gender, hypertension and ethnicity indicated that patients in WMP had a 
significantly longer event free period than those in CON (adjusted Hazard Ratio 0.452, 
95% CI 0.26 - 0.80; p = 0.007).   Participation in the WMP did not increase the likelihood 
of kidney transplantation waitlisting (OR 1.06, 95% CI 0.39 - 2.87; p = 0.9).  Lower 
baseline BMI and greater weight loss over 12 months were the only factors related to 
kidney transplantation waitlisting (adjusted R2=0.426).  Due to the observational study 
design these relationships are limited to associations only, and causality cannot be 
determined.  Furthermore, as this was a single centre study the findings may not be 
applicable to other populations of obese patients with CKD.  This study suggests that 
participation in a structured weight loss programme may be associated with improved 
survival in obese patients with CKD but did not impact upon the likelihood of kidney 




Obesity is a risk factor for both the development of chronic kidney disease (CKD) and the 
decline in kidney function leading to end stage kidney failure.  The efficacy of our renal 
Weight Management Programme (WMP) has been demonstrated previously, with patients 
achieving and sustaining 8% weight loss up to 2 years (MacLaughlin, Cook et al. 2010).  
However, weight loss in obese patients with CKD has not been directly related to 
improvements in blood pressure or favourable changes in blood lipid profile (MacLaughlin, 
Sarafidis et al. 2012), possibly due to the diminished haemodynamic control and 
dyslipidaemia associated with CKD (Levin 2003).   
 
Generally, weight loss of 5-10% in the overweight and obese general population is 
associated with reduction in blood pressure, improvement in blood lipid profile and 
reduced insulin resistance leading to improved glycaemic control (Pasanisi, Contaldo et al. 
2001).  It is now established, from a systematic review and meta analysis extracting data 
from 97 studies, that obesity, using standardised reference categories for BMI, is associated 
with a higher risk of all-cause mortality (Flegal, Kit et al. 2013).  Yet recent reviews of the 
effect of weight loss on mortality in overweight and obese populations in observational 
studies indicate that overall, the impact of weight loss on mortality is unclear, and weight 
loss has been associated with increased all-cause and cardiovascular mortality, decreased 
mortality and no association with mortality in observational and experimental studies 
(Poobalan, Aucott et al. 2007; Simonsen, Hundrup et al. 2008; Harrington, Gibson et al. 
2009).  The relationship between weight loss and mortality may be different between men 
and women, although confounding by other variables cannot be excluded in these 
predominantly observational studies (Poobalan, Aucott et al. 2007; Simonsen, Hundrup et 
al. 2008), particularly the intention to lose weight (Simonsen, Hundrup et al. 2008; 
Harrington, Gibson et al. 2009).   
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In the Copenhagen City Heart Study - an observational study of 19 329 randomly selected 
Danish citizens - weight change over 5 years was monitored, and mortality was recorded 
from the Danish Civil Registry for up to thirty years (Ostergaard, Gronbaek et al. 2010).  In 
the 3 078 obese and overweight subjects at baseline, who either lost weight or maintained 
weight during this period, weight loss was significantly associated with all-cause mortality.  
In those who commenced physical activity during the observation period, weight loss was 
not associated with increased mortality when compared to those subjects who remained 
inactive throughout the study.  The initiation of exercise may indicate intent to lose weight 
in this group, and appeared protective.  As this study was not designed to discriminate 
between intentional and unintentional weight loss, the results should be interpreted 
cautiously.  
 
In a review of studies designed to observe the effects of intentional weight loss on 
mortality, 9 out of 31 potentially relevant studies met the inclusion criteria of intentional or 
voluntary weight loss, with mortality as an outcome (Simonsen, Hundrup et al. 2008).  
These 9 studies were predominantly observational studies of population cohorts, with 
weight loss, and intentionality, as self reported findings.  Four studies found no relationship 
between weight loss and mortality, 2 studies reported decreased mortality and 3 studies 
reported increased mortality.  Potential confounders of the relationship between intentional 
weight loss and mortality were discussed, including baseline BMI, alcohol and smoking 
history, physical activity levels, socio-economic status, and rapid versus gradual weight loss.  
Additionally, intentionality was recorded only once in each study, therefore, both 
intentional and unintentional weight loss may have occurred in any subject despite 
classification of weight loss, as intentionality may change throughout the study observation 
period (Simonsen, Hundrup et al. 2008).  
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Concomitant changes in lifestyle habits occurring with weight loss or in the post weight 
loss period, such as changes in physical activity, and/or dietary intake, smoking status, and 
alcohol consumption, may also influence future mortality, either directly or indirectly as a 
consequence of diseases leading to unintentional weight loss.  Co-morbidities may account 
for some of the variability in study findings, however, due to the conflicting results of the 
studies reviewed and the potential unaccounted for confounders, the authors report that 
the relationship between intentional weight loss and mortality in apparently healthy 
populations cannot be adequately addressed in observational studies and randomised trials 
may more appropriate for addressing this question.  The relationship between weight loss 
and mortality in the apparently healthy population remains equivocal, and there are no 
prospective, randomised controlled trials conducted to specifically examine the effect of 
intentional weight loss, in obese patients, on mortality as the primary study outcome.    
 
In a secondary analysis of older adult patients, enrolled in a randomised controlled trial 
with a weight loss treatment group, to determine the effect of intentional weight loss on all 
cause mortality in older overweight or obese adults, there was no difference in mortality 
between the weight loss and non weight loss groups, after 12 years of follow up (Shea, 
Nicklas et al. 2011); indicating that there may be no benefit of weight loss on mortality in 
overweight and obese adults over 60 years of age.  The greatest weight loss in the group 
not randomised to a weight loss intervention was associated with a 2.5 times higher risk of 
mortality than in those who lost less weight, yet this effect was not evident in the group 
randomised to a weight loss intervention.  Thus, even though this analysis was of a 
randomised trial of weight loss rather than an observational study, weight loss intentionality 
was not ascertained, and it is possible that both intentional and unintentional weight loss 
has been captured in the analysis.  
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Additional analyses of the Sibutramine Cardiovascular OUTcomes (SCOUT) randomised 
controlled trial of sibutramine versus placebo for weight loss indicated that maintained 
weight loss across all treatment groups was significantly related to a reduction in 
cardiovascular mortality (Caterson, Finer et al. 2012).  Intentional weight loss achieved via 
specific weight loss programmes in populations of patients with existing co-morbidities, 
such as diabetes and cardiovascular disease, are associated with a lower likelihood of 
mortality (Williamson, Thompson et al. 2000; Caterson, Finer et al. 2012), or cardiovascular 
morbidity (Eilat-Adar, Eldar et al. 2005), indicating that intentional weight loss may reduce 
cardiovascular morbidity and all cause mortality in populations with established 
cardiovascular disease risk factors.  The presence of co-morbid risk factors is likely to 
influence any relationship with mortality, and undetected co-morbidities may confound 
studies in apparently healthy populations.   
 
The relationship between intentional weight loss and mortality and cardiovascular 
morbidity has not previously been explored in obese patients with CKD.  Obesity, 
cardiovascular disease and diabetes are all risk factors for the development and progression 
of CKD (Gelber, Kurth et al. 2005; Coresh, Selvin et al. 2007; Hsu, Iribarren et al. 2009), 
yet studies on the long term outcomes of weight loss interventions in obese patients with 
CKD are lacking.  Recent evidence also suggests that 50% of patients with CKD have 
actively attempted weight loss (Navaneethan, Kirwan et al. 2012), indicating that obesity 
and overweight may be of concern to the patient population, and weight loss treatments 
are being sought.   
	  
Study Aim 
This study aims to determine if participation in a weight loss programme impacts upon all-
cause mortality and cardiovascular morbidity in obese patients with CKD.   
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Primary Hypothesis 
The primary hypothesis is that participation in a structured weight management 
programme in obese patients with CKD will decrease the likelihood of pre-specified 
cardiovascular morbidity and all cause mortality, compared to obese patients with CKD 
who do not participate in the programme.   
 
Secondary Hypothesis 
The secondary hypothesis is that participation in a structured weight management 
programme in obese patients with CKD will increase the likelihood of kidney 
transplantation waitlisting in patients who are considered ineligible due to a high body mass 
index, compared to obese patients with CKD who do not participate in the programme.   
 
Methods 
Study population  
All male and female patients, aged 18-80 years, under the care of a Nephrologist and with a 
BMI of > 30 kg/m2 , or > 28 kg/m2 with at least one co-morbidity (hypertension, diabetes 
or dyslipidaemia), referred to the renal Weight Management Programme (WMP) at King’s 
College Hospital, London, between January 2005 and December 2009 were eligible for 
inclusion in the study cohort.   
 
All referred patients were invited to attend a 60-minute information session designed to 
provide further information about the programme and outline the responsibilities of the 
treating team and expectations and commitment required from participants.  Potential 
participants who attended this session were given a 7-day food and activity record to 
complete and return in a pre-addressed, postage paid envelope.  Return of the food and 
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activity record indicated consent to participate in the WMP group, and upon return of the 
record, patients were given their first appointment for the WMP clinic.   
 
Patients who either did not attend the information session or did not return the 7-day food 
and activity record were entered into the contemporaneous observational control (CON) 
group.  These patients continued to attend their usual care visits to the Consultant 
Nephrologist.  Study data were recorded at either WMP clinic visits or usual care visits.  All 
data were coded so that patients were unable to be identified and reporting of these data 
complied with the King’s College Hospital research ethics policy. 
 
Weight loss intervention 
There were four components to the WMP: a low-fat energy-reduced renal diet, regular 
exercise, and use of the anti-obesity medication orlistat (Xenical; Roche Products, Basel, 
Switzerland), implemented using behavioural therapy techniques.  The programme was led 
by an experienced Renal Dietitian (the candidate) and a Renal Physiotherapist, with support 
from the Consultant Nephrologist and a Renal Pharmacist as needed.  Patients attended 
the WMP clinic for the initial baseline assessment, then monthly during the 6-month 
intervention period, and for monitoring and support at 9 and 12 months.  Individualised 
diet and exercise regimens were developed with all patients using structured dietary 
education with motivational interviewing (Miller and Rollnick 2002) and cognitive 
behavioural therapy techniques to address barriers to lifestyle change; including food and 
activity diaries, stimulus control, through process evaluation, cost benefit analysis and 
problem solving (Cooper, Fairburn et al. 2003).  Treatment was structured and 
standardised, with checklists for each session developed to act as both cue for and record 




A low-fat energy-reduced renal diet, depending on body size, physical activity level and 
dietary intake at baseline, was negotiated with each patient based on food preferences and 
appropriate for each patient’s CKD stage.  Dietary modification was based on estimated 
energy requirement using the Schofield equation for resting metabolic rate based on age, 
gender, and actual body weight, plus an appropriate activity factor between 20% - 40%, less 
600 kcal/day for weight loss.  Protein intake was optimised for the stage of CKD for each 
patient, at 1.0 g protein/kg ideal body weight (IBW)/day for stage 3 CKD, 0.8 - 1.0 g of 
protein/kg IBW/day for stage 4 CKD, and 1.2 g of protein/kg IBW for stage 5 CKD 
patients requiring dialysis (EDTNA/ERCA Dietitians' Special Interest Group 2002).  Fat 
intake was limited to < 70 g/day to minimise the side effects of orlistat.  The remaining 
calories were consumed from carbohydrate sources, with higher fibre choices encouraged 
when possible.  All patients were encouraged to modify sodium intake to a “no added salt” 
diet level, of 80-100 mmol sodium per day (EDTNA/ERCA Dietitians' Special Interest 
Group 2002).  Potassium and phosphate intake were modified according to serum 
biochemistry and kidney function (Abbott, Glanton et al. 2004; Renal Association 2007).    
 
Adherence to dietary recommendations was monitored from the patients’ food diaries - 
written food intake records every month for up to 6 months.  At each visit, dietary 
education was provided as required, using a range of standardised modules (Table 2) with 
 
Table 2: Standardised dietary education modules used in the Renal Weight Management 
Programme 
Size Matters – portion control Identifying high risk situations 
Eating a low fat diet Meal Plan 
Low fat cooking + quick recipes booklet Problem solving techniques 
Eating Out Keeping going 
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written information and practical exercises plus visual content.  Patients generated at least 2 
dietary goals each month from baseline to month 6, facilitated by motivational interviewing 
techniques used by the dietitian (Miller and Rollnick 2002) 
Exercise Intervention 
Personal exercise plans were developed based on the patient’s individual current level of 
exertion and co-morbid conditions, and incorporated aerobic and muscular endurance 
activities to improve functional capacity and increase energy expenditure.  Frequency was 
at least 3 days/week, exercise duration was increased as tolerated up to 60 minutes, and 
intensity was set at Borg’s Scale of Perceived Exertion level of “somewhat hard” to “hard” 
(Borg 1998).  The exercise plan was adapted at each monthly visit in line with 
improvements in exercise capacity to facilitate a progressive training effect. 
 
Pharmacotherapy 
Patients were prescribed orlistat at the standard dose of 120 mg 3 times/day throughout 
the study.  Orlistat is a locally acting gastrointestinal lipase inhibitor that reduces the 
absorption of dietary fat by approximately 30%.  On-going education about the mechanism 
of action and the importance of limiting dietary fat intake to reduce the gastrointestinal side 
effects associated with the drug’s inhibition of dietary fat absorption was provided. 
 
Study endpoints  
The primary endpoint of the study was the combined event rate of all cause mortality, and 
the first occurrence during the study period of a cardiovascular event.  A cardiovascular 
event was defined as myocardial infarction, stroke or congestive heart failure requiring 
hospitalisation and treatment with ionotropes, vasodilators or diuretics. 
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Events were recorded from electronic patient medical records during the retrospective data 
collection period between December 2010 and March 2011.  Electronic patient records 
include details of patient medical history, current and previous medications, hospital 
admissions, details of events occurring between regular nephrology clinical out-patient 
visits, and date of death. 
 
The secondary endpoints were placement on the waiting list for kidney transplantation and 
all cause mortality.  Records of kidney transplantation status, including waitlisting were 
recorded in the study database from the renal speciality electronic patient database records.   
 
Measurements and Definitions 
A retrospective analysis of prospectively collected data was performed.  Baseline and 
follow up data were collected and recorded prospectively by the candidate for all patients 
from their initial WMP clinic appointment between January 2005 and December 2009, with 
final data for cardiovascular events and mortality recorded between December 2010 to 
March 2011.   
  
Demographic data including age, gender, ethnicity, weight history, estimated kidney 
function, and treatment clinic modality were collected at baseline.  Height was measured to 
the nearest 0.01 m using a fixed stadiometer.  Body weight was measured to the nearest 0.1 
kg in light clothing on a digital scale, and BMI was calculated as weight (kg)/height (m)2.  
For dialysis patients, estimated oedema free body weight was recorded at each clinic visit.  
Resting sitting BP was recorded using an automated sphygmomanometer and an 
appropriate-sized cuff.  Kidney function was assessed by eGFR, for all patients except 
those undergoing dialysis, and was calculated with the 4-variable Modification of Diet in 
Renal Disease (MDRD) Study equation using serum creatinine, age and sex, and corrected 
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for ethnicity (Levey, Bosch et al. 1999; Levey, Greene et al. 2000).  Patients were classified 
to a stage of CKD according to the National Kidney Foundation (NKF) Kidney Disease 
Outcomes Quality Initiative definition (2002).  Attendance at each of the 9 WMP sessions 
was documented for each patient.  The number of WMP visits attended, body weight, 
weight change, orlistat use, orlistat side effects, and co-morbidities, were recorded 
prospectively at WMP visits, for up to 12 months.   
 
Baseline for patients in the CON group was defined as the date of the initial information 
session the patient was invited to attend.  Body weight, height, BMI, eGFR (for non-
dialysis patients), treatment clinic modality, and body weight 12 months after baseline, were 
extracted retrospectively from electronic medical records.    
 
Hypertension status and diabetes status were determined for all patients at baseline.   
Hypertension status was defined as systolic BP > 140 mm Hg or diastolic BP > 90 mm 
Hg; or > 130/80 mm Hg in patients with proteinuria or diabetes; or the patient was 
prescribed at least one of the following classes of antihypertensive agents:  angiotensin 
converting enzyme inhibitors, angiotensin receptor II blockers, beta-receptor blockers, 
calcium-channel blockers and thiazide-type diuretics.   Hypertension was actively treated 
with multiple agents in WMP and CON groups and during follow up attending physicians 
could openly modify antihypertensive agents.   
 
Diabetes status was defined as the presence of type 1 or type 2 diabetes recorded in the 
electronic medical record or self-reported by the patient, or prescription of medication for 
controlling blood glucose level from any one or more of the following classes of drugs for 
the treatment of diabetes: sulphonylureas, biguanides, glitazones, DPP4 inhibitors/incretin 
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Data were analysed with SPSS version 17.0 (SPSS; Chicago, IL).  Normally distributed 
variables were expressed as mean ± standard deviation (SD), and skewed distributions 
reported as median (interquartile range, IQR).    
 
In order to detect a 33% reduction in the expected combined event rate in the WMP group 
with 70% power and accepting a 5% probability of type 1 error, with a ratio of one to one 
for intervention to control participants, 230 patients were required in each group.  This 
calculation was based on a combined event rate of 30% in the sample population of obese 
patients with CKD and an assumption that the event rate would be reduced to 20% in the 
WMP group.   
 
Comparisons between groups were performed using Student t-tests for normally 
distributed, or Mann-Whitney U tests for non-parametric, continuous variables and Chi 
squared tests for categorical variables, with Fisher’s Exact Test for categorical variables 
with small cell counts (< 5 per group). 
 
Univariate analyses of both the time to the combined event and the time to all cause 
mortality alone were conducted.  Kaplan Meier curves were constructed and log rank tests 
were performed to determine if the time to the combined event or mortality alone differed 
between groups.  Further modelling was then performed to determine the effect of co-
variants on the unadjusted model, using multivariable Cox regression analyses.  The crude 
model was adjusted for diabetes, hypertension, eGFR ≥ 15 ml/min/1.73m2, age, gender, 
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ethnicity, baseline BMI and 12-month weight change.  Hazard ratios (HR) were reported 
with 95% CI.  
 
Logistic regression modelling was performed to determine whether listing for kidney 
transplantation during the study follow-up period differed between the WMP and CON 
groups.  Patients with a functioning kidney transplant and those with stages 1 and 2 CKD 
were excluded, as they were unlikely to require kidney transplantation over the period of 
the study.  Other factors included in the model were baseline BMI, age, gender, ethnicity 




369 patients were referred to participate in the WMP over the study period.  Nine patients 
with baseline BMI < 28 kg/m2 were excluded.  185 (51.4%) patients elected to join the 
WMP and 175 (48.6%) patients did not enrol in the WMP, and became the observational 
control (CON) group (Figure 5).  Three patients were excluded due to missing data, and 4 
patients were excluded, 1 for each of the following reasons: sleeve gastrectomy weight loss 
surgery during study period; concurrently prescribed exenatide, an incretin mimetic agent 
known to induce weight loss (Waugh, Cummins et al. 2010); pregnancy at 12 month follow 
up; and significant worsening oedema through the study.  All 15 patients on peritoneal 







groups (13/15 in WMP and 2/15 in CON), leaving 169 patients in the WMP group and 
169 patients in the CON group at baseline.  
	  
The mean age of participants was 52.0 (±12.8) years, with a median BMI of 35.3 (28.7 to 
41.9) kg/m2.  55% were male, 47% were White and 40% were Black, with the remaining 
13% defined as Asian or other ethnicity.  94% of patients were hypertensive and 44% had 
diabetes.  There were no significant differences between groups for age, BMI, gender, 
Patients referred to the renal Weight Management 
Programme at King’s College Hospital 
n= 369 
Commenced weight management 
programme (WMP) 
n=185 
Elected not to commence weight 
management programme 
n=175 
Included in analysis for WMP group 
n=169 
Included in analysis for control 
(CON) group 
n=169 
Ineligible as BMI <28 kg/m2 
n=9 
Excluded n=6 
 Peritoneal dialysis n=2 
 Exenatide use n=1 
 Pregnancy n=1 
 Missing data n=1 
 Oedema n=1 
 
Excluded n=16 
            Peritoneal dialysis n=13 
            Sleeve gastrectomy n=1 
            Missing data n=2 
 
Figure 5: Flowchart outlining the process of deriving the study sample population of obese patients with 
chronic kidney disease 
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ethnicity, hypertension status, or renal treatment modality at baseline (Table 3).  The CON 
group included more patients with diabetes than the WMP group (49% vs 38%, p = 0.03). 
	  
Table 3: Baseline characteristics (mean ± SD, % or n) of obese patients with chronic kidney disease 








(n = 169) 
p 
Age (yrs)  52.3 ± 12.9 53.3 ± 12.7 0.478 
Gender Male (%) 51 58 0.184 
Female (%) 49 42  
Ethnicity 
(n) 
White 81 79 0.837 
Black 65 70  
Asian 19 15  
Other 4 5  
Treatment 
modality  
Nephrology or Renal-       
Diabetes Clinic 
72 82 0.113 
(n) Pre-dialysis Clinic 48 31  
 Post Transplantation 28 26  
 Haemodialysis 21 30  
Diabetes (%) 38 49 0.03 
Hypertension (%) 92 96 0.167 
Body Mass Index (kg/m2) 36.6 (± 5.3) 34.5 (± 5.1) 0.17 
n, number of patients; SD, standard deviation 
 
After 12 months, the mean (±SD) weight loss in all patients who commenced the WMP 
was 4.3 kg (± 5.5 kg) and 1.9 kg (± 6.6 kg) in all patients in the CON group (p = 0.001).  
 
Over the 6 years of cohort observation, the median follow up period was 32.1 (6.5 to 57.5) 
months, and 55 events occurred.  The combined event rate was 12% in the WMP group 
and 20% in the CON group (p=0.055) (Table 4), therefore the absolute event rate was 40% 
higher in the CON group than the WMP group.  Univariate analysis of time to the 
combined outcome of all cause mortality and cardiovascular morbidity, using Kaplan Meier 
analysis with log rank test, demonstrated a significantly longer time to event in the WMP 
group, compared to the CON group (p = 0.032), indicating that participation in the WMP 
is associated with improved survival.  The Kaplan Meier curves began to separate within 12 
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months and remained so for up to 60 months (Figure 6) although the curves did begin to 
converge again after 5 years. 
 
Table 4: Combined all cause mortality and cardiovascular morbidity in obese patients with chronic 





(n = 169) 
Control (CON) 
 
(n = 169) 
p 
Combined Event 21 34 0.055 
 Death 11 21 0.06 
 MI 4 7 0.54 
 Stroke 5 2 0.45 
 CHF hospitalisation 1 4 0.37 
MI - myocardial infarction; CHF congestive heart failure 
 
 
Figure 6: Kaplan Meier curves of combined all-cause mortality and cardiovascular morbidity in 
obese patients with chronic kidney disease referred to a weight loss programme 2005-2009 (p = 0.032 
for log rank test) 
 
Cox Regression modelling was used to determine the effect of participating in the WMP on 
the time to the combined event using unadjusted and multivariable models.  Possible 
confounding variables were added to the model one at a time in the following order: 
diabetes, hypertension, eGFR (≥ 15 ml/min/1.73m2 when compared to < 15 
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ml/min/1.73m2, including haemodialysis), age + gender + ethnicity, and baseline log-
transformed BMI (Table 5). 
	  
Table 5: Hazard ratios for combined mortality and cardiovascular morbidity outcome in obese 
patients with chronic kidney disease attending the Weight Management Programme from 2005-2009 
Model   β  (Hazard 
ratio)  
95% CI for β  P  
1  unadjusted model of WMP 
compared to CON 
0.556  0.32 to 0.96  0.032  
2  Model 1 + Diabetes  0.612  0.35 to 1.06  0.078  
3  Model 2 + Hypertension  0.588  0.34 to 1.02  0.059  
4  Model 3 + eGFR 
≥15ml/min/1.73m2  
0.539  0.31 to 0.93  0.028  
5  Model 4 + age + gender + 
ethnicity 
0.482  0.28 to 0.84  0.010  
6 Model 5 + baseline BMI  0.452 0.26 to 0.80 0.007 
CI, confidence interval; CON, control group; eGFR, estimated glomerular filtration rate; BMI, body mass index; WMP, 
weight management programme group 
 
In the unadjusted analysis, participation in WMP predicted a longer time to the combined 
event of all-cause mortality and cardiovascular morbidity, compared to the CON group 
(model 1).   This association was weakened after adjustment for diabetes and hypertension 
(models 2 and 3).  In models 4 and 5, additional adjustment for kidney function, age, 
gender and ethnicity strengthened the model and patients in the WMP group continued to 
be less likely to experience a shorter time to the combined outcome of death or 
cardiovascular event than those in the CON group (Model 5 adjusted HR 0.482, 95% CI 
0.28 - 0.84; p = 0.01).  After further adjustment for log-transformed baseline BMI (model 
6) the association between a longer event-free period for the combined event in the WMP 
group (adjusted HR 0.452, 95% CI 0.26 - 0.80; p = 0.007), was maintained.   
 
An additional model was created to include adjustment for 12-month weight change 
(model 6 plus 12 month weight change).  The association between improved survival and 
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the WMP group was attenuated with adjustment for weight change, but remained 
significant (adjusted HR 0.519, 95% CI 0.28 - 0.97; p = 0.04).   
 
In order to establish the robustness of the relationship between survival and attendance at 
the WMP, the Kaplan Meier Analysis with log-rank test was repeated for all cause mortality 
alone, to remove any bias occurring through the adjudication of the classification of the 
pre-determined cardiovascular events measured, and remained significant (p = 0.024).  The 
fully adjusted multivariable Cox Regression model suggests that WMP participants were 
less likely to have a shorter time to death than those in the CON group (adjusted HR 
0.378, 95% CI 0.172 - 0.829; p = 0.015), after adjustment for diabetes, hypertension, kidney 
function, age, gender, ethnicity and log-transformed baseline BMI. 
 
During the study observation period, 131 patients otherwise met the criteria for kidney 
transplantation waitlisting, except for BMI, and 68 were in the WMP group and 63 in the 
CON group.  19 patients in each group were added to the kidney transplantation waiting 
list, which was 28% of the eligible WMP group and 30% of the eligible CON group (p = 
0.78).   7/68 patients (10%) in the WMP group and 10/63 patients (16%) in the CON 
group underwent kidney transplantation during the study period. 
 
The logistic regression analysis examining factors related to kidney transplantation 
waitlisting, compared to not waitlisting for kidney transplantation, is summarised in Table 
6.  Participation in the WMP did not increase the likelihood of kidney transplantation 
waitlisting (OR 1.06, 95% CI 0.39 - 2.87; p = 0.91).  Lower baseline BMI and greater 
weight loss over 12 months were the only factors related to kidney transplantation 
waitlisting (adjusted R2 = 0.426).  For every 1.0 kg/m2 increase in baseline BMI, the 
likelihood of kidney transplant waitlisting decreased by 33%, and for every 1.0 kg of weight 
 86 
loss achieved over 12 months, the likelihood of transplant waitlisting increased by 15%.  
Age, gender, and ethnicity did not affect the likelihood of kidney transplantation waitlisting 
in this study.   The likelihood of multicolinearity in the model was low assessed by 
examining the poor correlation between variables and the size of the standard error of the 
mean for all variables.  The correlations between variables were poor and the standard 
error of the mean was less than 5 for all variables, indicating mulicolinearity was not 
present in the model. 
 
Table 6: Multivariable logistic regression for factors related to qualifying for listing for kidney 
transplantation in obese patients with chronic kidney disease referred to a weight loss programme 
2005-2009 
Parameter Odds Ratio (β) 95% CI for β P 
Group (WMP compared to 
CON) 
1.06 0.39 to 2.87 0.91 
Baseline BMI  0.67  0.56 to 0.80 <0.001 
Weight loss during first 12 
months  
1.15 1.05 to 1.26 0.003 
Age 0.97 0.97 to 1.02 0.25 
Gender  1.82 0.67 to 4.96 0.24 
Ethnicity 0.65 0.23 to 1.85 0.42 
WMP - weight management programme; CON - control group; BMI - body mass index; CI - confidence interval; Group 




This study has examined and compared the time to the combined outcome of all-cause 
mortality and cardiovascular morbidity in a population of obese patients with CKD who 
were referred for weight loss treatment.  There were significantly more primary events in 
the CON group than in the WMP group.  Patients who elected to join the WMP were 
significantly more likely to have a longer event-free period than those in the CON group, 
who chose not to participate in the structured weight loss programme, even after 
adjustment for possible confounding variables including baseline co-morbidities, age, 
gender, ethnicity, baseline BMI, kidney function, and weight change.  To the candidate’s 
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knowledge, this is the first study to report on participation in a weight loss programme and 
the combined outcome of mortality and cardiovascular morbidity in obese patients with 
CKD.  Furthermore, this study did not show any impact of participation in a weight loss 
programme on the likelihood of being wait-listed for kidney transplantation.     
 
The relationship between the combined outcome of all cause mortality and cardiovascular 
morbidity (defined as the occurrence of myocardial infarction, stroke, or hospitalisation for 
congestive heart failure) and participation in a structured weight loss programme for 
patients with CKD appeared to be partially attributable to the known risk factors for 
cardiovascular disease; diabetes and hypertension.  Correction for these 2 factors 
attenuated the relationship between WMP participation and the combined outcome, 
however further adjustment for age, gender and ethnicity counterbalanced the influence of 
diabetes and hypertension, and the relationship regained significance.  Furthermore, when 
the model was corrected for kidney function, the adjusted HR for the relationship between 
treatment group and combined mortality and cardiovascular morbidity continued to 
demonstrate an advantage for patients participating in the WMP.  Given that there is a 
known greater mortality and increased risk of cardiovascular disease as kidney function 
declines (Schiffrin, Lipman et al. 2007; Weiner, Tighiouart et al. 2007), this indicates that 
participation in the WMP may be protective for patients with all levels of kidney function.  
 
Importantly, there was no apparent disadvantage to participating in a weight loss 
programme for obese patients with CKD, regardless of kidney function.  Epidemiological 
studies demonstrate a survival advantage attributable to higher BMI in patients with kidney 
failure requiring haemodialysis (Abbott, Glanton et al. 2004; Johansen, Young et al. 2004; 
Kalantar-Zadeh, Kopple et al. 2005; Kalantar-Zadeh, Streja et al. 2010), although not all 
studies support this relationship.  Higher muscle mass may be protective, and further 
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adjustments for age and increasing the length of study follow up ameliorate the relationship 
between higher BMI and survival (Beddhu, Pappas et al. 2003; de Mutsert, Snijder et al. 
2007; Hoogeveen, Halbesma et al. 2012).   The finding in this study that participation in the 
WMP may be protective for all patients with CKD, including patients with stage 5 CKD on 
haemodialysis, supports the conclusions of the latter studies (Beddhu, Pappas et al. 2003; 
de Mutsert, Snijder et al. 2007; Hoogeveen, Halbesma et al. 2012), and may indicate that 
high levels of body fat are not necessarily protective in haemodialysis.  Therefore, 
participation in weight loss programmes by obese patients requiring haemodialysis should 
not be discouraged.   
 
Whilst the findings in studies of weight loss and survival in the overweight and obese 
apparently healthy population are equivocal, previous studies examining the relationship 
between all cause mortality, cardiovascular mortality or cardiovascular morbidity and 
intentional weight loss in overweight and obese patients with existing co-morbidities 
indicate that weight loss may be beneficial for long term outcomes (Williamson, Thompson 
et al. 2000; Eilat-Adar, Eldar et al. 2005; Caterson, Finer et al. 2012).  The findings of the 
present study concur with these studies and support the hypothesis that intentional weight 
loss is likely to be beneficial when existing co-morbidities known to increase cardiovascular 
disease risk are already present.    
 
The relationship between CKD and cardiovascular disease is bi-directional (Stenvinkel, 
Carrero et al. 2008), and cardiovascular risk increases progressively with declining kidney 
function (Vanholder, Massy et al. 2005).  Mechanisms of cardiovascular complications in 
CKD are related to inflammation, increased circulation of cytokines, endothelial 
dysfunction, activation of the renin-angiotensin system and impaired bone mineral 
metabolism (Schiffrin, Lipman et al. 2007).  Weight loss in obese patients without CKD 
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has been associated with reduction in the inflammatory markers IL-6 and CRP (Gallistl, 
Sudi et al. 2001), improved insulin sensitivity, and increased adiponectin (Esposito, Pontillo 
et al. 2003), reduced endothelial dysfunction (Pierce, Beske et al. 2008), and a reduction in 
carotid vessel wall volume, an emerging measure of carotid atherosclerosis (Shai, Spence et 
al. 2010).  Dietary restriction plus orlistat led to greater reductions in triglycerides and 
inflammatory markers, than dietary restriction alone, in obese women during a 6-month 
weight loss programme (Bougoulia, Triantos et al. 2006), and our previous work has 
suggested that a reduction in systolic BP was related to increased adherence to the WMP in 
obese patients with CKD (MacLaughlin, Sarafidis et al. 2012).  As these cardiovascular risk 
factors were not measured in the present study, it is not possible to suggest which, if any, 
of these changes occurred in patients participating in the WMP, and what the effect on 
macro- and micro-vascular disease may be over the study observation period, as 
improvements in many of these factors is likely to be associated with a slowing of the rate 
of progression of cardiovascular disease over decades, rather than over a shorter term.  
However, a reduction in carotid vessel wall volume was evident over 2 years with modest 
weight loss of 5 kg and associated most strongly with a reduction in BP (Shai, Spence et al. 
2010), indicating that changes brought about by weight loss can influence atherosclerotic 
processes over the relatively short term.  
	  
Weight loss in kidney transplantation waitlisted haemodialysis patients has been associated 
with increased mortality (Molnar, Streja et al. 2011).  However, this finding was generated 
in a study not restricted to overweight and obese patients, and the weight loss observed 
was deemed to be unintentional (Molnar, Streja et al. 2011), which is known to be 
associated with mortality in patients requiring haemodialysis (Campbell and MacLaughlin 
2010).  The slight attenuation of the relationship between the combined mortality and 
cardiovascular morbidity outcome following adjustment for weight loss in the present 
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study may indicate that some degree of unintentional weight loss occurred in the control 
group; but it is more likely that the attenuation of the effect indicates that weight loss is 
one, but not the only, contributing factor to the risk reduction.  
 
The study did not achieve its target sample size of 230 patients in each group.  However, as 
the actual difference in the combined event rate between the WMP and CON groups was 
40%, rather than the predicted 33%, a smaller sample size was adequate to demonstrate a 
significant treatment effect for participation in the WMP on all cause mortality and 
cardiovascular morbidity in both unadjusted and adjusted regression models.      
 
There was no difference in the number of patients qualifying for kidney transplantation 
waitlisting between the WMP and CON groups, over the course of the study.  Baseline 
BMI and weight loss over 12 months were the only variables related to kidney 
transplantation waitlisting in this study.  Further analyses of the baseline BMI and weight 
loss in the CON group patients achieving transplant waitlisting during the study support 
this finding.  Mean weight loss in those patients who were listed for kidney transplantation 
during the study was 5.0% in the WMP group and 4.3% in the CON group.  Therefore, the 
level of weight loss in CON group patients who were waitlisted for kidney transplantation, 
was similar to the 4.5% weight loss achieved in the WMP group overall, and was 
substantially greater than the overall mean weight loss in the CON group.  Patients who 
were listed for kidney transplantation in the CON group, had a mean baseline BMI of 31.6 
kg/m2, compared with the overall mean baseline BMI of 34.5 kg/m2 for the CON group.  
Kidney transplant waitlisting may be a sufficient motivating factor to assist obese patients 
to lose weight, as weight loss, rather than participation in the WMP, was related to kidney 
transplantation waitlisting in this study.  It should also be noted that kidney transplantation 
waitlisting is not dependent upon BMI or weight loss alone, as cardiovascular status, age, 
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cause of kidney disease, functional status and co-morbidities are also considered (Segev, 
Simpkins et al. 2008) when assessing eligibility for kidney transplant waitlisting.  
 
There are several limitations to this study which should be acknowledged.  The major 
limitation of this study is that allocation to treatment or control was not randomised, 
therefore, the relationship between treatment and the combined outcome cannot be 
directly attributed to participation in the WMP.  By design, this study cannot account for 
unmeasured factors or residual confounding, and factors such as the ability to travel to the 
hospital based clinic in order to participate in the WMP, socio-economic status, literacy and 
education level, social supports and motivation to change lifestyle related health 
behaviours, may account for the relationship observed.   Additionally, the dataset is 
relatively small for a time to event analysis, so the number of factors able to be included in 
a multivariable adjusted model of risk must be limited, to avoid overcorrection of the 
model and obtaining a statistically significant relationship by chance.  However, the size of 
the sample is reasonably large for a weight loss intervention carried out in a single centre, 
and there is a reasonably even distribution of patients with all stages of CKD within each 
group.  Furthermore, the groups are well matched at baseline for characteristics likely to 
impact upon the primary outcome of all cause mortality and cardiovascular morbidity, 
apart from the prevalence of diabetes, which was higher in the CON group.  Together, 
these attributes reduce the likelihood that the relationship between commencing a weight 
loss programme and achieving a longer combined-event free period, is due to confounding 
or chance.  The question of whether the relationship is due to an unmeasured variable, 
such as motivation to lose weight and adopt healthier behaviours such as increasing 
physical activity, can only be addressed by a randomised controlled trial, where these 
factors are likely to be equal across all groups studied.  A randomised controlled trial of 
weight loss interventions in obese patients with CKD powered to examine the effect of 
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weight loss or participation in a weight loss programme on survival, would have the added 
benefits of being sufficiently robust to examine a number of secondary outcomes that may 
impact upon the primary event, and hence may contribute to determining the mechanisms 
involved in the decreasing risk of cardiovascular morbidity or all cause mortality.    
 
Other limitations of the present study include the absence of correction for existing 
cardiovascular disease, statin use and albuminuria.  A new meta-analysis found that statin 
use is associated with decreased mortality in patients with stages 1-4 CKD (Palmer, Craig et 
al. 2012), and albuminuria has also recently been found to contributed to mortality risk in 
patients with CKD (Hallan, Matsushita et al. 2012), however neither of these associations 
were known at the outset of the study.  Statin use is highly prevalent in this study 
population and the majority of patients would have been prescribed statin therapy, and as 
information on albuminuria status is inconsistent across all stages of CKD in clinical 
practice, it was not included in the dataset.  Similarly, as the major risk factors for 
cardiovascular disease - hypertension, diabetes, and CKD - were included in the adjusted 
analyses, additional correction for existing cardiovascular disease may have over corrected 
the model, due to the likely high co-linearity with the predisposing risk factors listed above.  
Furthermore, any deaths or events occurring early in the observation period are unlikely to 
have been altered by the lifestyle changes or weight loss, and conversely, this study was also 
unable to elucidate any information on the time lag between lifestyle changes being made, 
weight loss occurring, and the observed reduction in risk of a shorter time to the combined 
endpoint following participation in the WMP.  The study results may not be generalisable 
to the wider population of obese patients with CKD, as the study was conducted in a single 
urban centre.  Additionally, the sustainability of the weight loss achieved after 12 months 
has not been explored in this study, although we have previously reported sustained weight 
loss up to 2 years in patients attending the WMP (MacLaughlin, Cook et al. 2010). 
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This study also has a number of strengths, particularly the robustness of the databases used 
to retrospectively collect data for the CON group, the use of a standardised, structured 
weight loss intervention delivered predominantly by a single experienced renal dietitian and 
a single experienced renal physiotherapist to the WMP group, and the continued 
observance of a significant relationship between the primary outcome and the WMP 
intervention even after accounting for potential confounding variables.  The significant 
relationship between the combined outcomes of cardiovascular morbidity and all cause 
mortality, and participation in the WMP, remained significant when the analysis was 
repeated for all cause mortality alone, which removes any adjudication bias inherent in 
classifying cardiovascular disease events. 
 
Participation in a structured weight management programme is associated with a reduction 
in the risk of a shorter time to the combined outcome of cardiovascular events and all 
cause mortality, yet has no impact upon the likelihood of kidney transplant waitlisting in 
obese patients with chronic kidney disease.  Obese patients with CKD should be offered 
the opportunity to participate in a structured weight loss programme, given the probable 
association with cardiovascular protection demonstrated in this study.  As the association 
evident in this observational study cannot be directly attributable to participation in the 
WMP, future research using adequately powered randomised controlled trials to determine 
the impact of weight reduction programmes on patient outcomes, including all cause 
mortality, cardiovascular morbidity and progression to end stage kidney disease, is 
warranted.  In particular, further investigations to determine the impact of intentional 
weight loss treatments on survival in obese patients requiring haemodialysis treatment are 
recommended. 
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Chapter 3: Laparoscopic sleeve gastrectomy  - a novel 




Obesity increases the risk of progression of chronic kidney disease (CKD) and kidney 
failure, and may preclude access to kidney transplantation.  Weight loss surgery remains 
relatively novel in obese patients with CKD, with several studies reporting results using 
Roux-en-Y bypass and adjustable gastric banding; however, the safety of these techniques 
in obese patients with CKD is not certain, as kidney damage after bypass surgery and band 
erosion and migration after kidney transplantation have been reported in obese patients 
with CKD.  This is the first study to describe the outcomes of the laparoscopic sleeve 
gastrectomy (LSG) technique in obese patients with CKD.  
 
Weight loss, blood pressure, lipid profile, estimated kidney function, surgical complications, 
and adverse events were studied in the first 9 patients with CKD undergoing LSG from 
March 2007 to August 2010.  Median excess BMI loss was 31% after 3 months and 49% 
after 6 months.  4/9 patients reduced anti-hypertensive medications.   4/5 patients on 
haemodialysis were added to the kidney transplantation waiting list after weight loss 
achieved post LSG.  3 adverse events occurred: myocardial infarction, acute kidney injury 
secondary to dehydration and compromised dialysis access.  1 patient also developed a 
gastric leak, detected 7 months after LSG, requiring further surgery and naso-jejunal 
feeding.  Preliminary evidence suggests that sleeve gastrectomy is an effective treatment for 
obesity in patients with CKD.  However, there may be additional risk associated with the 
procedure in patients with CKD, requiring further study.   
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Introduction 
Obesity is associated with CKD progression and kidney failure, and whilst the exact 
mechanisms remain unknown, inflammation, dyslipidaemia, insulin resistance, and 
hypertension contribute to obesity related kidney damage (Becker, Kronenberg et al. 2005; 
Kramer, Luke et al. 2005; Hsu, McCulloch et al. 2006; Axelsson 2008; Teplan, Vyhnanek et 
al. 2010).  Current practice guidelines for nutritional intervention in CKD provide very 
little guidance on the management of obesity in patients with CKD and the evidence is 
gleaned from epidemiological studies rather than clinical intervention trials (Fouque, 
Vennegoor et al. 2007; Holman, Paul et al. 2008; Wright and Jones 2010; Masoomi, Kim et 
al. 2011).    
 
Sleeve gastrectomy is a relatively novel form of restrictive weight loss surgery in which a 
tube-like stomach is created after two-thirds subtotal gastric resection of the fundus and 
body (Figure	  7), and is usually performed laparoscopically (ASMBS Clinical Issues 
Committee 2009).   
 
Figure 7: Diagram depicting sleeve gastrectomy 
 
Obesity has been identified as a risk factor for the development and progression of CKD, 
yet well designed weight loss intervention studies are lacking.  To date, studies on weight 
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loss surgery in obese patients with CKD have only examined gastric bypass and gastric 
banding surgical techniques, and detrimental effects related to the kidney have been 
reported with both procedures.  LSG is emerging as a novel surgical operation for weight 
loss that is as effective as gastric bypass for weight loss and cardiovascular risk reduction 
(Benaiges, Goday et al. 2011), and is known not to be associated with nephrolithiasis, a 
recently apparent complication emerging as a barrier to performing gastric bypass in obese 
patients with CKD (Nelson, Houghton et al. 2005; Sinha, Collazo-Clavell et al. 2007; Nasr, 
D'Agati et al. 2008; Semins, Asplin et al. 2010) .  Therefore, it appears reasonable to 
cautiously explore the use of LSG in the treatment of obesity in patients with CKD, 
initially with a small case series study of patients electing to undergo LSG and to report on 
observed weight loss and complications, with a view to conducting a set of prospective, 
controlled, intervention studies in this population. 
   
Study Aim 
To date, the safety and effectiveness of sleeve gastrectomy for the treatment of obesity in 
patients with CKD has not been reported in the literature.  This study aims to describe the 
first case-series of obese patients with CKD undergoing sleeve gastrectomy, performed in a 
single centre in the United Kingdom.  The study reports on the extent of weight loss 
achieved, and documents the surgical complications and post-operative adverse events over 
the observation period.    
 
Hypothesis 
Laparoscopic sleeve gastrectomy in obese patients with CKD results in weight loss 
equivalent to that reported in the literature for other patient groups undergoing this 
treatment for obesity. 
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Methods 
In order to provide evidence on the efficacy and safety of the LSG in obese patients with 
CKD, prior to the conduction of planned controlled intervention studies, a retrospective 
review of written and electronic medical records for consecutive patients with CKD, under 
the care of a nephrologist, who underwent LSG for weight loss between March 2007 and 
August 2010 at King’s College Hospital, London, was conducted.  All patients under the 
care of a nephrologist at King’s College Hospital have records of clinic visits, hospital 
admission, results of investigations and letters to other medical professionals stored on two 
electronic databases.  Prospective dietetic care records were kept for all patients and the 
databases were searched for the predetermined information from dietetic records, and 
records of routine surgical or nephrology appointments.  The study was classified as audit 
and therefore deemed not to require full ethical review and was approved by the King’s 
College Hospital Research Ethics Committee.   
 
The pre-specified measures selected to be examined were peri-operative length of hospital 
stay, post operative inflammatory response (C-reactive protein), all post surgical 
complications, weight loss, BP, triglycerides, and serum cholesterol, antihypertensive and 
lipid lowering medication changes, eGFR using the 4 variable Modification of Diet in 
Renal Disease Study equation in patients in stages 1-4 CKD (Levey, Bosch et al. 1999; 
Levey, Greene et al. 2000), kidney transplantation wait-listing, and all adverse events 
occurring during the follow-up period.  Complications may include gastrectomy leak, 
bleeding requiring transfusion or invasive intervention, and 30-day mortality.  Possible 
adverse events included compromised dialysis access, cardiovascular events including 
myocardial infarction, cardiac arrhythmia and stroke, acute kidney injury and re-
hospitalisation during the study period.  Data collection was completed between December 
2010 and March 2011. 
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Weight loss measures are defined in Table 7.   
 
Table 7: Definitions of weight loss parameters to define weight loss in patients undergoing 
laparoscopic sleeve gastrectomy 
Parameter Definition 
Absolute weight loss (kg) Body weight at baseline (kg) - body weight at defined time point (kg) 
 
% Weight loss [Absolute weight loss (kg)/body weight at baseline (kg)] x 100 
 
% Excess BMI loss [Absolute weight loss/difference between baseline BMI and BMI = 25 
kg/m2] x 100 
 
% Excess weight loss [Absolute weight loss/difference between baseline weight and the mid point 
of the 1983 Metropolitan Life Insurance Tables for medium build)] x 100 
(Deitel, Gawdat et al. 2007) 
 
BMI – body mass index (weight (kg)/height (m)2) 
 
All patients underwent a routine pre-operative evaluation prior to surgery.  This assessment 
included an evaluation of medical history, potential contraindications to surgery including 
individual patient anaesthetic risk, cardiac risk, wound healing risk secondary to diabetes or 
blood disorders, as well as outlining the known risks and benefits of the procedure in obese 
patients who do not have CKD.  Patients were provided with written information on the 
procedure and were given the opportunity to ask questions. 
 
A single experienced surgeon performed the LSG in all patients.  6 trocars were utilised 
and LSG was performed with standard techniques using a 38 French bougie.  After 
devascularisation of the greater curvature, the sleeve gastrectomy commenced 4 - 6 cm 
proximal to the pylorus on the greater curvature and continued towards the angle of His.  
The completed staple line was reinforced with sutures.  Post operatively, all patients 
received anti-coagulation therapy and wore compression stockings for embolism 
prophylaxis.  Within 3 – 6 days post-operatively, gastrograffin meal and follow-through 
analyses were performed for all patients to observe pyloric emptying function and 
methylene blue dye tests were carried out on patients with post-operative drains in situ to 
detect gastric leak.   
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Post-operative dietary education was provided by dietitians experienced in the dietary 
management of either weight loss surgery or CKD, but not both, due to the novelty of this 
procedure in patients with CKD.   Post operative diet consisted of fluids only for 4 weeks, 
pureed consistency foods for a further 2 - 4 weeks, followed by soft foods for an additional 
4 weeks, then the gradual return to normal foods in reduced portions.  Consumption of at 
least 2 litres of fluid per day was encouraged for patients with CKD not on dialysis.  
Appropriate fluid and intake and electrolyte management was incorporated into the dietary 
education for patients on dialysis on an individual basis due to varying levels of urine 
output and very limited kidney function in these patients. 
 
Protein and energy requirements were estimated for all patients and dietary education was 
individualised to meet these requirements.  Energy requirement was set at between 1 000 - 
1 200 kcal per day for all patients, to induce weight loss, induce satiety and to ensure that 
food intake did not exert excess pressure on the newly formed stomach staple line (Snyder-
Marlow, Taylor et al. 2010).  Protein requirement was established using the NKF-KDOQI 
guidelines of 0.75 g/kg ideal body weight (weight at BMI = 25)/day for patients with stage 
4 CKD (estimated kidney function of 15 – 29 ml/min/1.73m2) and 1.2 g/kg ideal body 
weight (weight at BMI = 25)/day for patients on dialysis (2000).  Patient in stages 1-3 CKD 
were encouraged to have a normal protein intake and not to exceed 1.3 g protein/kg body 
weight/day (Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group 
2013).  High protein liquid nutritional supplement drinks or specialist renal protein powder 
supplements were prescribed for dialysis patients to enable them to meet protein 
requirements within an energy, fluid and electrolyte restricted diet.  All patients received 
renal specific, written information on suitable foods and textures for each stage of the 
modified diet, together with suggested meal plans (Appendix A).    
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Results 
9 patients (3 Male; 6 Female) with CKD, median age 44.0 years, median weight 118.0 kg 
and median BMI 44.2 kg/m2 underwent LSG for treatment of obesity.  Baseline 
demographic and peri-operative data for all patients are listed in Table 8.  5 patients had 
stage 5 CKD and were undergoing chronic haemodialysis.  At the time of surgery, median 
dialysis vintage was 18 months (range 11 - 106 months).  4 patients were in stages 1-4 
CKD, with a baseline eGFR between 18 - 110 ml/min/1.73m2.  In this series, Patient J 
underwent a re-sleeve gastrectomy, after an initial procedure with a larger sleeve was 
performed 3.5 years earlier in another centre, and significant weight re-gain had occurred.  
Patients were followed up for between 6 - 39 months, with a median follow up period of 9 
months.   
 
Table 8: Baseline demographic and peri-operative data for 9 obese patients with chronic kidney 
disease who underwent laparoscopic sleeve gastrectomy for weight loss 











A 44 F 3 40% Porphyria no 147.3 49.8 9 
B 38 F 1 100%, with 
proteinuria 
FSGS no 118.6 46.3 4 
C 39 M 5-HD -­‐  FSGS no 125.0 41.8 16 
D 41 F 5-HD - APKD/DM yes 129.0 47.4 6 
E 53 F 5-HD - DM yes 113.0 36.5 10 
F 41 M 5-HD - HT no 114.0 33.3 9 
G 48 M 5-HD - HT no 140.0 44.2 9 
H 51 F 4 18% IgA no 99.0 43.0 8 
J 60 F 2 65% HT/Obesity no 117.1 46.3 6 
CKD stage: chronic kidney disease stage using KDIGO classification; DM: diabetes; BMI: body mass index (weight (kg)/height (m)2); 
LOS: peri-operative length of stay in hospital; HD: haemodialysis; FSGS: focal segmental glomerulosclerosis; AKPD: adult polycystic 
kidney disease; HT: hypertension; IgA: Immunoglobulin A nephropathy 
 
Median length of peri-operative hospital stay was 9 days (range 4 - 16 days).   Patient A was 
admitted to critical care for < 48 hours post operatively, with reduced kidney function on 
day 1 post-operatively, which recovered on day 2, and patient C required high dependency 
care post-operatively due to a chest infection.  Gastrograffin meal and follow through 
reports were negative for gastric leak in all patients, and delayed stomach emptying was 
observed in patient G.   
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C-reactive protein level rose in the immediate post operative period in all patients, peaked 
at days 4 to 7, but settled back to baseline level by three months.  eGFR fell in 3/4 patients 
in stages 1-4 CKD at day 1-2 post-operatively, but returned to baseline prior to discharge 
in all patients.   
 
There was no 30-day or overall mortality in this case series.  One surgical complication was 
evident in a single patient post-operatively.  Patient E, on haemodialysis, had a normal 
gastrograffin follow-through and methylene blue dye test prior to discharge.  Ongoing 
investigations of a persistently low haemoglobin level that was unresponsive to 
recombinant erythropoietin treatment led to detection of, initially, diverticulitis, and latterly, 
a small gastric leak associated with a subphrenic collection 7 months post-operatively.  
Patient E underwent two further surgical procedures requiring general anaesthesia, 
involving evacuation of the collection, stenting, and re-stenting of the leak via laparoscopy.  
Whilst the leak healed full nutrition was provided with enteral nutrition support with naso-
jejunal feeding for 7 weeks, and then a further 12 weeks after an unsuccessful trial of oral 
intake.   
 
Minor adverse events occurred in 2 of 9 patients, in patient F dialysis access was 
compromised by fistula thrombosis on day 1 post-operatively, requiring angioplasty and 
stenting on day 4 to re-establish permanent dialysis access.  Patient H experienced acute 
kidney injury secondary to dehydration 2 weeks post-operatively, requiring hopsitalisation 
and intravenous re-hydration.  Kidney function, in patient H, remained below baseline for 
2 months but returned to baseline after 3 months.   
 
One major adverse event occurred during the study period.  Patient E displayed non-
symptomatic significant electrocardiogram changes 3 weeks post-operatively suggestive of 
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myocardial infarction with non-Q wave coronary occlusion.   Subsequent angiography 
showed obstruction of the left anterior descending artery, requiring angioplasty and 
stenting.    
 
Weight loss parameters for each patient, and median weight loss, at 3 and 6 months 
following sleeve gastrectomy are presented in Table 9.  Median excess weight loss at 6 
months was 43.0% (range 31.2 - 53.6%).  Figure 8 displays the rate of % excess weight loss 
up to 1 year for each patient.  The rate of weight loss slowed after 3 months in all but 
patient B, who continued with a constant rate of weight loss for 6 months. 
 
Table 9: Weight loss parameters 3 and 6 months post laparoscopic sleeve gastrectomy in obese 
patients with chronic kidney disease 
Patient 
 
Absolute weight loss 
(kg) 
% Weight loss % Excess weight 
loss 
% Excess BMI loss 
 
 months post SG months post SG months post SG months post SG 
 3 6 3 6 3 6 3 6 
A  
21.1 
25.7 14.3 17.4 25.6 31.2 28.8 35.0 
B 16.6 32.3 14.0 27.2 27.6 53.6 30.4 59.2 
C 21.0 25.0 16.8 20.0 37.2 44.3 41.9 49.8 
D 24.6 30.0 19.1 23.3 36.2 44.2 40.4 49.2 
E 14.0 19.8 12.4 17.5 30.4 43.0 39.4 55.7 
F 14.0 14.0 12.3 12.3 35.9 35.9 49.2 49.2 
G 19.0 24.5 13.6 17.5 27.6 35.6 31.3 40.3 
H 13.1 21.0 13.2 21.2 28.5 45.7 30.6 49.1 



















SG – laparoscopic sleeve gastrectomy surgery for weight loss; % excess weight loss = [absolute weight loss/(baseline 
weight – ideal weight using mid point of 1983 Metropolitan Life Insurance Tables for medium frame)] x 100 (Deitel, 
Gawdat et al. 2007); BMI – body mass index [weight (kg)/height (m)2]; % excess BMI loss = [absolute change in 
BMI/(baseline BMI – 25)] x 100 
 
Median systolic BP decreased from 136 mm Hg to 126 mm Hg after 3 months, and there 
was no change in median diastolic BP.  Antihypertensive agents were reduced in 3/7 
patients on anti-hypertensive therapy, ceased in 1/7 patients and were unchanged in the 
remaining 3 patients.  Median serum cholesterol decreased from 5.5 mmol/L to 4.6 
mmol/L and medium triglycerides did not change after 3 months.   3 patients were on 
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statin therapy for lipid lowering at baseline, which was ceased in 1 patient, and remained 
unchanged in 2 patients.   
 
Figure 8: % excess weight loss* after laparoscopic sleeve gastrectomy in 9 obese patients with 
chronic kidney disease 
*% excess weight loss = [absolute weight loss/(baseline weight – ideal weight using mid point of 1983 Metropolitan Life 
Insurance Tables for medium frame)] x 100 
 
Of the 2 out of 9 patients with diabetes, only patient E was on insulin therapy.  The insulin 
dose was decreased from 50 to 38 units/day within 1 month of sleeve gastrectomy, and 
HbA1c improved from 9.0% to 6.1% after 6 months.   
	  
Hyperfiltration decreased in patient A, the only patient with hyperfiltration at baseline, but 
there was no change in estimated kidney function in any other patient following weight loss 
after 6 months.   
	  
Of the 5 patients on haemodialysis, patients C, D, E and F were listed for kidney 























Patient E was then suspended from the kidney transplantation waiting list 2 weeks after 
being listed, due to infection and then remained suspended following the diagnosis of 
gastric leak and subphrenic collection.  At the time of writing, Patient G had not yet been 
listed for kidney transplantation, as weight remained above the target BMI established by 
the transplant surgeon, 12 months after LSG.  
 
Discussion  
This is the first study to describe the weight loss achieved, adverse events and 
complications after LSG in obese patients with CKD.   After 6 months excess BMI 
decreased by 49.2% and excess body weight was reduced by 43.0%.  Systolic BP and serum 
cholesterol decreased, and anti-hypertensive and lipid lowering medications were reduced 
in some patients.  There was no mortality, one major surgical complication and 3 adverse 
events in this series.  This is the first study to support the use of LSG as an efficacious 
treatment for obesity in CKD.     
 
A systematic review of weight loss after sleeve gastrectomy in the general population 
indicates that excess body weight loss is between 36–85%, after a follow-up period of 3–60 
months, including excess weight loss of 35–59% after 6 months (Brethauer, Hammel et al. 
2009). As the median excess weight loss in this series was 43% after 6 months, this suggests 
that the weight loss achieved in patients with CKD is similar to that achieved in patients 
without CKD who have undergone the same weight loss procedure.  Longer-term follow 
up is required to determine whether weight loss is maintained over time.   
 
The rate of weight loss in this series began to differ between patients 3 months post-
operatively, once dietary restriction of all solid foods was no longer necessary. Differences 
in the rate of weight loss between patients became apparent once a larger variety of foods, 
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differing textures and quantities began to be tolerated, indicating that patients may still 
influence their individual degree of weight loss by their chosen food intake, which affects 
total energy intake.   The importance of considering the total weight loss in the context of 
the starting BMI is highlighted in this series by patient F, who still achieved a reduction in 
excess BMI of 49% despite no further weight loss after three months, due to a lower 
starting BMI than the rest of the patients in the series. 
 
Hyperfiltration decreased in one patient, and there was no change in eGFR after 6 months 
in the other 8 patients in this series.  eGFR is calculated using serum creatinine, which may 
fall as body size decreases if muscle mass is reduced as well as fat mass, therefore an 
improvement in eGFR with a reduction in muscle mass with weight loss may be expected 
(Delanaye, Radermecker et al. 2005).  Some studies of Roux-en-Y gastric bypass surgery 
and laparoscopic adjustable gastric banding demonstrate an improvement in eGFR after 6 
and 12 months (Alexander, Goodman et al. 2009; Navaneethan and Yehnert 2009). 
 
1 patient experienced major complications with a late detected gastric leak.  The same 
patient also required angioplasty and stenting of the left anterior descending artery after 
myocardial infarction detected 3 weeks post-operatively.  2 other adverse events occurred, 
although it is not possible to ascertain whether the occlusion of the arteriovenous fistula 
was related to the weight loss surgery or not.   There was no post-operative bleeding 
reported in this series and no evidence of nephrolithiasis or oxalate nephropathy – 
although this would not be expected in a restrictive procedure.  In the general obese 
population, a systematic review suggests major complications occur in 0 - 15.3% of patients 
post sleeve gastrectomy (Brethauer, Hammel et al. 2009).  Whilst it is not appropriate to 
extrapolate the complication rate in patients with CKD from the 9 patients in this series, as 
there were 3 complications and 1 major adverse event reported in a series of 9 patients, it is 
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reasonable to conclude that complications, and possibly unrelated events may be higher in 
obese patients with CKD than in the general population.  As patients with CKD 
demonstrate a higher risk of cardiovascular disease than the general population (Sarnak, 
Levey et al. 2003; Go, Chertow et al. 2004), this poorer vascular health in patients with 
CKD may impact upon healing, wound stabilisation and the cardiovascular event rate 
observed during the study.  Whilst a sub-analysis of 37 patients with ischaemic heart 
disease included in the Swedish Obese Subjects (SOS) study found no greater peri-
operative complication rate compared to obese patients without cardiovascular disease 
(Delling, Karason et al. 2010), recent large observational studies indicate that patients with 
CKD have a higher risk of complications post-operatively for all types of non-emergency 
surgery, and the risk of complications with weight loss surgery increases with higher stages 
of CKD (Nguyen, Masoomi et al. 2011; Turgeon, Perez et al. 2012).  Both the small sample 
size and the types of operations in the SOS study participants, which were predominantly 
the minimally invasive gastric banding or the now rarely performed vertical banded 
gastroplasty, both of which are lower risk operations than sleeve gastrectomy or gastric 
bypass, are limitations of the study and as it did not include patients with pre-existing CKD 
the results may not be applicable to CKD populations.   
 
Similarly, the likelihood of gastric leak following gastric bypass surgery is increased in 
patients with chronic renal failure (adjusted odds ratio 2.38), compared to patients without 
renal failure, although incidence of gastric leak was not affected by hypertension, 
hyperlipidaemia, diabetes, peripheral vascular disease or smoking (Masoomi, Kim et al. 
2011).  Whilst the surgical procedure differs, the risk of leak similar in all forms of weight 
loss surgery (Picot, Jones et al. 2009).  Therefore, the occurrence of gastric leak in this 
series would not be entirely unexpected, although the delayed detection of the leak is 
unusual.  Interestingly, patient E became anaemic prior to the detection of the gastric leak; 
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other causes of anaemia were investigated initially, yet anaemia may be an early sign of leak 
or bleeding post weight loss surgery.  
 
The importance of adequate hydration during rapid weight loss (Snyder-Marlow, Taylor et 
al. 2010), even in patients with impaired or depleted kidney function with reduced urine 
output, remains apparent, with 2 of 3 adverse events in this series likely related to 
inadequate hydration post-operatively, despite the use of intravenous fluids post-
operatively and provision of patient education on goal oral fluid intake after discharge. 
Four out of 5 patients on dialysis were listed for kidney transplantation within 12 months 
following weight loss achieved after LSG.  As the mean waiting time for kidney 
transplantation is now over 2 years, it remains too early to report on successful kidney 
transplantation in this series of patients.  Reductions in antihypertensive and lipid-lowering 
medications indicate that other factors associated with obesity may also be reduced in 
obese patients with CKD following weight loss surgery with LSG. 
 
This study is limited by its small sample size, and lack of control or comparison group.  
Safety of the LSG procedure for weight loss in obese patients with CKD cannot be 
determined from this case series.  Indeed, several large controlled trials or retrospective 
analyses of large databases will be required to establish the safety and risks of the procedure 
in obese patients with CKD.  Since the conception of this study it is now known that the 
risk of complications and mortality with other forms of weight loss surgery are increased in 
patients with CKD (Nguyen, Masoomi et al. 2011; Turgeon, Perez et al. 2012).  Therefore 
it is highly likely that the risk of complications and mortality may also be increased with the 
LSG procedure for weight loss in obese patients with CKD compared to obese patients 
without CKD.   
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In conclusion, this is the first study to describe the early course of obese patients with 
CKD electing to undergo LSG, in a single centre.  LSG appears to be a reasonable option 
to consider in the treatment of obesity in patients with CKD, particularly with a view to 
improving access to kidney transplantation waitlisting.   However, the procedure may carry 
a higher rate of complications and adverse events in patients with CKD than in those 
without CKD, so careful monitoring of fluid intake, kidney function and dialysis access is 
required, together with clear patient education on the importance of compliance to the 
post-operative diet.   Larger prospective controlled studies of LSG in obese patients with 
CKD are clearly needed to provide further evidence on the safety and effectiveness of this 




Chapter 4: A prospective cohort study of laparoscopic sleeve 
gastrectomy for weight loss in obese patients on haemodialysis 
- pilot study 
 
Chapter Summary 
One third of patients undergoing haemodialysis treatment die from complications related 
to cardiovascular disease, and kidney transplantation is the only effective treatment option 
to reduce mortality.  Obesity may restrict access to kidney transplantation, as many 
transplantation centres limit access to kidney transplants to patients with a body mass index 
(BMI) < 35 kg/m2.  Laparoscopic sleeve gastrectomy (LSG) is a relatively novel, restrictive, 
surgical weight loss procedure performed to reduce the size of the stomach by two-thirds, 
thereby limiting food intake.  Prior to our studies, there have been no reports of LSG as a 
weight loss treatment in patients with chronic kidney disease (CKD).  This prospective 
cohort pilot study aimed to evaluate the efficacy of LSG surgery in obese patients with 
kidney failure currently undergoing haemodialysis, as a strategy to increase eligibility for 
kidney transplantation.  The secondary aims of the study were to monitor surgical 
complications and adverse events, and the effect of weight loss on quality of life, insulin 
resistance, hypertension and dyslipidaemia.  Additionally, several cardiovascular disease risk 
biomarkers, including assessment of arterial stiffness with brachial-femoral pulse wave 
velocity (PWV) and measurement of the number and function of endothelial progenitor 
cells (EPC) were undertaken to determine the feasibility of using these measures in a larger 
trial.  The planned sample size for this study was 15 subjects undergoing surgery, with a 
similar-sized comparator group consisting of matched patients who did not undergo 
surgery.  Part way through this investigation, study approval was withdrawn by the host 
site, after 2 serious adverse events were reported.  18 patients were recruited prior to early 
suspension of the study.  6 patients in the LSG group were matched for age and gender 
with 6 patients electing to maintain usual care (UC), and a further 6 patients were recruited 
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to the LSG group but had yet to undergo baseline assessment prior to study suspension.  
Four patients underwent LSG before the study was suspended.  There were 2 serious 
adverse events, including 1 death post-operatively, and the host site suspended the study 
approval.   All 3 surviving patients in the LSG group reduced their weight to reach a target 
BMI < 35 kg/m2 and all 3 became eligible for kidney transplantation 3 months after weight 
loss surgery.  There were no adverse events in the UC group.  A further 2 patients allocated 
to the LSG group died prior to baseline assessment. The mortality in this study concurs 
with the known mortality rate in patients with kidney failure undergoing haemodialysis.  
The safety and efficacy of LSG in this patient group could not be determined, as the study 




There is little evidence informing clinical practice on the role of weight loss surgery for 
obese patients undergoing haemodialysis as treatment for kidney failure.  2 case reports 
(Knerr, Horbach et al. 2003; Holman, Paul et al. 2008; Tafti, Haghdoost et al. 2009) and 4 
small case series (Newcombe, Blanch et al. 2005; Koshy, Coombes et al. 2008; Takata, 
Campos et al. 2008; Alexander, Goodman et al. 2009) suggest that weight loss surgery may 
be beneficial in obese patients on haemodialysis to improve candidacy for kidney 
transplantation (Newcombe, Blanch et al. 2005; Koshy, Coombes et al. 2008; Takata, 
Campos et al. 2008), promote recovery of kidney function (Alexander, Goodman et al. 
2009; Tafti, Haghdoost et al. 2009) or improve viability of dialysis vascular access (Knerr, 
Horbach et al. 2003).  However, both laparoscopic gastric banding and gastric bypass 
surgery have been associated with negative effects on the kidney in a minority of patients 
(Nelson, Houghton et al. 2005; Buch, El-Sabrout et al. 2006; Sinha, Collazo-Clavell et al. 
2007; Nasr, D'Agati et al. 2008).   
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Chapter 3 detailed the results of using LSG as a novel treatment for weight loss in obese 
patients with CKD.  The case series included 5 patients undergoing haemodialysis.  
Significant weight loss was achieved, and 4 out of the 5 haemodialysis patients became 
eligible for kidney transplantation waitlisting.  However, one haemodialysis patient’s dialysis 
vascular access failed, and another patient experienced a myocardial infarction and gastric 
leak post LSG weight loss surgery.  The case series indicated that whilst LSG may be 
efficacious for weight loss and improve candidacy for kidney transplantation, there may be 
additional risks associated with the procedure in patients with CKD, indicating a need for 
an exploratory, yet systematic, prospective observational study of LSG for weight loss in 
obese patients undergoing haemodialysis.  
 
This chapter describes a prospective, observational, cohort pilot study of LSG, compared 
to usual care, in haemodialysis patients only, to determine the efficacy of the surgery for 
enabling the patient to achieve a BMI below the threshold acceptable for kidney 
transplantation in the study centre.  Secondly, this study aimed to monitor the safety of 
LSG in patients on haemodialysis, and to determine the effect on quality of life. 
 
Research Question: In obese patients with kidney failure on haemodialysis, is weight loss 
achieved with laparoscopic sleeve gastrectomy adequate to enable patients to meet kidney 
transplant waitlisting criteria? 
 
Study Aim  
This study aimed to evaluate the efficacy of the sleeve gastrectomy procedure to elicit 
sufficient weight loss to enable kidney transplantation in obese patients with kidney failure 
currently undergoing haemodialysis.   Additionally, the efficacy of the procedure for 
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improving quality of life, reducing insulin resistance, hypertension and dyslipidaemia was 
studied, and adverse effects were monitored.  Furthermore, this study intended to measure 
changes in selected cardiovascular biomarkers to determine the effect size attributable to 
weight loss and assess the practicality of these measurements in preparation for use in a 
future randomised controlled trial. 
 
Primary Hypothesis 
Obese haemodialysis patients with a body mass index of > 35 kg/m2 undergoing 
laparoscopic sleeve gastrectomy will reduce weight sufficiently to meet the kidney 
transplantation criteria of body mass index < 35 kg/m2 after 12 months, compared to 
those continuing best medical care.  
 
Primary outcome 
The primary outcome measure was weight loss and achievement of kidney transplantation 
listing body mass index criteria of BMI < 35 kg/m2 12 months post laparoscopic sleeve 
gastrectomy, compared to best medical care. 
 
Secondary Hypotheses 
The following hypotheses and outcomes were selected, as they are patient-focused 




1. Quality of life (Self Adminstered Short Form 36 and Hospital Anxiety and 
Depression Scale) scores improve following laparoscopic sleeve 
gastrectomy, compared to best medical care.  
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The self adminstered Short Form 36 (SF-36) is a widely used quality of life measurement 
tool assessing physical and mental health domains.  The tool measures eight dimensions of 
quality of life, with general health and vitality contributing to both the physical and mental 
domain scores, and physical functioning, role physical and pain also incorporated into the 
physical domain and social functioning, role-emotional and mental health into the mental 
domain score (Lacson, Xu et al. 2010).  Domain scores range from 0 to 100, with a higher 
score representing better self-reported health.  SF-36 scores are reduced in patients with 
CKD compared to healthy controls, and continue to decline as CKD progresses (Perlman, 
Finkelstein et al. 2005).  In haemodialysis patients, SF-36 score has inverse relationships 
with BMI, body fat level, and mortality (Kalantar-Zadeh, Kopple et al. 2001; Lowrie, 
Curtin et al. 2003).  Weight loss surgery is associated with improved quality of life in most, 
but not all studied populations (Ballantyne 2003).   
 
The Hospital Anxiety and Depression Scale (HADS) was developed as a self administered 
screening tool to detect anxiety and depression in hospitalised patients (Zigmond and 
Snaith 1983).  HADS scores for both the anxiety and depression scales have been 
demonstrated to decrease from high to normal values with weight loss following weight 
loss surgery after 1 and 2 years (Andersen, Aasprang et al. 2010).  Quality of life is 
important to measure to aid in future clinical treatment decisions.  If quality of life 
improves with weight loss, regardless of other outcome measures, the intervention 
treatment may be worth pursuing for perceived patient benefit alone. 
 
2. Weight loss following laparoscopic sleeve gastrectomy resolves or improves 
insulin resistance, hypertension and dyslipidaemia, compared to best 
medical care.  
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Insulin resistance, hypertension and dyslipidaemia are elements of metabolic syndrome, 
which is associated with both CKD and obesity (Wahba and Mak 2007; Sarafidis 2008).  
Weight loss in obese patients without CKD is known to improve all three elements (Klein 
2001; Bougoulia, Triantos et al. 2006), yet there is little information on the effect of weight 
loss on these parameters in obese patients with CKD.   Additionally, hyperglycaemia, 
hypertension and dyslipidaemia are largely managed with drug therapy in the dialysis 
population and the additional effect of weight loss, if any, is largely unknown.   HOMA-IR 
is a robust indirect indicator of insulin resistance (Matthews, Hosker et al. 1985), which has 
been demonstrated to increase with obesity in patients with CKD (Axelsson, Bergsten et al. 
2006), and is associated with cardiovascular mortality in patients undergoing haemodialysis 
(Shinohara, Shoji et al. 2002).   It is expected that an improvement in insulin resistance with 
weight loss may be associated with changes in inflammatory markers, body fat, body 
weight, waist circumference and/or adiponectin.  A reduction in systolic BP and an 
increase in HDL cholesterol has been demonstrated following weight loss surgery in 
patients without CKD (Martins, Strømmen et al. 2011), although systolic BP and lipid 
measures are not related to BMI in patients undergoing dialysis (Bossola, Giungi et al. 
2008).   
 
3. The complication rate for laparoscopic sleeve gastrectomy is no greater in 
obese haemodialysis patients than in non-dialysis patients undergoing the 
same procedure.  
Typical complications related to LSG weight loss surgery include gastrectomy leak, 
bleeding requiring transfusion, bleeding or restriction requiring surgical or endoscopic 




4. The adverse event rate over 12 months is no greater in obese haemodialysis 
patients undergoing laparoscopic sleeve gastrectomy than in obese patients 
on haemodialysis continuing with best medical care. 
Adverse events may include malnutrition, dehydration, vomiting, hypoglycaemia, 
constipation, epigastric pain, oedema, and cardiovascular events - including myocardial 
infarction, stroke and hospitalisation for heart failure.  This patient population has an 
elevated risk of cardiovascular events and malnutrition, and it is predicted that weight loss 
following LSG may reduce the incidence of adverse events in this group.  Malnutrition was 
assessed with the Subjective Global Assessment (SGA) nutrition assessment tool, validated 
for use in haemodialysis patients (Steiber, Leon et al. 2007).   
 
Additionally, this pilot study had a pre-defined a range of exploratory outcome measures 
selected in order to determine practicality of measurement, as well as effect size and 
direction in preparation for a future planned randomised controlled trial of LSG in obese 
patients on haemodialysis.   
 
The exploratory outcome measures were: 
 
Waist circumference and waist to hip ratio 
Waist to hip ratio is related to cardiovascular disease risk (myocardial infarction (MI) and 
fatal coronary disease) in patients with CKD (Elsayed, Tighiouart et al. 2008) and waist 
circumference and waist to hip ratio provide alternative measures of body fat distribution 
to BMI.   
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Obesity related inflammatory or anti-inflammatory factors: Fetuin-A, CRP, IL-6, TNF-alpha, leptin and 
adiponectin 
Leptin levels are associated with subcutaneous adipose tissue and adiponectin is associated 
with visceral adipose tissue in haemodialysis patients (Kaysen, Kotanko et al. 2009).  
Neither IL-6 nor TNF-α are associated with measures of fat mass or lean body mass in 
haemodialysis patients, indicating that the haemodialysis inflammatory state overrides other 
factors influencing inflammation evident in non-dialysis populations (Beberashvili, Sinuani 
et al. 2009), although the effect of weight loss on these relationships has not been assessed 
in obese patients on haemodialysis.  Fetuin-A is a peptide secreted exclusively by the liver, 
and it is a potent inhibitor of vascular calcification.  Fetuin-A also impairs insulin signalling, 
and is associated with metabolic syndrome in patients with CKD (Ix, Chertow et al. 2006; 
Axelsson, Wang et al. 2008; Ix and Sharma 2010).  Fetuin-A is increased in obesity and is 
associated with survival in dialysis patients (Hermans, Brandenburg et al. 2007). 
 
Arterial stiffness (aortic pulse wave velocity) 
Arterial stiffness is measured by carotid to femoral, and brachial to femoral, pulse wave 
velocity (PWV), by recording arterial pulse waveforms with a device such as the Vicorder 
oscillometric device (Skidmore Medical: United Kingdom).  Increased PWV, indicating 
increased aortic stiffness, is associated with measures of obesity, although the mechanism 
linking adiposity to aortic stiffness is not well defined (Safar, Czernichow et al. 2006).  The 
Vicorder, which measures both carotid to femoral PWV, and brachial to femoral PWV, has 
been validated against the recognised gold standard SphygmoCor system, which measures 
carotid to femoral PWV (Hickson, Butlin et al. 2009), and PWV is predictive of survival in 
haemodialysis patients (Morimoto, Yurugi et al. 2009).  Pulse wave velocity is also an 
independent predictor of cardiovascular events in patients with stages 4-5 CKD, even after 
adjustment for established cardiovascular risk factors (Zoungas, Cameron et al. 2007).  
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Reductions in arterial stiffness with therapeutic interventions, such as weight loss, represent 
a true reduction in arterial wall damage, rather than simply a change in cardiovascular risk 
scores achieved with reductions in hypertension, lipid lowering and improvement in 
glycaemic control (Laurent, Cockcroft et al. 2006).  
 
Endothelial progenitor cells (EPC) 
EPC are required for regeneration and repair of vascular tissue, and a reduction in EPC 
number and/or function has been demonstrated independently in CKD, end stage kidney 
disease, and obesity (Choi, Kim et al. 2004; de Groot, Bahlmann et al. 2004; Herbrig, 
Pistrosch et al. 2006; Muller-Ehmsen, Braun et al. 2008; Jourde-Chiche, Dou et al. 2009; 
Krenning, Dankers et al. 2009; MacEneaney, Kushner et al. 2009; Bahlmann, Speer et al. 
2010; Buemi, Costa et al. 2010; Heida, Müller et al. 2010; Jie, Zaikova et al. 2010).  
 
Intentional weight loss in overweight and obese subjects, without overt kidney disease, is 
linked to improvement in endothelial function (Pierce, Beske et al. 2008), an increase in 
number and functionality of EPC (Muller-Ehmsen, Braun et al. 2008; Heida, Müller et al. 
2010), and reduced CRP (Esposito, Pontillo et al. 2003).  There are no data available on the 
effect of weight loss on EPC in obese haemodialysis patients.  This information may help 
to determine whether weight loss reduces the inflammatory assault and increases the 
efficacy and number of EPC, which, in turn, may improve vascular function and reduce 
cardiovascular disease morbidity. 
 
Various methodologies have been used previously, as no unique cell surface marker/s of 
EPC have been identified, and all studies in haemodialysis patients have included only 
small numbers of patients (Krieter, Fischer et al. 2010).  The Colony Forming Unit-Hill 
(CFU-Hill) method of culturing EPC colonies, appears to be associated with EPC function, 
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and was chosen due to its association with Framingham risk score in apparently healthy 
men (Hill, Zalos et al. 2003). 
 
The cell surface markers CD34+/CD133+/KDR+ were selected, since various 
combinations of these have been used to detect EPC in peripheral blood mononuclear cells 
(PBMC) in obesity and CKD separately, however no existing data could be found on EPC 
counts for obese patients with CKD (Jourde-Chiche, Dou et al. 2009; Heida, Müller et al. 
2010).  CD 34+/CD 133+/KDR+ and CD34+/KDR+ and CD133+/KDR+ cell counts 
negatively correlate with BMI (Tobler, Freudenthaler et al. 2010), but there was no 
relationship between CD34+/CD133+ and BMI, and leptin is negatively correlated with all 
individual markers and combinations.   
 
Reduction in EPC number and/or function has been demonstrated independently in CKD, 
end stage kidney disease, and obesity (Choi, Kim et al. 2004; de Groot, Bahlmann et al. 
2004; Herbrig, Pistrosch et al. 2006; Jourde-Chiche, Dou et al. 2009; Krenning, Dankers et 
al. 2009; MacEneaney, Kushner et al. 2009; Bahlmann, Speer et al. 2010; Buemi, Costa et 
al. 2010; Heida, Müller et al. 2010; Jie, Zaikova et al. 2010), which may contribute to 
deterioration of endothelial function.  Weight loss in obese patients without CKD results in 
improvement in number and functionality of EPC (Muller-Ehmsen, Braun et al. 2008; 
Heida, Müller et al. 2010).  It is hypothesised that weight reduction will lead to an increase 
in EPC in obese patients on haemodialysis, which may contribute to an improvement in 






This study was an observational cohort study of obese haemodialysis patients who self 
selected to accept or decline LSG weight loss surgery (Figure 9). 
 
Ethical Review and Research Governance 
This study followed the principles of the Declaration of Helsinki – Ethical Principles for 
Medical Research Involving Human Subjects (World Medical Association 2008), and was 
submitted to the West London Research Ethics Committee in March 2010.  The 
committee did not give a favourable opinion for the study, due to differences between the 
study protocol and the Integrated Research Application System (IRAS) project information 
submitted for ethical review.  Significant amendments were made to the study protocol and 
the IRAS project information.  The study was then submitted to the Queen Square 
Research Ethics Committee in June 2010 and approved in October 2010, after further 
information was provided and amendments made to the written Information for 
Participants booklet (Appendix C) highlighting the unknown risk of LSG surgery in 
patients with CKD and informing the patient that undergoing weight loss surgery did not 
guarantee kidney transplant waitlisting.  King’s College Hospital Research and 
Development governance approval was granted in January 2011, followed by approval 




Figure 9: Schematic representation of study design and outcomes  
BMI – body mass index; CKD – chronic kidney disease; BP – blood pressure; HOMA-IR – method of homeostasis 
assessment for insulin resistance 
 
Recruitment of patients 
Recruitment commenced in January 2011 and ceased in December 2011, when the study 
was terminated early.  Patients were recruited from haemodialysis centres attached to the 3 
study sites.  
 
Preliminary Screening 
Screening existing patient databases and patient medical records at haemodialysis centres 
linked to the 3 study sites identified potential patients.  A member of the site clinical care 
team completed screening in conjunction with the candidate.  Screening was based on the 
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triple criteria of haemodialysis treatment for > 90 days, BMI >35 kg/m2, and potentially 
suitable for kidney transplantation following weight loss.  
 
The candidate then conducted a more detailed search of the medical records of the patients 
identified during preliminary screening, to determine if patients met the full study criteria 
and were eligible to participate in the study (Table 10).  The candidate is a Registered 
Dietitian with extensive clinical experience with patients with CKD, and obtained 
permission to access clinical records and talk to patients at NHS sites hosting the research 
study.   
Table 10: Inclusion and exclusion criteria for patient participation in a prospective cohort study of laparoscopic 
sleeve gastrectomy for weight loss in haemodialysis patients - pilot study 
Inclusion criteria Exclusion criteria 
Male or female, aged > 18 years Pregnancy 
Previously attempted weight loss History of chronic liver disease 
Fit for anesthesia and surgery Previous bariatric surgery, gastric surgery or large hiatus hernia 
Body Mass Index  > 35 kg/m2 Psychiatric illness including anxiety, mood and untreated eating 
disorders 
Written informed consent  Malnutrition (assessed by subjective global assessment) 
On haemodialysis for at least 90 days Infection or course of antibiotics within the last month 
 Current peritoneal dialysis treatment 
   
Final Recruitment 
Eligible patients were contacted initially by letter or approached in person in an outpatient 
clinic by the candidate or referred to the candidate by the patient’s Nephrologist.  All 
patients interested in accessing further information about the study were contacted by the 
candidate, either by telephone or in person, and were provided with verbal information and 
a written Information for Participants booklet on the study, with a follow up visit or 
telephone call 1-2 weeks later, where interested patients were given more information 
about the study protocol and an opportunity to ask questions about the study.  Information 
provided to the patient at this stage focused on the choice of surgical or best medical care 
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treatment, anticipated risks and benefits of surgery and best medical care treatment, 
number of study visits required and further explanations of the tests involved.  The 
candidate also emphasised that participation was voluntary and patients were free to 
withdraw from the study at any time without their medical care being affected.   
 
Eligible patients wishing to be considered for surgical treatment were discussed with each 
patient’s named nephrologist, and agreement that surgical treatment may be suitable was 
obtained prior to pre-surgery assessment.  Patients wishing to undergo LSG weight loss 
surgery were referred to the study surgeon for assessment for LSG.  A member of the 
surgical team completed the assessment, and the dietitian (the candidate) conducted an 
additional dietary assessment for weight loss surgery (method detailed in Appendix D).  
Patients may have required additional cardiovascular and respiratory assessments, and 
further surgical review, prior to being assessed as fit or unfit for weight loss surgery.  
Patients agreeing to participate in the study in the best medical care arm moved directly to 
the consent stage.  Patients unsure whether they wished to participate were given more 
time to consider the study and the candidate contacted the patient again after a mutually 
agreed timeframe.   
 
Consent 
The process and meaning of informed consent was discussed, including the right of 
withdrawal at any time without compromising medical care.  It was the responsibility of the 
person obtaining informed consent to assess capacity, and to ensure that they were satisfied 
that the patient understood the contents of the written Information for Participants 
booklet, the treatment choice offered, and the right to withdraw from the study at any time 
without penalty.  If the patient was willing to participate in the study, either the candidate, 
or the study surgeon or the patient’s named nephrologist obtained written informed 
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consent.  One copy of the completed consent form (Appendix C) was given to the patient, 
one copy was filed in the medical notes and the original consent form was filed in the study 
master file, together with a copy of the Information for Participants booklet.  All members 
of the study team had undertaken formal consent training and were able to assess capacity 
to consent.   
 
Interventions 
Patients were offered the choice of undergoing weight loss surgery using the laparoscopic 
sleeve gastrectomy procedure (LSG group) or continuing with best medical care (UC 
group).   
 
Usual Care (UC) 
All patients continued to receive medical treatment equivalent to that provided prior to 
study enrolment, including use of angiotensin-converting enzyme inhibitors, angiotensin II 
receptor blockers, erythropoiesis stimulating agents, iron, vitamin D, and phosphate 
binders; as well as therapies used to manage diabetes, obesity, other causes of CKD and 
other co-morbidities. 
 
All patients were offered appropriate individualised dietary education and support for 
weight loss.  Patients were invited to participate in existing weight loss programmes and/or 
exercise on dialysis schemes, attend supervised physical activity sessions or perform a 
home exercise programme.   In this study, active intervention for weight loss was optional 
in the UC treatment arm to reflect true usual care, and patients who participated in this arm 
of the study did not nessessarily choose to participate in a weight loss intervention.   
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Laparoscopic Sleeve Gastrectomy Weight Loss Surgery (LSG)  
Patients who elected to have weight loss surgery received best medical care, and some 
patients underwent laparoscopic sleeve gastrectomy, prior to the study ceasing early.  
Sleeve gastrectomy as a primary procedure consisted of a subtotal gastric resection of the 
fundus and body, to form a tube like stomach along the lesser curvature, with a final 
volume of 100 – 200 ml (Iannelli, Dainese et al. 2008).  The surgery was performed by an 
experienced minimal access surgeon, Mr Ameet Patel, who had already performed at least 
50 sleeve gastrectomy procedures.  Resected tissue samples were examined for evidence of 
helicobacter pylori, and treatment with a proton pump inhibitor and antibiotics was 
commenced if positive. 
 
Post Surgery Dietary Intervention 
Patients were provided with dietary education and renal-specific written information prior 
to the procedure or 1-2 days post the procedure as an inpatient.  Dietary intake and 
adequacy was reviewed at 1, 4, 6 and 12 weeks post-sleeve gastrectomy, then at 3-monthly 
intervals, and further education and written information was provided as required, until the 
study was terminated.  Dietary intake progressed in texture from liquid to puree, then to 
soft foods over 3 months, before finally re-introducing most normal foods 4 - 6 months 
post surgery (Snyder-Marlow, Taylor et al. 2010).  Volume of food or fluid intake was 
limited to 100 - 150 ml per meal, up to 6 times a day.  This level of intake is sustainable due 
to the reduced stomach volume.  Intakes greater than 150 ml may stress the suture line and 
create a leak, or may stretch the surgically reduced stomach capacity, increasing the risk of 
compromising the physical restriction imposed by the surgery, which may impede weight 
loss.   
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Dietary energy intake was restricted to approximately 1000 kcal per day post sleeve 
gastrectomy.  Protein intake was optimised for haemodialysis at 1.2 g protein/kg ideal body 
weight (IBW)/day (EDTNA/ERCA Dietitians' Special Interest Group 2002), and 
additional protein was provided via nutritional supplements (Prosource Liquid: Nutrinovo, 
UK; Fortisip Extra/Fortimel: Nutricia Clinical, UK) if required.  The remaining dietary 
energy was consumed from carbohydrate and fat sources, with low fat choices strongly 
encouraged.  Patients were also recommended to enjoy a wide variety of tolerated foods.  
All patients were encouraged to modify sodium intake to a “no added salt” diet level, of 80 
- 100 mmol sodium per day (EDTNA/ERCA Dietitians' Special Interest Group 2002).  
Potassium and phosphate intake was adjusted depending on residual kidney function, to 
maintain serum biochemistry within the recommended ranges (Abbott, Glanton et al. 2004; 
Renal Association 2007).   A daily multivitamin and mineral supplement suitable for 
patients with CKD was prescribed. 
 
Measurements 
A brief description of all measures is included here.  An in-depth description of those 
measures requiring a specific method of measurement or technique is outlined in Appendix 
D.  All measures were performed at the start of the study and then at 3-monthly intervals 
until the study was terminated.   
 
Demographics  
Baseline demographic data including date of birth, ethnicity, gender, and cause of CKD (if 
known) were recorded at study enrolment.  History of diabetes, cardiovascular disease, 
hypertension, dyslipidaemia, and surgical history were recorded at baseline.  Medication 




Venous blood samples were collected in blood collection tubes (BD Vacutainer BD: New 
Jersey), immediately prior to the start of dialysis, after a 12-hour fast, at baseline and at 3-
monthly intervals until the study was terminated.  Multiple samples were collected in 
EDTA coated tubes (2 x 8 mL, 2 x 4 mL) for PBMC collection for endothelial progenitor 
cell counting with FACS analysis and cell culture of CFU-Hill colony forming units, full 
blood count, and plasma extraction, fluoride and oxalate containing tubes (1 x 4 mL) for 
serum glucose, and silica coated serum separating tubes (3 x 5 mL) for serum leptin, 
adiponectin, fetuin-A, IL-6, lipids, hs-CRP, and insulin.   
 
Cell culture and flow cytometry 
Samples for PBMC extraction were processed within 2 hours of collection, and a detailed 
description of the methods for preparation of PBMC cell culture is presented in Appendix 
D.  PBMC were extracted using Ficoll-Paque PLUS (StemCell Technologies: France) 
density gradient centrifugation.  The layer of mononuclear cells was collected, and washed 
twice with PBS with 2% foetal FBS Gold bovine serum (PAA: Austria).  One quarter of 
the sample was suspended in 1 ml of CryoMaxx freezing medium (PAA: Austria) and the 
viable cells were counted using a Neubauer haemocytometer.  The sample was frozen 
slowly and stored at -80°C, for later analysis of endothelial progenitor cells using 
fluorescence-activated cell sorting (FACS) flow cytometry.  
	  
A 5-day cell culture was performed with the remainder of the PBMC sample to develop 
“colony forming units” (Hill, Zalos et al. 2003), known as CFU-Hill colonies.  The PBMC 
were plated, in duplicate, on fibronectin-coated 6-well plates in CFU-Hill liquid medium 
(StemCell Technologies: France), and incubated for 2 days to remove mature endothelial 
 127 
cells and some monocytes.  After 2 days the non-adherent cells were removed, counted, 
and re-plated, in duplicate, on fibronectin-coated 24-well plates in fresh medium and 
returned to the incubator.  After 3 days, the non-adherent cells were removed, the wells 
washed and the culture fixed with methanol and stained with Giemsa staining solution 
(Merck: Germany).  The CFU-Hill colonies were identified as a cluster with a central core 
of round cells with elongated spindle shaped cells radiating at the periphery, and were 
counted using a standard light microscope.  
 
In preparation for endothelial progenitor cell counting with flow cytometry, frozen PBMC 
were rapidly thawed in a 37°C water bath then washed twice in culture medium (RPMI 
with 10% foetal bovine serum and 1% penicillin and streptomycin), by centrifugation at 
300g for 8 minutes at 24°C with the brake ON.  The cells were re-suspended in medium 
and viable cells counted, and washed again in PBS with 2.5% foetal bovine serum.   
 
Cells were incubated with immunofluorescent-labelled antibodies against CD34+, KDR+ 
and CD133+ and corresponding isotype controls for 30 minutes at 4°C, washed twice, 
fixed in paraformaldehyde and suspended in PBS.  Quantitative analysis of cells expressing 
CD34+, KDR+ and CD133+ and co-expressing CD34+/KDR+ and CD133+/KDR+ 
and CD133+/CD34+ /KDR+ was performed on the prepared cells and control samples 
using FACS analysis (BD FACS-Canto II: Belgium). 
 
Biochemistry 
The remaining sample for plasma was centifuged upon arrival in the laboratory and all 
serum samples were left for 30 minutes to clot before being spun.  Samples for glucose, 
high density lipoprotein (HDL) fraction and total cholesterol, and a full blood count were 
processed immediately and the remaining serum and plasma was stored in aliquots at -80°C 
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for later analysis of serum leptin, fetuin-A, adiponectin, hs-CRP, IL-6 and insulin.  Serum 
and plasma were stored in case further biomarkers were added to the study at a later date.  
Commercially available quantitative sandwich enzyme-linked immunosorbent assays were 
used to measure serum leptin and adiponectin (R&D Systems: USA), fetuin-A (Assay Pro: 
USA), IL-6 (Randox: United Kingdom) and insulin (Siemens: United Kingdom).  Standard 
enzymatic techniques were used to measure the hs-CRP (Cormay: Poland), glucose 
(Siemens: United Kingdom), HDL fraction (Siemens: United Kingdom) and total 
cholesterol (Siemens: United Kingdom) on an Advia 2400 Chemistry System (Siemens: 
United Kingdom).  HOMA-IR was used to calculate an index of insulin resistance from the 
product of the fasting concentrations of serum insulin (microunits/ml) and serum glucose 
(mmol/l) divided by 22.5 (Matthews, Hosker et al. 1985).  The full blood count was 
performed using standard laboratory methods. 
 
Nutrition assessment 
Adherence to dietary guidelines was assessed with 3-day food intake records plus dietary 
interview to clarify and substantiate the content at baseline and every 3 months.  
Nutritional status was measured with Subjective Global Assessment (Detsky, MacLaughlin 
et al. 1987). 
 
Anthropometry 
Height was measured to the nearest 1cm without shoes using a wall mounted stadiometer.  
Weight was measured to the nearest 0.1 kg on a calibrated electronic scale with the patient 
wearing light clothing and without shoes.   Waist and hip circumferences were measured to 
the nearest 0.1 cm at the level of the umbilicus and the widest point around the buttocks, 




Arterial stiffness was measured by brachial-femoral pulse wave velocity (PWV).  PWV was 
measured with the patient lying supine, on an inter-dialysis day (Di Iorio, Nazzaro et al. 
2010) using the Vicorder device (Skidmore Medical, United Kingdom), with cuffs placed 
around the upper thigh and the upper arm (brachial-femoral).  The distance from the top 
of the brachial cuff to the top of the femoral cuff, in a straight line, was measured with a 
calibrated plastic tape measure, and entered into the Vicorder software, and PWV was 
calculated from this distance and the pulse transit time between the 2 points.  The 
measurement was performed twice and the average of the 2 measures used.  Inter- and 
intra- tester reliability was measured prior to the study. 
 
BP was measured with the patient seated in the dialysis chair, using an appropriate-sized 
cuff on the non vascular access arm prior to dialysis.  To account for changes in BP with 
changes in body water, mean monthly pre-dialysis blood pressure was calculated from 
thrice weekly pre-dialysis blood pressures recorded in dialysis patient records.   
 
Quality of life was assessed using the self-adminstered short form 36 (SF-36) questionnaire 
(Appendix B) and the self-administed Hospital Anxiety and Depression Scale (HADS) 
(Appendix B) (Zigmond and Snaith 1983; Lacson, Xu et al. 2010).    
 
Predefined complications of weight loss surgery included poor tolerance of liquids/puree/ 
soft diet, gastrectomy leak, bleeding requiring transfusion, bleeding or restriction requiring 
surgical or endoscopic intervention, longer than expected hospital admission, readmission 
to hospital directly related to weight loss surgery, post-operative infection, and 30 day 
mortality; and were recorded as soon as they became known to the study team.  The event 
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rate of post-operative complications was compared to the pooled event rate from 
published studies. 
 
Adverse events, including compromised dialysis access, cardiovascular events including 
myocardial infarction, stroke and hospitalisation for heart failure, gastro-oesophageal 
reflux, heart rhythm irregularities, malnutrition, dehydration, vomiting, hypoglycaemia, 
diarrhoea, constipation, epigastric pain, oedema and hospitalisation during the study 
period, were reported and recorded at study visits.   
 
Statistical Analysis 
Sample size calculation 
 In a population with a mean BMI of 42.0 kg/m2 and standard deviation of 5.9 kg/m2 at 
baseline, with the assumption that 70% of the surgery group and 10% of the usual care 
group will reach the BMI cut-off of <35 kg/m2 after 12 months, with type 1 error set at 
5% and 80% power, 12 patients were required in each group.   The planned study sample 
size was 15 patients in each group, to allow for drop-outs.   
 
Data analysis 
Due to the exploratory nature of this pilot study, the statistical analysis plan was limited to 
tests suitable for small samples.  Statistical analysis was performed using IBM SPSS 
Statistics 19.0 software.  Descriptive statistics are expressed as median (± IQR) values for 
continuous outcome variables and percentage values for categorical variables.  Differences 
between groups were analysed with the Hodges-Lehman median difference test for 
continuous variables and Pearson’s Chi Squared test or Fisher’s exact test for categorical 
variables.  It was planned to observe trends in the data over time and determine effect sizes 
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with weight loss within and between treatment groups with mixed modelling, with time as a 
random factor, however this was not possible with the amount of data collected.  
 
It was intended to compare the number of patients meeting the BMI cut-off criteria for 
transplant, and adverse event rate between treatment groups with Fisher’s exact tests.  
Complication rates in the haemodialysis LSG group were to be compared to the event rate 
in published studies of the general population, using contingency tables and Fisher’s exact 
test.  However, due to the small number of patients included in the study at termination, 
these comparisions would not be valid.  Instead, the primary event rates are reported but 
no statistical comparisions have been made. 
 
Relationships between weight loss and changes in exploratory outcomes, BP, quality of life, 
insulin resistance and blood lipids were to be investigated with simple linear regression 
analyses.  These analyses were not possible with the amount of data collected prior to the 
early termination of the study. 
 




Adverse events, study governance and early cessation of study 
The culmination of several events related to this study resulted in the suspension of the 
study half way through the planned study period.  A timeline of pertinent study events and 
milestones from inception to early termination and the post termination period is 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































2 serious adverse events occurred between June and September 2011, and a combination of 
proceedings led to the late reporting of these events to the Research Ethics Committee.  
Following submission of the reports in November 2011, the Research Ethics Committee 
issued a notice to suspend the study pending a request for further information relating to 
the 2 events and study governance in December 2011.  Before this information could be 
provided to the ethics committee, the King’s College Hospital Research and Development 
Department terminated the study site approval, and submitted a response to the Research 
Ethics Committee.  The response contained factual errors and the study team was asked to 
provide a corrected version, substantiated with documented evidence, to the King’s College 
Hospital Research and Development Director.  An independent mediator was recruited to 
review the study, including all documentation and reports, and make recommendations.  
 
The study results obtained prior to suspension and early termination of the study are 
presented below.  Body weight data and transplantation listing status was obtained from 
clinical records and included up to 12 months, with permission from the Research and 
Development Directorate. 
 
Characteristics of study participants 
Patients undergoing haemodialysis at the study sites were screened for possible inclusion in 
the study, and a flow diagram of patient recruitment is displayed in Figure 12.  At the point 
when the study was terminated, 51 patients met the screening criteria of BMI > 35 kg/m2 
and aged > 18 years and were approached to participate in the study.  19 patients were 
excluded for the following reasons: they were unlikely to qualify for kidney transplantation 
regardless of BMI (n = 5); BMI had decreased below 35 kg/m2 (n = 2); they were absent 
from their dialysis unit during the entire recruiting period (n = 1); or they declined to 
participate (n = 11).   Of the remaining 32 patients, 8 patients were already assessed and on 
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the waiting list for laparoscopic sleeve gastrectomy, 12 patients expressed an interest in 
weight loss surgery and were given an appointment with the study surgeon and 12 patients 
were considering participating as observational controls.    
 
Figure 12: Flow chart showing patient recruitment to a prospective cohort study of laparoscopic sleeve 
gastrectomy for weight loss in obese patients on haemodialysis - pilot study 
 
 
Prior to study suspension in December 2011, 18 patients had consented to participate in 
the study.  12 patients had commenced the study, 6 in the sleeve gastrectomy (LSG) group 
	  
Screening of patients undergoing haemodialysis treatment at all study sites 
n= 1 056 
Eligible patients meeting inclusion criteria for laparoscopic sleeve gastrectomy 
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1 005 patients excluded 
Patients interested in participating in the study 
n= 32 
19 patients excluded 
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(all approved for sleeve gastrectomy surgery prior to being approached for the study) and 6 
gender- and age-matched, patients in the best medical care (UC) group.  A further 6 
patients were recruited to the LSG group, but had not yet commenced the study, including 
2 patients who died after providing informed consent, but prior to the baseline assessment.   
The characteristics of the patients who consented to the study are presented in Table 11.  
The group of patients who had consented but not yet commenced the study had similar 
characteristics to the patients electing LSG who did commence the study, except that there 
was a greater prevalence of diabetes in those who did not commence the study.  The causes 
of death in the 2 patients who died prior to commencing the study were acute coronary 
syndrome, and hospital acquired pneumonia during admission for aortic valve replacement.   
 
Table 11: Baseline characteristics (median ± IQR; or %) of obese patients on haemodialysis commencing a 
pilot study of laparoscopic sleeve gastrectomy for weight loss 
Parameters LSG group 
(n=6) 
LSG group 







Age (years) 50.5 (44.8 to 60.8) 50 (47.5 to 58.5) 58 (55.5 to 64.3) 0.1 










Weight (kg) 113.3 (103.9 to 
126.8) 
113.5 (100.3 to 120.0) 105.5 (102.0 to 
113.5) 
0.5 
BMI (kg/m2) 42.0 (38.5 to 45.2) 41.9 (38.5 to 42.7) 42.3 (36.9 to 43.4) 1.00 
Diabetes 2 (33%) 4 (67%) 5 (83%) 0.01 
Hypertension  6 (100%) 6 (100%) 4 (67%) 0.1 
Sleep apnoea  2 (33%) 2 (33%) 1 (17%) 0.4 
Metabolic Syndrome  6 (100%) 5 (83%) 6 (100%) 0.3 
BMI, body mass index; IQR, inter-quartile range; LSG, laparoscopic sleeve gastrectomy; UC, best medical care 
 
At baseline, all patients met the revised ATP III criteria for metabolic syndrome, with at least 3 of 
the 5 risk factors present: increased waist circumference, elevated triglycerides, reduced HDL 
cholesterol, elevated BP or on antihypertensive treatment, and elevated fasting glucose or on drug 
treatment for elevated glucose (Grundy, Cleeman et al. 2005).  There were more females, and more 
patients with diabetes, in the UC group.  Median BMI for all patients was 42.3 kg/m2, and BMI was 
well matched between groups.  The primary cause of kidney disease was diabetes or hypertension in 
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7 patients, primary glomerulonephritis in 2 patients, adult polycystic kidney disease in 1 patient; in 2 
patients the cause of kidney disease was not known. 
 
In the LSG group who had surgery or had a planned date for surgery (n = 6), the mean (±SD) 
length of time from obtaining consent to the date of surgery (or planned surgery date) was 6.5 
months (±3 months).  The overall waiting time for surgery in this group was 11.3 months (±2 
months), as 5 of the 6 patients were already waitlisted for surgery before the study commenced.   
 
4 patients underwent LSG surgery to reduce stomach size by 2/3 to induce weight loss by 
restricting food intake.  Median inpatient length of stay was 11 days (range 6 - 17 days) and 
helicobacter pylori infection was negative in all cases.  The other 2 patients had both been allocated 
admission dates for surgery prior to study termination, but both admissions were cancelled due to 
lack of availability of hospital beds on the dates of planned admission. 
 
In the UC group, patients were offered support for weight loss, and were able to choose their own 
level of weight loss intervention, to best reflect true usual care for obese patients on haemodialysis 
in the study centres.  3 patients elected to join the renal Weight Management Programme, attending 
a multidisciplinary clinic once a month for 6 months, following a low fat diet, increasing physical 
activity and were prescribed orlistat 120mg tds, with self monitoring and patient led goal setting to 
facilitate behaviour changes (refer to Chapter 5 for full details of the Weight Management 
Programme).  1 patient elected to make dietary and physical activity changes independently, and 2 
patients maintained their current lifestyle and made minimal changes to their diet or physical 
activity.    
 
Achievement of BMI criteria for kidney transplantation waitlisting 
The study was ceased prior to any patients in the LSG group reaching 6 months follow up, with 
only standard clinical care follow-up permitted once the study was ceased, thus only body weight 
data are available up to 12 months.  All 6 patients in the UC group had 6 months follow up in the 
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study, at the time the study was terminated.  Data on changes in body weight, BMI and 
achievement of transplantation listing criteria of BMI < 35 kg/m2 are presented in Table	  12.  In 
patients undergoing LSG, median BMI decreased by 15.5%, to 33.5 kg/m2, after 3  
 
Table 12: Changes in body weight, body mass index (BMI) and kidney transplantation waitlisting in obese 





























LSG 1 43 F 103.0 
(40.2)  
-15.5 -20.0 -24.0 -6.1 -7.9 -9.5 Yes Yes 
LSG 6 51 F 106.5 
(43.8) 
-25.0 -28.5 -35.0 -7.6 -11.7 -14.4 Yes Yes 
LSG 9 32 M 120.0 
(35.8) 
-18.0 -23.0 -22.0 -5.3 -9.5 -6.5 Yes Yes 
UC 1 67 M 97.0 
(35.2) 
0 0 -0.5 0 0 -0.2 No No 
UC 2 57 F 102.0 
(35.3) 
0 0 -1.0 0 0 -0.4 No No 
UC 3 55 F 123.0 
(43.6) 
0 0 0 0 0 0 No No 
UC 4 51 F 115.0 
(42.8) 
-1.0 -2.0 -5.0 -0.6 -0.8 -1.9 No No 
UC 5 66 F 109.0 
(44.2) 
0 -9.0 -10.5 0 -3.6 -4.2 No No 
UC 6 59 F 102.0 
(41.9) 
-3.0 -8.0 -10.0 -1.2 -3.3 -4.1 No No 
BMI, body mass index in kg/m2; F, female; LSG, laparoscopic sleeve gastrectomy; M, male;  mth, months post 
intervention; UC, usual care. 
 
months, and decreased by 2.6% to 41.2 kg/m2 in the UC group over the same time period.  After 6 
months, median BMI decreased by 23.7%, to 31.1 kg/m2 in the LSG group, and by 6.5%, to 39.6 
kg/m2 in the UC group.  At 12 months medium BMI had decreased by 30% in the LSG group, to 
29.4 kg/m2, and by 8.2% in the UC group, to 38.9 kg/m2.  Statistical analyses were not performed, 
however, it is reasonable to state that the weight loss achieved after LSG is, at least clinically, 
significantly greater than the weight loss achieved after UC.  All patients in the LSG group were 
listed for kidney transplantation within 6 months of weight loss surgery, compared to none of the 
patients in the UC group, over the same time period.  One patient (LSG9) has since received a 
kidney transplantation from a living donor. 
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Safety of sleeve gastrectomy in haemodialysis 
There were no adverse events in the UC group.  Two serious adverse events had occurred in the 
LSG group at the time of study termination.   
 
In one patient (LSG 2), a small vessel was perforated to a length of 1mm during surgery, and 
required repair by laparotomy, post operatively.  The bleed was not able to be stopped quickly and 
respiratory and cardiac arrests followed.  The patient unfortunately remained comatose and died 17 
days later.  
 
The second adverse event related to post-operative failure of the patency of the patient’s (LSG 9) 
femoral polytetrafluoroethylene (PTFE) graft used for vascular access in haemodialysis, together 
with post-operative hyperkalaemia.  Patients usually have femoral dialysis access sites created when 
all sites for upper limb access have been exhausted.  A haemodialysis arterio-venous fistula (created 
with native vessels) or graft (created with an artificial component and native vessels) is formed to 
enable access to a large vessel to allow blood to flow out of the patient’s body, through the 
haemodialysis filter and back into the patient’s bloodstream.  These permanent forms of dialysis 
access have a lower risk of infection than that associated with temporary venous catheters for 
haemodialysis access, often used for emergency access.  After LSG surgery, the patient developed 
combined respiratory and metabolic acidosis, and a rise in serum potassium, requiring urgent 
haemodialysis and airway support.  The patient’s existing graft lost patency and could no longer be 
used to provide haemodialysis.  The patient was then admitted to the Surgical Critical Care Unit 
with on-going hyperkalaemia.  The potassium level continued to rise and several attempts were 
made prior to successful insertion of a temporary femoral catheter, with radiological guidance, after 
which haemofiltration was provided and the serum potassium level returned to normal.  The 
blocked fistula required thrombectomy and fistuloplasty to return it to patency. 
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Co-morbidities and quality of life 
All collected data on BP, insulin resistance and total cholesterol to HDL ratio are presented 
in Table 13.  
 
Median BP was 151/76 mm Hg in the UC group and 151/77 mm Hg in the LSG group at 
baseline.  Systolic BP increased slightly after 3 months, with median BP 154/65 mm Hg, 
and then decreased at 6 months to a median of 123/68 mm Hg in the UC group.  Diastolic 
BP was generally well controlled in the UC group across the 6-month observation period.  
The rise in BP at 3 months may be attributable to the temporal development of fluid 
overload in the patient UC 5, as the dry weight was not reduced temporally with the 
intentional weight loss.  Once the dry weight was corrected, the patient’s BP decreased 
accordingly.  BP lowering medications were not changed in 5 of the 6 patients in the UC 
group, and an additional antihypertensive agent was added for 1 patient.    
 
Table 13: Blood pressure, insulin resistance and blood lipids in obese patients on haemodialysis 







HOMA-IR Total cholesterol to 
HDL ratio 
Month 0 3 6 0 3 6 0 3 6 0 3 6 
LSG  LSG 1 158   80   4.3   3.3 2.6  
group LSG 2* 143   60   11.1   5.0   
 LSG 6  141   74   1.9   3.6   
 LSG 9 163   90   3.9   3.0   
              
UC  UC 1 156 124 122 82 68 65 3.4 3.7 4.4 4.0 4.3 3.8 
group UC 2* 166 176 165 77 79 89 9.8 2.5 2.6 3.4 3.5 3.6 
 UC 3* 148 173 123 82 90 67 10.2  30.2 4.8 4.8 3.9 
 UC 4* 101 102 104 60 60 62 85.0 52.7 57.4 5.9 5.6 6.0 
 UC 5* 153 171 140 74 62 79 27.8 15.8  4.5 5.0 4.4 
 UC 6* 133 136 119 72 57 69 4.7 9.0  3.1 2.6 2.6 
* patient has diabetes and uses insulin; HDL, high density lipoprotein; HOMA-IR. homeostasis method of assessment – 




HOMA-IR was higher in patients with diabetes than in those without diabetes.  HOMA-IR 
is associated with body weight (Spearman r = 0.67, p = 0.04), waist circumference 
(Spearman r = 0.62, p = 0.05) and triglycerides (Spearman r = 0.74, r = 0.01) in all patients 
at baseline.  However HOMA-IR was only associated with adiponectin in patients without 
diabetes at baseline (Spearman r = 1.00, p < 0.001).  There was no association between 
HOMA-IR and endothelial progenitor cell function (CFU-Hill colony counts) or arterial 
stiffness (brachial to femoral PWV) in patients with, or without diabetes, at baseline. 
 
Median total cholesterol to HDL cholesterol ratio was 4.3 in the UC group and 3.6 in the 
LSG group at baseline.  The ratio remained at 4.3 after 3 months and was 3.9 after 6 
months in the UC group.   
 
Table 14 lists the individual changes in the self-administered quality of life measures chosen 
for this study; the HADS scores (Zigmond and Snaith 1983) and the SF-36 Health Survey 
(Ware, Snow et al. 2000).   
 
Table 14: Quality of life scores in obese patients on haemodialysis undergoing laparoscopic sleeve 
gastrectomy for weight loss 








Month 0 3 6 0 3 6 0 3 6 0 3 6 
LSG 
group 
LSG 1 4   4   36.4   41.2   
 LSG 2 7   3   44.3   35.3   
 LSG 6 11   9   28.9   42.5   
 LSG 9 12   9   30.3   36.0   
              
UC 
group 
UC 1 1 4 2 2 6 2 
38.4 39.0 35.4 45.2 52.1 45.3 
 UC 2 1 0 1 1 2 1 32.0 25.9 29.0 39.7 40.6 48.2 
 UC 3 9 10 9 8 7 9 21.1 34.5 20.4 50.5 31.2 44.8 
 UC 4 8 6 1 2 1 1 24.8 27.2 34.9 53.0 45.5 32.7 
 UC 5 1 0 1 1 1 1 46.1 33.9 43.2 57.0 64.0 64.0 
 UC 6 1 1 1 1 1 1       
HADS, Hospital Anxiety and Depression Scale; LSG, laparoscopic sleeve gastrectomy; SF-36, Short Form (36) Health 
Survey; UC, usual care 
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Median SF-36 scores for the whole study population were 32.0 for the physical domain and 
42.5 for the mental domain.  Both the HADS and the SF-36 quality of life measures 
indicated a trend towards poorer mental health scores in the LSG group than in the UC 
group at baseline.  Anxiety and depression scores were higher (worse) at baseline for the 
LSG group than for the UC group, although not statistically significantly different.  Median 
SF-36 mental health domain scores were significantly lower in the LSG group, compared to 
the UC group, at baseline (UC 50.5, LSG 38.6; p = 0.048).  Anxiety and depression scores 
were largely unchanged over time in the UC group.  After 3 and 6 months, UC group 
mental health domain scores decreased by 5.0, and 5.2, respectively, although this is not 
thought to represent a clinical difference in mental health over time.  Median SF-36 
physical domain scores were 32.0 in the UC group and 33.4 in the LSG group at baseline (p 
= 1.00).  In the UC group, the median physical domain score remained quite steady, 
increasing by 1.9 after 3 months and 2.9 after 6 months.   
 
Exploratory outcomes 
Additional exploratory measures of anthropometry, arterial stiffness and endothelial 
progenitor cell function (CFU-Hill colony counts) (Table 15) and markers of inflammation  
	  
Table 15: Anthropometry, vascular stiffness and Hill-Colony Forming Units (CFU-Hill) in obese 
patients on haemodialysis undergoing laparoscopic sleeve gastrectomy for weight loss 
Measure CFU-Hill 
colony count 






Waist to Hip ratio 
Month 0 3 6 0 3 6 0 3 6 0 3 6 
LSG  LSG 1 0   16.2   125.5   0.98   
group LSG 2 11.8   10.8   146.6   1.03   
 LSG 6 3.3   10.4   117.1   0.89   
 LSG 9 3   34.2   127.6   1.02   
              
UC UC 1 4.5 4.3 4.5 16.8 17.6 26.7 124.3 123.8 123.7 1.08 1.05 1.04 
group UC 2 0 0 0 14.1 14.4 13.6 132.5 130.7 133.6 1.05 1.01 1.04 
 UC 3 10  4.8 13.4 13.0 19.7 136.5 138.8 138.7 0.99 1.02 1.08 
 UC 4 2.3 2.1 0.8 13.4 19.3 16.0 141.7 139.2 141.0 1.12 1.14 1.15 
 UC 5 0.5 0.5  36.4 40.3  122.3 127.5 125.5 0.91 0.94 0.94 
 UC 6 2.3 2.5  4.4 3.7  126.8 126.6 124.0  0.93 0.95 0.94 
LSG, laparoscopic sleeve gastrectomy; m/s, metres per second; MNC, mononuclear cells; PWV, pulse wave velocity; UC, 
usual care 
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(Table 16), and adipokines and fetuin-A (IL-6 was elevated in 3 of the 6 patients with 
elevated CRP, and there was no association between the inflammatory markers IL-6 and 
CRP at baseline (Spearman r = 0.37, p = 0.3).  Six of the 10 patients had an elevated hs-
CRP, defined as CRP > 5mg/L, at baseline.  In the UC group, those with an elevated hs-
CRP at baseline continued to have an elevated hs-  
 
Table 17) were assessed every 3 months, until the study was suspended.  Counts of 
CD133+, CD34+ and KDR+ cell by flow cytometry FACS analysis had not yet been 
performed when the study was terminated, as the samples were prepared and stored for 
later analysis. 
	  
Median brachial to femoral PWV was 13.5 m/s in the LSG group and 13.8 m/s in the UC 
group at baseline.  PWV remained relatively stable over 6 months in the UC group.  
Median waist to hip ratio was 1.00 in the LSG group and 1.02 in the UC group at baseline, 
and did not change over the study in the UC group.   
 
Figure 13 is a CFU-Hill colony at day 5 in culture from 1 of the study patients, after 
fixation with methanol and staining with Giemsa Blue.  A colony is defined as a cluster of 




Figure 13: A CFU-Hill colony at day 5 in culture medium from a haemodialysis patient (x20 magnification) 
 
all four CFU-Hill cell cultures prepared, was calculated at each time point.  Average within-
patient CFU-Hill colony counts ranged between 0 and 118 colonies per 107 cultured 
mononuclear cells at baseline, and the median colony count was 26.5 (IQR 5-45).  In the 
UC group CFU-Hill counts were either stable or declined during the 6-month follow-up 
period.  One patient in the UC group consistently produced no CFU-Hill colonies in any 
of the 3 cell cultures performed over 6 months.   
Table 16: Markers of inflammation in obese patients on haemodialysis undergoing laparoscopic sleeve 
gastrectomy for weight loss 
Measure IL-6 (ng/L) 
 
hs-CRP (mg/L) 
   Month 0 3 6 0 3 6 
LSG  LSG 1 3.8   1.7   
group LSG 2 2.0   10.1   
 LSG 6 28.5   38.3   
 LSG 9 2.6   11.9   
        
UC  UC 1 7.2 7.2 167.6 9.5 22.4 11.3 
group UC 2 3.8 3.7 0.4 1.1 2.5 6.1 
 UC 3 20.0  12.4 13.7  22.5 
 UC 4 13.4 16.7 15.8 16.3 48.1 31.8 
 UC 5 2.6 2.8  1.9   
 UC 6 3.1 2.9  2.8 3.9  
hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin 6; LSG, laparoscopic sleeve gastrectomy; UC, usual care 
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IL-6 was elevated in 3 of the 6 patients with elevated CRP, and there was no association 
between the inflammatory markers IL-6 and CRP at baseline (Spearman r = 0.37, p = 0.3).  
Six of the 10 patients had an elevated hs-CRP, defined as CRP > 5mg/L, at baseline.  In 
the UC group, those with an elevated hs-CRP at baseline continued to have an elevated hs-  
 
Table 17: Adipokines and Fetuin-A in obese patients on haemodialysis undergoing laparoscopic 
sleeve gastrectomy for weight loss 
Measure Fetuin-A (mg/L) Adiponectin (mg/L) Leptin (µg/L) 
   Month 0 3 6 0 3 6 0 3 6 
LSG  LSG 1 747.0   22.1   719.3   
group LSG 2 481.2   10.5   388.8   
 LSG 6 393.7   14.4   56.5   
 LSG 9 601.5   6.4   238.8   
           
UC  UC 1 790.9 476.3 1874 21.4 10.2 16.6 95.2 60.1 32.2 
group UC 2 402.5 564.7 468.2 24.0 26.6 24.9 87.3 119.8 58.6 
 UC 3 643.2  501.5 10.8  9.3 427.5  79.2 
 UC 4 606.8 710.6 527.0 21.4 15.6 20.9 198.9 204.5 262.1 
 UC 5 626.7 438.3  12.0 17.9  303.0 136.0  
 UC 6 482.4 497.4  22.9 34.6  269.3 204.9  
LSG, laparoscopic sleeve gastrectomy; UC, usual care 
CRP at 6 months.  Median (IQR) for fetuin-A at baseline was 604 (481-643) mg/L, and 
there was no relationship between fetuin-A and either adiponectin, HOMA-IR, arterial 
stiffness, systolic blood pressure, body weight, waist circumference, HDL cholesterol or 
triglycerides at baseline in the study sample.   
 
Total adiponectin was inversely correlated with baseline body weight (Spearman r = -0.82, 
p = 0.04), and did not differ between groups at baseline.  Serum leptin levels varied widely 
in the sample population, and ranged from 56.5 to 717.3 µg/L.  Median leptin was 313.8 
µg/L in the LSG group and 234.1 µg/L in the UC group at baseline.  Leptin levels 
decreased over 6 months to 68.8 µg/L in the UC group.  Baseline leptin was not associated 






This pilot study was designed to study the efficacy and safety of the LSG for weight loss in 
obese patients with kidney failure undergoing haemodialysis.  As the King’s College 
Hospital Research and Development Directorship stopped the study early, due to the 
occurrence of 2 serious adverse events, the study was unable to achieve its aim.  The results 
are inconclusive.  The following discussion will largely focus on determining the risks of 
LSG in obese haemodialysis patients and the ethical considerations in early cessation of 
research in clinical studies.   
 
Effect of weight loss surgery on kidney transplantation waitlisting 
All 3 surviving patients who underwent LSG, but no control patients, lost sufficient weight 
to reduce their BMI to < 35 kg/m2 and have commenced the process of assessment and 
preparation for kidney transplantation waitlisting or kidney transplantation from a living 
donor.  This is consistent with our previous uncontrolled observational study of obese 
patients with CKD undergoing LSG surgery, in which 4 out of 5 patients were listed for 
kidney transplantation after sufficient weight loss was achieved (MacLaughlin, Hall et al. 
2012).  
 
There are no other published studies of LSG in obese patients with CKD, however, gastric 
bypass and gastric banding have also been successfully used to achieve weight loss prior to 
kidney transplantation or waitlisting, with no peri-operative mortality reported 
(Newcombe, Blanch et al. 2005; Alexander and Goodman 2007; Koshy, Coombes et al. 
2008; Takata, Campos et al. 2008; Modanlou, Muthyala et al. 2009).   
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Quality of Life 
Baseline SF-36 scores in this study were similar to those reported in a study of 394 patients 
with stage 5 CKD and undergoing dialysis treatment in a Swedish CKD population (SF-36 
physical domain 32.9; SF-36 mental domain 38.5), and both the study group as a whole and 
HD patients in the Swedish study had lower SF-36 scores than the Swedish population 
mean (SF-36 physical domain 50; SF-36 mental domain 50) (Pagels, Soderkvist et al. 2012), 
although the UC group had a similar score to the population mean for the mental health 
domain.  The lower quality of life scores in the LSG group at baseline in the present study 
may go some way to suggest why those patients chose to undergo LSG, and those with 
higher quality of life scores chose not to be considered for weight loss surgery, given that 
treatment allocation was self-selected.  The study was unable to determine whether these 
quality of life scores improved after weight loss surgery due to early termination of follow 
up data collection.  
Exploratory Outcomes 
PWV values for patients in this study were higher than recently reported reference values 
for the healthy population, with normal median values ranging between 7-8 metres/second 
for 40-60 year olds (The Reference Values for Arterial Stiffness Collaboration 2010), and 
also higher than reported for normal weight haemodialysis patients (Georgianos, Sarafidis 
et al. 2011), which may have been expected as PWV also increases with obesity (Safar, 
Czernichow et al. 2006).  
 
Brachial to femoral PWV is relatively quick and simple to measure and can be performed 
post dialysis, although ideally it should be performed on an inter-dialysis day (Di Iorio, 
Nazzaro et al. 2010).  However, without the full study data, the usefulness of PWV 
measurement, and inflammatory and adipose tissue markers, to monitor the cardiovascular 
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effects of weight loss in haemodialysis patients in future studies, cannot be commented 
upon.   
 
As far as could be ascertained, there is only one other study measuring endothelial 
progenitors cells using the CFU-Hill colony culture assay in patients undergoing 
haemodialysis (Krieter, Fischer et al. 2010), and the results of the present study concur with 
the median CFU-Hill colony count of between 5.0 and 35.0 colonies per 107 mononuclear 
cells (range 0 - 262.5 per 107 mononuclear cells) for haemodialysis patients, (Krieter, 
Fischer et al. 2010), which is considerably lower that the intermediate level of 124 colonies 
per 107 mononuclear cells reported for healthy males (Hill, Zalos et al. 2003).   
 
Analysis of CFU-Hill colony forming units is a time-consuming process that must be 
initiated immediately on fresh blood samples, and unless a 7-day laboratory support service 
is available, would not be practical in larger studies of haemodialysis patients.  Without a 7-
day cell culture service, samples for CFU-Hill cultures can only be collected on 
Wednesdays, so that Days 0, 2 and 5 fall on weekdays.  However, this is not practicable, as 
only half of any haemodialysis population undergo dialysis on a Wednesday.   
 
The techniques for quantitative analysis of cells expressing CD34+, KDR+ and CD133+ 
and co-expressing CD34+/KDR+ and CD133+/KDR+ and CD133+/CD34+/KDR+, 
including preparation and immunofluorescent-labelling of the extracted PBMC and control 
samples, using FACS analysis (BD FACS-Canto II: Belgium), were observed, learned and 
practised by the candidate, but not performed on the stored study samples prior to the 
early termination of the study.   
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Serum leptin was not directly associated with body weight in this small study sample, which 
supports the hypothesis that reduced kidney function results in a decrease in leptin 
clearance in CKD (Axelsson and Stenvinkel 2008), which is independent of leptin 
resistance resulting in hyperleptinaemia evident with obesity (Kelesidis, Kelesidis et al. 
2010).  
 
Adiponectin is associated with body weight in this study sample, and with HOMA-IR in 
patients without diabetes.  Insulin resistance usually supresses adiponectin (Wiecek, 
Adamczak et al. 2007), but there was a direct correlation between adiponectin and HOMA-
IR in this sample, and no evidence of an inverse relationship between leptin and 
adiponectin, indicating that adiponectin, and/or leptin may be increased in haemodialysis 
patients either due to a reduced GFR, or alternatively, adiponectin rises in response to a 
high level of inflammatory signalling (Rabin, Kamari et al. 2005) in an attempt to suppress 
the atherosclerotic processes (Ouchi, Kihara et al. 1999).  
 
Levels of fetuin-A were similar to those published previously in haemodialysis patients 
(Hermans, Brandenburg et al. 2007).  Fetuin-A is a strong inhibitor of vascular 
calcification, and is inversely related to arterial stiffness in non-diabetic patients with stages 
3-4 CKD, and inversely with mortality in haemodialysis (Stenvinkel, Wang et al. 2005; 
Ford, Tomlinson et al. 2010).  There was no inverse relationship between fetuin-A and 
adiponectin, as has been reported in earlier stages of CKD (Ix, Chertow et al. 2006), and 
also no relationship between fetuin-A and insulin resistance and other metabolic syndrome 
components, which was evident in obese children without CKD (Reinehr, Roth et al. 
2008).  These findings may suggest that in haemodialysis patients, the relationship between 
fetuin-A and obesity (or metabolic syndrome) may be overshadowed by the deranged 
metabolic state of vascular calcification.  The effect of weight loss on fetuin-A levels in 
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obese haemodialysis patients cannot be elucidated from this study due to the early 
cessation of the research. 
 
Safety and efficacy of weight loss surgery 
This study attempted to monitor the safety and efficacy of LSG in obese patients with 
kidney failure undergoing haemodialysis.  A series of events occurred, resulting in early 
termination of the study.  The study was conducted following the study protocol, in which 
patients self-selected either LSG surgery, or maintained best medical care, and a range of 
clinical and laboratory based outcomes were measured at pre-established time points in all 
patients.   
 
The first patient to undergo LSG in the study died following complications post surgery.  
This was discussed with the Research and Development Department at King’s College 
Hospital, and as this patient was already due to undergo weight loss surgery prior to 
consenting to take part in the study, the event was deemed to be not directly related to the 
study.  The Chief Investigator (the candidate) was informed at the time that the event did 
not need to be reported officially to the Research Ethics Committee.   
 
Following the second case of LSG surgery, the haemodialysis team was not informed that 
this patient was being admitted and did not have adequate information to perform his 
haemodialysis safely without risking the patency of his vascular access graft.  Problems 
developed when the access was used and then failed.  This series of events was reported as 
a clinical adverse incident and it was unclear whether or not the access difficulties were 
directly related to the LSG surgery.  At this point the candidate met with the study surgeon 
and the senior clinical investigator to discuss 2 issues; firstly, should the patients who have 
provided consent be informed about the 2 adverse events related to LSG in haemodialysis 
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patients, and secondly, how can communication between the medical and surgical teams be 
improved?      
 
It was agreed that all patients with CKD undergoing LSG would be admitted to hospital 
under the care of the admitting Consultant Nephrologist on call, rather than the study 
surgeon.  This would ensure that adequate communication between the teams occurred 
prior to admission and that all necessary arrangements for haemodialysis were in place.  
The medical and surgical opinion was that it was too early in the study to determine 
whether the risk of surgery was increased in these patients and that informing patients of 
the adverse events may create unjustified concern.  
 
The 3rd and 4th sleeve gastrectomies proceeded uneventfully.  Both the 5th and 6th 
procedures were cancelled due to the hospital being unable to allocate a bed for an elective 
surgical procedure on the days of the planned admissions.  During completion of the study 
annual report in December 2011, the candidate informed the Research Ethics Committee 
of the 2 adverse events.  The committee determined these events were related to the study, 
and requested both further information and a meeting with the Chief Investigator (the 
candidate), together with a representative from the Research and Development 
Department at King’s College Hospital.  Upon receiving copies of the event notifications 
and the response from the Research Ethics Committee, the Research and Development 
Department decided to suspend the study and investigate the events.   
 
A meeting was held between the candidate, the lead clinical investigator and the Research 
and Development Manager, Director, and Deputy Director to discuss the events.  The 
approval to conduct the study at the host site was withdrawn, as the Research and 
Development team deemed that the study had met the predetermined stopping criteria of 
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consistent observation of early or late post surgical complications.  Additionally, the 
Research and Development team decided that the patients had not been informed 
sufficiently of the risk related to surgery and thereby could not provide informed consent.  
 
The written report of the meeting sent to the Research Ethics Committee contained errors 
and inconsistencies.  The candidate prepared and submitted a response, with documented 
evidence providing information to support corrections to the errors in the report.  An 
independent investigation into the study and its governance was commissioned.  Dr Frank 
Post, Senior Clinical Lecturer at King’s College London, conducted the investigation and 
produced a report with recommendations designed to improve study governance across 
the hospital trust.  Clearer guidance from both the Research and Development Department 
and the Research Ethics Committee was required, and slight but technically significant 
inconsistencies between the study design and the information listed on the IRAS project 
information, completed by a novice researcher, resulted in misinformation being provided 
at the crucial time of enquiry by the researcher. 
The timing of the adverse events may have affected the decision to terminate the study 
early.  If the adverse events had occurred later in the study, then the level of perceived risk 
may have been lower and the study may not have been ceased.  Furthermore, it is difficult 
to accept that complications and adverse events in 2 out of 4 patients can demonstrate a 
consistent observation of surgical complications, particularly when this patient group is 
known to have a mortality rate of 20% per year, with mortality directly related to 
inflammation (Pecoits-Filho, Barany et al. 2002).   
 
Additionally, a further 2 patients died whilst waiting to commence the study, and although 
these patients were to be allocated to the surgical group, they had not undergone surgery.  
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It is possible therefore, that the burden of co-morbidities in this patient population is 
responsible for the increase in perceived risk, rather than the surgical procedure itself.     
 
There are very few studies determining the risk of different surgical procedures for 
haemodialysis patients.  In 2 retrospective studies of perioperative mortality after 
abdominal aortic aneurysm repair, only 8 (0.8% of total study population) and 7 patients on 
haemodialysis, respectively, had undergone the procedure studied (Forbes and Lawlor 
2005; Lucas, Pereira et al. 2008).  Mortality varied considerably from 12.5% (Lucas, Pereira 
et al. 2008) to 0% (Forbes and Lawlor 2005), but it remains difficult to draw conclusions 
on the surgical risk in haemodialysis patients from these very small studies.  Additionally, 
no difference in complication rates or mortality was found between haemodialysis patients 
and otherwise healthy patients undergoing laparoscopic cholescystectomy (Yeh, Chen et al. 
2005).   
 
More recently, it has been reported that haemodialysis patients have an increased risk of 
morbidity and mortality after coronary artery bypass graft surgery (Yamauchi, Miyata et al. 
2012).  Similarly, in patients undergoing valve surgery, elevated parathyroid hormone, 
serum phosphate, and calcium x phosphate product were risk factors for increased 
mortality in haemodialysis patients (Yan, Sharma et al. 2011).  It is notable that neither of 
these studies was published prior to the present study commencing, and therefore were not 
able to be used in the assessment of risk to haemodialysis patients undertaking elective 
sleeve gastrectomy for weight loss.   
 
In the time following suspension of the present study, data on the impact of kidney 
function on the outcomes of bariatric surgery was recently published in May 2012.  Using 
the database of the American College of Surgeons National Surgical Quality Improvement 
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Program, all patients undergoing gastric bypass or gastric banding records between 2005 
and 2008 were classified by eGFR to determine stage of CKD (Turgeon, Perez et al. 2012).  
In over 27 000 patients, almost 7 000 patients were classified as having CKD stages 2-5, 
including 34 patients who were already undergoing dialysis.  The complication rate was 
almost 10% in patients with stage 5 CKD, and there was no difference in mortality 
between patients with and without CKD.  Therefore, it is likely that the risks in sleeve 
gastrectomy surgery for obese patients undergoing haemodialysis are higher than in obese 
patients without CKD, however the level of risk is unable to be assessed in the present 
study, and may relate more to high cardiovascular risk, a risk factor for any major surgery, 
rather than that specifically related to the LSG procedure itself.  Indeed, recent evidence 
suggest this is the case, as in a study of all non-emergent general surgery procedures, again 
using the database of the American College of Surgeons National Surgical Quality 
Improvement Program, the risk of complications and post-operative mortality was higher 
in patients undergoing dialysis treatment, than in non-dialysis patients undergoing the same 
procedures (Gajdos, Hawn et al. 2012). 
 
Consideration of the adverse events may have been alternatively managed by recruitment 
suspension, as recommended by the Research Ethics Committee, and further investigation 
of potential risk factors undertaken, prior to further recruitment.  Potential risk factors 
which may have been considered include the length of time patients had undergone 
haemodialysis treatment, pre-surgery BMI, the extent of the pre-surgery assessment 
including cardiac and respiratory investigations, co-morbidities and novel cardiovascular 
risk factors, including serum phosphate, calcium and hyperparathyroidism.   
 
Given the experience of this investigation, several changes have been made in clinical 
practice to minimise risk post LSG.  Factors identified during the study that may have 
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exacerbated risk were addressed and procedures put in place to minimise these known 
risks. The following changes were made to the standard care protocol to reduce the risks 
associated with surgery: a full “renal” assessment of each patient was to be conducted in 
close proximity to the surgery date; and patients are to be admitted to the renal ward under 
the on-call consultant nephrologist rather than to the surgical ward.  
 
In 2011, the first report of the United Kingdom National Bariatric Surgery Registry was 
published.  The risk of complications (2.6%) and mortality (0.1%) in obese patients 
undergoing bariatric surgery in the United Kingdom is very low, despite a high level of co-
morbidity in the patient population (Welbourn, Fiennes et al. 2011).  Presently, there is not 
a data field for registering CKD as a co-morbidity in the reporting forms.  However, this 
database may present an opportunity to measure the risk of weight loss surgery in obese 
patients with CKD in the future, especially with the recent change to commissioning of 
services and the requirement that all patients are followed up for 2 years post-operatively 
with the data reported on the National Bariatric Surgery Registry. 
Ethical issues to consider in this study 
A decision to cease a research trial can be made by the Research Ethics Committee 
responsible for providing the favourable opinion to conduct the research, a data 
management committee, the study sponsor, and the research investigators.  However, in 
this case, the research governance body at the primary study site withdrew site approval.  A 
study may be stopped when significant differences exist between benefits and harm in the 
study groups, or if an excessive number of adverse events have occurred in one group 
(Silverman 2007).  How to determine if the number of adverse events is excessive is 
difficult in the present study, given the relatively early cessation of the study and the known 
high mortality rate in this patient population, usually secondary to cardiovascular causes.  
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Interim assessments of clinical studies have the potential for concluding a false adverse 
effect (Silverman 2007), as the study denominator is undervalued.  It may have been 
prudent to have prospectively appointed a data monitoring committee for this study, and 
this will be the case for any future studies using interventional procedures for weight loss in 
obese patients with CKD.  However, if the study were to continue, this would have 
presented an ethical dilemma about informing the patients remaining in the study and 
those considering participating about the possibility of an increased risk attributable to a 
major surgical procedure, such as, but not limited to the LSG.  Furthermore, the 
conflicting priorities of the researcher and the patients may also influence this decision and 
must be recognised (Silverman 2007).  Patients should be informed of serious adverse 
events (Silverman 2007), however the balance of creating an informed consent process and 
overestimating the potential risk must be delicately handled to find equilibrium.  The 
Information for Participants booklet did list the known risks for weight loss surgery in the 
general population, but did not list CKD specific risks, as there were no reported studies of 
LSG in haemodialysis patients.  Attempts to compare the risk of this surgery with other 
types of abdominal surgery in patients without CKD, at the time the study was conceived, 
did not indicate that there was an increased risk of complications or mortality peri-
operatively in patients undergoing haemodialysis compared to those not undergoing 
haemodialysis (Yeh, Chen et al. 2005).   
 
Presently, the options available to obese patients with CKD on haemodialysis who are 
unable to be considered for kidney transplantation due to excessive BMI are limited.  In 
patients with a BMI > 30 kg/m2, individual assessment of risk for kidney transplantation, 
including assessment for cardiovascular disease, is recommended; and BMI should not be 
an absolute contraindication if the overall risks are tolerable, and it is perceived that 
mortality risk will be reduced (Dudley and Harden 2011).  This view is supported by a 
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recent analysis of the United States United Network of Organ Sharing database, which 
demonstrated a significant increase in risk of delayed donor grafted kidney function with 
obesity, with an multivariable adjusted OR of 2.46 for patients with a BMI ≥ 40 kg/m2 and 
a statistically significant, but unlikely clinically significant increase in risk of kidney graft 
failure of 3.6%, and no increased risk of all-cause mortality with obesity (Cannon, Jones et 
al. 2013).  These findings question the appropriateness of BMI cut offs of 30-35 kg/m2 for 
kidney transplantation.  However, 1 centre in New Orleans has increased the BMI cut-off 
for kidney transplantation to 42 kg/m2, with the addition of dietetic counselling for 
patients with a BMI of 35-42 kg/m2 and a weight contract for patients with a BMI 40-42 
kg/m2, who must be losing weight at the time of an offer of kidney transplantation.  
Patients with a BMI > 45 kg/m2 are referred for weight loss surgery prior to kidney 
transplantation waitlisting (Killackey, Zhang et al. 2010).   
 
Lifestyle weight loss treatments are potentially successful, yet require significant patient 
input and yield between 5-10% weight loss (MacLaughlin, Cook et al. 2010), yet this may 
be insufficient to reach a BMI of <35 kg/m2 in morbidly obese patients.  Very low calorie 
diets may be efficacious, but can be maintained in the short tem only and weight gain often 
occurs after cessation (Ryttig and Rossner 1995).  Given that the time lag between kidney 
transplantation wait-listing and actual transplantation is currently over 3 years in the United 
Kingdom, this treatment option is not likely to be effective as patients may be removed 
from the transplantation waiting list if their BMI subsequently increases above the 
threshold.  Finally, newer non-surgical obesity treatments that are inserted endoscopically, 
such as the intra-gastric balloon device and the duodenal-jejunal bypass sleeve, remain 
untested in obese patients with CKD, and may be studied in this population in the future. 
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Implications for future research 
Many lessons have been learned during the conduct of this study, most of which were 
unpredicted.  It became apparent after the adverse events that the level of understanding of 
the study from the teams supporting research was insufficient to advise and act 
appropriately on aspects of research governance.  For novice researchers, clearer guidance 
on, and greater scrutiny of information provided to research ethics committees is 
recommended, with perhaps a research governance mentorship structure in place, over and 
above the academic supervision provided to novice researchers during their training. 
 
While the design of this study fits the definition of a cohort study, the manner in which the 
intervention was provided approaches the characteristics of clinical trial methodology, and 
the blurring of this boundary was clearly problematic in this study.  In future, it may be 
prudent to call such a study as this, in which it is not absolutely clear whether the 
intervention being offered is standard care or experimental, a non-randomised intervention 
study. 
Patient choice was paramount in this study, as the risks of the procedure in the study 
populations were not known, and whilst attempts to make this clear were made, it is always 
possible to find ways to increase patient understanding of the level of unknown risk 
further.  One way to make this clearer to the public, potential participants, research ethics 
committee members and research governance teams would be to identify safety as the 
primary study outcome.  The use of safety as a primary outcome in studies of novel 
surgical procedures is discussed extensively in Chapter 7.      
 
Summary and conclusions 
The safety and efficacy of LSG for weight loss in obese patients undergoing haemodialysis 
remains unknown, as this study was ceased early.  Our available results demonstrate that 
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the procedure induces weight loss and aids patients in meeting the BMI criteria for kidney 
transplantation, and that in some patients at least, the risk of adverse events and mortality, 
may be increased.  Recent studies have demonstrated an elevated risk in haemodialysis 
patients undergoing heart surgery, all elective general surgery, and a 10% risk of 
complications in patients with stage 5 CKD undergoing other weight loss surgery 
procedures, than in patients without CKD (Gajdos, Hawn et al. 2012; Turgeon, Perez et al. 
2012; Yamauchi, Miyata et al. 2012).  Further research may be conducted to assess the risk 
through audit of national and international bariatric surgery registry records, prior to the 
conduct of any carefully planned future prospective study, and this is discussed in more 




Chapter 5: The effect of weight loss surgery on preservation of 
kidney function and cardiovascular disease risk factors in 
obese patients with chronic kidney disease: a randomised 
controlled pilot study 
 
Chapter summary  
Prevention of the progression of kidney damage is the ultimate goal of treatment in 
patients with stages 3-4 CKD, and it has been suggested that weight loss may play a role in 
improving kidney function, although this has not been tested in a randomised controlled 
trial, and previous studies have utilised estimated, rather than true markers of kidney 
function only.  This pilot study aimed to determine the effect of weight loss on measured 
kidney function in obese patients with stages 3-4 CKD.  A prospective, randomised 
controlled pilot study was conducted to examine the effect of laparoscopic sleeve 
gastrectomy (LSG) weight loss surgery, compared to best medical care including dietary 
and physical activity modifications, on kidney function.  16 patients were recruited to the 
study, 3 patients withdrew after randomisation, 1 patient withdrew during the intervention 
period and 1 patient remained on the LSG waiting list when baseline data collection was 
closed.  11 patients completed the study, with 5 patients undergoing sleeve gastrectomy 
(SG) and 6 patients in the best medical care (BMC) group.  Recruitment to a randomised 
trial of SG weight loss surgery compared to BMC was difficult and the waiting time for 
LSG was longer than anticipated.  There was significant weight loss over 12 months in 
both groups (BMC 4% p = 0.04; SG 35% p <0.001), and waist circumference, and body 
fat mass also decreased significantly in the SG group.  The mean difference in weight loss 
at 12 months was -29kg (95% CI -36, -22); median excess weight loss was 72.6% in the SG 
group and 9.5% in the BMC group.  Estimated kidney function significantly and 
consistently under-predicted measured glomerular filtration rate (mGFR) using the iohexol 
clearance method in all patients, with a greater bias in stage 3 CKD compared to stage 4 
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CKD.  Kidney function improved over 12 months, with a reduction in hyperfiltration, in 
the SG group, but not in the BMC group.  Serum adiponectin increased in the SG group 
compared to the BMC group at 12 months (median difference 6.1; 95% CI 1.0, 19.8), and 
decreasing weight was inversely associated with adiponectin (r = -0.75 p = 0.008).  
HOMA-IR decreased in the SG group compared to the BMC group at 12 months (median 
difference -7.7; 95% CI -28.8, -0.5), reflecting a reduction in insulin resistance with weight 
loss.  There were no changes in leptin or markers of inflammation (IL-6, CRP, TNF-α) 
between groups at 12 months.  3 out of 4 quality of life measures improved in the SG 
group compared to the BMC group at 12 months.  Fetuin-A, an inhibitor of vascular 
calcification, which rises with obesity, decreased equally in both groups after 12 months, 
although this decrease was not associated with any other variables in the study.  There were 
no significant changes in metabolic syndrome or hypertension with weight loss in this 
study.  There were 2 adverse events in the SG group and 1 in the BMC group during the 
study.  Weight loss surgery may potentially improve kidney function, insulin resistance and 
quality of life in obese patients with CKD.  Further studies are required to provide 





There is a paucity of robust, scientific evidence informing clinical practice in the 
management of obesity in patients with chronic kidney disease.  Prevention of the 
progression of kidney damage is the aim of treatment in patients with stages 3-4 CKD, and 
it has been suggested that weight loss may play a role in improving estimated kidney 
function (Navaneethan and Yehnert 2009), although this has not been tested in a 
randomised controlled trial.  Additionally, all patients with CKD have an elevated risk of 
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developing cardiovascular disease, compared to the general population.  The results in 
Chapter 2 demonstrated a relationship between participation in the Weight Management 
Programme (WMP) and a longer mortality and cardiovascular morbidity event-free period.  
This indicates that there may be a protective element associated with a programme of an 
energy reduced diet, increased physical activity and pharmacotherapy, however the effect of 
weight loss alone, such as that achieved through weight loss surgery, on cardiovascular 
outcomes in obese patients with CKD remains unknown.  Along with examining the effect 
of weight loss on kidney function, this study will also attempt to characterise the 
relationships between weight loss and changes in inflammatory markers and adipokines, 
both of which are novel cardiovascular risk factors also associated with CKD (Dogra, Irish 
et al. 2006; Addabbo, Mallamaci et al. 2007). 
 
This chapter describes a prospective, randomised controlled pilot study designed to 
compare the effect of 2 weight loss treatment strategies, LSG weight loss surgery or best 
medical treatment - including lifestyle modifications and anti-obesity medication, on kidney 
function.   
  
Research question: Does weight loss achieved with weight loss surgery improve kidney 
function and modify novel and traditional cardiovascular disease risk markers in morbidly 
obese patients with chronic kidney disease? 
 
Study Aims 
Aim: This randomised, controlled, parallel-design pilot sutdy aimed to evaluate the effect of 
LSG weight loss surgery on kidney function, compared to best medical treatment, 
including a structured multidisciplinary WMP, in obese patients with CKD (BMI 35 - 45 
kg/m2).   
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Secondary aims included studying the effect of weight loss surgery on measures of quality 
of life and monitoring surgical complications and adverse events.  Furthermore the effect 
of weight loss on reducing insulin resistance, hypertension, dyslipidaemia, inflammation 
and the adipokine response was studied, to determine whether weight loss reduced the 
cardiovascular burden associated with obesity and CKD in this patient group. 
 
Primary Hypothesis 
Weight loss following SG improves kidney function  (in obese patients with stages 3-4 
CKD, compared to BMC including a structured lifestyle based weight loss intervention, 
including dietary modification and increased physical activity, and anti-obesity medication.   
 
Primary Outcome  
The primary outcome measure was measured GFR (ml/min) using the iohexol clearance 
method 12 months post SG, compared to BMC. 
 
Determination of GFR is considered the gold standard for assessing kidney function, when 
measured using an inert substance which is cleared exclusively from the body by 
glomerular filtration.  Iohexol, is such a substance, and is an iodine based, non-ionic, 
radiological contrast agent, cleared exclusively by the kidneys.  Measurement of plasma 
iohexol clearance over time is considered a gold standard technique (Niculescu-Duvaz, 
D'Mello et al. 2006) as it correlates well with classical gold standard methods such as inulin 
or chromium-51 labelled ethylene diamine tetracetic acid (EDTA) clearance (O'Reilly, 
Brooman et al. 1986; Brown and O'Reilly 1991), although evidence of such comparisons in 
obese patients with CKD is lacking.  Indeed, there is a paucity of evidence on the use of 
iohexol measured GFR in obese subjects or obese patients with CKD.   
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As kidney function declines, determination of GFR using iohexol clearance can take up to 
5 hours, which is expensive and inconvenient to measure in a clinic.  Fingertip blood 
sampling onto blotting paper correlates well with serum sampling techniques (r2=0.953), 
and it is suggested that use of this technique allows patients to complete the test at home, 
with samples being returned in the post (Niculescu-Duvaz, D'Mello et al. 2006; Mafham, 
Niculescu-Duvaz et al. 2007).  This method reduces the time patients are required to attend 
a hospital or clinic for the measurement of kidney function, and appears to be a practical 
and efficient method of measuring GFR for both patients and the researcher.  Results of 
this method with patients actually performing their own fingertip blood sampling, 
compared to results obtained by researchers in a laboratory setting, have not been 
published.  Similarly, there are no data on the use of this method for repeated measures of 
GFR longitudinally.  Therefore, the utility of the method of GFR measurement, as much as 
the effect of the treatment on GFR itself, was explored in this study. 
 
Use of an exogenous marker that is cleared almost exclusively by the kidneys may eliminate 
problems associated with the measurement of changing kidney function with weight loss, 
as body composition changes.  GFR can be expressed relatively, after correction and 
standardisation for body surface area (ml/min/1.73m2) or in absolute terms (ml/min).  As 
changes in body surface area with weight loss affect the relative GFR, regardless of change 
in actual kidney function, absolute GFR, rather than relative GFR, was selected for use in 
this study (Delanaye, Radermecker et al. 2005).  Similarly, as muscle mass may decrease 
with weight loss alongside a decrease in fat mass, changes in estimates of GFR that are 
based on serum creatinine or cystatin-C (the former a product of muscle breakdown, and 
the latter produced in all nucleated cells, including adipocytes) are also unsuitable for use in 




Secondary Hypotheses and Secondary Outcomes 
1. Weight loss following laparoscopic sleeve gastrectomy resolves or improves 
co-morbidities including type 2 diabetes, insulin resistance, hypertension, 
proteinuria, hyperlipidaemia, and metabolic syndrome, compared to best 
medical care - including a structured lifestyle based weight loss intervention 
and anti-obesity medication.  
 
Insulin resistance (HOMA-IR), type 2 diabetes, blood pressure, blood lipids and metabolic 
syndrome 
Insulin resistance, hypertension and dyslipidaemia are elements of metabolic 
syndrome, which is associated with both CKD and obesity (Wahba and Mak 2007; 
Sarafidis 2008).  Weight loss in obese patients without CKD is known to improve 
all three factors (Klein 2001; Bougoulia, Triantos et al. 2006), yet there is little 
information on the effect of weight loss on these parameters in obese patients with 
CKD.  Previous research has demonstrated that multidisciplinary, targeted 
interventions in patients with stages 3-4 CKD - which were not specifically aiming 
for weight loss - can have positive effects on BP, dyslipidaemia, progression to 
kidney failure, and outcomes up to 2 years after the commencement of renal 
replacement therapy (Levin 2001). 
 
HOMA-IR is a validated model of estimating insulin resistance from steady state 
insulin and glucose concentrations, calibrated to give a normal insulin resistance 
equal to 1 using the estimation equation (Matthews, Hosker et al. 1985).  HOMA-
IR correlates with insulin resistance, measured by the standard glucose clamp 
method, in patients with CKD (Shoji, Emoto et al. 2001).  Patients with CKD, 
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without diabetes, have HOMA-IR scores 3 times higher than healthy controls, 
(mean HOMA-IR 2.9 (95% CI 2.4 to 3.5, vs 1.0 (95% CI 0.8 to 1.2), P < 0.001) 
(Dogra, Irish et al. 2006), even in the earliest stages of CKD when GFR is normal 
and when patients with CKD and healthy controls are matched for body weight 
(Becker, Kronenberg et al. 2005).  HOMA-IR is approximated as (fasting plasma 
insulin mU/L x fasting plasma glucose mmol/L) divided by 22.5, however, the 
mathematical model includes more sophisticated modelling to better replicate the 
physiology, particularly in more hyperglycaemic states (Levy, Matthews et al. 1998).  
There is no information on the effect of weight loss on insulin sensitivity in obese 
patients with CKD.  In obese women without CKD, insulin sensitivity improved 
with weight loss and was also related to favourable changes in adiponectin, free 
fatty acids (Esposito, Pontillo et al. 2003) and albuminuria (Gilardini, Zulian et al. 
2010). 
 
Hypertension and decreased HDL cholesterol are associated with the development 
of CKD (Fox, Larson et al. 2004), and elevated systolic BP is associated with CKD 
progression in patients with co-existing albuminuria (Yan, Zhu et al. 2012).  
Hypertension is highly prevalent in obese patients with CKD, despite management 
with multiple anti-hypertensive medications (MacLaughlin, Sarafidis et al. 2012).   
 
Urinary albumin-to-creatinine ratio and protein-to-creatinine ratio 
Albuminuria and proteinuria decrease with weight loss in both the general 
population and in obese patients with CKD (Bello, de Zeeuw et al. 2007; Agrawal, 
Krause et al. 2009; Navaneethan, Yehnert et al. 2009; Afshinnia, Wilt et al. 2010).  
Reduction in albuminuria is related to changes in CRP, BP, lipids and blood 
glucose, but remains independently associated with weight loss after adjustment for 
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these associations (Bello, de Zeeuw et al. 2007).  The impact of weight loss on 
proteinuria and albuminuria, both known cardiovascular disease risk factors, may 
be related to reductions in lipotoxicity, inflammation and oxidative stress, as well as 
changes in BP, blood lipids and blood glucose control, indicating that a mix of 
traditional and novel cardiovascular disease risk factors are involved (Afshinnia, 
Wilt et al. 2010). 
 
2. Quality of life scores improve and anxiety and depression scores decrease 
following laparoscopic sleeve gastrectomy, compared to best medical care.  
 
As decribed in Chapter 4, the self administered Short Form 36 (SF-36) and 
Hospital Anxiety and Depression Scale (HADS) (Appendix B) are widely used and 
validated measures of aspects of quality of life.  Weight loss surgery is associated 
with improved quality of life in most, but not all studied populations (Ballantyne 
2003).  Quality of life is an important measure to aid future clinical treatment 
decisions.  If quality of life improves with weight loss, regardless of other outcome 
measures, the intervention treatment may be worth pursuing for perceived patient 
benefit alone. 
 
3. Fat mass (derived from bioelectrical impedance analysis) and waist 
circumference decrease following laparoscopic sleeve gastrectomy and 
patients remain well nourished (measured by Subjective Global 
Assessment), compared to best medical care. 
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Body composition (weight loss (kg), percentage excess weight and BMI loss, waist and hip 
circumference, lean body mass and body fat mass measured with multi-frequency bioelectrical 
impedance analysis) 
Absolute weight loss is the difference between baseline weight and weight at the 
time-point of measurement, calculated as an absolute value and also as a percentage 
of baseline weight.  Excess BMI loss is calculated as the percentage of weight lost 
from the difference between actual body weight and body weight at a BMI = 25 
kg/m2, calculated as % excess BMI loss = [absolute weight loss/(baseline weight – 
weight if BMI = 25 kg/m2)] x 100.   Absolute weight loss as a percentage of 
baseline weight, and excess BMI loss are the preferred reportable standards for 
weight loss (Deitel, Gawdat et al. 2007), however excess weight loss has also been 
calculated and reported as a comparator to previous studies.  Excess weight loss is 
the most reported weight loss parameter for weight loss surgery, and is determined 
from the midpoint of the 1983 Metropolitan Life Insurance Tables for medium 
build, and calculated as % excess weight loss  = [Absolute weight loss/difference 
between baseline weight and the mid point of the 1983 Metropolitan Life Insurance 
Tables for medium build)] x 100 (Deitel, Gawdat et al. 2007). 
 
Lean body mass is calculated as body weight minus fat mass.  Fat mass is estimated 
from the relative resistance to an electrical signal as a function of body weight and 
height (adjusted for age and gender) using a multi-segmental body composition 
analyser (Biospace Inbody 720 analyser; Korea).  Assessment of body composition 
using multiple frequency bioelectrical impedance analysis demonstrated good 
agreement with dual-energy x-ray absorptiometry assessment of lean and fat mass 
during weight loss, in a study of obese and overweight women (Thomson, 
Brinkworth et al. 2007).  There are no published studies using bioelectrical 
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impedance to monitor body composition changes with weight loss in obese 
patients with CKD.   
 
Waist to hip ratio is related to cardiovascular disease risk (MI and fatal coronary 
disease) in patients with CKD (Elsayed, Tighiouart et al. 2008).  Waist 
circumference and waist to hip ratio provide alternative measures of body fat 
distribution to BMI, which is elevated when lean body mass is greater than normal, 
overestimating obesity.   
 
4. Adipokines and markers of inflammation improve with weight loss following 
laparoscopic sleeve gastrectomy, compared to best medical care.  A 
reduction in leptin, IL-6, TNF-α, hs-CRP, and fetuin-A, and an increase in 
adiponectin, is predicted with weight loss. 
 
An increase in adiponectin and a reduction in leptin, CRP and IL-6 occur with 
intentional weight loss in obese subjects (Gallistl, Sudi et al. 2001; Esposito, 
Pontillo et al. 2003; Kelesidis, Kelesidis et al. 2010).  With weight loss in obese 
patients with CKD, it is predicted that changes in leptin and adiponectin will reflect 
changes in adipocytes, and changes in IL-6 and TNF- α will reflect changes in an 
immune-modulated response from macrophages.  Fetuin-A is related to insulin 
resistance and metabolic syndrome characteristics, and decreases with weight loss, 
which may be associated with improved insulin resistance and an increase in 







This study was a prospective randomised controlled pilot study of SG weight loss surgery 
compared to BMC (Figure 14).  Patients were allocated to treatment groups in a 1:1 ratio. 
 
Ethical Review and Research Governance 
This study followed the principles of the Declaration of Helsinki – Ethical Principles for 
Medical Research Involving Human Subjects (World Medical Association 2008), and was 
approved by the London Surrey Borders Research Ethics Committee in November 2009 
(09/H0806/69).  All study patients provided written informed consent.  King’s College 
Hospital Research and Development governance approval was granted in January 2010, 
followed by approval from St Helier Hospital and Guy’s and St Thomas’ Hospital.  The 
study was registered in the Clinical Trials.gov registry with the unique trial number 
NCT01053130. 
 
A study protocol amendment was made to send letters of invitation to all patients meeting 




Figure 14: Schematic representation of study design and outcomes for the weight loss surgery in 
stages 3-4 chronic kidney disease (CKD) randomised controlled pilot study  
BMI, body mass index; GFR, glomerular filtration rate; HOMA-IR, method of homeostasis assessment for insulin 
resistance; IL-6, interleukin-6; R, randomisation; TNF-a, tumour necrosis factor-α 
 
 
Recruitment of patients 
The recruitment period commenced in March 2010 and continued until June 2011.  
Patients were recruited from outpatient clinics at all 3 study sites.   
 
Preliminary Screening 
Existing hospital patient databases and out-patient clinic appointment lists were searched 
for patients meeting the primary inclusion criteria of >18 years, BMI 35 - 45 kg/m2, and 
eGFR of 20 - 60ml/min/1.73m2.  The candidate is a Registered Dietitian with extensive 
clinical experience with CKD patients, and obtained permission to access clinical records 
and talk to patients at NHS sites hosting the research study.  Additionally, the candidate 
attended out-patient clinics to screen patients using the above criteria after height and 
weight measurements were taken, when this information was not available in existing 
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databases.  Patients meeting these criteria were then assessed against the full study inclusion 
and exclusion criteria (Table 18) from information in the patient’s medical record.  
Nephrologists from participating hospitals also referred potential participants for the study. 
 
Table 18: Inclusion and exclusion criteria for patient participation  
Inclusion criteria Exclusion criteria 
Male or female, aged > 18 years Pregnancy 
Previously attempted weight loss History of chronic liver disease 
BMI 35-45 kg/m2 Previous bariatric surgery, gastric surgery or large hiatus hernia 
Estimated glomerular filtration rate 
20-60ml/min/1.73m2 using the 4 
variable modified MDRD study 
prediction equation  
Psychiatric illness including anxiety, mood and untreated eating 
disorders 
Malnutrition (assessed by Subjective Global Assessment) 
Infection or course of antibiotics within the last month 
− Written informed consent Unfit for anaesthesia or surgery 
 Unwilling to consider surgical treatment 
 Previous kidney transplant  
BMI, body mass index; CKD, chronic kidney disease; MDRD, Modification of Diet in Renal Disease study 
 
All patients meeting the study inclusion criteria were then sent a letter of invitation to 
participate in the study, together with a form letter to complete and return in the enclosed 
reply paid, pre-addressed envelope, if they were interested in obtaining further information 
about the study. 
 
Patients who indicated they were interested in participating in the study by returning the 
form were contacted to arrange an individual appointment to further discuss the study.  At 
this appointment, the candidate explained the random allocation procedure and both study 
interventions to the potential participants.   Both the weight loss surgery procedure and the 
best medical care interventions were explained to potential participants, including the 
amount of weight loss expected with each, the number of study visits, and what was 
involved in each of the study measurements.  The risk of each study measurement was 
outlined.  Potential participants were given the opportunity to ask questions and were 
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provided with written Information for Participants (Appendix E).  The candidate also 
emphasised that participation was voluntary, and that the participant was free to withdraw 
from the study at any time, without their medical care being affected.  Patients decided at 
this point whether they were interested in taking part and could be contacted again by 
telephone 1-2 weeks later.   
 
Final Recruitment 
Patients interested in pursuing the study further were referred to the study surgeon for 
assessment for LSG.  A member of the surgical team completed the assessment, and the 
dietitian (the candidate) conducted an additional dietary assessment for weight loss surgery 
(Appendix D).  Patients were referred for additional cardiovascular and respiratory 
assessments and further surgical review, if deemed appropriate, prior to being assessed as 
fit or unfit for weight loss surgery.  If the patient was assessed as fit for surgery and agreed 
to participate in the study, written, informed consent was obtained.  Patients unsure 
whether they wished to participate were given more time to consider the study, and the 
candidate contacted the patient again after a mutually agreed time interval.   
 
Consent 
The process and meaning of informed consent was discussed, including the right to 
withdraw from the study at any time without compromising the patient’s medical care.  It 
was the responsibility of the person obtaining informed consent to assess capacity, ensure 
that they were satisfied that the patient understood the content of the Information for 
Participants booklet (Appendix E), the meaning of randomisation to treatment, and the 
right to withdraw.  If the patient was willing to participate in the study, the candidate, the 
study surgeon, or the patient’s named nephrologist, obtained written informed consent.  1 
copy of the consent form (Appendix E) was given to the patient, 1 copy was filed in the 
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medical notes, and the original consent form was filed in the study master file, together 
with a copy of the patient information booklet.  All members of the study team and 
medical care team had undertaken consent training and were able to assess capacity to 
consent.   
 
Randomisation 
After providing informed consent to participate in the study, each patient was randomised 
to 1 of the 2 study interventions.  Patients were assigned to either SG or BMC using a 
concealed random allocation method.  An independent professional not involved with the 
trial held the computer generated random allocation sequence generated using permuted 
blocks of 2 - 4.  After each consecutive patient provided consent, the candidate contacted 
the sequence holder by telephone to be informed of the next allocation in the sequence.  
Each patient was notified of his or her allocation by the candidate, within 3 days of 
providing consent to participate in the study. 
 
Interventions 
Best Medical Care (BMC) 
All patients randomised to the BMC treatment group were enrolled in the renal Weight 
Management Programme (WMP).  There are 4 components to the multi-disciplinary WMP: 
a low-fat energy-reduced renal diet, regular exercise, behaviour therapy, and use of the anti-
obesity medication orlistat (Xenical; Roche Products, Basel, Switzerland).  An experienced 
renal dietitian and physiotherapist conducted the programme, with support from the 
nephrologist and renal pharmacist as needed.  Patients attended the WMP for the initial 
baseline assessment, monthly during the 6-month intervention period, and for monitoring 
and support at 9 and 12 months.  Individualised diet and exercise regimens were developed 
with all patients using structured dietary education with motivational interviewing (Miller 
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and Rollnick 2002) and cognitive behavioural therapy techniques to address barriers to 
lifestyle change; including food and activity diaries, stimulus control, through process 
evaluation, cost benefit analysis, and problem solving (Cooper, Fairburn et al. 2003).  
Treatment was structured and standardised, with checklists for each session developed to 
act as both cue for, and record of, the session. 
 
Dietary Intervention 
A low-fat energy-reduced 1 400 – 1 800 kilocalorie renal diet, depending on body size, 
physical activity level and dietary intake at baseline, was negotiated with each patient based 
on food preferences and appropriate for each patient’s CKD stage.  Protein intake was 
optimised for the stage of CKD for each patient, at 1.0 g protein/kg ideal body weight 
(IBW)/day for CKD stage 3 and 0.8-1.0g protein/kg IBW/day for CKD stage 4 
(EDTNA/ERCA Dietitians' Special Interest Group 2002).  Fat intake was limited to less 
than 70 g per day, to minimise the side effects of orlistat.  The remaining energy was 
obtained from carbohydrate sources, with higher fibre choices encouraged when possible.  
All patients were encouraged to modify sodium intake to a “no added salt” diet level, of 80 
- 100 mmol sodium per day (EDTNA/ERCA Dietitians' Special Interest Group 2002).  
Potassium and phosphorous intake were modified according to serum biochemistry and 
kidney function (Abbott, Glanton et al. 2004; Renal Association 2007).  Adherence to the 
dietary intervention was assessed with 3-day food intake records at baseline and every 3 
months.  At each visit, dietary education was provided, as required, using a range of 
standardised modules (Table 19) with picture based resources and written information.  
Patients generated at least 2 dietary goals each month from baseline to month 6, facilitated 
by motivational interviewing techniques used by the dietitian (Miller and Rollnick 2002). 
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Table 19: Standardised dietary education modules in the renal Weight Management Programme 
Size Matters – portion control Identifying high risk situations 
Eating a low fat diet Meal Plan 
Low fat cooking + quick recipes booklet Problem solving techniques 
Eating Out Keeping going 
 
Exercise Intervention 
Personal exercise plans, developed from the patient’s individual current level of exertion 
and co-morbid conditions, incorporated both aerobic and muscular endurance activities to 
improve functional capacity and increase energy expenditure.  Frequency was at least 3 days 
each week, the duration was increased, as tolerated, up to 60 minutes each day, and the 
intensity was based on the Borg Scale for ratings of perceived exertion levels of somewhat 
hard to hard (Borg 1998).  The exercise plan was adapted at each monthly visit in line with 
improvements in exercise capacity to facilitate a progressive training effect.  
 
Pharmacotherapy 
Patients were offered orlistat at the standard dose of 120 mg 3 times a day (taken with each 
meal) during the study.  Orlistat is a locally acting gastrointestinal lipase inhibitor that 
reduces the absorption of dietary fat by approximately 30% (Guerciolini 1997).  On-going 
education about the mechanism of action and the importance of limiting dietary fat intake 
to reduce the gastrointestinal side effects associated with the drug’s inhibition of dietary fat 
absorption was provided.   
	  
Approximately 12 months after the study commenced, the manufacture of orlistat was 
temporarily halted, due to a manufacturing problem, and supply of the medication ceased 
soon afterwards.  Patients were unable to obtain orlistat from this point until the 
completion of the study. 
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Laparoscopic Sleeve Gastrectomy Weight Loss Surgery (SG) 
Patients randomised to the SG treatment group underwent laparoscopic sleeve 
gastrectomy.  SG as a primary procedure consisted of a subtotal gastric resection of the 
fundus and body, to form a tube like stomach along the lesser curvature, with a final 
volume of 100 - 200ml (Iannelli, Dainese et al. 2008).  The surgery was performed by an 
experienced minimal access surgeon, Mr Ameet Patel, who had already performed at least 
50 sleeve gastrectomies.  Resected tissue samples were examined for evidence of 
helicobacter pylori and treatment with a proton pump inhibitor and antibiotics was 
commenced if positive. 
 
Post Surgery Dietary Intervention 
Patients were provided with dietary education and renal-specific written information prior 
to the procedure, or 1-2 days post-procedure as an inpatient.  Dietary intake was reviewed 
at 1, 4, 6 and 12 weeks post-sleeve gastrectomy, then at 3-monthly intervals up to 12 
months.  Dietary intake progressed in texture from liquid to puree, then to soft foods over 
12 weeks, before finally re-introducing most normal foods between 4 - 6 months post-
surgery.  Volume of food or fluid intake was limited to 100 - 150 ml per meal, up to 6 times 
a day, with frequent sips of fluid encouraged.  This level of intake is sustainable due to the 
reduced stomach volume.  Intakes greater than 150ml at a time may stress the suture line 
and create a leak, or stretch the surgically reduced stomach capacity, increasing the risk of 
compromising the physical restriction imposed by the surgery - which may impede weight 
loss or result in weight gain.   
	  
Dietary energy intake was restricted to approximately 1 000 kcal per day post sleeve 
gastrectomy.  Protein intake was optimised for the stage of CKD for each patient, at 1.0 g 
protein/kg IBW/day for stage 3 CKD, and 0.8 - 1.0 g protein/kg IBW/day for stage 4 
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CKD (EDTNA/ERCA Dietitians' Special Interest Group 2002).  The remaining energy 
was obtained from carbohydrate and fat sources, with low fat choices strongly encouraged.  
Patients were also recommended to enjoy a wide variety of tolerated foods.  All patients 
were encouraged to modify sodium intake to a “no added salt” diet level, of 80 - 100 mmol 
sodium per day (EDTNA/ERCA Dietitians' Special Interest Group 2002).  Potassium and 
phosphorous intake were modified according to serum biochemistry and kidney function 
(Abbott, Glanton et al. 2004).  A daily multivitamin and mineral supplement suitable for 
patients with CKD was prescribed. 
 
Measurements 
A brief description of all measurements is included here, and an in-depth description of 
those measurements that require a specific method of measurement or technique is 
outlined in Appendix D.  To provide an overview of the data collection procedure, an 
outline of a study visit is presented in Figure 15.   
 








Baseline demographic data including date of birth, ethnicity, gender, and cause of CKD (if 
known) was recorded at study enrolment.  History of diabetes, cardiovascular disease, 
hypertension, dyslipidaemia, surgical history and body weight history (including attempts at 
weight loss) were recorded at baseline.  Medications, including daily or weekly doses, were 
recorded every 3 months.   
Questionnaires 
Blood pressure measurement  




Bioelectrical impedance analysis 
Height and weight 
Waist and hip circumferences 
Patient shown finger-prick blood sampling 
technique for iohexol clearance test 
Venous blood samples taken  
Administration of iohexol 






end of study visit (1hr) 
Pt continues finger-prick blood testing in hospital or at home  
Figure 15: Outline of study visit at baseline, 6 and 12 months for the weight loss surgery in 
the stages 3-4 chronic kidney disease randomised controlled trial pilot study 
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Table 20: Timetable of intervention and data collection visits for the weight loss surgery in the 
stages 3-4 chronic kidney disease randomised controlled trial pilot study 
 Best Medical Care (BMC) Sleeve Gastrectomy (SG) 
Month Pre assessment 
Including assessment for surgery and completion of 3 day food and exercise diary Date 
0  Study visit 1: baseline (beginning) data collection 
Weight management clinic 1st 
appointment 
Surgery – laparoscopic sleeve gastrectomy  
Post operative surgical review 
dietary reviews by telephone 
1  1 month review dietary review by telephone 
2  2 month review dietary review by telephone 
3  Study visit 2: 3 month review + data collection 
4  4 month review - 
5  5 month review - 
6  Study visit 3: 6 month review + data collection 
9  Study visit 4: 9 month review + data collection 
12  Study visit 5: 12 month review + data collection 
 
Laboratory assessments 
Venous blood samples were collected in blood collection tubes (BD Vacuainer: New 
Jersey) after a 12-hour fast.  Multiple samples were collected in EDTA-coated tubes for full 
blood count and plasma extraction, fluoride oxalate-containing tubes for plasma glucose, 
and silica-coated serum-separating tubes for serum leptin, adiponectin, fetuin-A, IL-6, 
TNF-α, lipids, hs-CRP, and insulin.   
 
The sample for plasma was centrifuged upon arrival in the laboratory, and the samples for 
serum were left for 30 minutes to clot before being spun.  Samples for glucose, hs-CRP, 
full lipid profile, and a full blood count were processed immediately, and the remaining 
serum and plasma was stored in aliquots at -80° C for later analysis of serum leptin, fetuin-
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A, adiponectin, IL-6,  TNF-α, and insulin.  Spare aliquots of serum and plasma were stored 
in case further biomarkers were added to the study at a later date.   The Renal Association 
targets for total cholesterol and low density lipoprotein (LDL) cholesterol were used to 
classify a reduction in dyslipidaemia (Renal Association 2007). 
 
Serum leptin, fetuin-A, adiponectin, hs-CRP, insulin, IL-6 and TNF-α were measured using 
commercially available quantitative sandwich enzyme-linked immunosorbent assays 
(ELISA) (R  and D systems, Minneapolis, MN) in the King’s College Hospital 
Biochemistry Laboratory, under the supervision of Professor Roy Sherwood.  Standard 
enzymatic techniques were used to measure lipid fractions and total cholesterol.  Glucose 
was measured in venous fluoride EDTA plasma using standard enzymatic techniques.  
HOMA-IR was used to calculate an index of insulin resistance from the product of the 
fasting concentrations of plasma insulin (microunits/ml) and plasma glucose (mmol/l) 
divided by 22.5 (Matthews, Hosker et al. 1985).  Given that insulin resistance is evident in 
CKD even at normal body weight and without diabetes, a HOMA-IR level ≥ 2.0 was 
selected to indicate insulin resistance in the present study.   
 
Patients were asked to provide a urine sample in a universal container.  The sample was 
sent to the biochemistry lab with the blood samples for analysis of protein-to-creatinine 
ratio (proteinuria) and albumin-to-creatinine ratio (albuminuria), according to standard 
clinical methods.  Clinically significant proteinuria and albuminuria were defined according 
to the National Institute for Health and Clinical Excellence (NICE) clinical guidelines for 
CKD (CG73), as > 50 mg/mmol and > 30 mg/mmol, respectively, in people without 
diabetes.  In those with diabetes, albuminuria was defined as > 2.5 mg/ mmol in women or 
> 3.5 mg/mmol in men as these levels are considered clinically significant (National 
Institute for Health and Clinical Excellence 2008).  
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Kidney function was measured by GFR using the gold standard iohexol clearance method, 
with finger-prick blood sampling (Appendix D).  Iohexol is an iodine- containing contrast 
medium that is not metabolised and has no uptake in tissue.  After injection, iohexol is 
rapidly distributed throughout the extracellular fluid and excreted almost exclusively by the 
kidneys via glomerular filtration (Stevens and Levey 2009).  Briefly, timed fingerprick blood 
samples were taken before and 2, 3, and 4 hours (5 hours if eGFR <  30ml/min/1.73m2) 
after administration of a 5ml bolus of iohexol.  The patient took the fingerprick sampling 
kit home to complete the test and returned the equipment in the pre-addressed, pre-
stamped envelope provided. 
 
Nutrition assessment 
Adherence to dietary guidelines was assessed with 3-day food intake records with dietary 
interviews to clarify and substantiate the content at baseline and every 3 months.  
Nutritional status was measured with Subjective Global Assessment - a validated tool 
assessing nutritional status with information on weight loss, dietary intake, gastrointestinal 
symptoms, physical capacity and muscle and fat stores (Detsky, Mclaughlin et al. 1987). 
 
Anthropometry 
Height was measured to the nearest 1 cm without shoes using a wall-mounted stadiometer.  
Weight was measured to the nearest 0.1 kg on a calibrated electronic scale with the patient 
wearing light clothing and without shoes.  Waist and hip circumferences were measured to 
the nearest 0.1 cm at the level of the umbilicus and the widest point around the buttocks, 
respectively, with a calibrated plastic tape measure.   
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Fat mass, percentage body fat and fat free mass were measured using multi-frequency, 




BP was measured with the patient seated in a chair and rested for at least 10 minutes, with 
3 measures made using an appropriate-sized cuff.  The average of the 2 closest readings for 
systolic BP were used.  Hypertension was defined using the NICE guidance for CKD 
criteria of a blood pressure > 140/90 mm Hg, or > 130/80 mm Hg in those with 
proteinuria or diabetes (National Institute for Health and Clinical Excellence 2008), or use 
of antihypertensive medications, including diuretics.  Antihypertensive medication use was 
scored according to type and dose of medication, using the Antihypertensive Score (AHS) 
method (Fricke, Doehn et al. 1998; Meier, Nitschke et al. 2006), and statin doses were also 
recorded, at baseline, and up to 12 months. 
 
Quality of life was measured using the self adminstered HADS and SF 36 questionnaires.  
 
 Metabolic syndrome was assessed according to the revised ATP III criteria (Grundy, 
Cleeman et al. 2005).   
 
Predefined complications of weight loss surgery included poor tolerance of 
liquids/puree/soft diet, gastrectomy leak, bleeding requiring transfusion, bleeding or 
restriction requiring surgical or endoscopic intervention, longer than expected hospital 
admission, readmission to hospital directly related to weight loss surgery, post-operative 
infection, and 30 day mortality; and were recorded as soon as they became known to the 
study team.   
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Adverse events, including acute kidney injury, cardiovascular events including myocardial 
infarction, stroke and hospitalisation for heart failure, gastro-oesophageal reflux, heart 
rhythm irregularities, malnutrition, dehydration, vomiting, hypoglycaemia, diarrhoea, 
constipation, epigastric pain and oedema and hospitalisation during the study period, were 
reported and recorded at study visits.   
 
Statistical Analysis 
Sample size calculation 
The sample size was calculated for detecting a difference in measured kidney function at 12 
months, based on the results of an observational study of change in estimated kidney 
function following weight loss surgery in a small group of patients with stage 3 CKD 
(Navaneethan and Yehnert 2009).  The sample size was estimated using the following 
assumptions: 12 months duration of follow-up; maintenance of kidney function in the 
control group at 12 months, and an improvement in kidney function of 18% (SD 10.2%) in 
the study group at 12 months (based on the improvement in eGFR observed in obese 
patients with stage 3 CKD after weight loss surgery (Navaneethan and Yehnert 2009)); 
80% power to detect a 5% significance level.  Allowing for a 20% drop out rate, the sample 
size required was 27 patients randomised to SG and 27 patients randomly allocated to 
BMC.   
 
This sample size was deemed impractical given the constraints of capacity for elective 
surgery at the study hospital, current waiting times for weight loss surgery (which can be up 
to 12 months),  and the human resources available to conduct the study.  The candidate 
was the only person working on screening, recruitment, data collection and providing the 
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dietetic components of both interventions to all study participants.  Therefore, a pilot study 
was conducted, which aimed to recruit a total of 16 patients (8 per group).  It was deemed 
appropriate to conduct a pilot study of this size to examine the feasibility of recruiting to a 
randomised study surgical treatment compared to medical care, to determine the effect size 
of changes in measured kidney function, markers of inflammation and adipokines, and to 
monitor the frequency and types of adverse events and surgical complications. 
   
Data analysis 
Expert statistical advice from a statistician, Dr Salma Ayis, Lecturer in Medical Statistics, 
King’s College London, was sought prior to, and continued throughout, the pilot study.  
Comparative statistical analyses using quantitative data were performed using IBM SPSS 
Statistics version 19.0.  The normality of data distribution was assessed visually using 
histograms with normal curves.  For non-normally distributed data, due to the small sample 
size, log transformation was not performed, and non-parametric statistical methods were 
adopted.   
 
Baseline data are described as mean ±SD (median and inter-quartile range (IQR) for non-
parametric distributions) for all continuous outcome variables.  Event rates of categorical 
variables within and between groups were listed in contingency tables.  Changes in 
variables over time are displayed as means (95% CI), or median (IQR).  The difference in 
body composition measures, markers of inflammation and adipokines, within groups from 
baseline to 12 months were measured with paired Student’s t-tests, and the between group 
differences at 12 months were determined with the Mann-Whitney U test, Hodges-Lehman 
median difference, or with analysis of variance between groups at 12 months with 
correction for baseline values, with 95% confidence interval reported for differences 
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between groups.  Differences in adipokines and markers of inflammation were calculated 
for exploratory purposes only, as it was known at the outset of the study that it was 
unlikely that the sample size would be adequate to detect differences in these variables.  
Differences in diabetes, insulin resistance, hypertension, proteinuria, hyperlipidaemia and 
metabolic syndrome over time are described empirically.   
 
Given the small sample size in this pilot study, relationships between variables were 
examined with Spearman’s rank correlation, to explore the associations between weight 
loss, and changes in adipokines, markers of inflammation, and measures of body 
composition.  The relationship between measured GFR and eGFR using the MDRD study 
equation at baseline, 6 and 12 months, was examined with Spearman’s rank correlations.   
 





The flow of participants through each stage of the study is shown in Figure 16.  During the 
15-month recruitment period, 182 patients at the 3 study sites met the preliminary 
inclusion criteria and were contacted either by letter or during a scheduled outpatient clinic 
visit.   
 
93 patients expressed an interest in the study and were given the patient information 
booklet, which outlined both intervention treatments, and the random allocation process 
was explained in both written and verbal forms.  51 patients declined to participate and a 




Figure 16: CONSORT diagram showing the flow of participants through each stage of the Stages 3-4 
Chronic Kidney Disease randomised controlled trial pilot study of laparoscopic sleeve gastrectomy 
compared to best medical care 
BMI, body mass index; eGFR, estimated glomerular filtration rate 
 
 
The mean (± SD) length of time between requesting a surgical assessment appointment 
and obtaining consent was 3 months (± 1.48 months).  7 patients were excluded prior to 
obtaining consent, as they were assessed as unsuitable for weight loss surgery, due to co-








































































bipolar disorder, or unsuitable for anaesthesia; 1 patient was a Jehovah’s Witness, and so 
was deemed unsafe for surgery given the risk of bleeding and refusal to accept blood 
transfusion.   4 patients did not wish to be randomised to a treatment group after surgical 
assessment, and 4 patients did not attend the surgical assessment appointment, despite 
multiple appointments being offered.  A further 4 patients were still awaiting cardiology or 
respiratory review as part of surgical assessment in June 2011, which was the final month 
when assessment could be practically completed to allow for a minimum of 3 months on 
the surgical waiting list and 12 months of follow up.  16 patients elected to enrol in the 
study and 5 of the 8 patients in the SG group and 6 of the 8 patients in the BMC group 
completed the study.   
 
Recruitment and randomisation was completed by June 2011 and the final patient follow-
up was in September 2012.  The mean length of time from randomisation to intervention 
(surgery) in the SG group was 5.6 months (± 2.2 months).  Overall, patients commenced 
the study 5.8 months (± 3.1) after the initial approach and provision of the patient 
information. 
 
The baseline characteristics of the 2 groups are presented in Table 21.  All patients had 
metabolic syndrome, and all were prescribed antihypertensive medications and a statin.  
There were no statistically significant differences in demographics, anthropometric, clinical 
and metabolic variables, although there was a tendency towards greater prevalence of 
diabetes and insulin resistance (HOMA-IR), and higher systolic BP in the BMC group, 
despite randomisation.  None of these differences were statistically significant, possibly due 
to the small sample size.  Median leptin was also higher in the BMC group, despite closely 
matched levels of fat mass between groups at baseline.   
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Table 21: Baseline characteristics of obese patients with stages 3-4 chronic kidney disease 





Best Medical Care 
(BMC) 
p*  
n 5 6  
Age (years) 51 (47.5-55) 53 (46.5-66) 0.78 
Gender   5 Female 4 Female, 2 Male 0.46 
Ethnicity 3 White, 2 Black 3 White, 3 Black 1.00 
Diabetes  1/5  4/6 0.24 
Metabolic syndrome 5/5 6/6 1.00 
Antihypertensive use  5/5 6/6 1.00 
Statin use 4/5 3/6 0.55 
estimated GFR (MDRD) 
(ml/min/1.73m2) 
43 (20-54) 34 (26-39) 0.72 
GFR (ml/min) 105 (35) 100 (36) 0.83 
BMI (kg/m2) 40.3 (37.3-43.5) 37.4 (35.8-40.0) 0.14 
Systolic blood pressure (mmHg) 118 (116-142) 135 (117-144) 0.47 
Diastolic blood pressure (mmHg) 80 (72-88) 81 (65-92) 0.86 
Total cholesterol to HDL cholesterol 
ratio 
4.9 (3.5-5.7) 4.1 (3.2-4.6) 0.27 
Triglycerides (mmol/L) 1.5 (1.3-2.2) 1.2 (0.9-1.7) 0.31 
Weight (kg) 109.8 (8.0) 108.9 (13.2) 0.89 
Fat mass (kg) 51.9 (5.5) 46.7 (6.5) 0.22 
Waist (cm) 125.7 (8.6) 121.3 (8.8) 0.42 
Waist to hip ratio 0.91 (0.91-1.00) 1.01 (0.94-1.02) 1.00 




































HOMA-IR 3.0 (1.8-8.5)  7.8 (4.5-25.6) 0.20 
data expressed as mean, (standard deviation, SD), or median (inter-quartile range) unless otherwise stated; BMI, body 
mass index; GFR, glomerular filtration rate,  hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model 
assessment of insulin resistance; IL-6, interleukin-6; MDRD, 4-variable Modification of Diet in Renal Disease study 
equation; TNF-α, tumour necrosis factor alpha; *p values obtained with independent samples Mann-Whitney U test, 
Student t-test, or Fisher’s exact test as appropriate 
 
There was wide variation in the leptin values, with one outlier value of > 400 µg/L in the 
BMC group.  All other leptin values at baseline ranged between 17-130 µg/L. 
There was wide variation in hs-CRP at baseline, with values ranging from 0.8 to 28.1 mg/L.  
6 patients had an elevated hs-CRP > 5mg/L, and 5 patients had normal hs-CRP levels at 
the beginning of the study.  IL-6 and TNF-α values were lower than those previously 
reported for obese patients with stages 3-4 CKD and were similar to levels reported in 
healthy subjects (Teplan, Vyhnanek et al. 2010; Spoto, Leonardis et al. 2012). 
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GFR values were consistently higher than the eGFR values in both groups at baseline, with 
eGFR under predicting GFR, on average, by 65.9 ml/min at baseline (p < 0.001).  Patients 
classified as stage 3 CKD by eGFR at baseline showed a greater bias in the underestimation 
of GFR by eGFR than patients with eGFR-determined stage 4 CKD (Figure 17).  There 
were no associations between eGFR and GFR values at baseline (Spearman r = 0.54, p = 
0.11), or 12 months (Spearman r = -0.05, p = 0.89), but there was a significant association 
between eGFR and GFR at 6 months (Spearman r = 0.80, p = 0.01). 
 
 
Figure 17: Bias between eGFR and GFR in CKD stages 3-4 obese patients at baseline.  The error 
bars represent one standard deviation. 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate using the 4-variable modification of diet in renal 
disease study equation; GFR, glomerular filtration rate measured using the iohexol clearance method 
 
Compliance with interventions 
All 8 patients allocated to the BMC group were invited to attend our Renal WMP.  One 
patient withdrew from the study prior to baseline data collection.  6 of the remaining 7 
patients commenced the programme, and 4 completed the full 12-month programme with 
attendance at 90% of sessions.  1 patient withdrew from the study after 5 months, and 1 
patient attended 67% of the sessions and completed the study.  1 patient completed the 
























p < 0.001 
p = 0.07 
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Half of the patients attending the WMP were unable to obtain orlistat for the full duration 
of the study due to an international problem with production of the drug, which occurred 
from late 2011 and continued until the end of the study.  All patients attending the WMP 
were compliant with both the dietary and physical activity components of the programme 
up to 6 months.  Physical activity decreased after 6 months in most patients due to injury, 
change of environment and feeling unsafe to exercise outdoors, or reported low mood. 
 
8 patients were randomised to the SG group.  2 patients refused the surgical intervention 
after randomisation and withdrew from the study.  Five patients had SG surgery during the 
study and 1 patient was still on the waiting list for this procedure at the point at which 
baseline data collection was finalised, and could not be included in the study. 
 
Compliance with post-weight loss surgery dietary recommendations was generally good, 
with 5 out of 6 patients following a high protein liquid diet in the initial post-operative 
period.  One patient misunderstood the instructions and continued with clear fluids only 
for 4 weeks.  All 6 patients in the SG group progressed to soft foods and then normal 
foods with considerably reduced portions, and continued to eat smaller meals portions up 
to 12 months.  All patients were encouraged to increase their physical activity level, and 
many reported being more active, although this was not measured objectively during the 
study.   
 
All patients were well nourished at baseline and remained well nourished throughout the 
study with Subjective Global Assessment ratings of A – well nourished (Detsky, 
Mclaughlin et al. 1987), achieved by all patients at 3-monthly intervals throughout the 




Figure 18 illustrates the changes in both measured and estimated kidney function over 12 
months in both treatment groups displayed as boxplots (median, interquartile range).  The 
SG group show a decrease in hyperfiltration after 12 months, which is not evident in the  
 
  
Figure 18: Boxplots of (a) measured GFR and (b) estimated GFR in obese patients with CKD 
randomised to either laparoscopic sleeve gastrectomy (SG) or best medical care (BMC) 
eGFR, estimated glomerular filtration rate using the 4-variable Modification of Diet in Renal Disease study equation; 
GFR, glomerular filtration rate measured using the iohexol clearance method 
 
BMC group.  Changes in eGFR do not appear to predict changes in GFR in obese patients 
after weight loss surgery.  
 
As the eGFR classified CKD stage 3 group demonstrated hyperfiltration at baseline, 
changes in GFR over 12 months were also examined separately by baseline CKD stage 
(Figure 19).  In patients classified as CKD stage 3, there was a trend towards a reduction in 
hyperfiltration over time in the SG group, but not in the BMC group.  Patients with stage 4 
CKD displayed a trend towards a slight improvement in GFR over 12 months in the SG 





Figure 19: Changes in GFR over time by eGFR classified CKD stage in obese patients with CKD 
after (a) sleeve gastrectomy, or (b) best medical care 
Error bars represent one standard deviation; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate 
using the 4-variable modification of diet in renal disease study equation; GFR, glomerular filtration rate measured using 
the iohexol clearance method 
 
Improvements in or resolution of co-morbidities 
Table 22 and Table 23 outline the changes in co-morbidities related to obesity and CKD over 
the course of the study.  There was no change in diabetes prevalence throughout the study.  
The 1 patient on insulin therapy in the SG group decreased their insulin dose by 59%, and 
the 4 patients requiring insulin in the BMC group decreased their median insulin dose by 
7% over 12 months.   
 
Table 22: Changes in diabetes, insulin resistance and hypertension in obese patients with stages 3-4 
chronic kidney disease after laparoscopic sleeve gastrectomy or best medical care 










Group Y N  Y N Y N  
SG baseline 1 4 102 4 1 5 0 86 
 6 months 1 4 55 0 5 5 0 62 
 12 months 1 4 43 1 4 5 0 62 
 
BMC baseline 4 2 60 5 1 6 0 74 
 6 months 4 2 52 5 1 6 0 74 
 12 months 4 2 56 4 2 6 0 63 
          
BMC, best medical care; HOMA-IR, Homeostasis Model Assessment of Insulin Resistance, ≥ 2.0 indicates insulin 





In patients who were insulin resistant at baseline, insulin resistance resolved in 3 out of 4 
patients in the SG group, and in 1 of 5 patients in the BMC group.  Whilst all patients in 
the study remained hypertensive throughout, antihypertensive medication use, quantified 
using the Antihypertensive Score method (Meier, Nitschke et al. 2006), decreased by 28% 
in the SG group and by 15% in the BMC group (p > 0.05 between groups at 12 months).   
 
Table 23: Changes in proteinuria, blood lipids and metabolic syndrome status in obese patients with 





< 4 mmol/L 
LDL 
cholesterol    
< 2 mmol/L 
Metabolic 
syndrome 
Group Yes No Yes No Yes No Yes No Yes No 
SG baseline 3 2 2 3 0 5 0 5 5 0 
 6 months 1 4 0 5 0 5 0 5 2 3 
 12 
months 
2 3 1 4 1 4 2 3 3 2 
 
BMC baseline 3 3 1 5 2 4 2 4 6 0 
 6 months 2 4 2 4 3 3 3 3 6 0 
 12 
months 
3 3 2 4 3 3 3 3 6 0 
            
Albuminuria albumin:creatinine ratio >30 mg/mmol if no diabetes, or  >2.5 mg/mmol in women or >3.5 mg/mmol in 
men with diabetes; BMC, best medical care; Proteinuria protein:creatinine ratio >50 mg/mmol; SG, sleeve gastrectomy 
 
At 6 months, albuminuria fell below the clinically significant threshold in 2 of the 3 patients 
in the SG group with albuminuria at baseline.  However, by 12 months, 1 of these patients 
had again developed albuminuria.  2 of 5 patients in the SG group were proteinuric at 
baseline, which resolved in both patients by 6 months, but returned at 9 months in 1 
patient.  There were no improvements in albuminuria or proteinuria in the BMC group.   
 
All 5 patients in the SG group had total and LDL cholesterol levels above the Renal 
Association guideline of < 4 mmol/L and < 2 mmol/L (Renal Association 2007), 
respectively, at baseline.  The total cholesterol target was reached by 1 of the 5 patients, 
and the LDL cholesterol target was reached by 2 of the 5 patients, at 12 months.  In the 
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BMC group, 2 of the 6 patients met both guideline recommendations at baseline, and 3 of 
the 6 patients met the recommendations for total and LDL cholesterol after 12 months. 
 
Metabolic syndrome resolved in 3 of the 5 patients in the SG group at 6 months, but 
remained resolved in only 2 patients by 12 months.  There was no resolution of metabolic 
syndrome in the BMC group.   
 
Quality of Life measures 
There was a decrease in anxiety and depression scores from baseline to 12 months in the 
SG group, but not in the BMC group (Table 24).  
	  
	  
Table 24: Hospital Anxiety and Depression Scale (HADS) measures in obese patients with stages 3-
4 CKD after sleeve gastrectomy or best medical care 
Parameter Treatment 
Group 
Baseline 6 months 12 months 12 month 
difference  
HADS Anxiety Scale SG 7 (2, 12) 5 (0, 10) 2 (0, 7) -4 (-7 to -1) 
 BMC 7 (3, 12) 6 (2, 11) 7 (3, 13)  
HADS Depression Scale SG 7 (1, 13) 2 (0, 6) 1 (0, 6) -5 (-8 to -2) 
 BMC 7 (2, 12) 5 (2, 8) 7 (2, 11)  
Values are mean (95% confidence interval); mean difference for between group analysis of variance corrected for baseline 
values; BMC, best medical care; SG, sleeve gastrectomy 
 
At 12 months, HADS scores were significantly reduced in the SG group, compared to the 
BMC group, after adjustment for baseline scores.   Changes in SF-36 quality of life domain 
scores are displayed in Figure 20.  SF-36 physical domain quality of life scores improved in 
the SG group, and declined in the BMC group over 12 months.  At 12 months, the SG 
group had a significantly higher SF-36 physical domain score compared to the BMC group, 
after correction for baseline values (mean difference 20; 95% CI 4 to 35).  There was no 
difference in SF-36 mental domain quality of life scores between groups at 12 months, 




    
Figure 20: SF-36 physical and mental health domain summary scores in obese patients with stages 3-
4 CKD after sleeve gastrectomy or best medical care 
 
Weight loss and body composition changes 
After 12 months, median % weight loss was 27.6% in the SG group and 4% in the BMC 
group.  Median % excess BMI loss was 91.5% in the SG group and 11.1% in the BMC 
group.  For comparison with previous studies of weight loss surgery, median excess weight 
loss was 72.6% in the SG group and 7.3% in the BMC group.  Parameters of weight loss 
and changes in BMI are presented in Table 25.   
 
Table 25: BMI and weight loss measures in obese patients with stages 3-4 chronic kidney disease 
after laparoscopic sleeve gastrectomy or best medical care 









(30.9 - 36.8) 
29.0  
(27.3 - 34.3) 
26.8 
(26.4 - 33.4) 
26.3  
(25.7 - 32.3) 
8.1  
(3.6, 13.7) 




(32.4 - 38.7) 
36.5  
(30.9 - 37.8) 
36.6  
(32.0 - 38.3) 
36.5  
(33.5 -39.4) 
% weight  
lossb 
SG - 






-5.12 (3.8) -7.4 (5.7) -5.0 (4.2) -3.1 (2.6) 
% excess  
BMI lossb 
SG - 






-10.7 (13.0) -15.4 (19.6) -9.8 (14.5) -8.4 (18.4) 
for definitions of weight loss see Chapter 3; adata are presented as median (inter-quartile range); bdata are presented as 
mean (95% confidence interval); cHodges-Lehman median difference (95% confidence interval) between groups at 12 
months or mean difference (95% confidence interval) between groups at 12 months corrected for baseline values; BMC, 
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  4,35) 
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The difference in BMI between groups after 12 months was 8.1 kg/m2 (95% CI 3.6 to 13.7 
kg/m2).  Patients in the SG group decreased their weight progressively throughout the 
study, whilst weight loss was maximal after 6 months in the BMC group, with some weight 
regain evident from 6 to 12 months.  
 
Changes in body weight and body composition are illustrated in Figure 21.  There was 
statistically significant mean weight loss between baseline and 12 months within both the 
BMC group (p = 0.04) and in the SG group (p <0.001).  The SG group also demonstrated 
statistically significant reductions in waist circumference (p = 0.002), fat mass (p = 0.004) 
and lean body mass (p = 0.008) after 12 months.  Changes in waist circumference, fat mass 
and lean body mass loss were not statistically significant in the BMC group between 
baseline and 1 year. 
 
Greater reductions in body weight, waist circumference, and body fat mass were evident in 
the SG group, when compared to the BMC group after 12 months (Figure 21).  Mean 
differences (95% CI) for body weight, waist circumference, fat mass and lean mass, 
corrected for baseline values, were -29 (-36.4 to -22.3) kg, -29.1 (-40.6 to -17.6) cm, -24.1 (-
32.5 to -15.7) kg, and -5.9 (-8.5 to -3.3) kg, respectively.  Mean waist-to-hip ratio decreased 
from 0.95 to 0.87 after 12 months in the SG group and from 0.99 to 0.96 in the BMC 
group.  After 12 months the mean difference in waist to hip ratio between groups was        
-0.09 (-0.18 to -0.008).  
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Figure 21: Mean (a) body weight; (b) waist circumference; (c) body fat mass; and (d) lean body mass 
in obese patients with chronic kidney disease stages 3-4 after sleeve gastrectomy or best medical 
care 
Error bars represent ±1 standard deviation; p values represent between group differences at 12 months corrected for 
baseline values 
 
While it is clear that the SG group lost more weight and fat mass than the BMC group, 
examination of the changes in body fat and lean body mass highlight some differences 
between the groups over the course of the study.  The SG group showed a rapid decrease 
in fat mass over the first 6 months, and the BMC group lost fat mass more gradually over 
the same time period.  Body fat mass remained quite stable in both groups between 6 and 
12 months.  The weight gain evident between 6 and 12 months in the BMC group may be 
partially attributed to an increase in lean body mass over this period, which was not seen in 




(b) p<0.001 p<0.001 
p<0.001 p=0.001 
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Adipokines, insulin resistance, markers of inflammation, and fetuin-A  
Table 26 displays the changes in adipokines, insulin resistance, inflammatory markers, and 
fetuin-A, all considered to be novel indicators of cardiovascular disease risk, over 12 
months after patients were randomly assigned to either SG or BMC.  It should be noted 
that this pilot study was not powered to detect changes in these markers and the analyses 
were performed for exploratory purposes only.   
 
Table 26: Changes in novel cardiovascular disease risk factors over 12 months in obese patients with 
stages 3-4 chronic kidney disease after sleeve gastrectomy or best medical care 
Parameter Baseline 
 













































































































































































* p < 0.05 within group difference from baseline; a data are presented as mean (SD); b data are presented as median (inter-
quartile range); c mean differences (95% confidence interval) between groups at 12 months corrected for baseline values 
or Hodges-Lehman median difference (95% confidence interval) between groups at 12 months; BMC, best medical care 
group; HOMA-IR, homeostasis method of assessment – insulin resistance; hs-CRP, high sensitivity C-reactive protein; 
IL-6, interleukin-6; SG, sleeve gastrectomy group; TNF-α, tumour necrosis factor - alpha 
 
Leptin levels decreased in the SG group yet in the BMC group leptin levels rose up to 6 
months, then returned to baseline by 12 months.  Despite the decrease in serum leptin 
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level in the SG group at 12 months, this was not significantly different to the BMC group 
due to the wide variation in serum leptin levels throughout the study.  
 
Median serum adiponectin increased significantly in the SG group, compared to BMC at 12 
months.  HOMA-IR, a measure of insulin resistance, decreased in the SG group, compared 
to BMC at 12 months, reflecting the increase in adiponectin.  Insulin resistance was higher 
in the BMC group, more patients were requiring insulin therapy for blood glucose control 
in this group at baseline.  The reduction in HOMA-IR over 12 months was adequate to 
reduce insulin resistance to a subclinical level in most patients in the SG group, but not in 
the BMC group.  
 
The reductions in hs-CRP evident in the both the SG group and the BMC group brought 
the hs-CRP level below the conventional threshold level for normal hs-CRP in both groups 
by 12 months, indicating that the reduction in hs-CRP may be clinically relevant across the 
whole study population.  There was a decrease in Fetuin-A within both groups from 
baseline to 12 months, which mirrored the reductions in HOMA-IR and hs-CRP. 
 
The large variation in IL-6 results may be explained by two spurious individual values, 
reflected by the large changes in the standard deviations for the SG group at 9 months and 
for the BMC group at 12 months, compared to the confidence intervals for the other time 
points.  Notwithstanding these anomalies, there may be up to a 50% decrease in IL-6 in 
both groups 12 months after commencing either weight loss surgery or the weight 
management programme. TNF-α decreased between baseline and 6 months in the SG 
group, but remained stable in the BMC group.  At 9 months, TNF-α increased in the SG 
group, then returned to baseline by 12 months.  TNF-α increased in the BMC group 
between 6 and 12 months (p = 0.01).  
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Associations between changes in weight loss and exploratory variables 
Spearman rank correlations were performed to determine if changes in body weight and fat 
mass were related to changes in quality of life, and metabolic and haemodynamic variables.  
Weight loss was associated with an improvement in the SF-36 physical domain score (r =   
-0.88, p = 0.002), a reduction in the HADS depression score (r = 0.65, p = 0.06), and an 
increase in adiponectin (r = -0.75 p = 0.008), in the entire study group after 12 months.  In 
the SG group only, weight loss was associated with a decrease in leptin (r = 0.9 p = 0.04), 
and the change in leptin was inversely associated with the change in adiponectin (r = - 0.9 p 
= 0.04) after 12 months.  In the BMC group only, weight loss, and fat mass loss were both 
associated with a reduction in triglycerides (r = 0.89, p = 0.04; and r = 0.95, p = 0.05, 
respectively). 
 
In all patients, a reduction in fat mass was related to an increase in adiponectin (r = -0.77, p 
= 0.02), and a decrease in waist circumference (r = 0.9, p = 0.001), indicating that 
abdominal obesity was reduced with both weight loss interventions.  Yet, neither changes 
in fat mass, insulin resistance, leptin or adiponectin were associated with changes in 
markers of inflammation after 12 months.  However, in the BMC group only, associations 
were observed between increased in leptin and hs-CRP (r = 0.89, p = 0.02), and between 
increased TNF-α and HOMA-IR (r = 0.94, p = 0.005), after 12 months. 
Proteinuria was positively associated with adiponectin (r = 0.74, p = 0.09) and inversely 
associated with hs-CRP (p = -0.73, p = 0.01), at baseline.  A change in proteinuria was not 
related to a change in adiponectin in the entire study group, or in either of the intervention 
groups after 12 months.  However, a change in proteinuria was directly associated with a 
change in HOMA-IR (r = 0.66, p = 0.04), in both the entire study group, and in the BMC 
group (r = 0.9, p = 0.04), after 12 months, despite no relationship between these variables 
at baseline.  In the BMC group, changes in HOMA-IR were positively correlated with 
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changes in adiponectin (r = 0.9 p = 0.04) at 12 months.  In the SG group, the change in 
proteinuria was related to the 12-month changes in both systolic and diastolic blood 
pressure (r = 0.9 p = 0.04 for both).  There was no relationship between changes in 
proteinuria and either fat mass or weight loss.   Fetuin-A is known to increase with obesity, 
and fetuin-A levels decreased in both groups over 12 months, although this was not 
associated with weight loss or change in fat mass in this study.   
 
Safety and adverse events 
Orlistat, when available for use in this study, was well tolerated in the BMC group.  
Episodes of diarrhoea – a common side effect of a moderate to high fat intake 
concomitant with orlistat - occurred during the first 2 months of orlistat use only, whilst 
the patients adapted to a low fat diet.  There was no incidence of acute kidney injury or 
acute oxalate nephropathy, both of which have been previously reported with orlistat use 
in patients with CKD (Singh, Sarkar et al. 2007; Weir, Beyea et al. 2011). 
 
In the SG group, the median length of perioperative stay was 5 days, and ranged from 2 to 
8 days.  There were 2 post-operative re-admissions to hospital.  Two weeks post-
operatively, a patient was admitted with acute kidney injury secondary to dehydration. The 
patient was treated with intravenous fluids and discharged after 2 days, and serum 
creatinine returned to baseline within 3 months. The second patient was admitted 4 weeks 
post-operatively with dehydration, secondary to nausea and vomiting.  No surgical reason 
was found for the nausea and vomiting, and a liquid and puree diet was encouraged.  Prior 
to admission this patient experienced a decline in her mobility and her discharge was 
delayed, as she required rehabilitation therapy.   
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Two patients in the SG group reported epigastric pain, occurring at 1 and 3 months post-
operatively.  One patient in the SG group reported constipation at 9 months.  One patient 
in the BMC group reported foot and lower leg pain at 6 months and this was investigated 
for possible deep vein thrombosis, which was not found.  This patient was subsequently 
diagnosed with neuropathic arthropathy of the ankle (Charcot Foot), which may have been 
exacerbated by his increased physical activity level during the study. 
 
All patients were well nourished using the Subjective Global Assessment (Detsky, 
Mclaughlin et al. 1987) when commencing the study.  The patient admitted to hospital 4 
weeks post-sleeve gastrectomy, had mild to moderate malnutrition based on the Subjective 
Global Assessment of nutritional status at the time of hospitalisation.  Nutritional status 
had returned to baseline by 3 months post-operatively.  All other patients remained well 
nourished throughout the study.  
 




This study is the first randomised controlled study of sleeve gastrectomy compared to best 
medical care, including a structured lifestyle modification programme, in obese patients 
with stages 3-4 CKD.  A pilot study design was chosen to explore the primary and 
secondary outcomes, and also to examine the feasibility of the study design and examine 




Significant weight loss was achieved after 12 months in both the SG and BMC groups, and 
weight loss was associated with increases in serum adiponectin and the SF-36 physical 
domain quality of life score, and a reduction in HADS depression score.  Reductions in fat 
mass were associated with a decrease in waist circumference and an increase in serum 
adiponectin after 12 months.  In the SG group, weight loss was associated with a decrease 
in serum leptin, and leptin was inversely related to adiponectin, and changes in proteinuria 
were associated with changes in systolic and diastolic BP.  
 
Weight loss in the present study compares favourably with the reported 56.1% excess 
weight loss 12 months after sleeve gastrectomy, in a 2012 meta-analysis of 123 studies 
published between 2003 and 2010 (Fischer, Hildebrandt et al. 2012).  The greater excess 
weight loss achieved in the present study is likely to be attributable to the lower baseline 
BMI of the group, as an equivalent amount of absolute weight change equates to a greater 
excess weight loss when starting BMI is lower.  Absolute percentage weight loss after 12 
months in the present study was similar to findings reported in a non-randomised study of 
an otherwise similar design, for both weight loss surgery and for a lifestyle intervention 
conducted in a hospital outpatient clinic setting (Martins, Strømmen et al. 2011).   
 
Kidney function 
As far as could be determined there are no previous studies examining changes in 
measured kidney function with weight loss in obese patients with CKD.  The present study 
hypothesised that kidney function would improve with weight loss, and this was apparent 
in the SG group, with trends towards a reduction in hyperfiltration, which was not evident 
in the BMC group.  
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Previous studies examining changes in estimated kidney function in obese patients with 
CKD after weight loss surgery have demonstrated reductions in hyperfiltration (Navarro-
Diaz, Serra et al. 2006) and improvements in eGFR in patients with CKD stage 3 
(Navaneethan and Yehnert 2009).  However, as there was no association between eGFR 
and GFR in the present study, the effect of weight loss on eGFR in obese patients with 
CKD should be interpreted cautiously.  
 
Although it has been reported that eGFR underestimates GFR in the obese (Delanaye, 
Radermecker et al. 2005), the degree of bias in the eGFR measurement in the present study 
was unexpected.  A similar level of bias in eGFR was recently reported in overweight and 
obese patients with diabetic nephropathy, using the EDTA plasma clearance method of 
GFR measurement; eGFR under-predicted measured GFR with a progressively increasing 
bias with each stage of CKD through stages 1-4 (Nair, Mishra et al. 2011), although in the 
present study, the bias was greater in CKD stage 3 than stage 4.   
 
Iohexol clearance measured GFR was also recently reported for the first time in obese 
subjects without CKD (Friedman, Strother et al. 2010).  The MDRD study equation eGFR 
slightly over-predicted measured kidney function in obese subjects, and was associated with 
body weight and lean body mass only.  Serum creatinine was inversely related to fat mass, 
but was not associated with lean body mass (Friedman, Strother et al. 2010).  This reported 
lack of association between lean body mass and serum creatinine in obese subjects might, 
at least in part, explain the poor prediction of GFR by estimation equations based on 
serum creatinine in obese patients with CKD.  Other reasons for the lack of association 
between eGFR, using the MDRD study prediction equation, and measured GFR include 
the under-representation of obese patients in the MDRD study sample, and the use of 
normalised body surface area, which is known to under-represent body surface area in 
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obesity (Levey, Bosch et al. 1999; Levey, Greene et al. 2000; Levey, Stevens et al. 2009; 
Friedman, Strother et al. 2010).  
 
The degree of hyperfiltration evident in the eGFR classified stage 3 CKD patients was 
somewhat unexpected, and brings into question the use of eGFR classifications of CKD 
stage for obese patients.  However, the clinical management would be largely unchanged, 
with the therapeutic aims to reduce blood pressure, optimise blood glucose control and 
blood lipids, reduce proteinuria, and achieve and maintain a healthy weight remaining 
paramount.  The smaller change in kidney function with weight loss in patients with stage 4 
CKD may be attributable to more advanced CKD in which the kidney damage already 
incurred may have been less reversible with weight loss (Palatini, Saladini et al. 2013). 
 
As the change in kidney function may have differed by baseline CKD stage, and the sample 
size is small, it is difficult to examine the effect of the change in kidney function on other 
variables.  The relationship between change in kidney function and change in adiponectin, 
would have been pertinent to examine.  The associations between adiponectin and 
reduction in weight and fat mass in the present study may have mediated the change in 
kidney function evident with weight loss.  Adiponectin receptors are present in renal 
tubular cells and are likely to play a role in the inhibition of angiotensin II-induced 
oxidative stress and fibronectin expression, which may impact upon the progression of 
CKD by limiting oxidative stress, inflammation and fibrosis (Fang, Liu et al. 2013).  
Further studies, in which adiponectin levels are manipulated to mimic adiponectin 
deficiency in obesity and increasing adiponectin with weight loss, may help to elucidate 
some of the mechanisms of the effect of weight loss on kidney function.   
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Novel cardiovascular risk factors 
It may be useful to put the study group into context by comparing baseline levels of, and 
changes in, adipokines with those in obese patients without CKD.  Patients in the present 
study had higher baseline leptin and adiponectin levels than obese patients without CKD 
undergoing weight loss surgery, who underwent either sleeve gastrectomy or gastric bypass, 
and demonstrated a relatively lower reduction in leptin and increase in adiponectin, which 
was remarkably consistent between the other two studies (Serra, Granada et al. 2006; 
Woelnerhanssen, Peterli et al. 2011).  These comparisons indicate that there is likely to be 
an additive effect of obesity and CKD on serum levels of adipokines in obese patients with 
CKD, and that weight loss results in favourable improvements in adipokines.  Both leptin 
and adiponectin remained elevated after weight loss, when compared to levels 12 months 
post weight loss surgery in obese patients without CKD (Serra, Granada et al. 2006; 
Woelnerhanssen, Peterli et al. 2011).  This result may reflect the impact of CKD upon 
serum leptin and adiponectin levels, masking the full physiological impact of weight loss in 
obesity.  This phenomenon may go some way to explaining the disparate findings of 
studies demonstrating that both high and low levels of adiponectin are related to poorer 
outcomes in patients with CKD (Zoccali, Mallamaci et al. 2002; Iwashima, Horio et al. 
2006; Menon, Li et al. 2006; Iglesias and Diez 2010), as there may be an anti-inflammatory, 
anti-atherosclerotic mechanism driving a rise in adiponectin, developed as a counter-
regulatory response to the hyperleptinaemic, uraemic, pro-inflammatory environment of 
CKD.  
 
Despite significantly greater weight loss, and reductions in waist circumference and body 
fat mass in the SG group compared to the BMC group after 12 months, there was no 
remission in diabetes or reduction in hypertension, and little change in blood lipids and 
metabolic syndrome in the SG group.  This finding supports a previous randomised trial of 
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gastric banding weight loss surgery, compared to lifestyle weight loss treatment in obese 
adolescents, which demonstrated no changes in blood lipids or blood pressure after weight 
loss surgery despite substantial weight loss (O'Brien, Sawyer et al. 2010), yet contrasts to 
previous studies of weight loss surgery in obese patients without CKD (Hofso, Nordstrand 
et al. 2010; Martins, Strømmen et al. 2011).  In the SG group, the change in proteinuria was 
related to the 12-month changes in both systolic and diastolic BP (r = 0.9, p = 0.04 for 
both), and this may have been influenced by an increase in BP and proteinuria in one 
patient, who ceased taking anytihypertensive medication 3-6 months post SG, given the 
small sample size in this study, and countered any effect of weight loss on improvements in 
proteinuria or BP overall.  
 
In the BMC group, weight loss was associated with a reduction in triglycerides, and 
changes in HOMA-IR were positively associated with changes in adiponectin after 12 
months.  Weight loss in the BMC group was achieved with a combination of dietary 
modifications to reduce total fat and energy intake, an increase in physical activity, and the 
lipase inhibitor orlistat.  Previous studies on lifestyle-based weight loss interventions have 
used mainly dietary restrictions in obese patients with CKD, and have largely been focused 
on patients with proteinuria (Navaneethan, Yehnert et al. 2009), without stating the eGFR 
range, so differences in the level of kidney function may impact upon the results.  Most 
studies report a reduction in proteinuria with lifestyle-based weight loss interventions, yet 
there was little proteinuria at baseline in the present study.  There was no change in 
triglycerides with weight loss in a combined analysis of previous studies (Navaneethan, 
Yehnert et al. 2009), so the change evident in the present study may be attributable to the 
use of orlistat (Bougoulia, Triantos et al. 2006), rather than to physical activity (Fayh, Lopes 
et al. 2012).  The weight loss achieved in the current study appeared insufficient to induce a 
change in adiponectin in the BMC group.  Studies achieving >10% absolute weight loss 
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with lifestyle modifications report positive changes in adiponectin, triglycerides, IL-6, CRP, 
insulin resistance and leptin in obese women without CKD (Esposito, Pontillo et al. 2003; 
Bougoulia, Triantos et al. 2006). 
 
There was no association found between weight loss and changes in markers of 
inflammation in the present study, which may be attributed to the relatively low level of IL-
6 and hs-CRP in the study participants at baseline, compared to obese patients without 
CKD undergoing weight loss surgery or lifestyle weight loss treatment, and non-obese 
patients with CKD (Esposito, Pontillo et al. 2003; Bougoulia, Triantos et al. 2006; Illan-
Gomez, Gonzalvez-Ortega et al. 2012; Spoto, Leonardis et al. 2012).  Previous cross-
sectional studies have demonstrated inflammation across patients with stages 2-5 CKD, 
with increases in serum IL-6 evident in the earlier stages of CKD and remaining elevated, 
and an eGFR dependent rise in serum TNF-α (Spoto, Leonardis et al. 2012).  Studies differ 
in their findings for changes in TNF-α with weight loss, yet no change in TNF-α after 
weight loss surgery has been reported previously, and the authors postulated that adipose 
tissue TNF-α, may not directly influence serum levels of TNF-α (Illan-Gomez, Gonzalvez-
Ortega et al. 2012).  Indeed, measured adipose tissue mRNA levels of pro-inflammatory 
cytokines IL-6 and TNF-α do not correlate with serum levels, indicating that markers of 
inflammation evident in serum samples may be related to uraemia or macrophage 
concentration, rather than to adipocytes (Spoto, Leonardis et al. 2012).  As inflammation is 
likely related to kidney function, it may be postulated that the lower than expected levels of 
inflammatory markers are perhaps due to the measured GFR being much higher than the 
eGFR in this study, and thus, the study participants are not directly comparable to non-
obese patients with stages 3-4 CKD. 
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Proteinuria was positively associated with adiponectin at baseline, which has also been 
reported previously in CKD (Looker, Krakoff et al. 2004).  This may reflect a counter-
regulatory response to limit kidney damage, as adiponectin acts via the mitogen-activated 
protein kinase pathway to reduce oxidative stress, and may play a role in podocyte foot 
process fusion in an attempt to prevent further albuminuria or proteinuria (Liao, Sung et al. 
2012).  Podocyte hypertrophy has also been characterised in obesity-related glomerulopathy 
(Serra, Romero et al. 2008) and may occur as an adaptive response to an early increase in 
oxidative stress and microalbuminuria, in order to prevent further damage to the podocyte 
and maintain protein homeostasis by maintaining the integrity of the filtration barrier 
(Fornoni 2010).  The change in proteinuria was not related to changes in adiponectin in 
either of the intervention groups after 12 months.  In the entire study population, changes 
in proteinuria after 12 months were associated with changes in insulin resistance, measured 
by HOMA-IR, and changes in the pro-inflammatory cytokine TNF-α, a finding also 
reported previously in a study of weight loss in non-diabetic obese women with and 
without albuminuria (Gilardini, Zulian et al. 2010).  Insulin resistance can be induced by 
TNF-α, and high levels of TNF-α inhibit insulin signalling and glucose uptake in humans 
(Liao, Sung et al. 2012).  Fetuin-A may also induce insulin resistance and correlates with fat 
mass and truncal fat mass in CKD (Axelsson, Wang et al. 2008; Liao, Sung et al. 2012).  
 
Serum fetuin-A decreased in both the groups after 12 months.  Weight loss was not 
associated with a reduction in fetuin-A, proteinuria or insulin resistance in the present 
study.  Fetuin-A is a known inhibitor of adiponectin mRNA in adipose tissue, so a fall in 
fetuin-A levels with weight loss would reduce the inhibition of adiponectin production in 
adipose tissue, which may then result in a rise in serum adiponectin, which was evident in 
the present study.  The lack of association between weight loss and fetuin-A or between 
fetuin-A and adiponectin may be due to the study’s small sample size, or an unaccounted 
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for metabolic effect of CKD.  Recent evidence suggests that obesity and diabetes are co-
variates in the relationship between fetuin-A and cardiovascular risk (or metabolic 
syndrome), which may provide an alternative explanation, although the small sample size in 
this present study precludes investigation of this effect (Ismail, Ragab et al. 2012; Jensen, 
Bartz et al. 2012). 
 
Quality of Life 
An improvement in the SF-36 physical domain score and a reduction in depression score 
were both associated with weight loss in the present study.  These tools are robust 
measures of aspects of quality of life, and are easy to administer.  Evidence of 
improvements in quality of life after sleeve gastrectomy in obese patients with CKD is a 
significant positive patient focused outcome.  It has been demonstrated previously that SF-
36 physical domain scores decrease progressively as CKD stages increase, and obesity also 
contributed to a further deterioration in the SF-36 physical health domain scores, 
compared to those of normal weight, regardless of CKD stage (Pagels, Soderkvist et al. 
2012).   Therefore, an improvement in SF-36 score in the present study related to weight 
loss likely reflects an improvement in the additional reduction in SF-36 score related to 
obesity in patients with CKD.   
 
Safety of interventions for weight loss in stages 3-4 CKD 
Whilst the sample size in the present study is too small to ascertain the safety of SG in 
obese patients with CKD, the experience of performing SG in this patient group may 
provide some learning points for future practice.  2 out of 5 patients in the SG group 
experienced dehydration requiring hospital readmission in the 30-day post operative 
period.  Fluid, electrolyte or nutritional depletion occurs in 2% of patients undergoing 
sleeve gastrectomy (Hutter, Schirmer et al. 2011).  The reduction in kidney function in this 
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patient group, with the encouraged reduction in fluid intake as CKD progresses to prevent 
and manage oedema, may increase the risk for dehydration post-operatively when total 
intake is volume restricted, yet fluid intake is encouraged, requiring a significant change in 
the pattern of fluid ingestion to maintain euvolaemia.   
 
These results, taken together with those in the previous studies in Chapters 3 and 4, 
provide valuable early data to describe the experience of obese patients with CKD 
undergoing LSG weight loss surgery.  CKD, in addition to obesity, may increase the risks 
of adverse events with LSG weight loss surgery, although the benefits must be balanced 
against the possible increase in risk in this population group.   The benefits of weight loss 
in obese patients with CKD may include decreased insulin resistance, reduced insulin 
requirements, and decreased antihypertensive medication dose after 12 months.  
Furthermore, weight loss was associated with an improvement in quality of life scores in 
stages 3-4 CKD and an increased likelihood of qualifying for kidney transplantation in 
patients on haemodialysis, and these beneficial outcomes can be considered together with 
possible risks when making treatment decisions with individual patients.  
 
Strength and limitations 
Performing a pilot study was useful in several ways unrelated to the actual primary and 
secondary outcome measures.  Conducting this pilot study identified significant problems 
in recruiting patients to a randomised controlled study of surgery compared to a non-
surgical intervention.  The recruitment process was very time-consuming and required 
many hours of not only screening databases and clinic lists, but then also talking to patients 
to provide enough information to them to enable them to make an informed decision 
about participating in the study.  Waiting times for surgical appointments were long and 
this extended the recruitment time, as patients required a surgical assessment prior to being 
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able to provide informed consent.  Capacity for elective surgery at the study centre was also 
compromised by a rise in acute medical care provision, including emergency surgery, which 
limited bed capacity and theatre time for elective surgery provision during the study period.   
Whilst the issue of capacity for delivering the required amount of surgical care in clinics 
and operating theatre lists was addressed prior to the study, and assurances were given that 
there would be capacity to accommodate the study patients, this was found not to be the 
case and was beyond the researchers’ control.  The rate of uptake into the study was only 
9% of patients approached to participate.  Additionally, 3 of the 16 patients consenting to 
the study declined the intervention they were allocated to, significantly reducing the 
numbers of patients actually commencing the study. 
 
We now have over a decade of research on the effects of weight loss surgery, and an 
abundance of studies on medical and lifestyle adaptations for weight loss interventions for 
the management of obesity.  However, there are still very few randomised trials exploring 
the differential effects of weight loss achieved by lifestyle or medical treatment, compared 
to weight loss surgery in obesity (O'Brien, Dixon et al. 2006; Dixon, O'Brien et al. 2008; 
O'Brien, Sawyer et al. 2010; Dixon, Schachter et al. 2012; Mingrone, Panunzi et al. 2012; 
Schauer, Kashyap et al. 2012).  The majority of these studies have focused on the effects of 
the extent of weight loss achieved via the two approaches on outcomes related to the 
management of diabetes (O'Brien, Dixon et al. 2006; Dixon, O'Brien et al. 2008; O'Brien, 
Sawyer et al. 2010; Mingrone, Panunzi et al. 2012; Schauer, Kashyap et al. 2012), and one 
study examined the effects of weight loss surgery and low calorie diets on sleep apnoea 
events (Dixon, Schachter et al. 2012).  The paucity of randomised intervention studies 
examining weight loss surgery and lifestyle management of obesity suggests that these trials 
may be difficult to conduct, and a number of factors may be contributory, such as expense, 
availability of expert clinicians to conduct the interventions, the difficulty in controlling the 
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environment sufficiently in a multi-modal intervention to maintain scientific rigour, or 
hesitancy on the part of prospective volunteers to participate in such a study. 
 
The adoption of a randomised controlled study design and use of measured GFR as the 
primary outcome measure, were deemed strengths of the study design, prior to execution 
of the study.  However, the very nature of the randomisation process itself, in such a 
design, with allocation by chance to surgery or lifestyle treatment, increased both the time 
taken for recruitment and the dropout rate.  The dropout rate in the present study 
immediately after randomisation was 3/16 patients (18%), compared to 10% or less 
dropout at the same point in other randomised trials (Dixon, O'Brien et al. 2008; Dixon, 
Schachter et al. 2012).  It was difficult to find patients actually in a state of equipoise 
themselves about treatment, so recruitment look longer than expected.  Similarly, with only 
one person working on recruitment in 2 of the 3 centres, it was a slow methodical process 
to find patients meeting the study inclusion criteria.  With such a small sample size and the 
pilot nature of the study, the results of the actual outcome measures themselves cannot 
always be interpreted, but the utility and practicality of the measures under study can be 
defined. 
 
Use of measured GFR using the iohexol clearance method with fingertip blood sampling 
reduced the study visit time for patients, but may have impacted on the validity and 
reliability of the measure.  The reliability is dependent upon the patients correctly recording 
the timing of their own blood sampling.  Whilst they were provided with a battery operated 
device to make this process easier, the devices did not always work and the process is still 
reliant on the patient pressing the button at the time of blood sampling.  This two-step 
process may have been difficult with many things to remember when carrying out this 
procedure in patients unfamiliar with the process.  Patients demonstrated the technique 
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prior to leaving the clinic, however, there may have been errors made in this patient-
performed data collection.  The measurement of iohexol concentration from fingertip 
blood sampling onto blotting paper assumes that the volume of blood is a fixed amount 
across a given surface area (Mafham, Niculescu-Duvaz et al. 2007).  As patients were 
instructed to completely fill the pre-marked circle on the blotting paper, a greater volume 
of blood may have been present if several drops of blood were used to fill the space, rather 
than the preferred single sample.  Further validation of both the patient-provided sampling 
technique, and iohexol clearance GFR in obese patients with CKD itself, are required 
before further intervention studies exploring the effect of weight loss on kidney function in 
obese patients with CKD are undertaken. 
 
An examination of the literature identified no previous studies using the iohexol clearance 
method for calculating GFR specifically in obese adults with known CKD, prior to the 
present study.  It is now evident that a validation study may have been prudent, prior to 
embarking on a randomised controlled pilot study with iohexol GFR as the primary 
outcome measure.  In a study published in 2010, notably after the study design for the 
present study was finalised and recruitment had begun, measurement of iohexol GFR using 
population pharmokinetics methodology was performed in 29 obese subjects without 
known CKD (Friedman, Strother et al. 2010).  Iohexol clearance was found to follow a 
two-compartment model, rather than a one-compartment model, as used in the present 
study, although as there was a similar relationship between serum iohexol and total body 
iohexol reported in previous studies, it was concluded that there was no distribution of 
iohexol into body fat (Friedman, Strother et al. 2010).  Lean body mass and total body 
weight, were the only factors impacting upon GFR, indicating that metabolic load is the 
major influence on GFR (Friedman, Strother et al. 2010).  Additionally, both early (within 
20 minutes) and later (2 to 4 hours) sampling times were required for optimal GFR 
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calculation; however the authors did acknowledge that a longer sampling period would be 
required in patients with CKD, due to slower iohexol clearance rates.  Thus, the 
importance of the earlier sampling time in obese patients with CKD remains unknown 
(Friedman, Strother et al. 2010).  The within-subject variability of GFR reported from up 
to 6 iohexol clearance measures was 8.8% (Friedman, Strother et al. 2010).  This level of 
variability in obese patients may also impact upon the measurement of change in GFR, 
particularly over a 12-month time period, when expected changes may not be greater than 
this inherent variability.  
 
The major limitation of this study is the sample size, and limitations of the applicability and 
external validity of the results that this brings.  The study results are hypothesis-generating, 
and the data gathered would support the calculation of the required sample size to conduct 
a definitive study.  Given the wide variation in the results for leptin and IL-6, adequately 
powered studies to address research questions pertaining to the effects of weight loss on 
these outcomes would need to be very large indeed.  What should also be considered is the 
ability of any future study design to distinguish between the effect of weight loss, and any 
possible change in kidney function, on other outcomes.  If weight loss is associated with an 
improvement in kidney function, the change in any secondary outcome may be associated 
with either effect, and it would be difficult to ascertain the pathways of these effects in a 
clinical study. 
  
A realistic assessment of the likelihood of taking this research forward into a definitive 
study to address the principal research question in the present study, may indicate that it 
would be too onerous and expensive to conduct.  Given that the number of patients 
requiring screening was in the thousands, prior to a final recruitment ratio of 1 patient in 17 
approached to participate in the study, then a further drop-out rate of 25% after consent, 
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the patient population to draw these numbers from would need to be at least national, if 
not international.  Furthermore, the waiting time for weight loss surgery was up to 12 
months in some cases, which coupled with the length of follow-up required to observe a 
change in kidney function, may make the study prohibitively lengthy. 
 
A protracted study would be expensive given the level of staffing required to adequately 
conduct screening and provide study information to potential participants in a timely 
manner given the potentially very large target population required to recruit an adequate 
number of participants.  After recruitment, the time required for surgical wait-listing and 
follow-up would be lengthy, and the high cost of staffing multiple centres with 
professionals to deliver lifestyle modification programmes and post-surgical dietary 
education, plus research support staff to undertake blinded data collection, may be 
unaffordable.  The benefits of the study findings would need to be adequately balanced 
against the costs of conducting such a study. 
 
Furthermore, prior to any such study being conducted, the measure of kidney function in 
obese patients with CKD, iohexol clearance GFR or otherwise, would been to be validated 
in the target population, both internally for reliability, and externally against the gold 
standard inulin clearance method.  In retrospect, the battery of measures undertaken in the 
present pilot study was too extensive, even for an exploratory study.  A study primarily 
examining the relationship between weight loss and kidney function could be limited to the 
primary outcome and patient-focused outcomes only, such as quality of life, with the 
majority of the mechanistic markers omitted, especially given the likelihood of a very 
extensive sample size required to provide adequate power to elicit a significant intervention 
effect.  Adiponectin, leptin, HOMA-IR and possibly fetuin-A may be helpful if a “reverse” 
translational approach was adopted which would lead to further mechanistic studies, to 
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elucidate the mechanisms involved.  The low level of inflammation in the study 
participants was not expected and may reflect the inadequacy of eGFR as a measure of 
kidney function in obese patients with stages 3-4 CKD, and the added value of 
inflammatory markers in addressing the primary outcome is negligible.    
 
One such trial is indeed planned, as our clinical research team was recently contacted by 
Professor Vincent Esnault, from the Departments of Nephrology and Clinical 
Immunology, Nantes University Hospital, Nantes, France, regarding the potential pooling 
of data from the present study, with the planned French multi-centre study.  This planned 
study is adopting a similar protocol, hoping to recruit 100 patients in France, randomising 
them to either weight loss surgery or standard care (personal communication Professor 
Vincent Esnault, 2012).   Even if the full sample size for this study to determine the effect 
of weight loss surgery on kidney function is achieved, it is unlikely to be powered to 
explore the secondary relationships best determined though multiple linear regression 
models using mixed methods analysis.   
 
Problems associated with conducting a randomised controlled intervention study 
Problems were also identified in controlling the multicomponent interventions, such as the 
WMP included as part of best medical care.  The WMP is a multi-disciplinary, structured 
intervention using diet, exercise and pharmacotherapy, delivered using behavioural therapy 
techniques.  The requirements of the research data collection did not correspond with the 
practicalities of research patients joining an existing clinical service, and not all patients 
were able to experience the full benefit of the WMP, and were unable to see the 
physiotherapist at every clinic visit.  Fasting blood measures were optimally taken in the 
morning, which made it difficult for patients with other commitments to also attend 
corresponding WMP appointments in the afternoons.  Furthermore, orlistat became 
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unavailable half-way through the study, an occurrence which was unable to be controlled 
by the researchers, and compromised the integrity of the WMP as a package of care, and 
no alternative medication was available.    
	  
Compliance with the WMP appeared poorer in this study than is usually apparent in 
routine clinical practice.  Several factors may have contributed to this, such as the type of 
patient enrolling in the study may have been atypical for the WMP, as patients participating 
in a randomised controlled study for surgery may have preferred surgical treatment, and 
may have been less motivated to engage with the necessary dietary and exercise changes 
needed for successful weight loss without surgery.  In routine clinical practice, patients are 
required to complete and return a 7-day food and activity diary prior to participating in the 
WMP, and this particular criterion was removed in the present study.  In a similar, but non-
randomised, study of surgery compared to lifestyle weight loss treatment, compliance may 
have been better since patients self-selected their treatment group, and the lifestyle 
treatment group had a period of residential treatment, which impacted upon food and 
activity choices (Hofso, Nordstrand et al. 2010). 
 
Compliance with the patients’ usual prescribed medications was variable during the study.  
Variable compliance may have confounded the insulin resistance and BP results, and the 
cessation of the production of orlistat during the study also may have impacted upon 
weight loss and blood lipids.  Even with extremely careful recording of BP medications and 
standardised measurement of BP, non-compliance with medication for known 
hypertension during the study, may have impacted upon the results for associations 
between weight loss and hypertension, and proteinuria, particularly in this study with a 
small number of participants.  The use of HOMA-IR as a measure of insulin resistance in 
patients both with and without diabetes, may have been problematic.  Even though 
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patients attended data collection visits in a fasted state and without administering their 
usual insulin dose, insulin levels were still very high in some patients.  There was only a 
small change in HOMA-IR evident throughout the study, despite significantly more weight 
loss in the SG group.     
 
The weight regain after 6 months in the BMC group, may have been related to changes in 
physical activity status in some patients in this group.  One patient developed a condition 
requiring non-weight bearing immobilization of the foot in a plaster cast from month 9 
until the end of the study, one patient moved to a new area and felt unsafe exercising out-
of-doors and did not find an indoor alternative.  Furthermore, another patient in the BMC 
group developed a concurrent undiagnosed condition with pain behind the eyes, which 
made focusing on weight loss difficult for the patient, and distracted from weight loss, and 
one patient did not attend any Weight Management Programme appointments.  
 
Summary and conclusions 
Use of both a structured lifestyle modification programme and LSG surgery resulted in 
significant weight loss after 12 months in obese patients with stages 3-4 CKD.  Weight loss 
was associated with improvements in quality of life scores, and both weight loss and 
reduction in fat mass were related to an increase in adiponectin across both intervention 
groups.  LSG weight loss was associated with positive changes in adipokines, and lifestyle 
weight loss was associated with a reduction in triglycerides.  Estimated kidney function 
using the 4-variable MDRD study equation greatly underestimated kidney function.  
Weight loss may improve kidney function in obese patients with CKD, although methods 
of measuring kidney function in obese patients with CKD should be validated before 
further intervention studies are undertaken in this area.   
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Clinical intervention trials, particularly, those with multi-component interventions are 
difficult to conduct and to control adequately.  Further observational research could be 
conducted on a national and international scale to provide more extensive safety and 





Chapter 6: Prevalence of Chronic Kidney Disease by Body 
Mass Index in the Health Survey for England 2010 and in 
patients with Acute Coronary Syndromes in England and 
Wales 
 
Chapter summary  
Cross-sectional and longitudinal studies in European, North American and Japanese 
populations have demonstrated that obesity is a risk factor for chronic kidney disease 
(CKD).  Studies examining the relationship between obesity and CKD in the United 
Kingdom (UK) have been conducted in local populations, but there are no studies 
evaluating the risk of CKD with overweight and obesity in a nationally representative 
sample in the UK.  The aim of this study was to determine if overweight and obesity are 
independently associated with the prevalence of CKD in two national datasets, the 
Myocardial Infarction National Audit Project (MINAP) and 2010 Health Survey for 
England (HSE) cohorts.  Data was examined retrospectively from 2 prospectively collected 
national data sets.  CKD was defined as estimated kidney function < 60 ml/min/1.73m2 
calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 
formula using serum creatinine, age, gender and race variables.  As previous studies used 
the Modification of Diet in Renal Disease (MDRD) study equation to estimate kidney 
function, the analysis was repeated with this definition to allow comparisons.  Multivariable 
logistic regression models were developed to calculate odds ratios (OR) and 95% 
confidence intervals (CI) for CKD risk by BMI categories.  The BMI reference category 
was 18.5 kg/m2 – 24.9 kg/m2.  The relationship between obesity and the risk of CKD 
could not be determined in the MINAP population as the complete dataset was less than 
10% of the initial sample and may not be representative of the MINAP population in its 
entirety.  The prevalence of CKD was 5.9% in the HSE 2010 population, which was similar 
to previous studies.  The risk of CKD was over 2.5 times higher in obese participants, 
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compared to normal weight participants in the HSE 2010 study population, after 
adjustment for age, gender, ethnicity, smoking, diabetes and hypertension (adjusted OR 
2.78 (95% CI 1.75 to 4.43) for BMI 30.0 - 39.9 kg/m2; adjusted OR 2.68 (95% CI 1.05 to 
6.85) for BMI ≥ 40.0 kg/m2).  The risk for CKD increased with increasing BMI in the UK 
population, supporting the findings from previous epidemiological studies.  Given the 
relatively low prevalence of CKD compared to obesity, and it remains unclear whether 
obesity increases prevalence of CKD early in the course of CKD, or accelerates 
progression, or both, yet recent evidence suggests a latent effect, which may account for at 
least some of the differential findings in previous studies.  Future service delivery planning 
should account for possible latent increases in CKD in the years following an epidemic rise 




Obesity has been demonstrated to be a novel risk factor for prevalent CKD, and the 
development of CKD and end stage kidney failure over time, in North American, Japanese, 
Thai, and European populations (Fox, Larson et al. 2004; Gelber, Kurth et al. 2005; 
Kramer, Luke et al. 2005; Hallan, de Mutsert et al. 2006; Hsu, McCulloch et al. 2006; 
Foster, Hwang et al. 2008; Kawamoto, Kohara et al. 2008; Munkhaugen, Lydersen et al. 
2009; Satirapoj, Supasyndh et al. 2012).  This relationship has not been well investigated in 
national population studies within the United Kingdom (UK).  To date, there are only 5 
published studies examining the association between obesity and CKD in the UK, all of 
which are in local, not national, population samples (Othman, Kawar et al. 2009; Hobbs, 
Farmer et al. 2011; Brown, Mohsen et al. 2012; Burton, Gray et al. 2012; Mohsen, Brown et 
al. 2012).  In a recent cross-sectional study of a population of 61 000 primary care patients 
in Kent, South East England, the relationship between an eGFR of < 60/ml/ min/1.73m2 
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(MDRD study equation) and BMI was examined (Hobbs, Farmer et al. 2011).  The authors 
showed a statistically significant trend for a difference in eGFR across BMI categories 
using an analysis of variance (p<0.001).  However, the authors reported that as this 
difference was small and not evident once BMI was greater than 25 kg/m2, it was unlikely 
to be biologically significant.  2 separate logistic regression models were created, both 
adjusted for age, gender, diabetes and hypertension, but not ethnicity, in patients with an 
eGFR of < 120 ml/min/1.73m2 and < 60 ml/min/1.73m2, and with BMI as a continuous 
variable.  The results display models stratified by age but do not state what the age range 
reference category is, and are difficult to interpret.  Crucially, there appears to be no 
estimate of the odds ratio for the risk of CKD, defined by an eGFR < 60ml/min/1.73m2, 
with BMI as a categorical variable; which limits comparisons between this study and 
previous studies in non-UK populations (Kramer, Luke et al. 2005; Hallan, de Mutsert et 
al. 2006; Kawamoto, Kohara et al. 2008).  The second UK population cross-sectional study 
examined the relationship between measures of obesity and CKD in almost 6 500 
randomly selected patients without diabetes from General Practices in Leicestershire 
(Burton, Gray et al. 2012).  The risk of CKD increased with increasing BMI (OR 1.04, 95% 
confidence interval 1.02 to 1.05; p < 0.0001), yet the level of increased risk was small, and 
did not change after adjustment for other known CKD risk factors including age, gender, 
albuminuria and hypertension.   
 
There are 3 longitudinal studies examining the relationship between baseline BMI and 
progression of established CKD in UK local populations (Othman, Kawar et al. 2009; 
Brown, Mohsen et al. 2012; Mohsen, Brown et al. 2012).  Baseline BMI was found to 
predict CKD progression in 125 patients with an eGFR < 60 ml/min/1.73m2, over a 
median follow up period of 9 years (Othman, Kawar et al. 2009), but did not predict 
progression of CKD in over 700 patients, also with an eGFR < 60 ml/min/1.73m2, over 3 
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years (Brown, Mohsen et al. 2012; Mohsen, Brown et al. 2012).  It is likely that 3 years of 
follow up may have been inadequate to examine the relationship, and only 2 measures of 
eGFR were used in the latter studies, which may not be sufficient to observe change, given 
the normal variation in eGFR (Chang and Kramer 2012).   
 
The primary cause of the kidney disease may alter the rate of CKD progression.  Obesity 
related glomerulopathy, with its associated glomerular lesions and podocyte hypertrophy 
(Serra, Romero et al. 2008), might progress at a slower rate than CKD primarily due to 
hypertension or diabetes with obesity as a secondary factor (Kambham, Markowitz et al. 
2001).  Recent evidence suggests that it is the duration of obesity that is predictive of 
development of CKD, indicating that progression to overt CKD with a decline in eGFR 
occurs over many years (Silverwood, Pierce et al. 2013).  The difference in progression 
rates between primary and secondary obesity related CKD could impact on the relationship 
observed between obesity and the progression of CKD in longitudinal studies.   
 
Furthermore, the duration and severity of the hypertension or complications of diabetes at 
entry into the study, and/or the successful control of hypertension and blood glucose 
levels, irrespective of BMI, may also impact on the rate of disease progression, and these 
factors may be difficult to control for in large studies.  For example, severe uncontrolled 
hypertension with mild obesity is likely to result in the development of CKD faster than 
severe obesity with mild hypertension, yet in studies using categorical data at least, these 
differences may be difficult to distinguish.   
 
In recent years, 2 large, prospectively collected, national data sets have included a single 
serum creatinine measure, together with data on age, gender, ethnicity and BMI, providing 
an opportunity to determine the prevalence of CKD in these populations and the risk of 
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CKD associated with BMI.  In 2010, the Health Survey for England included serum 
creatinine (from which eGFR can be calculated) in the dataset to assist in determining the 
prevalence of CKD in the population (Roth, Roderick et al. 2011).  This dataset provides a 
randomly selected general population sample (Craig and Mondell 2011), which may include 
both healthy individuals and those with acute and chronic illnesses, in which to explore the 
relationship between obesity and the CKD at a whole population level. 
 
The Myocardial Ischemia National Audit Project (MINAP) database holds prospectively 
collected, anonymous data on the management of acute coronary syndromes from all 
National Health Service (NHS) hospitals across England and Wales since 2000.  As the 
NHS is the predominant provider of immediate clinical management post acute myocardial 
infarction, MINAP is a unique dataset on a contemporary population-based cohort of 
patients with acute coronary syndromes (Herrett, Smeeth et al. 2010).   
 
There is considerable overlap in the known risk factors for CKD and CVD, notably, 
diabetes, hypertension, dyslipidaemia and obesity (Levey, Coresh et al. 2003; Gelber, Kurth 
et al. 2005), and these factors are the components of metabolic syndrome (Grundy, 
Cleeman et al. 2005).  Similarly, CKD is associated with progressively increasing 
cardiovascular disease (CVD) risk as kidney function declines (Vanholder, Massy et al. 
2005).  As CKD and CVD appear to be intricately linked, and the risk of developing one 
increases with the other, the MINAP database is likely to contain a significant proportion 
of patients with CKD, and therefore, presents itself as a useful tool with which to explore 
the relationship between obesity and CKD in a UK based population with existing 




This study aims to determine if the risk of CKD increases with overweight and obesity in 
two nationally sampled UK datasets - the Health Survey for England 2010, and the 




Overweight and obesity are independently associated with the risk for CKD (eGFR < 60 
ml/min/1.73m2) in both the general population and in a cohort of adults with 




This was a retrospective cohort study of 2 prospectively collected national data sets. 
 
Study Population and Setting 
Data were extracted from the anonymised Health Survey for England 2010 and the 
MINAP database of adults with acute coronary syndrome events from all NHS hospitals 
managing these patients in England and Wales (n=242) between January 2008 and April 
2010.  The Health Survey for England is carried out by the Joint Health Surveys Unit of 
the National Centre for Social Research (NatCen) and the Department of Epidemiology 
and Public Health at the University College London (UCL) Medical School (Craig and 
Mondell 2011).  During the initial data collection visit, with participants’ consent, a second 
visit with a nurse is arranged for physical measurements, and collection of blood, saliva and 
urine samples.  The Health Survey for England data set includes a vast array of 
information, including demographics, socio-economic status, self reported dietary 
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information, medications, co-morbidities, and mental health measures.  In the Health 
Survey for England 2010 population, the study included adult participants over 18 years, 
with a valid serum creatinine measurement and calculable BMI. 
 
The current MINAP dataset includes information on pre- and in-hospital treatment, 
patient demographics, previous medical history and vital status.  Data are collected by 
nurses, doctors and clinical audit staff at the participating hospitals and entered into a 
dedicated database.  Data quality is assessed annually using a validation tool requiring 
hospitals to re-submit a random subset of records to measure the agreement between the 
original record and re-submitted data.   The study was limited to adult patients with non-ST 
elevation myocardial infarction (nSTEMI) acute coronary syndrome, the commonest type 
of acute coronary syndrome observed in the MINAP population.   
 
Use of the MINAP study database was approved by the South East London Research 
Ethics Committee 2 (11/LO/0246) the Health Survey for England data was accessed from 
the Economic and Social Data Service at the UK Data Archive for use in the present study 
(National Centre for Social Research and Royal Free and University College Medical 
School. Department of Epidemiology and Public Health 2012).  Ethical approval to use the 
Health Survey for England dataset was not required as it is an anonymised, publicly 
available set of data provided by the UK Data Archive for the purposes of research and 
education.  
 
Main Outcome and Measures 
The primary outcome was the risk of concomitant CKD, defined as eGFR < 60 
ml/min/1.73m2, as BMI increases in the Health Survey for England 2010 and MINAP 
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nSTEMI acute coronary syndrome populations with both BMI and a single serum 
creatinine measure recorded.  
 
Collection of a single serum creatinine value obtained on hospital admission is part of the 
routine MINAP data set for each individual, and was also included in routine data 
collection in the Health Survey for England in 2010.  Blood samples were analysed and 
serum creatinine values were obtained in a single laboratory in the Health Survey for 
England, and in the MINAP study serum creatinine values are standardised to an isotope 
dilution method mass spectrometry method so serum creatinine values collected at 
different data collection sites are comparable.  Kidney function was defined as estimated 
glomerular filtration rate (eGFR) in ml/min/1.73m2 calculated using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) formula using serum creatinine, age, 
gender and ethnicity variables (Levey, Stevens et al. 2009).  Kidney function was 
subsequently categorised using the Kidney Disease Outcomes Quality Initiative (KDOQI) 
stages of CKD (2002), and CKD was classified as CKD stage 3 or above, with an eGFR of 
< 60 ml/min/1.73m2.   
 
The CKD-EPI equation, developed using data from ten pooled studies with measured 
GFR and validated from a separate database of a further sixteen studies, is more accurate 
than the Modification of Diet in Renal Disease (MDRD) study equation, with a lower bias 
at higher estimates of GFR due to the use of a linear spline term, not present in the 
MDRD study equation (Levey, Stevens et al. 2009).   The CKD-EPI equation was validated 
on a broader population than the MDRD study equation and improves the general 
applicability, as well as decreasing the false positive rate of classification of stage 3 CKD 
(Levey, Stevens et al. 2009).  The CKD-EPI equation, developed in 2009, has not yet been 
widely adopted as the preferred method for estimating GFR, but may become the 
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preferred estimation equation in future if further validation studies support the initial 
findings (MacGregor and Taal 2011).  The Health Survey for England dataset included 
both creatinine and eGFR using the MDRD study equation (Roth, Roderick et al. 2011), so 
serum creatinine values were used to re-calculate eGFR using the CKD-EPI equation for 
the present study. 
 
BMI was calculated as weight (kg)/height (m) x height (m) from hospital measured height 
and body weight, recorded in routine MINAP data collection, and from nurse measured 
height and weight in the Health Survey for England 2010, and categorised into 
underweight, normal range, overweight and obese classifications according to the World 
Health Organisation (WHO) criteria (World Health Organisation 2006).  Diabetes, and 
hypertension status data were collected routinely as part of both data sets.  Diabetes was 
classified as a previous diagnosis of diabetes and/or the use of an oral hypoglycaemic agent 
or insulin, and/or fasting blood glucose > 6.7 mmol/L and/or a random blood glucose of 
> 11 mmol/L prior to admission (2011).  Hypertension was classified as already receiving 
treatment (drug, dietary or lifestyle) for hypertension or with a recorded blood pressure of 
>140/90 measured by the survey nurse in the Health Survey for England (Craig and 
Mondell 2011), or recorded on at least two occasions before admission in the MINAP data 
set (2011).  Smoking status was defined as never smoked (reference category), ex-smoker 
and current smoker.   
 
Statistical analyses 
Statistical analysis was completed using STATA version 11 (StataCorp: College Station, 
TX) and SPSS version 19 (IBM: Armonk NY).  Descriptive statistics were expressed as 
mean (SD) or median (interquartile range IQR) for parametric and non-parametric 
continuous variables, respectively.  Categorical variables were expressed as percentages.  
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Baseline comparisons between continuous variables were performed using Student’s T-test 
or Mann-Whitney U test for parametric and non-parametric variables, respectively, and 
Pearson’s chi-squared (χ2) test for categorical variables.  Normality of the data sets was 
established using visual assessment of histograms representing a normal curve, and non-
parametric continuous variables were converted into categorical variables. 
 
Patients with both a single serum creatinine value and calculated BMI between 15-60 
kg/m2 were included in the study.  BMI outside this range was deemed to be either 
incorrect or not representative of population norms and was therefore excluded.  Baseline 
characteristics in both populations, with an estimate of kidney function using the CKD-
EPI equation, were reported, including age, gender, ethnicity and eGFR, and diabetes and 
hypertension status. 
 
Patients and survey participants were split into 2 groups according to estimated kidney 
function.  The CKD group had an eGFR < 60 ml/min/1.73m2, and the non-CKD group 
had an eGFR ≥ 60 ml/min/1.73m2.  Baseline characteristics of the two groups were 
compared for age, gender, ethnicity, diabetes and hypertension.  Patients in both groups 
were classified by WHO BMI criteria of underweight (< 18.5 kg/m2), normal range (18.5 – 
24.9 kg/m2), overweight (25 - 29.9 kg/m2), obese classes I and II (30.0 - 39.9 kg/m2), and 
obese class III (≥ 40 kg/m2).  The distribution of patients across BMI categories, in the 
CKD group and the non-CKD group were compared using Pearson’s chi-squared test. 
 
To evaluate the relationship between CKD and obesity in the each study population, whilst 
accounting for other patient characteristics and conditions, multivariable logistic regression 
models were developed to calculate OR and 95% CI.  The BMI reference category was 
18.5 kg/m2 – 24.9 kg/m2.  The unadjusted model (model 1) was sequentially built upon to 
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include the pre-determined co-variables age, gender and ethnicity (model 2), plus smoking 




The MINAP population data from 1st January 2008 to 1st April 2010 included 181 490 
patients with an acute coronary syndrome.  47 094 patients were excluded as they had 
missing data on age, gender, ethnicity or serum creatinine, and therefore, estimated kidney 
function could not be calculated.  A dataset of 36 598 patients with nSTEMI events, with 
complete data for age, gender, blood pressure, diabetes, hypertension, cardiovascular co-
morbidities and previous cardiac interventions or procedures, serum creatinine, and index 
of multiple deprivations score was created for a separate study analysing the likelihood of 
intensive or conservative intervention treatment post nSTEMI in patients with, and 
without, CKD (classified by NKF-KDOQI CKD stage).  25 743 patients were excluded 
with missing data for height, and/or weight, or with a calculated BMI of < 15 kg/m2, 
leaving a total of 10 855 patients in the dataset for the present study (Figure 22).    
 
As this data set was less than 10% of the original sample, it was deemed inappropriate to 
continue the analysis further on the MINAP population, as the sample may not be 
representative of the entire MINAP population. 
 
 The Health Survey for England 2010 study population included 8 420 adults and 5 692 
children.  This study was limited to adult participants so all children were excluded.  4 957 
of the 8 420 adult participants were excluded due to missing serum creatinine, height, 




sample population of 3 463 adults with a valid BMI and calculable eGFR (Figure 23); 
equivalent to 41.1% of the original adult study population.  The characteristics of the 
Health Survey for England study population are presented in Table 27. 
 MINAP population Jan 2008 - April 2010 
n= 181 490 
n = 134 396 
No age, ethnicity, gender,  
or serum creatinine  
nSTEMI MINAP population 
n=36 598 
non nSTEMI events, <18 years 
Or eGFR <0 or >130 
No diabetes status, hypertension status,  
CVD history or cardiac intervention 
history 
with BMI 15-60 kg/m2 
n = 10 855 
No height and/or no weight  
and BMI <15  n = 25 743 
No diabetes status n=631 
Figure 22: Selection of study population from MINAP database 




Table 27: Characteristics of the Health Survey for England 2010 study population with valid BMI 
and CKD-EPI equation estimated kidney function (n = 3 463) 
Age 51.1 (±16.7) years 
Gender 44.2% Male; 55.8% Female 
Ethnicity 92.8% White, 1.9% Black, 3.3% Asian, 2.0% Other 
Diabetes 6.0% 
Hypertension 24.8% 
CKD-EPI eGFR  93.0 (±19.3) ml/min/1.73m2 
BMI  27.6 (±5.2) kg/m2 
BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration 
 
Table 28 displays the distribution of BMI in the Health Survey for England 2010 
participants.  Over 65% of the population were overweight or obese.   
 
Health Survey for England 2010  
Adults with valid eGFR and BMI  
n = 3 463 
Health Survey for England 
study population 
n = 14 112 
 
Less than 18 years old 
n = 5 692 
Adults 
n = 8 420 
Height or weight not available/not valid n = 1 448 
Creatinine not available/not valid n = 3 319 
No ethnicity/diabetes/hypertension status n = 10 
Figure 23: Selection of study population from Health Survey for England 2010 
BMI, body mass index; eGFR, estimated glomerular filtration rate 
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Table 28: Distribution across body mass index categories for the Health Survey for England 2010 
population with valid BMI and CKD-EPI equation estimated kidney function (n = 3 463) 
Body Mass Index (BMI) category (kg/m2) 











CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration;  
 
204 (5.9%) participants in the Health Survey for England 2010 had an eGFR < 60 
ml/min/1.73m2 and were thus defined as having CKD.  Mean age and BMI and gender, 
ethnicity, diabetes and hypertension status, and BMI are described in Table 29.  
 
The Health Survey for England population with CKD were older, had more diabetes and 
hypertension, and a higher mean BMI than those without CKD.  The non-CKD group had 
greater representation from Black, Asian and other ethnic groups than the CKD group.  
The higher levels of diabetes and hypertension in the CKD group were expected, as these 
are known risk factors for the development of CKD. 
 
Table 29: Description of the Health Survey for England 2010 study population defined by CKD 
statusa 
 Non-CKD group 
 
eGFR ≥ 60 ml/min/1.73m2 
n = 3 259 
CKD group 
 
eGFR < 60 ml/min/1.73m2 
n = 204 
p 
Age (years) 49.7 (± 16.0) 73.0 (± 11.6) < 0.001 
Gender (Male) 44.3% 44.1% 0.96 
Ethnicity 92.5% White, 2% Black, 3.5% 
Asian, 2% Other 
98.5% White, 0% Black, 1.0% 
Asian, 0.5% Other 
0.03 
Diabetes 5.3% 16.7% < 0.001 
Hypertension 22.7% 57.4% < 0.001 
BMI (kg/m2) 27.5 29.3 < 0.001 
a data presented as mean (± standard deviation) or prevalence; (BMI, body mass index; CKD, chronic kidney disease; 




The distribution of participants across BMI categories, by CKD group, in the Health 
Survey for England 2010 population is presented in Table 30.  There were more normal 
weight and overweight participants in the non-CKD group, than in the CKD group.  
Conversely, the CKD group had a greater percentage of obese patients than the non-CKD 
group.  The distribution of BMI was not the same in the CKD and non-CKD groups (χ2 = 
30.85, degrees of freedom = 4, p < 0.001). 
 
Table 30: Distribution across BMI categories by CKD status in the Health Survey for England 2010 
study population 
CKD status  BMI category (kg/m2) 
 <18.5 18.5-24.9 25.0-29.9 30.0-40.0 >40.0 
Non-CKD group 
(eGFR ≥ 60 
ml/min/1.73m2) 




(eGFR < 60 
ml/min/1.73m2) 
n = 204  1.0% 18.1% 38.2%  38.7% 3.9%  
 
n = 3 463, χ2 = 30.85, degrees of freedom = 4, p < 0.001 
BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation;  
 
The unadjusted and adjusted odds ratios and 95% confidence intervals for the risk of CKD 
as BMI increases are displayed in Table 31.  The risk of developing CKD increases as BMI 
increases in the Health Survey for England 2010 population.  In the unadjusted model 
(model 1), the risk of CKD is almost 3 times higher in those with a BMI of 30 - 39.9 kg/m2 
than in those with normal BMI.  After adjustment for age, gender and ethnicity (model 2), 
the risk is attenuated, but remains significant, for the overweight group, and the risk 
increases with a BMI ≥ 30 kg/m2.  With further adjustment for smoking, diabetes, and 
hypertension (model 3), the risk of CKD is mitigated slightly, but remains over 2.5 times 
higher in those with a BMI ≥ 30 kg/m2, compared to those of normal weight.  In the 
overweight group the risk of CKD is fully attenuated by adjusting for diabetes, 
hypertension and smoking status.  
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Table 31: Logistic regression models for risk of concomitant CKD (CKD-EPI eGFR< 60 
ml/min/1.73m2) by body mass index (BMI) in the Health Survey for England 2010 study population  




Model 1 -unadjusted  




Model 2 - adjusted for 
age, gender and ethnicity  




Model 3 - adjusted for 
age, gender, ethnicity 
smoking, diabetes and 
hypertension 
BMI < 18.5 kg/m2  2.16 (0.50 to 9.43) 2.28 (0.30 to 17.16) 2.08 (0.27 to 15.74) 
18.5 - 24.9 kg/m2 1.00 1.00 1.00 
25.0 - 29.9 kg/m2 1.75 (1.17 to 2.61)** 1.57 (1.01 to 2.44) * 1.48 (0.94 to 2.31) 
30.0 - 39.9 kg/m2 2.98 (2.00 to 4.46)*** 3.14 (2.00 to 4.92)*** 2.78 (1.75 to 4.43)*** 
≥ 40.0 kg/m2 2.92 (1.31 to 6.47)** 3.42 (1.37 to 8.56)** 2.68 (1.05 to 6.85)* 
*** p < 0.001; ** p < 0.01; * p < 0.05; CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration equation; eGFR, estimated glomerular filtration rate 
 
In order to make comparisons with other studies, this analysis was repeated using the 
MDRD study equation to calculate eGFR (Levey, Bosch et al. 1999; Levey, Greene et al. 
2000), and the results did not change markedly – although risk is lower and becomes non 
significant when BMI ≥ 40.0 kg/m2 (Table 32).  The prevalence of CKD in the study 
population defined by the MDRD study equation was 7.4% (n = 254), with 38.1 % of 
those with CKD with BMI ≥ 30 kg/m2 compared to 42.6% using the CKD-EPI equation. 
 
Table 32: Logistic regression models for risk of concomitant CKD (MDRD eGFR< 60 
ml/min/1.73m2) by body mass index (BMI) in the Health Survey for England 2010 study population  




Model 1 -unadjusted  




Model 2 - adjusted for 
age, gender and ethnicity  




Model 3 - adjusted for 
age, gender, ethnicity 
smoking, diabetes and 
hypertension 
BMI <18.5 kg/m2 1.53 (0.35 to 6.62) 1.81 (0.34 to 9.74) 1.73 (0.32 to 9.47) 
18.5-24.9 kg/m2 1.00 1.00 1.00 
25.0-29.9 kg/m2 1.70 (1.20 to 2.40)** 1.41 (0.98 to 2.03) 1.37 (0.95 to 1.99) 
30.0-39.9 kg/m2 2.42 (1.69 to 3.43)*** 2.14 (1.46 to 3.12)*** 2.02 (1.37 to 2.97)*** 
≥40.0 kg/m2 2.35 (1.12 to 4.96)* 2.29 (1.03 to 5.10)* 2.01 (0.89 to 4.54) 
*** p < 0.001; ** p < 0.01; * p < 0.05; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; MDRD, 




Obesity is associated with a significantly increased risk of CKD in a large, randomly 
selected, nationally representative population sample in the United Kingdom.  As far as can 
be determined, this is the first report of an association between obesity and CKD risk in a 
nationally representative sample of the United Kingdom population. 
 
The prevalence of CKD in the Health Survey for England group was just under 6% using 
the CKD-EPI equation, which is similar to the reported prevalence of 6% in women and 
7% in men in the 2010 Health Survey for England report, using the MDRD equation 
(Roth, Roderick et al. 2011), and the 5% reported in the HUNT II study in Norway, with 
the same definition of CKD as an eGFR < 60ml/min (Hallan, de Mutsert et al. 2006).  
  
In the present study, there were a greater percentage of overweight and obese patients in 
the CKD group, compared to the non-CKD group.  The risk for CKD increased with 
increasing BMI, supporting the findings from previous epidemiological studies in 
European, Japanese and North American populations (Kramer, Luke et al. 2005; Hallan, de 
Mutsert et al. 2006; Kawamoto, Kohara et al. 2008).  In cross-sectional studies of 
community based samples, the fully adjusted risk for CKD with obesity, compared to 
normal weight controls, increased by 44% in the HUNT II study population for eGFR < 
45 ml/min, and by 57% when adjusted for age and gender only for eGFR < 60 ml/min 
(Hallan, de Mutsert et al. 2006), and the risk for CKD, with overweight and obesity 
combined, doubled in a Japanese community population (Kawamoto, Kohara et al. 2008).  
In the current study, the risk of CKD was similar, using the MDRD equation, yet the fully 
adjusted risk for CKD, using the CKD-EPI equation, was over 2.5 times as high for obese 
participants than normal weight controls.   Although the overall percentage of participants 
classified with CKD was lower using the CKD-EPI equation than the MDRD equation, 
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there was a greater proportion of obese participants in the CKD-EPI classified CKD group 
than in the MDRD defined CKD group.   
 
In patients with known risk factors, the fully adjusted risk of CKD with obesity was 23% 
higher in patients with hypertension (Kramer, Luke et al. 2005), indicating that the added 
risk of obesity is lower in populations with other previously identified risk factors for 
CKD, such as hypertension, than in studies of mixed or apparently healthy community 
populations.  The independent risk of obesity appears greater in the “healthy” obese 
populations, not because the absolute risk is any higher, but because the risk in the 
comparator group is lower, as in the “healthy” populations, the comparator group lack 
other contributing risk factors for CKD, which are present in the populations with existing 
CVD disease and hypertension.  
 
The results of this study differ to previous cross-sectional studies of the relationship 
between obesity and CKD, which were conducted in a local, rather than national United 
Kingdom population samples.  In the previous studies, there was a very small or no 
relationship between eGFR and BMI in the regression models, after adjustment for age, 
gender, diabetes and hypertension, in samples of participants from General Practices in 
Kent and Leicestershire (Hobbs, Farmer et al. 2011; Burton, Gray et al. 2012).  The present 
study demonstrated a significant effect of obesity on the odds of having CKD in the 
Health Survey for England 2010 population after adjustment for the abovementioned 
factors.  These differences may reflect sampling biases in local versus national population 
datasets, or differences in General Practitioner derived versus randomly selected by 
postcode population samples.  The methodology for the statistical analyses are difficult to 
interpret in the previous UK studies, and in one study the statistical model was not 
corrected for ethnicity, as it was inconsistently reported in the dataset (Hobbs, Farmer et al. 
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2011).   Failure to include ethnicity as a baseline variable in the dataset puts the validity of 
the eGFR data at risk, given that ethnicity is one the required variables to calculate the 
MDRD eGFR value (Levey, Bosch et al. 1999; Levey, Greene et al. 2000).  
 
The strengths of this study include the use of datasets compiled of information collected in 
a uniform fashion with defined terms and standardised methods of data input.  The data 
extracted from the both datasets contain nationally representative populations of healthy 
participants and patients with CVD, and the analyses were corrected for known potential 
confounding variables including age, gender and ethnicity, and smoking status, diabetes and 
hypertension as co-morbidities.  Data monitoring audits of the MINAP database analyse 
data recording in a standardised sub-set of 20 fields (Herrett, Smeeth et al. 2010).  Whilst 
this ensures robustness of the data set for these fields, other fields, such as height and 
weight, remain unmonitored and prone to missing data.  The dataset was substantially 
reduced once patients without a calculable BMI or eGFR were excluded, and as it may not 
have been representative of the substantive MINAP population, the dataset was excluded 
from further analysis.  The utility of the MINAP dataset for use in an expanding array of 
analyses may be compromised by the extent of missing data. 
 
The cross-sectional design used in this study to examine the relationship between obesity 
and CKD in UK populations has several limitations.  Firstly, by design, the study cannot 
determine causality, or monitor the development of CKD over time.  Secondly, whilst the 
Health Survey for England was carried out in peoples’ homes, and they were apparently 
well at the time of the survey, it cannot be ruled out that the single creatinine measure 
obtained was not representative of usual kidney function for all patients.  The study sample 
may include patients with undetected acute kidney injury (AKI), although this is unlikely, as 
well as those with CKD.   The serum creatinine value used in the Health Survey for 
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England was from a single time point only, so the true definition of CKD, with repeated 
tests repeated over at least three months, was not met in this study, nor in any other 
population based study of the relationship between obesity and CKD.  Furthermore, there 
may also be other, unconsidered and therefore unaccounted for, variables, which may 
affect the relationship examined.   
 
There is a potential to misclassify participants by using an estimate of GFR calculated from 
serum creatinine, rather than measured GFR, and this potential is higher in obese patients, 
as reported in Chapter 5 and in obese patients with diabetic nephropathy (Nair, Mishra et 
al. 2011).  Using the CKD-EPI equation reduced the proportion of patients classified with 
CKD, compared to the MDRD equation in the present study.  However, not all studies 
report large differences in measured and estimated GFR in obese subjects (Michels, 
Grootendorst et al. 2010).  In a pragmatic sample of subjects and patients with measured 
kidney function, serum creatinine and height, weight and ethnicity, both the CKD-EPI 
equation and the MDRD study equation were 86%, and 78% accurate, respectively, in 
overweight and obese patients, compared to measured GFR (Michels, Grootendorst et al. 
2010), although the level of kidney function for the obese patients in the study was not 
reported, and the measured GFR was adjusted for body surface area.  Measured kidney 
function adjusted for body surface area in obese patients may not be physiologically 
appropriate, and masks the increase in single nephron GFR (Delanaye, Radermecker et al. 
2005).   
 
Whilst it is established that eGFR may overestimate the risk of CKD in the obese, given 
the histological evidence of obesity related glomerulopathy (Kambham, Markowitz et al. 
2001; Serra, Romero et al. 2008) and the increased risk of both CKD progression and end 
stage kidney failure with obesity (Hsu, McCulloch et al. 2006; Hsu, Iribarren et al. 2009; 
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Othman, Kawar et al. 2009), it is likely that kidney damage does occur secondary to obesity 
(Wu, Liu et al. 2006).  Recent evidence suggests that onset of overweight during early 
adulthood or the duration of overweight, rather than absolute BMI, is associated with the 
risk of development of CKD in the longer term (Silverwood, Pierce et al. 2013), indicating 
that the effect is latent.  It is possible that the latency of the effect explains much of the 
discrepancy in the relationship between obesity and CKD in previous studies.   
 
Obesity may not be a completely independent factor for development of CKD, given the 
relatively low prevalence of CKD compared to obesity, and it remains unclear whether 
obesity increases prevalence of CKD early in the course of CKD, or accelerates 
progression, or both (Chang and Kramer 2012).  Other traditional risk factors for the 
development of CKD, including hypertension and dyslipidaemia, often evident alongside 
obesity, have a greater likelihood of leading to the development of CKD (Thomas, Sehgal 
et al. 2011).  Alternatively, there may be other mechanisms that are evident in obesity that 
may be exacerbated in some patients, independently of increased adiposity, such as 
hyperleptinaemia, hypoadiponectinaemia and inflammation, which increase the risk of 
developing CKD in some obese patients, and further mechanistic studies on novel risk 
factors, such as these, are required.   
 
The evidence presented in this study demonstrates a concomitant relationship between 
obesity and CKD in a nationally representative randomly selected sample from the UK 
population, and supports the findings of previous studies.  The implications for this finding 
are evident with epidemic rates of obesity in the UK (National Centre for Social Research 
and Royal Free and University College Medical School. Department of Epidemiology and 
Public Health 2012) and the relationship between obesity and the progression of CKD in 
large population studies (Hsu, McCulloch et al. 2006; Munkhaugen, Lydersen et al. 2009; 
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Othman, Kawar et al. 2009).  Whilst the findings of the present cross-sectional study do 
not directly implicate the development or progression of CKD with increasing obesity, 
future service delivery planning should account for possible latent increases in CKD in the 
years following an epidemic rise in population obesity rates.  From the preceding studies 
presented in chapters 2-5, it is evident that weight loss interventions in patients with CKD 
are complex, with lifestyle treatments offering possible protection against cardiovascular 
morbidity and mortality, and whilst weight loss surgery produces greater weight loss, the 
risk benefit profile of this intervention remains unclear in obese patients with CKD.  
Effective strategies for weight loss to prevent the development of CKD and possibly slow 
progression of existing CKD remain a priority for investigation.    
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Chapter 7: Discussion 
 
Chapter summary 
This final chapter presents a summary of the findings of the 5 studies included in this thesis 
and discusses some of the strengths and weaknesses of the different study designs and 
weight loss interventions explored in this body of work.  A detailed discussion is presented 
on developing future studies of weight loss surgery interventions in obese patients with 
CKD, using a structured framework for research in surgical innovation.  Using this 
theoretical framework, it is clear that further observational studies and small, randomised, 
controlled, feasibility trials should be undertaken to establish the safety of surgical 
procedures, prior to undertaking larger research studies with clinical outcomes.  We have 
established the London Renal Obesity Network as a starting point to develop a research 
database for weight loss interventions in obese patients with CKD.  The feasibility of 
conducting a large randomised controlled trial to measure clinical outcomes is explored and 
the difficulties incurred when conducting clinical intervention studies are discussed.  Other 
future weight loss interventions are explored briefly and the chapter concludes with a final 
summary of the findings of the thesis and recommendations for refining outcome 
measures and enabling patients to make informed choices about weight loss treatments. 
 
Summary of thesis findings 
This body of work has broadly explored the topic of obesity in patients with chronic 
kidney disease.  Initially, the benefits of the Renal Weight Management Programme (WMP) 
on cardiovascular disease risk and survival were explored in an analysis of the time to a 
combined event of all cause mortality, and cardiovascular morbidity, defined as myocardial 
infarction, stroke or hospitalisation for congestive heart failure.  Compared to patients who 
did not commence the WMP, patients who chose to commence the WMP had a reduced 
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risk of the combined event; however, there was no benefit for achieving kidney transplant 
waitlisting.  The second study was the first case series reporting on the safety and efficacy 
of laparoscopic sleeve gastrectomy (LSG) weight loss surgery in obese patients with CKD, 
with a particular focus on the utility of this procedure to reduce weight to enable otherwise 
eligible patients with CKD to become listed for kidney transplantation after adequate 
weight loss.  The study found that LSG was effective for weight loss and for kidney 
transplantation waitlisiting, but the procedure may be associated with additional risks in 
patients with CKD, than had previously been reported in non-CKD populations.   
 
These 2 studies led to the design and conduct of 2 clinical intervention studies, to further 
examine the use of LSG as a treatment for weight loss in obese patients with CKD.  A 
randomised controlled pilot study of the effect of sleeve gastrectomy (SG group) or best 
medical care (BMC group) including a lifestyle modification programme, on kidney 
function, measured by iohexol clearance glomerular filtration rate (GFR), was undertaken 
in patients with stages 3-4 CKD.  Estimated GFR (eGFR) consistently under predicted 
kidney function in obese patients with CKD, and the difference was greater in stage 3 
CKD than in stage 4 CKD.  Hyperfiltration decreased in the SG group compared to the 
BMC group at 12 months.  When separated by CKD stage, the reduction in hyperfiltration 
appeared to occur predominantly in the stage 3 CKD classified patients after SG.  Patients 
with stage 4 CKD may have demonstrated a slight trend towards an improvement in 
kidney function after SG, although as the number of patients was very small, and further 
research is required to validate these preliminary findings.  Significant weight loss was 
achieved in both groups from baseline to 12 months, however significantly greater weight 
loss was achieved in the SG group compared to the BMC group after 12 months.  Weight 
loss was associated with an improvement in quality of life indices and an increase in 
adiponectin.  Fetuin-A decreased in both groups after 12 months.  The decrease in fetuin-A 
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was not associated with a change in any other variable measured in the study, yet it is 
known that fetuin-A decreases with weight loss.  Insulin resistance decreased, and 
antihypertensive medication dose was reduced in the SG group, and some patients in both 
groups demonstrated improvements in blood lipid levels.  There were no major adverse 
events in the SG group, although 2 patients experienced dehydration requiring hospital 
admission during the immediate 30-day post-operative period.  One patient in the BMC 
group developed Charcot’s foot during the study, likely secondary to an increase in weight-
bearing physical activity to elicit weight loss.  The LSG is likely to be a safe and effective 
procedure for weight loss in obese patients with stages 3-4 CKD, although further studies 
are required to support this finding, and the potential increased risk of dehydration, 
compromising kidney function, should be emphasised. 
 
The second clinical intervention study was an observational cohort study of LSG for 
weight loss in obese patients with end stage kidney disease on haemodialysis.  This study 
was designed to prospectively systematically examine the safety and efficacy of LSG in 
patients undergoing haemodialysis renal replacement therapy, who were not listed for 
kidney transplantation primarily due to an elevated BMI.  18 patients entered the study, and 
4 underwent weight loss surgery before the study was terminated due to safety concerns.  2 
severe adverse events occurred and the study was terminated before the safety and efficacy 
of LSG in obese patients undergoing haemodialysis could be determined. 
 
Finally, the relationship between obesity and prevalent CKD was studied in 2 United 
Kingdom (UK) populations: a nationally representative, randomly selected, sample of 
participants surveyed in the Health Survey for England 2010 (HSE), and a cohort of 
patients with known cardiovascular disease from the Myocardial Infarction National Audit 
Project (MINAP) database.  Similar studies have previously been conducted in the United 
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States, Japan and Europe, and in 2 local populations in the UK, but not in any national UK 
population sample.  There was a high level of missing data in the MINAP population 
dataset.  The MINAP sample population with adequate data was <10% of the original 
MINAP population, so this study sample was excluded from the analysis, as the study 
cohort may not represent the original MINAP population.  In the HSE population, the risk 
of CKD increased as BMI increased, after correction for age, ethnicity, gender, diabetes, 
smoking and hypertension.  These results support the previously published data in healthy 
European and Japanese populations, and patients with hypertension in the United States.   
 
The implications of this link between obesity and CKD in the UK are highly relevant given 
the rising prevalence of obesity, with 26% of adults in the 2010 HSE classified as obese (a 
rate almost double that reported in 1993 (Hirani 2011)), and the likelihood that this will 
translate into an increase in the prevalence of CKD in the future.  The prevalence of stages 
3-5 CKD in adults in the UK has recently been reported as 6% in men and 7% in women 
(Roth, Roderick et al. 2011).  Obesity-related kidney damage appears to progress slowly, 
but nevertheless can result in end-stage CKD, so the impact upon prevalence rates of CKD 
may be latent (Kambham, Markowitz et al. 2001; Praga, Hernandez et al. 2001). 
 
Overall discussion of weight loss interventions in CKD 
This thesis has explored the effects of weight loss interventions in obese patients with 
CKD, in an attempt to begin to define possible treatments for obesity and their effects on 
kidney function, qualification for kidney transplantation, and quality of life measures.  
Furthermore, the importance of developing and implementing safe and effective weight 
loss interventions in obese patients with CKD on a national scale is supported by the 
identification of a relationship between obesity and CKD in a UK cohort.  
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Participation in a structured, multidisciplinary weight loss programme may be effective for 
reducing the risk of cardiovascular morbidity and all cause mortality in obese patients with 
CKD; however it is very likely that this relationship is confounded by the observational 
study design, as patients choosing to participate in a weight loss programme are more likely 
to be motivated to make lifestyle changes that may result in a reduction in cardiovascular 
and all-cause mortality risk.  These actions may include not only dietary and physical 
activity changes, but may extend to greater compliance with medication and specialist clinic 
visits, and also engaging in fewer high-risk behaviours.  However, regardless of the 
potential confounding factors, this study highlights that motivation is a key requirement to 
make lifestyle changes that improve outcomes.  Alternative treatments may be needed for 
patients without this internal motivation to change modifiable risk factors with lifestyle 
focused actions, and also for those who have been unsuccessful when attempting this 
established pathway to reduce cardiovascular and renal risk factors. 
 
Weight loss surgery is 1 such alternative treatment that may be beneficial for obese patients 
with CKD.  The 2 small pilot studies undertaken in this programme of research have 
indicated that it is likely, in the short term at least, that LSG weight loss surgery results in 
greater weight loss than best medical care, and is associated with an improvement in quality 
of life indices, and a reduction in insulin resistance, in obese patients with stages 3-4 CKD.  
Greater weight loss is also likely following the LSG procedure in patients requiring 
haemodialysis, however, there may be a greater risk for adverse events than in patients 
without CKD.  This preliminary finding is supported by several recent publications on the 
risks of all non-emergent surgery, vascular surgery and weight loss surgery specifically, in 
patients with CKD requiring renal replacement therapy (Gajdos, Hawn et al. 2012; Gajdos, 
Hawn et al. 2012; Turgeon, Perez et al. 2012).  Together, these studies indicate that patients 
with end-stage kidney disease have a greater risk for many types of surgery, and that the 
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risk is not specifically related to weight loss surgery alone.  The elevated risk of adverse 
events post-surgery is likely related to the increased cardiovascular disease risk in patients 
with end-stage kidney disease, with a common aetiology of compromised vascular structure 
and function.  It remains to be determined whether weight loss surgery can have a positive 
effect on cardiovascular or mortality outcomes in obese patients with CKD.  Indeed, it has 
been suggested that the beneficial effects of weight loss surgery may outweigh the 
increased risk of adverse events or complications (Turgeon, Perez et al. 2012), and one 
such scenario where this may be relevant is in obese patients requiring dialysis who are not 
able to qualify for kidney transplantation waitlisting due to their elevated BMI.  It is also 
possible that in patients with earlier stages of CKD, the benefits of weight loss surgery may 
outweigh the risks, if improvements in kidney function and quality of life, evident in the 
pilot study in chapter 5, are borne out in larger studies in future.  
 
Design of future research and theoretical framework for surgical research 
Given the experience conducting the pilot study of LSG in obese patients undergoing 
haemodialysis in Chapter 4, with the early cessation of the research due to 2 adverse events 
and the above, more recent publications on the risk of elective surgery in patients 
undergoing haemodialysis treatment, the design of future research studies of weight loss 
surgery in obese patients with CKD must be carefully considered.  It seems prudent to 
recommend a passive observational study design, in which only patients already referred 
for, and accepting LSG weight loss surgery would be included, perhaps together with a 
second group of patients not referred for surgery, to be followed as controls, although this 
additional group adds another layer of complexity to any proposed study of this format.   
 
The strengths of this design include the elimination of possible coercion into a treatment 
group in a study where the risks of the proposed intervention may outweigh the benefits, 
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as the long-term benefits are not yet known.  Any decision made by a participant to 
undergo weight loss surgery would be made prior to the same patient being approached to 
participate in the study.  A true observational study design would also reduce the risks 
attributable to the study itself, as the weight loss surgery would not be a study procedure.  
Additionally, such a study may be more easily conducted on a national or international 
scale, and indeed, a large sample size is likely to be required to adequately examine safety.  
In order to minimise confounding, a prospective study design is recommended, as although 
retrospective data can be collated more quickly, in a prospective design, both the surgical 
intervention itself, and the peri-operative management of factors including diet, fluids and 
medication adjustments could be standardised, although this may be difficult in a truly 
observational study.  Furthermore, if the LSG procedure is deemed reasonably safe, data 
generated on efficacy as a secondary outcome would be useful to determine the sample size 
required in an interventional study, such as a randomised controlled trial. 
 
Other factors to consider with this study design are co-morbidities and kidney function at 
baseline.  It would be prudent to predetermine study entry criteria and separate patients 
with diabetes, from those without, a priori, as the risk factors in each group of patients may 
be different.  Additionally, it has been demonstrated in these studies that the risk of the 
LSG specifically, and weight loss surgery generally (Turgeon, Perez et al. 2012), may 
increase as CKD progresses from earlier to more advanced stages. 
 
There are inherent weaknesses to this type of study design.  Primarily, causality cannot be 
determined, and even if a control group is included there are problems involved with 
matching these 2 groups, primarily the reasons why 1 group was referred and listed for 
weight loss surgery, and why the other group was not.  Differences between these groups 
could include age, co-morbidities, baseline BMI, likelihood of kidney transplantation 
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waitlisting, and importantly, as discussed earlier, patient motivation to comply with 
treatment, including medication compliance.  Secondly, there are ethical considerations 
relating to the safety of the procedure, which need to be addressed.  Is a weight loss 
surgery procedure, that has been deemed high risk in patients undergoing dialysis, safe 
enough to be offered as “standard care” outside a controlled research study, before it has 
been adequately examined with appropriate safety studies?  The introduction of new drugs 
requires a stepped series of phased clinical trials prior to use, after approval by the drug 
regulatory authorities, and yet surgical procedures are not subject to this same level of 
rigour.   
 
The balance between ethical considerations for protecting patients, and the development of 
novel treatments, may be best explored at this point, using a theoretical framework for 
surgical studies.  The current paradigm for investigating new medicines, with phased 
studies moving from measuring safety in a small group of healthy subjects in phase 1, to 
randomised controlled trials in phase 3 and ongoing efficacy studies and pharmacovigilance 
in phase 4, is difficult to translate directly, as surgical and lifestyle interventions are 
complex and have multiple components that cannot be separated out and controlled as 
easily as in a pharmacological intervention (Ergina, Cook et al. 2009).   
 
Surgical interventions, and other complex interventions including dietary studies and other 
lifestyle modifications such as exercise, are multifaceted, and usually involve multiple 
factors, any of which may alter the result of the treatment or procedure.  Figure 24 
illustrates the levels and layers of surgical interventions, from the procedure itself at the 
centre, which is dependent on the skill of the surgeon, the nursing team, and the condition 
of the individual patient, out to the pre- and post-operative care, and the interdependent 
effects of the medical and anaesthesia teams (Ergina, Cook et al. 2009).  
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Figure 24: Complexity of a surgical intervention, from (Ergina, Cook et al. 2009) 
 
Using the IDEAL framework  
Perhaps due to this complexity, there has been a lack of accepted guidelines for generating 
valid evidence in surgery (Ergina, Cook et al. 2009).  The Balliol Collaboration - developed 
out of the Balliol Colloquia, a series of meetings initially established to clarify methods 
related to the evaluation of surgical procedures - is a group of an invited international 
expert surgeons, methodologists, statisticians and epidemiologists from the UK, Europe 
and North America who met several times between 2007 and 2009, to explore the barriers 
to surgical research and to discuss and develop tools for surgical evaluation and innovation 
(Meakins 2007; Barkun, Aronson et al. 2009).  The Balliol Collaboration constructed a 
paradigm to describe the development of evidence-based healthcare in surgery, the current 
standard for the development of medical knowledge (Barkun, Aronson et al. 2009), using a 
framework describing 5 stages of surgical innovation; Innovation, Development, 
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Exploration, Assessment and Long-term study (IDEAL) (Table 33) (Barkun, Aronson et 
al. 2009).   
 
Table 33: Framework for a describing the surgical development process 
Stage Name Brief Description 
1 Innovation First time procedure performed in humans, establishes proof of 
concept 
2a Development Few surgeons performing procedure, safety data gathered 
2b Exploration Many surgeons and more groups of patients, research databases 
established for safety outcomes 
3 Assessment Many surgeons and patients, clinically focused outcomes 
4 Long-term study Variations, long term outcomes and quality assurance 
 
The Innovation stage is the first stage of the paradigm and includes the first time the new 
procedure is performed in humans, establishing a proof of concept.  Very few surgeons 
perform the procedure at this time and publication of case reports is recommended, 
including both successful and non-successful procedures.  The second stage is 
Development, as the procedure is refined, and safety and technical data begin to be 
reported.  Exploration is the third stage, as the procedure is performed on many patients 
and the range of indications for use may expand.  Safety outcomes are still the primary 
reportable measures at this stage, including the establishment of research databases, yet 
some data on clinical outcomes should be generated in small exploratory or feasibility 
controlled trials.  Assessment of the procedure is the fourth stage, as use of the procedure 
expands to many surgeons, and it is only at this stage that the focus shifts to clinical 
outcomes.  Finally, Long-term Study, the fifth stage, describes regional variations and audit 
of the procedure as data is collected in registries and routine databases, and reporting 
focuses on long term outcomes and quality assurance. (McCulloch, Altman et al. 2009) 
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Whilst the LSG itself is a reasonably established technique, which is endorsed by the 
Clinical Issues Committee of American Society for Metabolic and Bariatric Surgery 
(ASMBS Clinical Issues Committee 2009; ASMBS Clinical Issues Committee 2012), and 
has been reviewed in a Health Technology Assessment of weight loss surgery (Picot, Jones 
et al. 2009), its use in patients with CKD has not previously been studied.  Therefore the 
IDEAL framework may be useful to address the ethical and practical issues of studying this 
procedure in obese patients with CKD.  The case series reported in Chapter 3 aligns to the 
Stage 1 Innovation, as it established proof of concept of the procedure in a population in 
which it was not previously reported.  Data on safety and efficacy were presented, 
including successful use of the procedure for weight loss and enabling kidney 
transplantation waitlisting, and some unexpected complications, such as loss of dialysis 
access and late-onset gastric leak (MacLaughlin, Hall et al. 2012).  The prospective study of 
sleeve gastrectomy in obese patients undergoing haemodialysis presented in Chapter 4 is a 
Stage 2a Developmental study, and the randomised, controlled pilot study of LSG in obese 
patients with stages 3-4 CKD in Chapter 5 is an example of a Stage 2b Exploration study.  
 
It can be difficult to define the point at which to move from an exploratory, or purely 
observational stage to a defined intervention trial, as if done too early, the standardisation 
required for a randomised or non-randomised trial may limit refinement of the technique, 
and if left too late, genuine equipoise may no longer be present (Ergina, Cook et al. 2009).  
Perhaps the most important consideration for determining when surgical research should 
move from an observational approach in the idea and development stages to small or pilot 
interventions in the exploration stage is the ethical examination of the risks and benefits 
profile of the procedure under study.  Using the IDEAL framework, safety is the 
recommended primary outcome for all stage 2 studies (McCulloch, Altman et al. 2009).  
Indeed, in the case of weight loss surgery in obese patients with CKD, prior to the studies 
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in this thesis, there were no published reports specifically relating to LSG in patients with 
CKD.  The IDEAL framework provides guidance on the appropriate study designs to 
focus on, to gather research data on the risk benefit profile of the procedure, prior to the 
expansion of practice and large interventional trials.  
 
It has been suggested that, whilst the IDEAL framework supports the establishment of 
safety, efficacy, and effectiveness to reduce risks to patients, further consideration of 
broader ethical issues such as conflict of interest, informed consent, and improving public 
education and understanding of innovative surgery would enhance the recommendations 
(Johnson, Rogers et al. 2010).  Conflict of interest between the surgeon as a researcher and 
the same surgeon as a clinician is a situation often present in surgical research.  This 
conflict of interest presents a risk of influencing clinical judgement, which is not in the best 
interests of the patient (Johnson, Rogers et al. 2010).  Addressing the potential conflict of 
interest in study design may be difficult, but nevertheless, should be acknowledged and 
declared if the risk is apparent.  Explaining the risks of innovative surgery can be complex 
when little is known about the risks of innovative procedures, or about the risks of 
developing procedures in a novel population group.  It is important that both known risks 
and the lack of information about possible or potential unknown risks, is adequately 
communicated to patients, since failing to communicate the lack of evidence to patients 
can impair the decision making process of informed consent (Johnson, Rogers et al. 2010).  
Improving public understanding of innovative surgical research is important to support the 
informed consent process.  Greater public appreciation of the risks and potential harms 
associated with innovative treatment; together with the appreciation that novel procedures 
may not result in improved outcomes, is required to support the ethical adoption of 
innovative surgical research (Johnson, Rogers et al. 2010).  Since this is likely to add 
another layer of complexity to the education and counselling required preoperatively, 
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improved education on healthcare and the process of research may reduce the burden of 
the decision-load on patients at the time a decision is required (Johnson, Rogers et al. 
2010). 
 
Using the IDEAL paradigm as a theoretical framework to underpin further research on 
surgical, or complex dietary and lifestyle, interventions for weight loss in obese patients 
with CKD, and to address the ethical issues raised in such interventions, further 
observational research is required before consideration can be given to the development of 
intervention trials in the assessment stage (Stage 3). 
 
As the stages 3-4 CKD pilot study in chapter 6 had a primary outcome of efficacy, or 
clinical impact, rather than safety of the study procedure, it is placed at Stage 2b 
Exploration in the IDEAL framework.  This trial may have been conducted prematurely, 
and perhaps research should have focused on further stage 2a safety research first, by 
establishing a research database in a retrospective or prospective observational study across 
several centres.  This may have resulted in a study of a larger number of patients to better 
establish the safety of the procedure in obese patients with CKD, before commencing a 
pilot efficacy study.  The studies in chapters 4 and 5 were conducted simultaneously in real 
time, therefore the risks of the procedure were unknown at the commencement of the 
exploratory study. 
	  
Establishing prospective studies and the London Renal Obesity Network 
1 of the recommendations from the review of the study on haemodialysis patients 
presented in Chapter 4 was to gather together data on safety and efficacy of weight loss 
surgery in obese patients with CKD from other centres where the surgical procedures may 
also be taking place.  We have since established the London Renal Obesity Network 
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(LonRON), as a pan-London interest group, consisting of Nephrologists, Bariatric 
Surgeons, Bariatric Physicians, Dietitians and Clinical Research Fellows.  The initial aim of 
the network is sharing information and co-ordinating collection of safety and efficacy data 
from all bariatric surgery procedures in obese patients with CKD.  2 meetings have been 
held and retrospectively collected data on 70 patients is being collated and a joint renal-
bariatric surgery protocol is being developed.  This data collection and formation of a 
research database is further IDEAL Stage 2 Development and Exploration research.  It is 
expected that the group will expand to a national network in due course, and will act as the 
research collaborative driving future studies on weight loss interventions in obese patients 
with CKD. 
 
There is a need to establish a prospective research database, to further extend the work in 
Stage 2b Exploration, and the parameters for this have largely been established within the 
LonRON network.  The next steps are to formalise the protocol and seek ethical approval, 
following the IDEAL recommendation (McCulloch, Altman et al. 2009), and seek funding 
to expand the database nationally.  As the primary aim of this prospective study remains an 
examination of safety, with patient-centred and efficacy measures remaining secondary 
outcomes, no dilemma is presented about controlling aspects of the study which would 
need to be controlled in an intervention study, such as sample size, matched groups at 
baseline, and the robustness, validity and reliability of effectiveness outcome measures.  
This study may present an opportunity to refine clinical effectiveness outcomes.  
Furthermore, if such a study establishes that 1 or more of these procedures are likely to be 
safe, and the risks of the procedure/s can be presented to patients such that they can 
understand both the established short-term risks, but that long-term risks may still be 
unknown.  Such a study would also generate data to enable calculation of the size of the 
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treatment effect, and the variation between patients, for planning a future controlled 
intervention trial.   
 
Alongside such an observational study, further feasibility randomised controlled trials could 
be established, as well as further IDEAL Stage 2a safety and efficacy studies on other novel 
but non-surgical techniques (Barkun, Aronson et al. 2009), such as placement of 
intragastric balloon and/or endoluminal malabsorptive devices, by endoscopy, the results 
of which have not yet been reported in obese patients with CKD.  It is recognised that 
studies of these devices will be as difficult to conduct as studies of weight loss surgery, in 
such that there are multiple components of the interventions to control to ensure the 
methodology is robust.  Yet, as the procedures are temporary and reversible, patient 
recruitment may not be as difficult for a randomised trial study design, as compared with a 
study of a surgical weight loss procedure with randomised allocation to treatment.   
 
Once the safety of 1 or more procedures is established in patients with CKD, if there is 
genuine equipoise over a study question explored in 1 or more further feasibility 
randomised controlled trials relating to a clinical outcome, a full randomised controlled trial 
with a primary clinical outcome may be justified.  Despite the difficulties associated with 
standardisation of surgical techniques based on skill and adaptation to individual patients, 
and the challenges in designing such studies, the randomised controlled trial design remains 
the gold-standard study design to assess therapeutic interventions (Ergina, Cook et al. 
2009).  
	  
There are several learning points to acknowledge from the study design presented in 
Chapter 5, which would need to be addressed and corrected in the design of a larger study.  
The use of a single study surgeon, even in a pilot study, may have been impractical, as the 
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results have no generalisability to other surgeons or centres.  The number of secondary 
outcomes could be reduced to focus on clinical and patient-focused outcomes, such as 
changes in kidney function, proteinuria, metabolic syndrome components, insulin 
resistance and quality of life measures; and mechanistic outcome measures could be 
omitted.  Defining the research question in an ideal randomised controlled trial also 
warrants greater consideration, as the choice of comparator is vitally important (Cook 
2009).  In the pilot trial presented in Chapter 5, the use of a lifestyle treatment comparator 
group did address the study question, and compared current standard care to the new 
procedure in question.  However, as evident in the study in Chapter 5, recruitment to such 
a trial would be extremely difficult (Cook 2009), and is prone to a high attrition rate, as it is 
impossible to blind the patients to their treatment group, and techniques such as sham 
surgery or late randomisation several days before planned theatre are likely to be deemed 
unethical (Cook 2009; Ergina, Cook et al. 2009).  The resulting groups, after attrition, may 
then not be matched at baseline as it is possible that patients likely to want surgery may be 
different to those likely to not want surgery, and allocation is no longer truly random.  This 
could not be rectified using an intention-to-treat study design, as the level of cross-over 
between study groups may reduce the likelihood of a treatment effect being evident in 
either group.  Another possible study design would be to randomise patients to surgery, or 
to a group waitlisted for surgery for 12 months; however, this prohibits any longer term 
follow up of kidney function and morbidity and mortality over time between groups.   
 
These challenges, along with others, such as the learning curve evident in surgical practice 
with new procedures, funding of surgical studies and independent, blinded assessment of 
outcomes, have been highlighted in a recent review of challenges in the design and conduct 
of surgical randomised controlled trials (Cook 2009).  The learning curve issue was 
addressed in the observational study in Chapter 4 and the pilot study in Chapter 5 by pre-
 259 
specifying a level of expertise obtained by performing at least fifty procedures previously; 
however, it became evident that in patients with end-stage kidney disease on haemodialysis 
treatment, that the condition of the vasculature was different in this patient group and the 
procedure required some minor alterations.  With adequate resource, outcome assessors 
can be blinded to treatment allocation, even when it is not possible to blind patients or 
treatment providers.   
 
3 recommendations have been made to foster the use of the randomised controlled trial 
methodology in surgical research: firstly, the most relevant and high impact innovations 
should be selected for randomised controlled trial research when the method of evaluation 
is ethical and feasible; secondly, a pragmatic approach to clinical research is useful and 
could be undertaken more often; and thirdly, the use of the randomised controlled trial 
method in exploratory research is recommended (Cook 2009) (and indeed may be more 
likely, given that the sample sizes for such research are likely to be smaller and equipoise is 
still genuinely evident). 
 
If a randomised, controlled trial study design is truly impracticable, then one or more well-
designed, high-quality prospective, large, cohort observational studies is recommended to 
identify treatment effects, patient-centred outcomes and cost-effectiveness (Ergina, Cook 
et al. 2009), and this may be the best approach to take in future studies of LSG, or other 
weight loss interventions, in obese patients with CKD, to determine the efficacy of the 
procedure for improving, or preventing decline, in kidney function. 
 
A prospective, non-randomised, controlled, national study of LSG and other surgical 
procedures such as Roux-en-Y gastric bypass and adjustable gastric banding, with matching 
against other patients undergoing other weight loss procedures, such as lifestyle treatment, 
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with or without very low energy diets, with standardised methodology and rigorous 
attention to detail during data collection to limit missing data, is likely to be the most 
practicable and realistic study design to address the questions relating to clinical outcomes 
after LSG in obese patients with stages 3-5 CKD, including the nephron-protective effect 
of the procedure.  Weaknesses in this study design are differences pre-treatment between 
groups and maintaining uniform treatment procedures in both surgical and non-surgical 
groups in a multi-site national study.  The appointment of skilled researchers to maintain 
study integrity and perform outcome measurements in an observer-blinded manner, and 
skilled clinicians to deliver the interventions, together with surgeons with an established 
track record with the procedure/s in patients without CKD may address the second issue.  
Differences in groups pre-treatment is more difficult to address but may be surmountable 
if adequate information on potential patients is available prior to the study to enable 
matching across the country from a single electronic database.  The establishment, and use, 
of such a database would also require ethical approval, but would also have benefits 
outwith the study.   
 
The study would need both clinical and patient-reported outcomes (Ergina, Cook et al. 
2009) such as health-related quality of life, and anxiety and depression scores, such as those 
in the studies presented in chapters 4 and 5.  While interpretation of these scores may be 
difficult when groups are not well matched for these variables at baseline, it is difficult to 
control for this in an observational study design, and variables based on changes in these 
scores are recommended.   
 
The primary outcome measure of kidney function with weight loss interventions in obese 
patients with CKD also needs to be considered.  The use of the fingertip blood spot 
technique for iohexol clearance measurement of GFR was explored in the pilot feasibility 
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study presented in Chapter 5.  This study revealed likely problems with this technique, as it 
is reliant on the correct timing and recording of the blood spots by the patients themselves.  
Furthermore, whilst iohexol measured GFR correlates highly with inulin clearance, the 
absolute gold standard measure (Brown and O'Reilly 1991), use of iohexol clearance in 
obese patients with CKD has not been compared to inulin clearance (Friedman, Strother et 
al. 2010), and use of patient-generated blood spot technique samples for iohexol clearance 
has not been validated in any patient population.  Therefore, it is recommended that if the 
blood spot technique is to be used, it is performed by trained staff in a clinical setting, and 
that validation studies are carried out in obese patients with CKD prior to use in a large 
clinical trial.   The use of serum cystatin C as a measure of kidney function is also currently 
being explored.  Cystatin C is a basic protein produced in nucleated cells and removed by 
glomerular filtration and metabolised by the proximal tubules when kidney function is 
normal (Jesudason and Clifton 2012).  Higher serum cystatin C is associated with renal 
dysfunction, and GFR can be estimated from the inverse of cystatin C concentrations or by 
using equations (Jesudason and Clifton 2012).  However, there is still controversy in the 
current literature over the use of cystatin C measures of GFR in obese patients, particularly 
when measuring a change in kidney function after weight loss, which involves a change in 
body composition, due to an association with body weight, and/or an association with 
body fat (Naour, Fellahi et al. 2009; Friedman, Strother et al. 2010; Jesudason and Clifton 
2012). 
 
Therefore, there is much to be considered and examined before a large intervention trial 
examining the effect of weight loss interventions on kidney function in obese patients with 
CKD stages 3-4 is undertaken.  Particular attention must be paid to establishing a valid and 
reliable measure of kidney function in obese patients that remains robust with changes in 
both fat and lean muscle mass over time, and the way in which the study designs will help 
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to answer the broader study question of “Does weight loss have an independent effect on 
kidney function in obese patients with CKD?”.  
 
Conducting interventional clinical research studies, even with small sample sizes, such as in 
this thesis, is difficult, due to the complex nature of interventions and external variations 
such as patient behaviour, availability of medication, surgical waiting times, and the time 
required to establish and then recruit to clinical studies with ethical and research and 
development department approvals on multiple study sites.  In particular, studies of weight 
loss take a long time to complete, and run the risk of not achieving the intended weight 
loss, due to the presence of so many potential variations beyond the control of the 
researchers.  Analysis of some novel parameters can be particularly time consuming, 
expensive and may not contribute significantly to the final study results, particularly when 
studies are ceased early due to safety concerns.  Finally, in clinical interventions involving 
surgery, there is a demonstrated lack of research funding allocated to surgical academic 
training pathways, compared to that available and funded in medicine (Ergina, Cook et al. 
2009), nursing, and allied health professions. 
 
Whilst it is acknowledged that clinical intervention research is difficult, we have 
demonstrated that the risk for CKD increases as BMI increases in the UK population.  
Furthermore, a recent study from the United States indicated that 50% of overweight and 
obese patients with CKD in the NHANES 1999-2006 survey were seeking or undertaking 
weight loss treatments (Navaneethan, Kirwan et al. 2012).  Therefore, there is a need to 
pursue this field of research despite the difficulties arising, and perhaps approach the 
problems with unique solutions based on the learning from the studies conducted in this 
thesis, and the recent literature on obesity and CKD.   
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Lifestyle interventions may delay mortality and cardiovascular morbidity, at least in the 
short-term; however a larger study with a longer follow-up period is recommended to 
substantiate this initial finding.  Similarly, longer follow up of weight-loss outcomes for 2, 
3, and up to 5-10 years after weight loss interventions is also warranted.  Establishment of 
a national database of outcomes following weight loss intervention treatments in renal 
units across the UK would also support these types of studies, and the infrastructure of the 
Renal Registry is already in place to collect such data (United Kingdom Renal Registry).  
However the completeness of this database currently relies on the voluntary returns of 
these outcomes, and the quality of data is often dependent on the strengths and 
adaptability of the electronic medical records at individual hospital nephrology services.  
 
New pharmacological treatments may also be developed, although no new weight loss 
drugs have been licenced since Rimonibant in 2006, which was subsequently withdrawn 
from sale in 2008 as the risk:benefit profile became unfavourable.  The recent early 
cessation of the phase 3 BEACON trial of bardoxolone methyl, due to excess adverse 
events in the bardoxolone treatment group brings to a halt another line of investigation of 
a treatment, designed to slow CKD progression in patients with diabetes, but which also 
led to concurrent weight loss .  Exenatide, a glucagon-like peptide-1 agonist, used to treat 
diabetes by enhancing insulin secretion from beta cells in the pancreas and suppressing 
glucagon, has been found to induce weight loss in patients with diabetes.  A trial is 
currently underway to determine the effect of exenatide on weight loss in obese 
participants without diabetes .  Other techniques are being investigated, such as 
Transcranial Direct Current Stimulation, in which a stimulus is delivered to the dorsolateral 
prefrontal cortex to mimic fullness, to determine the effect on food intake and weight loss . 
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It is likely that a combination of short-to medium-term clinical intervention studies to 
demonstrate the safety and efficacy of weight loss interventions in patients with CKD, 
together with large observational studies with outcomes such as kidney transplantation, 
cardiovascular event rates and mortality may be optimal to provide adequate insight into 
the utility of weight loss interventions in obese patients with CKD. 
  
Conclusions 
The key findings from this thesis are presented in Table 34. 
Table 34: Key findings from the studies comprising Weight Loss Interventions in Obese Patients with Chronic 
Kidney Disease 
Obesity is associated with an increased risk of CKD in a nationally representative sample of the 
population of England. 
Patients participating in the Renal Weight Management Programme (diet, exercise and anti-
obesity medication) may have a reduced risk of a combined event of all cause mortality, and 
cardiovascular morbidity, defined as myocardial infarction, stroke or hospitalisation for 
congestive heart failure, compared to patients who are referred to, but do not commence the 
programme.  
Weight loss and fat mass loss achieved in the Renal Weight Management Programme is 
associated with a reduction in triglycerides. 
Sleeve gastrectomy is an effective treatment for obesity and aids in meeting the criteria for 
kidney transplantation waitlisiting.  
Sleeve gastrectomy may be associated with additional risks in patients with CKD, than had 
previously been reported in non-CKD populations, such as dehydration causing acute kidney 
injury, and loss of dialysis access.   
Haemodialysis patients are likely to be at a greater risk for complications or adverse events after 
sleeve gastrectomy than patients with earlier stages of CKD and non-CKD patients. 
Sleeve gastrectomy was associated with improvements in quality of life scores, and an increase 
in adiponectin, and decrease in insulin resistance compared to best medical care. 
Sleeve gastrectomy was associated with a reduction in hyperfiltration at 12 months, compared to 
best medical care. 
Estimated GFR consistently underestimated measured GFR in obese patients with CKD. 
Large prospective observational studies in conjunction with smaller, well designed clinical trials 
of weight loss surgery are warranted, together with studies validating measures of kidney 
function in obese patients with CKD. 
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Obesity is a known risk factor for CKD, and this thesis reports evidence of this 
relationship for the first time in a UK nationally representative, randomly selected, 
population.  Furthermore, the weight loss interventions presented in these studies provide 
initial evidence for beneficial treatment of obesity in patients with CKD.  Compliance with 
lifestyle interventions was associated with improved blood pressure and a reduction in 
morbidity and mortality.  This thesis also demonstrated the efficacy of LSG surgery for 
weight loss in patients with CKD for the first time, and showed improvements in kidney 
transplantation waitlisting in the case-series in Chapter 3, and improvements in adiponectin 
and quality of life measures with weight loss, and probable improvements in kidney 
function after weight loss surgery, in a small group of patients in the randomised controlled 
trial pilot study in Chapter 5.  The studies also suggest that LSG surgery may be associated 
with an increased risk of complications in patients undergoing haemodialysis treatment, an 
effect borne out in other studies of weight loss surgery and all elective surgery (specifically 
in this patient group) published recently.   Future research should focus on validation of a 
measure of kidney function in obese patients with CKD and on the development of a 
national research database of weight loss interventions in obese patients with CKD as a 
foundation to build upon for future interventional studies.   
 
Presently, it is recommended that the selection of weight loss interventions should be 
individualised, based not only on an assessment of the risks and benefits of individual 
weight loss intervention procedures and the level of kidney function, but also in 
combination with thorough consideration of patient preferences, motivations, confidence, 
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Dietary information  
for Patients with Chronic Kidney Disease  





Dietitian Name:                                                    
 




What is a Sleeve Gastrectomy?   
The stomach is made much smaller by cutting from top to bottom 
and leaving a banana shaped stomach along the inside curve.  The 
stomach is reduced to one-third to one quarter of its usual size, but 
it still functions normally  
 
The new stomach can only hold a few tablespoons of food after 
surgery, and eventually it will hold only about ½ to 1 cup.  This will 
significantly reduce the amount of food you can eat. 
 
The Eating Plan 
After surgery you must stick to a strict eating plan to allow your new 
stomach to heal and to lose weight.    
 
You should start with just liquids, followed by pureed and mashed 
foods and gradually move back to normal foods after the operation.  
To ensure you lose weight and keep it off, small meals are best in 
the long term.   
 
Getting to your weight loss goal will still be difficult. Having 
surgery is only the first step, as it makes it harder, but not 
impossible to eat lots of calories.  Greatest success is achieved 
with careful eating and by becoming more active. 
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What you can eat after your weight loss surgery will change as you recover from 
surgery and your stomach adjusts to its new size. 
 
Stage  Time After Surgery Eat/Drink  
In hospital 2-5 days Sips of clear fluids only 
1 1-4 weeks Fluids only 
2 4-6 weeks Puree and all fluids 
3 6 weeks onwards Soft foods and all fluids 
 
First 2 to 5 days: Clear Fluids  
 
In hospital you will have only clear sugar free liquids until after your dye test or 
gastrograffin test. 
 
You can drink:  
Ø water 
Ø no added sugar squash 
Ø clear soups  
Ø tea and coffee without sugar 
Ø unsweetened pure fruit juice  
 
Notes: 
Ø Try to sip fluids, so that you are drinking 80-100ml every hour 
that you are awake.  
Ø Use a Cup.   
Ø Sipping fluids out of a bottle, sports bottle or through a 
straw may cause gas or bloating. 
 
1-4 weeks post op: Stage 1 – Fluids only 
 
Once you have managed clear fluids and leave hospital, you may begin to have other 
liquids.  Drinks that contain protein MUST be included to meet 
your needs for wound healing, organ function and to prevent loss of 
muscle.  
Examples of fluids containing protein are:  
Ø Semi Skimmed milk (you can add 2 tsp of skimmed milk powder to a glass of milk for 
extra protein)   
    (You can use LactoFree® or soy milk with soy protein powder if you don’t tolerate 
milk) 
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Ø Protein shakes: Ensure Plus, Fortisip Extra, Fortimel, Build Up® soups, Nepro 
Ø Yogurt drinks and Smoothies  
Ø Strained smooth soups e.g. cream of chicken or creamy vegetable with 2 tsp skim milk 
powder added 
 
You will also need a chewable or crushed Multi-Vitamin and Mineral tablet twice a 
day.  Sanatogen® Gold, Centrum® or Forceval® (prescribed by your GP) can be crushed 
between two spoons. 
You may also need a special protein powder such as Renapro, Protifar or Forceval Protein 
which you can add to any drink 1-4 times per day, depending on your protein needs and 
your kidney function.  
 
Sample meal plan for Stage 1: Fluids Only 
 
 
4 -6 weeks post  op:  Stage 2 -  Puree die t    
 
Ø Food at this stage should fall off the spoon and be smooth with no lumps.  
Option 1 Option 2 Option 3  
Breakfast  8am 
½ cup semi skimmed milk 
flavoured with instant coffee or 
espresso 
¼- ½ cup of ready prepared 
smoothie  
Banana smoothie    (blend ¼- ½ 
cup semi skimmed milk with ¼- 
½ banana and 4 teaspoon of 
skimmed milk powder & honey) 
Mid morning: 100 ml  Ensure Plus, Fortisip Extra, Fortimel, Nepro 
Lunch 12pm 
½ cup-a-soup (strained) with 4 
tsp skimmed milk powder added 
½ cup semi skimmed milk with 4 
tsp skimmed milk powder, 
flavoured with drinking 
chocolate/nesquik 
¼- ½ cup of liquid yoghurt (eg: 
Danone® Actimel Strawberry 
0.1% Fat) 
Mid afternoon: 100 ml  Ensure Plus, Fortisip Extra, Fortimel, Nepro 
Dinner 6pm 
Strawberry smoothie (blend ¼- ½ 
cup semi skimmed milk with ¼ 
cup berries and 2 teaspoon of 
skimmed milk powder) 
100 ml  Ensure Plus, Fortisip 
Extra, Fortimel or Nepro 
½ cup-a-soup (strained) with 4 
tsp skimmed milk powder added  
Snack 8pm  
100 ml  Ensure Plus, Fortisip 
Extra or Fortimel 
¼- ½ cup semi skimmed milk + 4 
tsp skimmed milk + 2tsp drinking 
chocolate   
¼- ½ cup of smoothie or fruit 
juice  
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Ø All freshly prepared low fat low sugar foods can be eaten as long as they are put into 
a blender and the final consistency is puree.  
	  
Ø Liquid will need to be added when blending foods (eg: fruit juice when blending 
fruits, gravies, stock or soup when blending meats, beans and vegetables).  
	  
Ø On some days you may tolerate foods well, but other days you may not. Retry foods 
you don’t tolerate a few days later.  
	  
Ø Sip liquid between meals. Do not drink during meals.  Try to drink _____cups of 
water, sugar free squash, skim milk, clear soup, coffee or tea daily 
	  
 
Ø Continue to take a Multi-Vitamin and Mineral Supplement: eg: Centrum®, 
Sanatogen® Gold or Forceval® once a day (can be prescribed by your GP)  
	  
 
Ø If you need a “ready meal” try any meat, fish or chicken stage 1 baby meal. They are 
the perfect portion size too. 
 
Ø After a couple of weeks you can once you tolerate sloppy pureed foods, you can 
begin to include mashed consistency foods like: 
• thoroughly mashed tuna salad/moist fish/eggs with added extra light mayonnaise  
• well mashed ripe bananas, cooked/canned apples, pears, apricots 
Continue to sip 100-150 ml fluid every hour  
throughout the day.   
You will need to drink at least 1500-2000 ml of 
water/tea/coffee/squash/herbal tea/clear soup 
every day. 
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Stage 2: Puree diet (from approx weeks 4 to 6 post op) 
 
Food Group Serving size & serves/day Food Choices 
Pasta, bread, cereal 
and rice 
 
1-2 serving per day  
1 serving = ¼ cup 




2 servings per day  
1 serving = ¼ cup 




2 servings per day 
1 serving = ¼ cup 
Well cooked soft vegetables (such as courgettes, 
broccoli, cauliflower, swede) blended or mashed 
with a fork with gravy or vegetable stock added to 
achieve correct consistency  
Smooth blended soups -minestrone, cream of 
tomato, country vegetable – all well blended 
without lumps 
Meat, Poultry, Fish, 
Beans, Eggs (high 
protein) 
 
3-4 servings per day  
1 serving = ¼ cup 
Chopped up soft poached eggs or scrambled eggs. 
Blended moist meat, chicken and flaked fish 
cooked very soft and moist. Add water, stock, or 
milk when blending to a smooth puree.   
Milk, cheese, yoghurt 
(high protein)
 
3 servings per day  
1 serving = ¼ cup* 
Low fat cottage cheese or ricotta cheese (*1 serve 
= ½ cup for these);  reduced fat cheddar cheese 
(melted); Custard made without sugar, quark, fat 
free,  sugar free yogurt 
Other 
 
1-2 servings per day  
1 serving = ¼ cup 
Sugar free jelly, low calorie hot chocolate mixes 
(eg: Options®, Cadburys® Highlights). 
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Sample Meal Plan for Stage 2:  
 
Option 1 Option 2 Option 3  
Breakfast  8am 
¼ cup Porridge/1 Weetabix®/¼ 
cup Ready Brek® made with ½ 
cup milk  
¼ cup diet/plain yoghurt or 
fromage frais 
¼ cup pureed fruit 
1 scrambled or poached egg  
¼ cup pureed fruit or juice 
 
Mid morning: 100ml Ensure Plus, Fortisip Extra, Fortimel, Nepro 
Lunch 12pm 
¼ cup egg salad (chopped up 
boiled egg with low fat mayo add 
very finely chopped fresh chives) 
¼ - ½ cup blended chicken soup 
¼ - ½ cup canned celery soup   
¼- ½ cup flaked tuna mixed with 
low fat mayo  
¼ cup pureed fruit 
¼ - ½ cup low fat cottage cheese 
¼ cup unsweetened apple sauce 
with cinnamon or pureed 
broccoli or peas 
Dinner 7pm 
¼ cup tuna with low fat mayo  
½ cup blended vegetable soup 
¼ cup pureed fruit 
 ¼ cup meat or chicken pureed 
with gravy  
1 egg sized potato mashed  
¼ cup pureed veg 
¼ cup white fish pureed with 
milk  
1 egg sized potato mashed with 
milk,  
¼ cup pureed veg 
Mid morning: 100ml Ensure Plus, Fortisip Extra, Fortimel, Nepro 
Snack 
¼ cup pureed canned fruit   ½ cup skimmed milk 2tsp low 
calorie hot chocolate   
¼ cup diet/plain yoghurt with ¼ 
cup sugar free jelly 
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6 weeks post op: Stage 3 - soft diet 
  
You can now begin to add: 
• tofu, fish and seafood, thinly sliced turkey, ham or other lean cold meats 
• slices of low fat cheese 
• unsweetened canned or cooked fruit, 
• potatoes, butternut squash 
• unsweetened cereal (ie. Cornflakes®, Rice Krispies®, Cheerios®) with skimmed 
milk 
• crisp toast and crackers, well cooked pasta 
• beans and peas, and lean, moist minced chicken and beef 
 
As soon as you feel pressure in the centre of your abdomen stop eating and drinking. If 
you feel nauseous stop eating. One extra mouthful of food after these early signals can lead 
to pain, discomfort and vomiting. 
 
Eat slowly and chew thoroughly- at least 25 times until food reaches a puree texture. It 
should take at least ½ hour for each meal. 
 
Adult Multi-Vitamin and Mineral Supplement: Centrum®, Sanatogen® Gold or 
Forceval® (can be prescribed by your GP), once a day.  
 
High protein milk drink – add 4 tsps of skimmed milk powder to ½ cup of skimmed 




Sample Meal Plan Stage 3  
Breakfast  8am 
Option 1 Option 2 Option 3  
¼ cup Special K®  
½ cup skimmed milk  
1 small banana 
1Weetabix®  
½ cup skim milk  
¼ - ½ cup frozen berries 
1 Egg scrambled  
30g reduced  fat cheddar + 1/2 
grilled tomato  
Mid morning: high protein milk drink  
Lunch 12pm 
Option 1 Option 2 Option 3  
1 slice granary bread, toasted 
30g reduced fat cheese  
1 tomato, sliced 
1-2 Ryvitas® or  
3-4 water crackers 
¼ cup reduced fat hummus  
mixed salad leaves 
30g ham 
1 Small boiled potato (don’t eat  the 
skin)  
¼ cup baked beans & 30g reduced 
fat cheese  
Dinner 7pm 
Option 1 Option 2 Option 3  
¼ cup minced meat, cook with 
garlic and herbs 
¼ - ½ cup carrots  and cauliflower 
2 egg sized potatoes mashed 
½ cup pasta, ¼ to ½ cup reduced 
fat ricotta cheese 
 ½ cup boiled veg, mashed  
¼ cup fish, with low fat white 
sauce  
¼- ½ cup sweet potato, mashed  
¼- ½ cup aubergine and courgette 
with italian dried herbs  
Snack 
¼ cup sugar free jelly + ¼ cup fat 
free, sugar free yoghurt  
¼ cup Canned fruit with ¼ - ½ 
cup low fat,  low sugar custard 
½ cup skimmed milk 2tsp low 




2 Months post -op:  Diced poultry (no skin), vegetable 
burgers, soft cooked vegetables, soft fruits (watermelon, 
honeydew, peaches, plums) 
 
3 Months post -op:  Rice, soft bread, lean and moist meat 
and poultry 
 
4 Months post -op:  crunchy fruits and vegetables including 
salads 
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Life long Nutri t ion Habits 
 
To keep the weight off you will need to maintain a healthy eating plan for the rest 
of your life.  
 
Include protein and fruit and/or vegetables in each meal every day to keep meals 
high in protein and low in calories.  Choose: 
• fish, chicken, turkey, lean meat, eggs, tofu, skimmed milk, low fat yoghurt for 
protein  
• fresh, frozen, or canned fruits and vegetables (without syrup, juice, added fat or 
sauces). Eat 2 pieces of fruit and 2 different vegetables every day – for fibre, 
vitamins and minerals. 
 
Limit starchy foods as these are the easiest to over eat and may stretch you new stomach.  
Stick to 3 small serves of starchy foods each day. One serving = a slice of wholegrain 
bread, ½ cup cereal, ½ potato; ½ cup of cooked rice or pasta 
 
Continue to eat three regular meals and one snack each day.  If you snack throughout the 
day you will probably over eat and your weight loss will slow down or stop. 
Liquids should always be calorie free. Always choose water, no added sugar squash, tea, 
coffee or skimmed milk. 
 
Adult Multi-Vitamin and Mineral Supplement: eg: Centrum®, Sanotagen® Gold or 
Forceval® (can be prescribed by your GP), once a day. 
 
Remember that food preparation is important – avoid fried foods and roasting with added 
fats.  Choose to grill, steam, bake or boil your meals. Remove all visible fat and skin from 
meats before cooking.  If you do fry, use a non-stick pan with an oil spray or a tablespoon 




Always avoid these high calorie foods and drinks: 
• squash, fizzy drinks, milkshakes, lucozade  
• whipped cream, double cream, ice cream, condensed milk, evaporated milk 
• butter, lemon curd, chocolate spread 
• regular cheese and hard cheeses   
• nuts, crisps, chips, dried fruit, bombay mix 
• chocolate, sweets, cake, muffins and biscuits  
• breakfast cereals with sugar or chocolate coating 
• muesli bars/flap jacks/cereal bars with chocolate 
• deep fried foods, pastries, palm oil 
• creamy or oil based salad dressings  
• sugar, glucose, invert syrup, high fructose corn syrup, golden syrup, treacle 
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Alternative Meal Plan for Stage 1 – Fluids only 
 































For more information on weight loss surgery, try these UK websites 
 
British Obesity Surgery Patient Association: 
http://bospa.org.uk/Information.aspx?Page=13  
 
Obesity Surgery Advice: 
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Appendix B - SF-36 Quality of Life Questionnaire and Hospital Anxiety 














Hospital Anxiety and Depression Scale (HADS) 
	  
Choose	  one	  response	  from	  the	  four	  given	  for	  each	  statement,	  to	  describe	  your	  
feelings	  today.	  	  	  The	  response	  should	  be	  the	  first	  one	  that	  appears	  to	  apply	  and	  you	  
should	  not	  think	  for	  too	  long	  about	  your	  answers.	  	  	  
	  
A	   I feel tense or 'wound up':	   	  
	   Most of the time	   3	  
	   A lot of the time	   2	  
	   From time to time, occasionally	   1	  
	   Not at all	   0	  
	  
	  
D	   I still enjoy the things I used to enjoy:	   	  
	   Definitely as much	   0	  
	   Not quite so much	   1	  
	   Only a little	   2	  
	   Hardly at all	   3	  
	  
	  
A	   I get a sort of frightened feeling as if 
something awful is about to happen:	  
	  
	   Very definitely and quite badly	   3	  
	   Yes, but not too badly	   2	  
	   A little, but it doesn't worry me	   1	  
	   Not at all	   0	  
	  
	  
D	   I can laugh and see the funny side of things:	   	  
	   As much as I always could	   0	  
	   Not quite so much now	   1	  
	   Definitely not so much now	   2	  
	  
	  
A Worrying thoughts go through my mind:  
 A great deal of the time 3 
 A lot of the time 2 
 From time to time, but not too often 1 
 Only occasionally 0 
 
 
A I can sit at ease and feel relaxed:  
 Definitely 0 
 Usually 1 
 Not Often 2 




D I feel cheerful:  
 Not at all 3 
 Not often 2 
 Sometimes 1 
 Most of the time 0 
  
 
D I feel as if I am slowed down:  
 Nearly all the time 3 
 Very often 2 
 Sometimes 1 
 Not at all 0 
 
 
A I get a sort of frightened feeling like 
'butterflies' in the stomach: 
 
 Not at all 0 
 Occasionally 1 
 Quite Often 2 
 Very Often 3 
 
 
D I have lost interest in my appearance:  
 Definitely 3 
 I don't take as much care as I should 2 
 I may not take quite as much care 1 
 I take just as much care as ever 0 
  
 
A I feel restless as I have to be on the move:  
 Very much indeed 3 
 Quite a lot 2 
 Not very much 1 
 Not at all 0 
 
 
D I look forward with enjoyment to things:  
 As much as I ever did 0 
 Rather less than I used to 1 
 Definitely less than I used to 2 




A I get sudden feelings of panic:  
 Very often indeed 3 
 Quite often 2 
 Not very often 1 
 Not at all 0 
 
D I can enjoy a good book or radio or TV 
program: 
 
 Often 0 
 Sometimes 1 
 Not often 2 
 Very seldom 3 
  Thank you 
Scoring (add the As = Anxiety.  Add the 
Ds = Depression).  The norms below 
will give you an idea of the level of 
Anxiety and Depression. 
 
0-7 = Normal  
8-10 = Borderline abnormal  
11-21 = Abnormal  
Total for A = Total for D = 
Reference: Zigmond and Snaith (1983) 
Patient ID:  CKD 34 oooooooB/3/6/9/12 (circle) 
Score entered onto database □ 
Date ___________________  Signature ______________________ 
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Appendix C - Information for Participants and Consent Form for 
Weight loss surgery for obesity in haemodialysis patients (Chapter 4) 
 
 
    
 
 
Information for Participants 
 
Research Ethics Committee Reference Number: 10/H0716/55 
 
Study Title: Weight loss surgery for obesity in haemodialysis patients 
 
We would like to invite you to participate in this original research project.  You should only 
participate if you want to; choosing not to take part will not disadvantage you in any way.  
Before you decide whether you want to take part, it is important for you to understand why 
the research is being done and what your participation will involve.  Please take some time 
to read and consider the following information carefully and discuss it with friends, 
relatives or your doctor if you want to.  Ask us if there is anything that is not clear, or if 





Research Aim – what we would like to find out 3 
Background Information – what we already know 3 
The 2 treatment options 5 
Collecting Information 7 
Telling your GP 7 
Before you decide to join the study 7 
Tests and measurements during the study 315 
Adverse Events and Complications 315 
Bioelectrical Impedance Analysis 8 
Blood Tests 9 
Blood Pressure 9 
Blood vessel stiffness (Pulse Wave Velocity) 10 
Food and Activity Diaries 10 
Nutrition Assessment (SGA) 10 
Questionnaires 11 
Weight, waist and hip circumferences 11 
It is up to you to decide whether to take part or not 11 
Consent to participate 12 
Who is organising and funding the research? 12 
Who has reviewed the study? 12 
Can I speak to anyone not involved in the study about 
participating in research? 
13 
Number of visits 14 




Research Aim - What we would like to find out 
This study's purpose is to determine if keyhole surgery for weight loss surgery using the 
sleeve gastrectomy operation is effective for weight loss in haemodialysis patients with a 
body mass index (BMI) greater than 35 kg/m2.  The research will also monitor changes in 
blood pressure, blood fats, quality of life and the side effects of the operation in 
haemodialysis patients.   
 
We would like to study patients who wish to have weight loss surgery and also those who 
wish to continue with their current medical care.  If you were to participate, you can 
choose to have keyhole surgery to permanently remove two-thirds of your stomach in a 
procedure called a sleeve gastrectomy, or choose to continue with your current treatment.  
Both groups will have follow-up appointments every 3 months for 1 year.   
 
Background Information – What we already know 
We know that obesity and chronic kidney disease both increase the risk of heart and blood 
vessel disease, and that patients on dialysis have a very high risk of dying from heart 
problems.  Obesity also stops patients from being able to get on to the kidney 
transplantation waiting list.   
 
Weight loss surgery is well established as the most effective method of achieving and 
sustaining long term, significant weight loss in people with normal kidneys.  On average, 
patients lose 30% of their body weight within 1 year.  It is not without risks though, and 
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because not many patients on dialysis have had this type of surgery, we do not know all the 
risks yet.  However, the bigger you are, the more risky any operation will be.   
 
Some weight loss operations may not be good for patients with kidney disease.  Both the 
gastric bypass and gastric band may cause complications, particularly after a kidney 
transplant.  This research study will measure the amount of weight loss achievable and 




The 2 treatment options  
If you volunteer to participate in this research you can choose to join the surgery group or 
the best medical care (no surgery) group.   
 
Best Medical Care 
You will continue to receive your current level of medical care from your kidney doctor 
and the dialysis team.  You will also be able to access personalised dietary education and 
support for weight loss from the renal dietitian working in the study. 
 
Weight Loss Surgery  
If you choose to have weight loss surgery, you will continue with your current medical care 
form the kidney doctor and the dialysis team.  You will also have an operation called a 
laparoscopic sleeve gastrectomy.  
 
Sleeve gastrectomy is a relatively new procedure for weight loss surgery and so far, it has 
been seen as safe and effective.  However there is no information on its success and safety 
for patients on dialysis.   
 
It is a permanent operation which reduces the size of the stomach.  After a general 
anaesthetic to put the patient to sleep, the surgeon will insert a laparoscope (thin, tube like 
instrument with a camera to see inside the body) and other slender surgical instruments 
into the abdominal cavity, through very small surgical cuts in the abdomen.  The surgeon 
will then remove about 2/3 of the stomach using a cutting and stapling device after 
disconnecting the blood supply.  The stomach will function as normal, but the reduced size 
means patients should feel fuller, sooner, so eat less.  The level of the hunger hormone, 
Ghrelin, which is produced in the stomach, will be reduced, and this should reduce 
appetite.  
 
The surgeon may also take a small sample of your fat tissue whilst he is performing the 
surgery.  This tissue will be frozen and stored for later analysis related to this research. 
 
The risks associated with the sleeve gastrectomy are the same as those for any other major 
abdominal procedure and include haemorrhage (bleeding), leaks from staple lines, 
anaesthetic and drug reactions, deep vein thrombosis (DVT), pulmonary embolus (blood 
clots on the lung), infection, marginal ulcer, and lung problems.  Overall the risk for any of 
these early complications varies between 3-7% (or 3-7 times in 100) and with an 
experienced surgeon the risk of death during a sleeve gastrectomy is very low – around 0.1-
0.5% (or 1 in 500 to 1 in 1000).  There is also a small chance that weight loss will be less 
than expected.  Weight re-gain may occur in 2-3 years if a low fat, low sugar eating plan is 
not followed in the long term.   
 
After the operation, patients are encouraged to perform exercises to improve lung function 
and swallow a special fluid to check for leaks in the new stomach, as there is a long staple 
line in the stomach afterwards.  Most patients will stay in hospital for 2-5 days.   
 
Collecting Information 
The study team will collect information about patients throughout the study.  All data will 
have patient identifiable information removed (name, address, date of birth) before it is 
coded and entered into the research database.  A separate code breaker file will be kept 
securely in the study office, to identify patients when new data is added.   
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The results of the study will be analysed and a report will be written, which may be 
published in a science journal within two years.  If the study finds out something significant 
the study team may contact the media, and a summary of the results may be published in 
newspapers.  No patient who takes part in the study will be identified in any way in the 
results.   
 
Telling your GP 
The study team will write to your GP to let them know you are participating in this study.   
 
 
Before you decide to join the study 
Patients who are interested in participating in the study will discuss the study and the 
additional appointments involved with the study dietitian and their kidney doctor.  If you 
know you do not want to have surgery but are willing to participate in the study, you will 
be invited to an appointment for the baseline assessment.   
If you would like to consider having surgery you will be invited to a pre-assessment 
appointment with the weight loss surgeon and dietitian.  The surgeon will check your 
medical history and answer all the questions you have about the risks and benefits of 
surgery.  The dietitian will give you information about eating after surgery, including a 
phase of up to 6 months with fluids only and progression to texture modified meals.     
 
Tests and measurements during the study 
The study involves 5 study visits over 1 year, plus the pre-surgery assessment appointment.  
Each study visit will involve monitoring of dietary intake and physical activity, fasting 
blood tests and other measurements.  Each visit will last about 1 hour and where possible, 
will be on the same day as your dialysis.   
Adverse Events and Complications 
For the length of the study, any new medical problems or any admissions to hospital will 
be recorded for all patients.  This will help to determine what side effects or complications, 
if any, may be related to the weight loss operation in dialysis patients.   All information will 
be strictly confidential and none of this information will be able to be traced back to any 
individual patient enrolled in the study. 
Bioelectrical Impedance Analysis 
This is a device similar to a pair of scales but instead of measuring only your weight it also 
measures your body water, muscle and fat levels. You will need to remove your socks and 
shoes.  An undetectable current passes from underneath the feet around the body, 
measuring the amount of water in the body.  Estimates of body fat and lean tissue are then 
determined.  Patients must not eat or drink anything for 2 hours before the test is done.  
The measurement will be made at baseline and every 3 months up to 1 year.  
 
Blood Tests 
Fasting blood samples 
The study will involve providing an early morning fasting blood sample at the beginning 
and every 3 months up to 1 year.  Patients will have to attend the hospital in the morning 
after not eating for 6-12 hours.   
 
Approximately 40 ml of blood will be taken on each occasion, usually from the dialysis 
machine.  If the blood has to be taken directly from you, there is a possibility that some 
bruising may occur at the site after the sample has been taken.   
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Some of this blood will be analysed for this study and some samples from this study may 
be used in future research, relating to this study only, when new techniques are available for 
measuring previously unknown risk markers. 
 
Blood Pressure 
Blood pressure will be measured whilst you are on dialysis and an average of the values 
calculated over a two week period.  The measurement will be made at baseline and every 3 
months up to 1 year. 
 
Blood vessel stiffness (Pulse Wave Velocity) 
Pulse wave velocity measures the time it takes for a pulse or wave to travel through your 
blood vessels.  One pressure sensor will be put on your neck and another on your thigh 
whilst you lie flat and rest for 10 minutes.  After the rest period, the time between your 
pulse detected at your neck and your thigh is measured and your blood pressure will be 
taken several times.  The measurement will be made at baseline and every 3 months up to 1 
year. 
 
Food and Activity Diaries 
Patients will be required to keep a detailed written record of all food and drink consumed 
and all activity undertaken for a 3 day period, including 1 weekend day, at baseline and 
every 3 months, up to 1 year.  The diary will be provided by the study team and can be 
returned in a pre-stamped pre-addressed envelope provided.   
 
 
Nutrition Assessment (SGA) 
This test is used to monitor nutritional status and to detect poor nutrition in patients, and 
is used as part of a standard nutrition assessment in dialysis patients.  It involves answering 
some general questions about weight change, activity, food intake and gastro-intestinal 
symptoms, and having a health professional examine your head, shoulders, arms and legs 
for muscle wasting. You may have to remove some of your clothing so the health 
professional can see your shoulders, arms, knees and ankles.  The measurement will be 
made at baseline and every 3 months up to 1 year. 
 
Questionnaires 
Patients will be asked to complete two questionnaires. The Renal Quality of Life 
questionnaire is 12 pre-set questions relating to your own perception of your quality of life.  
The Hospital Anxiety and Depression Score questionnaire is set of 14 multiple choice 
questions.  The questionnaires will be completed at baseline and every 3 months up to 1 
year.   
 
Weight, waist and hip circumferences 
Body weight will be measured by standing on digital weighing scales in light clothing.  
Waist and hip circumferences will be measured over light clothing with a soft tape measure.  
These measurements will be made at baseline and every 3 months up to 1 year. 
 
It is up to you to decide whether to take part or not 
It is up to you to decide whether or not to take part.  If you do decide to take part, please 
keep this information sheet.  If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  This will not affect the standard of care you receive. 
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Consent to participate 
If you decide to join this study you will be asked to sign a consent form.  The consent form 
will ask that you agree to participate in this study in the treatment arm that you have 
chosen.  The consent form will also ask that you allow your blood, urine and tissue samples 
to be kept for future research related to this study only.   
 
Who is organising and funding the research? 
The study is organised and funded by King’s College London and King’s College Hospital.  
Your Doctor, Dietitian and the lead investigator are not being paid to recruit you to this 
study. 
Who has reviewed the study? 
This study has been reviewed by the King’s College Hospital Research and Development 
Committee and approved by the Central London Research Ethics Committee 3. 
 
Can I speak to anyone not involved in the study about participating in research? 
If you are thinking about participating, and you would like to speak to someone not 
directly involved with the study, you can contact PALS (the patient advice and liaison 
service), or the renal anaemia research team to get independent advice about participating 
in research.   
 
PALS  
King’s College Hospital tel 020 3299 9000 ext 3601 or visit them on the ground floor, 
Hambledon Wing 9am to 6pm Monday to Friday 
Guy’s and St Thomas’ Hospital tel 020 7188 8801 or visit them on the second floor, 
Southwark Wing (Thomas Guy House) 12pm to 3pm Monday to Friday 
St George’s Hospital tel 020 8725 2453 or visit them in the main corridor between 
Grosvenor and Lanesborough Wing near the lift foyer 9am to 5pm Monday to Friday 
St Helier Hospital tel 020 8296 2508 or visit them on the ground floor next to reception at 
the main entrance 9am to 5pm Monday to Friday 
 
Or log on to the PALS website 
http://www.pals.nhs.uk/ 
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Number of visits 
Overall, there are up to 5 study visits to the hospital over 1 year (plus the surgery pre-
assessment for those who choose have weight loss surgery) if you participate in the 
research.   
 




Date Best Medical Care 
 
Weight Loss Surgery 
-3   - assessment for 
surgery 
 






weight loss surgery 
operation 
 
3 2  3 month tests 3 month tests 
 
6 3  6 month tests 6 month tests 
 
9 4  9 month tests 9 month tests 
 




Dr Iain Macdougall 
Consultant Nephrologist 
King’s College Hospital NHS Foundation Trust 
 
Mr Ameet Patel 
Consultant Surgeon 
King’s College Hospital NHS Foundation Trust 
 
Miss Helen MacLaughlin 
Lead Renal Dietitian  
King’s College Hospital NHS Foundation Trust 
 
Dr Paramit Chowdhury 
Consultant Nephrologist 
Guy’s and St Thomas’ Hospital NHS Foundation Trust 
 
Dr Mysore Phanish 
Consultant Nephrologist 
St Helier Hospital NHS Trust 
 
Dr Iain McPhee 
Consultant Nephrologist 
St George’s Hospital NHS Trust 
 
Professor Tom Sanders  
Head of Nutritional Sciences Division 
King’s College London  
 
Details of local contact  
If you require any more information or have any questions, please contact the study co-
ordinator: 
Helen MacLaughlin   
Renal Dietitian   
King’s College Hospital  
020 7848 0431  





Weight loss surgery for obesity in haemodialysis patients 
PARTICIPANT	  CONSENT	  FORM	  
                                                                                            
REC Reference Number:  10/H0716/55 
Patient identification number for this trial: 
 
Study title: A prospective cohort study of laparoscopic sleeve gastrectomy for weight loss 
in obese patients on haemodialysis. 
 
Lead Investigators/Researchers: 
Helen MacLaughlin – Lead Renal Dietitian King’s College Hospital & PhD student King’s 
College London 
Dr Iain Macdougall – Consultant Nephrologist King’s College Hospital 
Mr Ameet Patel – Consultant Surgeon King’s College Hospital 
Dr Paramit Chowdhury – Consultant Nephrologist Guy’s Hospital 
Dr Mysore Phanish – Consultant Nephrologist St Helier Hospital 
Dr Iain McPhee – Consultant Nephrologist St George’s Hospital 
Professor Tom Sanders – Head of Nutritional Sciences Division King’s College London  
 
Please initial the boxes 
 
1. I confirm that I have read and understood the information sheet (version 2.0) for 
the above study and have had the opportunity to ask questions. 
 
2. I confirm that the risks and benefits of participating in the study have been 
explained to me in a way that I understood. 
 
3. I confirm that the risks and benefits of the individual procedures in the study have 
been explained to me in a way that I understood. 
 
4. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason and without my medical care or legal rights 
being affected. 
 
5. I understand that responsible individuals from King’s College Hospital may look at 
relevant sections of my medical history. I give permission for these individuals to 
have access to my records. 
 
6. I agree that the researchers may contact my GP to inform them of my participation 









7. I agree to have the study measurements completed and have blood samples taken 
for use in this study and to also have samples stored for later research related to 
this study only. 
 
For Weight Loss Surgery Treatment only 
8. I agree to take part in the above study, and I understand that I will undergo a 
permanent surgical procedure called a laparoscopic sleeve gastrectomy which will 
require life long alterations in my eating habits in order to lose weight and maintain 
weight loss over time.   
 
9. I agree to have a fat tissue biopsy taken at the time of surgery and for the tissue to 




Name of Patient___________________________________ Date __________  
Patient’s Signature_________________________________ 
 
Name of Researcher _______________________________  Date __________ 







Appendix D - Instructions for Recruitment, Pre-assessment Data 
Collection and Monitoring 
 
 
The effect of weight loss surgery on preservation of kidney function and 
cardiovascular disease risk factors in obese patients with chronic 
kidney disease: a randomised controlled pilot study 
REC Reference Number: 09/H0806/69 and R&D Reference Number: KCH 1639 
and 
A prospective cohort study of laparoscopic sleeve gastrectomy for 
weight loss in obese patients on haemodialysis: pilot study 
REC Reference Number: 10/H0716/55 and R&D Reference Number KCH 11-014 
  Detailed methodology for Recruitment, Pre-






Patients will be recruited through existing outpatient clinics linked with the 3 study sites.  
Referrals will be made to the study co-ordinator or renal dietitian by the treating clinic team 
for eligible patients who agreed to be referred for weight management treatment.  All 
referred patients will be contacted by the study co-ordinator by telephone or in person and 
sent/given written information on the study, with a follow up telephone call 1-2 weeks 
later.  If the patient is interested in the study they will be invited to attend the pre-surgery 




Patient attends the pre-assessment appointment with Surgeon and Dietitian to determine 
legibility for surgery and allow the patient find out further information about the study and 
ask questions to satisfy the terms of informed consent.   
The patient will see the renal dietitian initially, who will explain the current treatment 
option of weight management clinic, including the expectations of the patient and treating 
team, optional medication use, programme results and effect on kidney function with level 
of weight loss achieved.  The dietitian will also explain that the study is exploring an 
additional form of treatment for weight loss, which is effective for weight loss in the 
general population but relatively new in patients with chronic kidney disease. 
The patient will then see the surgeon and dietitian together: 
a. Surgeon asks patient whether they are willing to have an operation to lose 
weight, discusses history of being overweight and attempts at weight loss, 
records detailed medical history (includes identification of sleep apnoea risk), 
surgical history, family history of chronic diseases, bowel diseases and 
inheritable conditions, especially those relating to bleeding or clotting, reasons 
patient wants to lose weight and what the patient expects from weight loss 
surgery 
b. Surgeon conducts abdominal examination 
c. Surgeon makes assessment about suitability for weight loss surgery 
d. If patient suitable for weight loss surgery the consultation continues, Surgeon 
explains the research study, including the weight loss operation involved 
(laparoscopic sleeve gastrectomy), process of randomisation, giving informed 
consent, freedom to withdraw, and the study outcomes and how these are 
relevant to the patient 
e. Dietitian records dieting history and eating habits, including any out of control 
experiences to determine potential eating behaviour barriers to weight loss (can 
use Binge Eating Scale* if appropriate) 
f. Dietitian explains the dietary and lifestyle considerations for each treatment arm 
including low fat calorie reduced diet for lifestyle modification and texture 
modified progression and lifelong altered portion size for surgical treatment 
arm 
g. Dietitian explains level of likely weight loss in each treatment arm, number of 
appointments in each treatment arm and tests involved 
h. Discussion about the study with patient and answer all patient questions 
i. If patient willing to participate, obtain informed consent to participate in 
randomised controlled trial  
j. Refer to sleep clinic or other services as required 
k. If participating in trial, patient informed of randomisation process and to await 
results of randomisation allocation 
l. If patient does not wish to be considered for the trial, surgeon will continue 
appointment to determine course of treatment 
*BES – Binge Eating Scale 
Give patient the questionnaire and ask them to complete according to the instructions on 
the questionnaire.  You may read out the instructions. 
 
To score the BES, add up the scoring weights in parentheses.  Scores of 16 or less 
indicated no binge eating problem identified, scores of 17-26 indicate mild to moderate 
binge eating problem identified, and scores of 27 or more indicate severe binge eating 
problem identified.  Patients scoring 17 or more should undergo treatment for Binge 




Eating Habits  Checkl i s t  
 
Instructions.  Below are groups of numbered statements.  For each group, read 
all of the statements and mark on this sheet the one that best describes the 
way you feel about the problems you have controlling your eating behaviour. 
 
#1 
(0) 1. I don’t feel self-conscious about my weight or body size when I am with 
others. 
(0) 2. I feel concerned about how I look to others, but it normally does not make 
me feel disappointed with myself. 
(1) 3. I do get self-conscious about my appearance and weight which makes me feel 
disappointed in myself. 
(3) 4. I feel very self-conscious about my weight and frequently, I feel intense shame 





(0) 1. I don’t have any difficulty eating slowly in the proper manner. 
(1) 2. Although I seem to “gobble down” foods, I don’t end up feeling stuffed 
because of eating too much. 
(2) 3. At times, I tend to eat quickly and then, I feel uncomfortably full afterwards. 
(3) 4. I have the habit of bolting down my food, without really chewing it.  When 




(0) 1.  I feel capable to control my eating urges when I want to. 
(1) 2. I feel like I have failed to control my eating more than the average person. 
(3) 3. I feel utterly helpless when it comes to feeling in control of my eating urges. 
(3) 4. Because I feel so helpless about controlling my eating I have become very 




(0) 1. I don’t have the habit of eating when I’m bored. 
(0) 2. I sometimes eat when I’m bored, but often I’m able to “get busy” and get my 
mind off food. 
(0) 3. I have a regular habit of eating when I’m bored, but occasionally, I can use 
some other activity to get my mind off eating. 
(2) 4. I have a strong habit of eating when I’m bored.  Nothing seems to help me 
break the habit. 
 
#5 
(0) 1.  I’m usually physically hungry when I eat something. 
(1) 2. Occasionally, I eat something on impulse even though I really am not hungry. 
(2) 3. I have a regular habit of eating foods, that I might not really enjoy, to satisfy a 
hungry feeling even though physically, I don’t need the food. 
(3) 4. Even though I’m not physically hungry, I get a hungry feeling in my mouth 
that only seems to be satisfied when I eat a food, like a sandwich, that fills my 
mouth.  Sometimes, when I eat food to satisfy my mouth hunger, I then spit 
the food out so I won’t gain weight. 
 
#6 
(0) 1. I don’t feel any guilt or self-hate when I overeat. 
(1) 2. After I overeat, occasionally I feel guilt or self-hate. 
(3) 3. Almost all the time I experience strong guilt or self-hate after I overeat. 
 
#7 
(0) 1. I don’t lose total control of my eating when dieting even after periods when I 
overeat. 
(2) 2. Sometimes when I eat a “forbidden food” on a diet, I feel like I “blew it” and 
eat even more. 
(3) 3. Frequently, I have the habit of saying to myself, “I’ve blown it now, why not 
go all the way” when I overeat on a diet.  When that happens I eat even more.   
(3) 4. I have a regular habit of starting strict diets for myself, but I break the diets by 
going on an eating binge.  My life seems to be either a “feast” or “famine”. 
 
#8 
(0) 1. I rarely eat so much food that I feel uncomfortably stuffed afterwards. 
(1) 2. Usually about once a month, I eat such a quantity of food, I end up feeling 
very stuffed. 
(2) 3. I have regular periods during the month when I eat large amount of food, 
either at mealtime or at snacks. 
(3) 4. I eat so much food that I regularly feel quite uncomfortable after eating and 




(0) 1. My level of calorie intake does not go up very high or down very low on a 
regular basis. 
(1) 2. Sometimes after I overeat, I will try to reduce my calorie intake to almost 
nothing to compensate for the excess calories I’ve eaten. 
(2) 3. I have a regular habit of overeating during the night.  It seems that my routine 
is not to be hungry in the morning but overeat in the evening. 
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(3) 4. In my adult years, I have had week-long periods where I practically starve 
myself.  This follows periods when I overeat.  It seems I live a life of either 
“feast or famine”. 
 
#10 
(0) 1. I usually am able to stop eating when I want to.  I know when “enough is 
enough”. 
(1) 2. Every so often, I experience a compulsion to eat which I can’t seem to 
control. 
(2) 3.  Frequently, I experience strong urges to eat which I seem unable to control, 
but at other times I can control my eating urges. 
(3) 4. I feel incapable of controlling urges to eat.  I have a fear of not being able to 
stop eating voluntarily. 
 
#11 
(0) 1. I don’t have any problem stopping eating when I feel full.  
(1) 2. I usually can stop eating when I feel full but occasionally overeat leaving me 
feeling uncomfortably stuffed. 
(2) 3. I have a problem stopping eating once I start and usually I feel uncomfortably 
stuffed after I eat a meal. 
(3) 4. Because I have a problem not being able to stop eating when I want, I 
sometimes have to induce vomiting to relieve my stuffed feeling. 
 
#12 
(0) 1. I seem to eat just as much when I’m with others (family, social gatherings) as 
when I’m by myself. 
(1) 2. Sometimes, when I’m with other persons, I don’t eat as much as I want to eat 
because I’m self conscious about my eating. 
(2) 3. Frequently, I eat only a small amount of food when others are present, 
because I’m very embarrassed about my eating. 
(3) 4. I feel so ashamed about overeating that I pick times to overeat when I know 
no one will see me.  I feel like a “closet eater”. 
 
#13 
(0) 1. I eat three meals a day with only an occasional between meal snack. 
(0) 2. I eat 3 meals a day, but I also normally snack between meals. 
(2) 3. When I am snacking heavily, I get in the habit of skipping regular meals. 




(0) 1. I don’t think much about trying to control unwanted eating urges. 
(1) 2. At least some in the time, I feel my thoughts are pre-occupied with trying to 
control my eating urges. 
(2) 3. I feel that frequently I spend much time thinking about how much I ate or 
about trying not to eat anymore. 
(3) 4. It seems to me that most of my waking hours are pre-occupied by thoughts 





(0) 1. I don’t think about food a great deal. 
(1) 2. I have strong cravings for food but they last only for brief periods of time. 
(2) 3. I have days when I can’t seem to think of anything else but food. 
(3) 4. Most of my days seem to be pre-occupied with thoughts about food.  I feel 




(0) 1. I usually know whether or not I’m physically hungry.  I take the right portion 
of food to satisfy me. 
(1) 2. Occasionally, I feel uncertain about knowing whether or not I’m physically 
hungry.  At these times it’s hard to know how much food I should take to 
satisfy me. 
(2) 3. Even though I might know how many calories I should eat, I don’t have any 
idea what is a “normal” amount of food for me. 
 
 
Patient ID:  CKD34/HDoooooooB 
 
 
Date:  ___________________________ 
 
Added to database o 
 
 
Note.  The scoring weights are in parentheses next to each statement.  Total scale score is 
the sum of the weights for the 16 items. 
 
Reference: Gormally J, Black S, Daston S, Rardin D.  The assessment of binge eating 
severity among obese persons.  Addictive Behaviors 1982, 7: 47-55. 
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Outcome measures data collection 
The patient arrives at the study centre and the study conditions checklist is completed on 
the front page of the data collection form.  The data required at each visit will be collected 
according to the tables attached. 
 
Questionnaires 
Patients will be seated and given 2 questionnaires to complete.  The Renal QOL - Quality 
of Life Questionnaire for the research and the HADS (Hospital Anxiety and Depression 
Scale) as part of the clinical assessment.  Code each questionnaire with the patient’s 
individual study ID number and visit code.  Patients return the completed questionnaires to 
the clinic team. 
 
SF-36 QOL 
Ask the patient to read each question and circle the answer that most applies to them right 
now.   
 
HADS – Hospital Anxiety and Depression Scale 
Patients	  are	  asked	  to	  choose	  one	  response	  from	  the	  four	  given	  for	  each	  statement.	  	  
They	  should	  give	  an	  immediate	  response	  and	  be	  dissuaded	  from	  thinking	  too	  long	  
about	  their	  answers.	  	  The	  questions	  relating	  to	  anxiety	  are	  marked	  "A",	  and	  to	  
depression	  "D".	  	  The	  score	  for	  each	  answer	  is	  given	  in	  the	  right	  column.	  	  Instruct	  the	  
patient	  to	  answer	  how	  it	  currently	  describes	  their	  feelings.	  
 
Questionnaire Scoring 
Scoring the Renal QOL is completed using a pre-formulated excel spreadsheet. 
 
For	  the	  HADS,	  the	  questions	  relating	  to	  anxiety	  are	  marked	  "A",	  and	  to	  depression	  
"D".	  	  The	  score	  for	  each	  answer	  is	  given	  in	  the	  right	  column.	  	  Add	  up	  the	  total	  scores	  




Clinic  b lood pressure and heart  rate   
Ensured that the patient is calm and relaxed.  
 
Allow the patient to rest quietly at a comfortable room temperature for ten minutes before 
measurements are performed.  
The patient will sit quietly with their legs uncrossed and feet flat on the floor.  
Measure blood pressure three times at two minute intervals and record all measurements. 
 
For HD patients, predialysis blood pressure is measured according to standard protocol.  




Using a wall-mounted stadiometer, the patient will be asked to stand upright with heels and 
shoulders against the measuring rod, knees and back straight and looking forward. The 
measuring slide will be pushed onto the head so that it is touching without bending. Body 
height can be obtained from the read-off mark to the nearest whole centimetre.  
 331 
 
If the patient is unable to stand, demi-span will be measured to estimate height. 
 
Weight 
The scales are placed on a firm, level surface and regularly calibrated. Ask the patient to 
remove their shoes and any outer clothing, then to step on the platform and remain still; 




Waist and Hip Circumference 
For both waist and hip, each measure is taken twice and recorded, if the two readings are > 
0.7 cm apart, then further measures should be taken and recorded until two measures are 
obtained within 0.7 cm of each other. 
Protocol for waist and hip circumference measurement: 
	  
- Ask	  the	  patient	  to	  lift	  any	  outer	  clothing	  clear	  of	  the	  abdomen,	  but	  to	  leave	  the	  
innermost	  layer	  in	  position.	  	  Belts	  and	  buttons	  should	  be	  unfastened	  to	  release	  
restrictions.	  	  	  
- Ask	  the	  patient	  to	  stand	  with	  their	  feet	  shoulder	  width	  apart	  and	  arms	  crossed	  
over	  the	  chest	  in	  a	  relaxed	  manner.	  	  Kneel	  on	  one	  side	  of	  the	  patient.	  	  	  
- The	  waist	  circumference	  measurement	  should	  be	  taken	  at	  the	  level	  of	  the	  
umbilicus.	  	  Ask	  the	  patient	  to	  palpate	  the	  abdomen	  gently	  to	  find	  this	  landmark,	  
then	  once	  located,	  to	  return	  their	  arms	  to	  the	  crossed	  position	  over	  the	  chest.	  	  
- Position the tape directly around the abdomen so that the inferior edge of the tape is 
at the level of the land marked point. Use a cross-handed technique to bring the zero 
line of the tape in line with the measuring aspect of the tape. Ensure that the 
measuring tape is positioned in a horizontal plane around the abdomen. Apply tension 
to the tape to ensure it is snug, without causing indentation to the skin.  
- At the end of a normal expiration, take the measurement to the nearest 0.1cm. 
- The hip circumference measurement should be taken at the widest part of the hips, 
usually at the greatest protrusion of the buttocks. 
- Position the tape directly around the hips, ensuring the tape remains horizontal and 
parallel to the floor.  Use a cross-handed technique to bring the zero line of the tape in 
line with the measuring aspect of the tape. Apply tension to the tape to ensure it is 






Blood and urine sampling 
Urine sampling (CKD 3-4 Study only) 
Patients will be asked to provide a 25 ml urine sample in a universal container.  The sample 
is sent to the biochemistry lab with the blood samples. 
 
Blood sampling 
Patients will be asked to provide a blood sample, taken by a health care assistant, nurse, 
doctor or qualified phlebotomist.   
CKD 3-4 Study: Samples required are 2 x 5ml purple top (EDTA), 4 x 5ml gold top 
(serum) and 1 x 5 ml grey top (fluoride) vacutainer collection tubes.  
HD Study: Samples required are 2 x 5ml purple top (EDTA), 3 x 5ml gold top (serum), 1 x 
5 ml grey top (fluoride), and 2 x 10ml large purple (EDTA) vacutainer collection tubes. 
	  
Measurement of Glomerular Filtration Rate using Iohexol Clearance (CKD 3-4 
Study only) 
Iohexol Clearance Administration Instructions 
Administration of iohexol must be performed by a doctor or nurse in an environment with 
access to resuscitation facilities. 
1. Ensure patient has fasted for 12 hours before undertaking the test and has 
refrained from drinking caffeinated beverages for at least 6 hours 
2. Ensure all venous blood samples and baseline fingerprick blood spot are collected 
before administering iohexol, and leave the butterfly collection set in place 
3. Flush the needle with normal saline to ensure patency 
4. Administer 5ml of 300mg/ml iohexol solution (Omnipaque 300, Nycomed 
Amersham Plc, Buckinghamshire, UK) through the collection set and note the 
exact time on the data collection sheet and blood spot card. 
5. Flush the needle with 10ml of 0.9% saline 
6. Remove the needle and allow the patient to return to the waiting area to be 
observed for 15 minutes in case of an adverse reaction 
 
Instructions for fingertip blood sampling prior to and 120, 180 and 240 (or 300) 
minutes after administration of iohexol (adapted from (Mafham, Niculescu-Duvaz 


















Mafham, M. M., I. Niculescu-Duvaz, et al. (2007). "A practical method of measuring 
glomerular filtration rate by iohexol clearance using dried capillary blood spots." 







1. Arrange equipment (retractable lancet, cotton wool, blood spot 
card, watch, timer or clock). 
 
2. Wash and dry hands. 
 
3. Prepare retractable lancet (Pictures 1-2). 
 
4. Select sample site. Use the side of the end of one finger (Picture 3). 
 
5. Hold retractable lancet firmly against the sample site and squeeze 
trigger (Picture 4). 
 
6. Massage finger above sample site until a large droplet has formed 
(Picture 5). 
 
7. Apply a single large drop to the card surface taking care not to 
touch the card with the finger. Do not apply several drops to the same 
card area. 
 
8. Repeat steps 6 and 7 once to collect a second drop onto a separate 
area of the card. 
 
9. Press the sample site with the cotton wool. 
10. Record EXACT time on the card. 
 
11. Allow blood spot card to dry. 
 
12. Return the dried blood spot card to the study clinic using the 




Measurement of Endothelial Progenitor Cells by Flow Cytometry and Cell Culture 
(HD study only) 
Samples	  for	  endothelial	  progenitor	  cell	  analyses	  were	  taken	  to	  the	  laboratory	  for	  
immediate	  processing	  and	  analysis,	  performed	  by	  the	  candidate,	  and	  the	  remaining	  
samples,	  for	  biochemistry	  analysis	  were	  sent	  to	  the	  Biochemistry	  Laboratory	  at	  King’s	  
College	  Hospital	  for	  processing	  and	  storage,	  and	  were	  analysed	  in	  batches	  at	  the	  end	  
of	  the	  study.	  	  	  
	  
Separation of peripheral blood mononuclear cells (PBMC) for endothelial 
progenitor cell counting and colony-forming unit-Hill (CFU-Hill) colony cell 
culture  
Two	  x	  8	  mL	  samples	  of	  peripheral	  blood	  collected	  immediately	  prior	  to	  the	  start	  of	  
dialysis,	  in	  EDTA	  coated	  tubes	  (BD	  vacutainer	  BD:	  New	  Jersey),	  were	  processed	  as	  soon	  
as	  possible	  and	  within	  two	  hours	  of	  collection.	  	  
	  
Procedures	  for	  separation	  of	  PBMC	  and	  preparation	  of	  cell	  cultures	  were	  performed	  in	  
a	  biological	  safety	  cabinet	  (hood)	  using	  aseptic	  techniques.	  	  	  	  
	  
Using	  a	  Neubauer	  haemocytometer,	  nucleated	  cells	  were	  counted	  using	  3%	  Acetic	  Acid	  
solution	  with	  Methylene	  Blue	  at	  a	  1/20	  dilution	  on	  whole	  blood	  (10	  μL	  of	  blood	  and	  
190	  μL	  of	  Acetic	  Acid	  solution).	  
	  
16	  mL	  of	  peripheral	  blood	  was	  diluted	  1:1	  with	  phosphate	  buffer	  solution	  (PBS)	  (PAA:	  
Austria),	  before	  gently	  layering	  8	  mL	  diluted	  blood	  on	  to	  each	  of	  4	  x	  4ml	  Ficoll-­‐Paque	  
PLUS	  (StemCell	  Technologies:	  France)	  in	  4	  x	  15ml	  polypropylene	  tubes	  for	  density	  
gradient	  centrifugation.	  	  The	  tubes	  were	  centrifuged	  at	  300	  g,	  at	  24°C	  for	  25	  minutes	  
with	  the	  brake	  OFF	  for	  extraction	  of	  peripheral	  blood	  mononuclear	  cells.	  
	  
The	  layer	  of	  mononuclear	  cells	  between	  the	  plasma	  and	  the	  Ficoll-­‐Paque	  PLUS	  was	  
collected	  from	  each	  tube	  with	  a	  sterile	  pipette,	  and	  combined	  in	  a	  50ml	  polypropylene	  
tube,	  and	  washed	  twice	  with	  PBS	  with	  2%	  FBS	  Gold	  fetal	  bovine	  serum	  (PAA:	  Austria).	  	  
In	  the	  first	  wash,	  the	  final	  volume	  was	  brought	  to	  40	  mL	  with	  PBS	  with	  2%	  fetal	  bovine	  
serum	  and	  the	  tube	  was	  centrifuged	  at	  300	  g,	  at	  24°C,	  for	  7	  minutes	  with	  the	  brake	  ON	  
to	  pellet	  the	  suspension.	  	  The	  supernatant	  was	  removed	  and	  the	  tube	  tapped	  to	  re-­‐
suspend	  the	  cells,	  and	  6	  mL	  of	  PBS	  with	  2%	  fetal	  bovine	  serum	  was	  added	  for	  the	  
second	  wash.	  	  Prior	  to	  centrifugation,	  the	  sample	  was	  re-­‐divided	  into	  4	  equal	  volumes	  
in	  4	  x	  15	  mL	  polypropylene	  tubes,	  a	  further	  6	  ml	  of	  PBS	  with	  2%	  fetal	  bovine	  serum	  
was	  added	  to	  the	  50	  mL	  tube,	  mixed	  with	  a	  pipette	  to	  include	  any	  remaining	  cells,	  then	  
added	  in	  4	  equal	  volumes	  to	  the	  4	  x	  15	  mL	  polypropylene	  tubes.	  	  The	  4	  x	  15	  mL	  tubes	  
were	  spun	  at	  300g	  for	  at	  24°C,	  for	  7	  minutes	  to	  complete	  the	  second	  wash.	  	  	  
	  
The	  supernatant	  was	  removed	  from	  all	  four	  samples	  and	  the	  pellets	  re-­‐suspended	  in	  
the	  residue.	  	  	  
	  
PBMC for endothelial progenitor cell counts 
The	  sample	  in	  1	  x	  15	  mL	  tube	  was	  re-­‐suspended	  in	  1	  mL	  CryoMaxx	  freezing	  medium	  
(PAA:	  Austria)	  and	  transferred	  to	  a	  2	  mL	  CryoTube	  tube	  (Nunc:	  Denmark)	  for	  storage	  at	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-­‐80°C,	  after	  the	  nucleated	  cells	  were	  counted	  using	  a	  1/20	  dilution	  of	  sample	  to	  3%	  
Acetic	  Acid	  with	  methylene	  blue	  (10	  μL	  of	  sample	  and	  190	  μL	  of	  Acetic	  Acid	  solution).	  	  
The	  sample	  was	  frozen	  slowly	  at	  1°C/min	  in	  an	  insulated	  box	  at	  -­‐80°C,	  and	  stored	  at	  -­‐
80°C	  for	  later	  analysis	  of	  CD133+,	  CD34+	  and	  KDR+	  cell	  counts	  using	  fluorescence-­‐
activated	  cell	  sorting	  (FACS)	  flow	  cytometry.	  	  
	  
PBMC for CFU-Hill colonies cell culture 
The	  cell	  culture	  for	  formation	  of	  CFU-­‐Hill	  colonies	  was	  performed	  by	  the	  candidate	  
according	  to	  the	  procedure	  outlined	  in	  the	  technical	  manual,	  version	  3.0.0	  (StemCell	  
Technologies:	  France)	  	  [1].	  The	  samples	  in	  the	  other	  3	  x	  15	  mL	  tubes	  were	  re-­‐
suspended	  in	  1	  mL	  CFU-­‐Hill	  Liquid	  Medium	  in	  each	  tube,	  then	  all	  three	  samples	  
combined	  into	  one	  of	  the	  tubes.	  	  The	  nucleated	  cells	  were	  counted	  using	  a	  1/20	  
dilution	  of	  sample	  to	  3%	  Acetic	  Acid	  with	  methylene	  blue	  (10	  μL	  of	  sample	  and	  190	  μL	  
of	  Acetic	  Acid	  solution).	  	  2	  mL/well	  of	  CFU-­‐Hill	  Liquid	  Medium	  was	  added	  to	  each	  of	  
two	  wells	  of	  a	  6-­‐well	  fibronectin	  coated	  (BD	  Biocoat)	  plate	  (BD	  Biosciences:	  MA,	  USA),	  
to	  perform	  the	  experiment	  in	  duplicate,	  and	  5	  x	  106	  cells	  were	  plated	  in	  each	  well.	  	  The	  
plates	  were	  incubated	  at	  37	  °C	  with	  95%	  humidity,	  5%	  CO2,	  for	  two	  days,	  to	  remove	  
mature	  endothelial	  cells	  and	  some	  monocytes	  (Day	  0).	  
	  
After	  2	  days	  (Day	  2)	  the	  non-­‐adherent	  cells,	  containing	  the	  CFU-­‐Hill	  colony-­‐forming	  
cells,	  were	  collected	  and	  cultured	  for	  an	  additional	  three	  days	  to	  allow	  for	  formation	  of	  
CFU-­‐Hill	  colonies.	  	  	  
	  
On	  day	  2,	  the	  non-­‐adherent	  cells	  were	  collected	  by	  gently	  pipetting	  the	  medium	  up	  
and	  down	  three	  times	  using	  a	  2	  mL	  pipette.	  	  The	  cells	  and	  medium	  from	  each	  well	  
were	  gently	  removed	  with	  a	  pipette	  and	  placed	  in	  separate,	  labelled,	  15	  ml	  
polypropylene	  tubes.	  	  The	  cells	  in	  each	  tube	  were	  counted	  using	  a	  1/10	  dilution	  of	  
Acetic	  Acid	  with	  Methylene	  Blue	  (10	  μL	  of	  sample	  and	  90	  μL	  of	  Acetic	  Acid	  solution).	  	  
From	  each	  well,	  1	  x	  106	  cells	  were	  re-­‐plated,	  in	  duplicate,	  on	  24-­‐well	  fibronectin-­‐
coated	  (BD	  Biocoat)	  plates	  (BD	  Biosciences;	  MA,	  USA),	  and	  new	  CFU-­‐Hill	  Liquid	  
Medium	  was	  added	  to	  achieve	  a	  final	  volume	  of	  1.0	  mL	  per	  well.	  	  The	  plates	  were	  
incubated	  at	  37	  °C	  with	  95%	  humidity,	  5%	  CO2	  for	  three	  days.	  	  
	  
On	  day	  5,	  the	  medium	  in	  each	  well	  was	  gently	  pipetted	  up	  and	  down	  three	  times	  to	  
suspend	  the	  non-­‐adherent	  cells,	  and	  discarded.	  	  The	  wells	  were	  gently	  washed	  with	  1	  
mL	  PBS	  and	  the	  PBS	  was	  removed.	  	  The	  cell	  cultures	  were	  fixed	  by	  gently	  adding	  300	  
μL	  of	  methanol	  very	  slowly	  down	  the	  sides	  of	  the	  entire	  circumference	  of	  each	  well	  
wall,	  and	  the	  plate	  was	  incubated,	  at	  37	  °C	  with	  95%	  humidity,	  and	  5%	  CO2,	  for	  3	  
minutes,	  timed	  with	  an	  electronic	  timer.	  	  The	  methanol	  was	  removed	  and	  the	  cultures	  
were	  stained	  with	  Giemsa	  Staining	  Solution	  (Merck:	  Germany)	  diluted	  1/20	  in	  distilled	  
water	  (60	  μL	  of	  Giesma	  solution	  and	  1140	  μL	  of	  distilled	  water),	  and	  incubated	  for	  a	  
further	  3	  minutes.	  	  The	  residual	  staining	  solution	  was	  removed	  and	  the	  wells	  were	  
rinsed	  gently	  with	  plain	  water	  pipetted	  into	  the	  well	  and	  removed,	  and	  repeated	  until	  
the	  colonies	  were	  clearly	  visible	  with	  very	  little	  background	  staining.	  	  The	  plates	  were	  
stored	  at	  room	  temperature.	  	  The	  absolute	  numbers	  of	  CFU-­‐Hill	  cell	  colonies	  per	  well	  
were	  counted	  using	  a	  light	  microscope.	  	  A	  single	  CFU-­‐Hill	  colony	  was	  defined	  as	  a	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central	  core	  of	  round	  cells	  surrounded	  by	  long,	  thin,	  spindle-­‐like	  cells	  radiating	  
outwards	  [2].	  
 
Body composition by bioelectrical impedance  
 
The Biospace Inbody 720 analyser will be used.   
 
In HD patients this should be completed on a non HD day.  If completed on a HD day, 
then please note this on the data collection form and continue to collect on HD days for 
this patient throughout study.   
	  
Measurement	  of	  body	  composition	  by	  bioelectrical	  impedance	  analysis	  is	  able	  to	  be	  
performed	  on	  patients:	  
- who	  are	  able	  to	  stand	  with	  their	  arms	  held	  away	  from	  their	  body,	  unaided,	  for	  two	  
minutes	  
- who	  do	  not	  have	  a	  pacemaker	  or	  metal	  implant	  
	  
If	  able,	  ask	  patients	  to	  urinate	  and	  defecate	  before	  undergoing	  BIA	  measurement.	  	  
Request	  patient	  to	  remove	  outside	  clothing,	  empty	  pockets	  of	  heavy	  items	  and	  remove	  
shoes	  and	  socks	  or	  stockings.	  
	  
Prior to measurement, the operator should ensure that the results proforma is placed in the 
printer paper tray, face down, with the heading nearest the outer edge of the tray.  Results 
are printed onto the proforma by the printer attached to the analyser.   
- Ask the patient to step onto the 4 cm high platform and place their bare feet slightly 
apart onto the two footpads which act as electrodes.  
- Wipe the hands and feet and electrodes with electrolye coated tissue to ensure good 
contact.  Electrolyte tissue may also need to be placed on top of each foot electrode 
(not touching each other) to get good contact in patients with thick skin on the soles 
of their feet. 
- Once the patient is still body weight will be recorded.  Enter the patient’s study ID 
number including study visit code (B, 3, 6, 9 or 12), age, sex and height (m).   
- When the patient is standing comfortably, with their feet placed over the electrodes on 
the platform, ask them to hold the handgrips (which also act as electrodes) in each 
hand, and extend their arms straight and away from the body to be clear of their torso. 
- Press the Enter key and ask the patient to maintain this position for approximately two 
minutes, whilst the analysis is performed. 
 
Vascular Stiffness - Pulse Wave Velocity using Vicorder (HD study only) 
 
Set up the laptop and vicorder according to the instruction manual.   
Add each new patient as follows 
Surname  - HD+initials 
Forename – study ID 
Study ID – study ID 
 
Go to PWV and ensure correct ID is listed and file is saving to HD pilot study file 
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Brachial to Femoral 
- Put cuffs around non fistula arm and top of thigh on same side of body and connect 
to vicorder, red lead to brachial cuff and blue to femoral cuff 
- Measure distance in straight line from top of brachial cuff to top of femoral cuff, 
record distance 
- Press space bar to record PWV, wait 2 cycles and then press space bar, save data and 
record time and velocity, repeat 
 
Carotid to Femoral 
- Remove brachial cuff and place neck band around neck with space for 1-2 fingers 
inside and connect to vicorder, red lead to neck band and blue to femoral cuff 
- Measure distance in straight line from sternal notch to top of femoral cuff, Measure 
distance from lower edge of carotid band to sternal notch and subtract the distance 
from the carotid cuff to the sternal notch from the listance between the sternal notch 
and the femoral cuff 
- Enter this distance in the software 
- Press space bar to record PWV, wait 2 cycles and then press space bar, save data and 
record time and velocity, repeat 
 
Measurement of Vascular Stiffness methodology 
Vascular	  (arterial)	  stiffness	  was	  measured	  with	  carotid-­‐femoral	  and	  brachial-­‐femoral	  
pulse	  wave	  velocity	  (PWV).	  	  	  PWV	  was	  measured	  on	  an	  inter-­‐dialysis	  day	  of	  the	  week	  
using	  the	  Vicorder	  device	  (Skidmore	  Medical,	  United	  Kingdom),	  using	  the	  oscillometric	  
technique.	  	  	  With	  the	  patient	  lying	  in	  a	  supine	  position,	  a	  blood	  pressure	  cuff	  was	  
placed	  around	  the	  upper	  thigh	  and	  upper	  arm	  (brachial-­‐femoral)	  or	  a	  partial	  cuff	  
placed	  around	  the	  neck	  at	  the	  level	  of	  the	  carotid	  artery	  (carotid-­‐femoral).	  	  Using	  a	  
calibrated	  plastic	  tape	  measure,	  the	  distance	  between	  the	  top	  of	  each	  cuff	  (brachial	  to	  
femoral)	  or	  the	  distance	  between	  the	  sternal	  notch	  and	  the	  top	  of	  the	  femoral	  cuff	  via	  
the	  umbilicus	  (carotid-­‐femoral),	  in	  a	  straight	  line,	  minus	  the	  distance	  between	  the	  
lower	  edge	  of	  the	  carotid	  cuff	  to	  the	  sternal	  notch,	  was	  measured	  and	  entered	  into	  the	  
Vicorder	  software.	  	  Both	  cuffs	  were	  inflated	  simultaneously	  to	  65	  mm	  Hg	  for	  5-­‐10	  
seconds	  whilst	  the	  carotid	  and	  femoral	  wave-­‐forms	  were	  simultaneously	  recorded	  and	  
the	  oscillometric	  signal	  from	  each	  cuff	  is	  digitally	  analysed	  to	  determine	  the	  real	  time	  
pulse	  delay	  between	  the	  two	  detected	  wave-­‐forms.	  	  	  	  Pulse	  wave	  velocity	  was	  
calculated	  from	  the	  distance	  measured	  and	  the	  pulse	  transit	  time	  between	  the	  two	  
points.	  	  Each	  measurement	  was	  performed	  at	  least	  twice	  and	  the	  average	  velocity	  




1. Energy and Macronutrient Prescription 
Weight Management Programme 
Energy requirements for weight loss will be 1400-1800 kcal/day  
Protein intake will be optimised for the stage of CKD for each patient, at 1.0 g protein/kg 
IBW/day for CKD stage 3 and 0.8-1.0g protein/kg IBW/day for CKD stage 4.   
Fat intake will be limited to less than 70g per day to minimise the side effects of orlistat.  
The remaining kcal will be consumed from carbohydrate sources, with higher fibre choices 
encouraged when possible.   
All patients will be encouraged to modify sodium intake to a “no added salt” diet level, of 
80-100 mmol sodium per day.  Potassium and phosphate intake will be modified according 
to serum biochemistry and residual kidney function.   
Weight Loss Surgery 
Goal energy intake is 1000 kilocalories /day.    
Protein intake will be optimised for the stage of CKD for each patient, at 1.0 g protein/kg 
IBW/day for CKD stage 3, 0.8-1.0g protein/kg IBW/day for CKD stage 4, and 1.2 g 
protein/kg IBW/day for stage 5 on haemodialysis.   
The remaining kcal will be consumed from carbohydrate and fat sources, with low fat 
choices strongly encouraged.  A wide variety of tolerated foods should be eaten.   
All patients will be encouraged to modify sodium intake to a “no added salt” diet level, of 
80-100 mmol sodium per day.  Potassium and phosphate intake will be modified according 
to serum biochemistry and residual kidney function.   
2. Monitoring intake 
All study patients 
Patients will keep food, fluid and activity diaries for the entire 6 month intervention period.  
In-depth 3 day food and fluid intake records, followed by dietary assessment interview with 
the study dietitian will be completed at baseline, 3 months and 6 months during the 6 
month intervention period and 3 monthly thereafter, up to 12 months.  Patients will be 
taught how to complete the 3 day food and fluid record using standard household 
measures to record portions served and plate waste.  The study Dietitian will verify the 
portions using household measures, actual size photographs, product packaging and 
questioning to verify the record.   
 
Patients consuming >10% more or less kilocalories or protein than prescribed will work 
with the study Dietitian to adjust intake to meet requirements.   
  
Exercise and Physical Activity 
Exercise and physical activity will be monitored using the 3-day food and activity records 
and direct questioning.  Physical activity level will be recorded at 3 monthly intervals.  In 
the Weight Management Programme, formalised testing of exercise parameters is 
conducted every 3 months. 
 
Subjective Global Assessment 
Complete the Subjective Global Assessment with both the medical assessment and physical 
examination and record the overall rating on the data collection form for each visit.  
 
Post Surgical Complications (weight loss surgery group only) 
Record all reported post surgical complications on the data collection form for each study 
visit.  A review of each patient’s medical records will be completed periodically throughout 
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the study to cross check complications from inpatient admissions and post surgical follow 
up.   
 
Adverse Events 




Appendix E - Information for Participants and Consent Form for The 
effect of weight loss surgery on preservation of kidney function and 
cardiovascular disease risk factors in obese patients with chronic 
kidney disease: a randomised controlled pilot study (Chapter 5) 
 
   
 
 
Information for Participants 
 
Research Ethics Committee Reference Number: 09/H0806/69 
 




We would like to invite you to participate in this original research project.  You should only 
participate if you want to; choosing not to take part will not disadvantage you in any way.  
Before you decide whether you want to take part, it is important for you to understand why 
the research is being done and what your participation will involve.  Please take some time 
to read and consider the following information carefully and discuss it with friends, relative 
or your doctor if you want to.  Ask us if there is anything that is not clear, or if you would 




Research Aim - What we would like to find out 3 
Background Information – What we already know 4 
The 2 treatments 5 
 Weight loss programme 6 
Surgery 6 
Collecting Information 8 
Telling your GP 9 
Before you decide to join the study 9 
Tests and measurements during the study 9 
It is up to you to decide whether to take part or not 14 
Consent to participate 14 
Who is organising and funding the research? 15 
Who has reviewed the study? 15 
Can I speak to anyone not involved in the study about 




Number of visits 17 
Study Team 18 
 
  
Research Aim - What we would like to find out 
This study's purpose is to determine if weight loss can improve kidney function in patients 
with a body mass index between 35-45 plus chronic kidney disease (CKD).  Patients will be 
randomly allocated to one of two treatments, and followed up over at least 1 year, to find 
out whether the greater weight loss achieved with surgery improves kidney function and 
delays progression of chronic kidney disease to end stage when dialysis or a kidney 
transplant is required. 
 
If you were to participate, you would be allocated by chance to either our established 
lifestyle-based weight loss programme for 12 months, or to have keyhole surgery to 
remove two-thirds of your stomach in a procedure called a sleeve gastrectomy, with follow-
up for 12 months.   
 
After 12 months, the investigators would like to continue observing patients for another 2 
years, with follow up at 2 years and 3 years from the start of the study, to see if there any 
differences seen between the two treatments are maintained over a longer period of time.    
 




Background Information – What we already know 
Over the last 10 years research has shown that obesity is a risk factor for getting chronic 
kidney disease, even when accounting for high blood pressure and diabetes, the two main 
causes of chronic kidney disease.  Chronic kidney disease and obesity are both high level 
risk factors for heart disease.    
 
Being overweight or obese may actually damage kidneys by adding pressure to the kidneys, 
increasing the work done by the kidneys in filtering waste out of the blood and causing 
small amounts of protein to leak into the urine.  Patients with a body mass index of > 35 
kg/m2 are not eligible for kidney transplantation and may also be limited in their options 
for dialysis.   
 
Weight loss surgery is well established as the most effective method of achieving and 
sustaining long term, significant weight loss.  Patients lose an average of 30% of their body 
weight within 1 year.  It is not without risks though, and the bigger you are, the more risky 
any operation will be.  One recent small study suggests that surgery can improve kidney 
function with weight loss.   
 
Weight loss can also be achieved with our renal weight management programme.  The 
programme uses a combination of low fat eating, exercise and a weight loss medication, 
called orlistat, and patients lose 5-10% of body weight after 6 months, and this weight loss 
is sustained up to 2 years.  Blood pressure is reduced, exercise capacity improves and 
patients feel better.  About 35% of patients become eligible for kidney transplantation.  So 
far, we have demonstrated stabilisation, but not improvement, in kidney function with this 
level of weight loss.   
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There are many hormones and proteins produced by fat cells, the liver and immune cells 
that circulate around the body.  Changes in the levels of these hormones and proteins will 
occur with weight loss and provide information about the risk of heart and blood vessel 
disease.    
 
 
The two treatments  
Please remember that you will not be able to choose which treatment you have.   You will 
be put into one group or the other by chance to ensure that patients in both treatment 
groups are similar at the beginning of the research.   
 
Weight loss programme 
The renal weight management clinic has been running at King’s College Hospital for 5 
years and at Guy’s Hospital for 3 years.  The weight management programme is an 
intensive treatment programme including a low fat eating plan, increased activity and 
exercise with, or without, a weight loss medication called orlistat (or Xenical).  When 
orlistat is taken with meals, it blocks 1/3 of the fat you eat from being absorbed by your 
body.  Orlistat is taken with every meal.  Eating fatty foods with orlistat can cause 
diarrhoea, flatulence or bloating.  These side effects are avoided if low fat foods are eaten.       
 
The clinic is run by a specialist Renal Dietitian and Physiotherapist who guide patients to 
develop their own goals for changing their eating and exercise habits.  Patients keep a 
detailed food and activity diary every month for 6 months.  Patients attend the clinic at 
King’s or Guy’s hospital once every month for 6 months, and have follow-up visits after 9 
months and again at 1 year.   
 
Patients who follow the programme completely and attend all sessions lose an average of 
10kg, but many have lost more weight.  Patients who do not attend all the sessions tend to 
lose less weight.   
 
Surgery 
Sleeve gastrectomy is a relatively new procedure for weight loss surgery and so far, it has 
been seen as safe and effective, however there is no information on its success rate after 3 
years.  It is a restrictive, irreversible, procedure which involves removal of the major 
portion of the stomach.  After a general anaesthetic induces unconsciousness, the surgeon 
will insert a laparoscope (thin, tube like instrument with a camera to see inside the body) 
and other slender surgical instruments into the abdominal cavity, through very small 
surgical cuts through the abdomen.  The surgeon will then remove about 2/3 of the 
stomach after disconnecting its blood supply.  This is done with surgical staplers and other 
instruments.  The abdominal wall is then closed with stitches.        
 
The stomach will function as normal, but the reduced size means patients should feel 
fuller, sooner, so eat less.  The level of the hunger hormone, Ghrelin, which is produced in 
the stomach, will be reduced, and should result in a decreased appetite.  
 
The surgeon may also take a small sample of your fat tissue whilst he is performing the 
surgery.  This tissue will be frozen and stored for later analysis related to this research. 
 
The risks associated with the sleeve gastrectomy are the same as those for any other major 
abdominal procedure and include haemorrhage (bleeding), leaks from staple lines, 
anaesthetic and drug reactions, deep vein thrombosis (DVT)/ pulmonary embolus (blood 
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clots on the lung), infection, marginal ulcer, and lung problems.  Overall the risk for any of 
these early complications varies between 3-7% ( or 3-7 in 100) and in experienced hands 
the risk of death during a sleeve gastrectomy is very low – around 0.1-0.5% (or 1 in 500 to 
1 in 1000).  There is also a small chance that weight loss will be less than expected.  Weight 
re-gain may occur in 2-3 years if a low fat, low sugar eating plan is not followed in the long 
term.   
 
After the operation, patients are encouraged to perform exercises to improve lung function 
and have a test involving swallowing a special fluid to check for leaks in the new stomach, 
as there is a long staple line in the stomach afterwards.  Most patients will stay in hospital 
for 2-5 days.   
 
Collecting Information 
The study team will collect information about participants throughout the study.  All data 
will have patient identifiable information removed (name, address, date of birth) before it is 
coded and entered into the research database.  A separate code breaker file will be kept 
securely in the study office, to identify patients when new data is added.   
 
The results of the study will be analysed and they may be written up and published in a 
science journal within two years.  If the study finds out something significant the study 
team may contact the media, and a summary of the results may be published in 
newspapers.  No patient who takes part in the study will be identified in any way in the 
results.   
 
Telling your GP 
The study team will write to your GP to let them know you are participating in this study.   
 
Before you decide to join the study 
Patients who are interested in participating in the study will be invited to a pre-assessment 
appointment with the weight loss surgeon and dietitian.  The surgeon will check your 
medical history and answer all the questions you have about the risks and benefits of 
surgery.  The dietitian will give you information about eating after surgery and about the 
lifestyle-based weight loss programme.   
 
Tests and measurements during the study 
The study involves 7 study visits over 3 years to perform a range of tests, with 5 of these 
visits in the being completed in the first 12 months of the study.  All tests will be done at 
the beginning, at 6 months and at 12 months after starting the study.  Some tests, such as 
body weight, exercise, blood pressure and blood tests, will be every 3 months, up to 1 year.  
Only a few tests will be repeated at year 2 and 3 study visits.   
 
Bioelectrical Impedance Analysis 
This is a device similar to a pair of scales but instead of measuring only your weight it also 
measures your body water, muscle and fat levels. You will need to remove your socks and 
shoes.  An undetectable current passes from underneath the feet around the body, 
measuring the amount of water in the body.  Estimates of body fat and lean tissue are then 
determined.  Patients must not eat or drink anything for 2 hours before the test is done.  
The measurement will be made at baseline and every 3 months up to 1 year.  
 
Blood Tests 
Fasting blood samples 
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The study will involve providing an early morning fasting blood sample at the beginning 
and every 3 months up to 1 year.  Patients will have to attend the hospital in the morning 
after not eating for 6-12 hours.   
 
Approximately 30 ml of blood will be taken on each occasion.  There is a possibility that 
some bruising may occur on the arm after the sample has been taken.   
 
Some of this blood will be analysed for this study and some samples from this study may 





Blood pressure will be measured using an auto upper arm blood pressure monitor when 
the patient is calm and relaxed, and seated with their legs uncrossed and feet flat on the 
floor. Blood pressure will be measured three times on one arm with a two minute break 
between each measurement.  The measurement will be made at baseline and every 3 




Patients will be asked to perform a few simple exercise tests, used routinely in the weight 
management programme, to measure fitness and muscle strength.  Patients only perform to 
the level they are capable of, and can stop the tests at any time.  The tests will be completed 
every 3 months, up to 1 year. 
 
Flow Mediated Dilatation 
An ultrasound scan of the forearm or upper arm is conducted using a blood pressure cuff 
inflated to reduce blood flow to the forearm, then released.  A second scan will be taken 
after the patient has placed a tablet of glycerol trinitrate (GTN, 25 µg) under their tongue, 
to open up the blood vessels.  Side effects of this medication can include headache and 
dizziness.  The measurement will be made at the beginning, at 6 months and at 1 year. 
	  
	  
Food and Activity Diaries 
Patients will be required to keep a detailed written record of all food and drink consumed 
and all activity undertaken for a 3 day period, including 1 weekend day, every 3 months, up 
to 1 year.  The diary will be provided by the study team and can be returned in a pre-
stamped pre-addressed envelope provided.   
 
Kidney Function Test 
Kidney function will be measured using the iohexol clearance method with finger prick 
blood sampling.   This test takes several hours to complete, but the patient may leave the 
unit after the initial phase and finish the test elsewhere.   
 
A 4 ml blood sample is taken and the patient will be shown how to perform a self 
administered fingerprick test and give a sample of two drops of blood onto blotting paper.  
This is done in exactly the same way someone with diabetes would test their blood sugar.   
 
A small amount of iohexol (5ml) will be slowly injected into a vein in the patient’s arm, 
followed by 10ml of saline.  Iohexol is a substance containing iodine, often given to 
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patients prior to x-rays to highlight a specified area of the body such as the digestive tract 
or spine, or to test kidney function.  Possible side effects of iohexol include headache, 
nausea or vomiting.  The patient will then rest for 15 minutes and be monitored for 45 
minutes.  Other study measurements may be completed during this time.   
 
Two, three and four or five hours later, the patient will perform a self administered finger 
prick test using a spring loaded single use safety lancet, to place two separate drops of 
blood on a strip of blotting paper.  Once the strips are dry they can be returned in the pre-
stamped, pre-addressed envelope provided.  The measurement will be made at the 
beginning, 6 months, and at 1, 2 and 3 years. 
 
Quality of Life Questionnaire 
Patients will be asked to complete the SF-36 Quality of Life questionnaire.  This is 12 pre-
set questions relating to your own perception of your quality of life.  The questionnaire will 
be completed at the beginning, 6 months, and at 1, 2 and 3 years. 
 
Subjective Global Assessment 
This test is used to monitor nutritional status and to detect poor nutrition in patients.  It 
involves answering some general questions about weight change, activity, food intake and 
gastro-intestinal symptoms, and having a health professional examine your head, shoulders, 
arms and legs for muscle wasting. You may have to remove some of your clothing so the 
health professional can see your shoulders, arms, knees and ankles.  The measurement will 
be made at the beginning, at 6 months and at 1 year. 
 
Urine 
An early morning urine sample (25ml) will be collected in a standard sample pot at the 
beginning, at 6 months, and at 1, 2 and 3 years.   
 
Weight, waist and hip circumferences 
Body weight will be measured by standing on digital weighing scales in light clothing.  
Waist and hip circumferences will be measured over light clothing with a soft tape measure.  
These measurements will be made every 3 months up to 1 year, and again at 2 and 3 years. 
 
	  
It is up to you to decide whether to take part or not 
It is up to you to decide whether or not to take part.  If you do decide to take part, please 
keep this information sheet.  If you decide to take part you are still free to withdraw at any 
time and without giving a reason.  This will not affect the standard of care you receive. 
 
If you do not wish to participate in this study, the study team may ask if you would be 
prepared to complete some of the tests, and repeat these 6 months and 1 year later, without 
undertaking any weight loss treatment.   
 
Consent to participate 
If you decide to join this study you will be asked to sign a consent form.  The consent form 
will ask that you agree to participate in this study, including random allocation to undergo 
weight loss surgery or to attend the weight management clinic.  The consent form will also 
ask that you allow your blood, urine and tissue samples to be kept for future research 
related to this study only.   
 
Who is organising and funding the research? 
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The study is organised and funded by King’s College London and King’s College Hospital.  
Your Doctor, Dietitian and the lead investigator are not being paid to recruit you to this 
study. 
 
Who has reviewed the study? 
This study has been reviewed by the King’s College Hospital Research and Development 
Committee and approved by the London Surrey Borders Research Ethics Committee. 
 
Can I speak to anyone not involved in the study about participating in research? 
If you are thinking about participating, and you would like to speak to someone not 
directly involved with the study, you can contact PALS (the patient advice and liaison 
service), or the renal anaemia research team to get independent advice about participating 
in research.   
 
PALS  
King’s College Hospital tel 020 3299 9000 ext 3601 or visit them on the ground floor, 
Hambledon Wing 9am to 6pm Monday to Friday 
 
Guy’s and St Thomas’ Hospital tel 020 7188 8801 or visit them on the second floor, 
Southwark Wing (Thomas Guy House) 12pm to 3pm Monday to Friday 
St George’s Hospital tel 020 8725 2453 or visit them in the main corridor between 
Grosvenor and Lanesborough Wing near the lift foyer 9am to 5pm Monday to Friday 
St Helier Hospital tel 020 8296 2508 or visit them on the ground floor next to reception at 
the main entrance 9am to 5pm Monday to Friday 
 
Or log on to the PALS website 
http://www.pals.nhs.uk/ 
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Number of visits 
Overall, there are 10 visits to the hospital for the weight management programme treatment and 7 visits to 
the hospital for the surgery treatment in the first 12 months of the study. 
 
 Weight Management 
Programme 
Weight Loss Surgery 
Month Pre assessment 
Including assessment for surgery and completion of 3 day 
food and exercise diary Date 
0  Study visit 1: baseline (beginning) tests 
Weight management clinic 
1st appointment 
Surgery – laparoscopic sleeve 
gastrectomy 
1  1 month r/v Post op surgical review + 
diet and exercise review 
2  2 month r/v - 
3  Study visit 2: 3 month r/v + tests 
4  4 month r/v - 
5  5 month r/v - 
6  Study visit 3: 6 month r/v + tests 
9  Study visit 4: 9 month r/v + tests 
12  Study visit 5: 12 month r/v + tests 
24  Study visit 6: 2 year r/v + tests 
36  Study visit 7: 3 year r/v + tests 
 349 
Study Team 
Dr Iain Macdougall 
Consultant Nephrologist 
King’s College Hospital NHS Foundation Trust 
 
Mr Ameet Patel 
Consultant Surgeon 
King’s College Hospital NHS Foundation Trust 
 
Miss Helen MacLaughlin 
Lead Renal Dietitian  
King’s College Hospital NHS Foundation Trust 
 
Dr Paramit Chowdhury 
Consultant Nephrologist 
Guy’s and St Thomas’ Hospital NHS Foundation Trust 
 
Dr Mysore Phanish 
Consultant Nephrologist 
St Helier Hospital NHS Trust 
 
Dr Iain McPhee 
Consultant Nephrologist 
St George’s Hospital NHS Trust 
 
Professor Tom Sanders  
Head of Nutritional Sciences Division 
King’s College London   
 
Details of local contact  
If you require any more information or have any questions, please contact the study co-
ordinator: 
 
Helen MacLaughlin   
Renal Dietitian   
King’s College Hospital  




Weight Loss in Chronic Kidney Disease Patients with BMI 35-45 kg/m2 
PARTICIPANT	  CONSENT	  FORM	  
                                                                                            
REC Reference Number:  09/H0806/69 
Patient identification number for this trial: 
 
Study Title:  The effect of weight loss surgery on preservation of kidney 
function and cardiovascular disease risk factors in obese patients with stages 
3-4 chronic kidney disease: a randomised controlled trial 
 
Lead Investigators/Researchers: 
Helen MacLaughlin – Renal Dietitian King’s College Hospital and PhD candidate King’s 
College London 
Dr Iain Macdougall – Consultant Nephrologist King’s College Hospital 
Mr Ameet Patel – Consultant Surgeon King’s College Hospital 
Dr Paramit Chowdhury – Consultant Nephrologist Guy’s Hospital 
Dr Mysore Phanish – Consultant Nephrologist St Helier Hospital 
Dr Iain MacPhee – Consultant Nephrologist St George’s Hospital 
Professor Tom Sanders – Head of Nutritional Sciences Division King’s College London  
 
Please initial the boxes 
 
1. I confirm that I have read and understood the information sheet (version 3 
November 2009) for the above study and have had the opportunity to ask 
questions. 
 
2. I confirm that the risks and benefits of participating in the study have been 
explained to me in a way that I understood. 
 
3. I confirm that the risks and benefits of the individual procedures in the study have 
been explained to me in a way that I understood. 
 
4. I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason and without my medical care or legal rights 
being affected. 
 
5. I understand that responsible individuals from King’s College Hospital may look at 
relevant sections of my medical history. I give permission for these individuals to 








10. I agree to take part in the above study, and I understand that I will be allocated a 
treatment of EITHER diet, exercise and medication for weight loss OR weight loss 
surgery.  I understand that I do not get to choose which treatment I will receive.   
 
11. I agree that the researchers may contact my GP to inform them of my participation 
in this study. 
 
12. I agree to have blood and urine samples taken for use in this study and to also have 
samples stored for later research related to this study only. 
 
13. If I am allocated to the surgery treatment, I agree to have a fat tissue biopsy taken 
at the time of surgery and for the tissue to be stored for later research related to 
this study only. 
 
Name of Patient___________________________________ Date __________  
Patient’s Signature_________________________________ 
 
Name of Researcher _______________________________  Date __________ 
Researcher’s Signature _____________________________ 
 






Appendix F - Best Medical Care Weight Management Programme 
Patient Information (Example) for “The effect of weight loss surgery on 
preservation of kidney function and cardiovascular disease risk factors 
in obese patients with chronic kidney disease: a randomised controlled 



















1 serve = 
- 1 slice of bread 
- ½ medium bread roll 
- ¼  cup cooked rice 
- ½ cup cooked pasta or noodles 
- ½ cup porridge 
- 2/3 cup (20 g) cereal flakes, or 
rolled oats 
- ¼ cup untoasted muesli 
- < ⅓ cup flour 
- 1 small (egg sized) potato 
These foods are good sources 
of energy, carbohydrate, 
protein, dietary fibre and 
folate.  Wholemeal or  
wholegrain varieties have more 




1 serve = 
- 2 heaped tablespoons (80 g or 
½ cup) cooked vegetables 
- ½ cup cooked dried beans, peas 
or lentils 
- ¼ tin tomatoes 
- 1 cup mixed salad, salad leaves 
These foods are good sources 
of vitamins, minerals, dietary 
fibre and carbohydrate. In 
particular, Vitamin A, C and 
folate. Dried beans, peas and 
lentils are an excellent source 
of protein. 
Fruit 2 
1 serve = 
- 1 medium piece (150 g) of fruit 
(apple, pear, ½ banana, orange) 
- 2 small pieces (150 g) of fruit 
(apricot, plum,  satsuma) 
- 1 small handful (10-12) grapes, 
berries or cherries 
- 1 cup (150 g) chopped fruit or 
canned fruit in syrup, drained 
- 1 tablespoons sultanas  
- 4 dried apricot halves 
- 125 mL fruit juice 
These are a good source of 
Vitamin C and folate, 
carbohydrate and fibre, 
especially in the edible skins.  
Juices have much lower fibre 







1 serve = 
- ½  cup (125 ml) semi skimmed 
milk / soy milk (calcium 
enriched) 
- 1 slice (20 g) cheese 
- 1 small tub (125 g) low fat 
yogurt 
- ½  cup (125 ml) low fat 
custard 
Dairy foods are good sources of 
calcium, protein, riboflavin and 
vitamin B12. Choosing the low 
fat varieties will reduce your 
calories eaten and reduce your 






1 serve = 
- 65-100g cooked lean beef, 
lamb, pork, chicken or turkey 
(eg ½ cup lean mince, 2 small 
chops, 2 slices roast meat, 1  
chicken thigh or small breast) 
- ¾ cup cooked dhal, lentils, 
chick peas, kidney beans, other 
dried beans and peas 
- 80-120 g cooked fish  
- 2 small eggs 
- ⅓ cup almonds 
- 1 tablespoon seeds 
- 100-150g Quorn or tofu 
These are good sources of 
protein, iron, niacin and vitamin 
B12.  Trimming all meats or 
visible fat will reduce the energy 
content. 
Water 1 serve = 125 ml glass or cup 
 - water 
 - tea and coffee 
 - diet squash and fizzy drinks 
 - soup 
 - ice cubes 
Keep within your fluid 
allowance each day 
Extras 




1 serve = 
- 2 tsp oil or margarine 
- 1 mini bar or 3 squares 
chocolate 
- 10 rice crackers or mini rice 
cakes; 2 ryvita, 2 cream crackers 
- 2 plain biscuits 
- 1 cup popcorn 
- 100 ml wine, 375ml light or 
250 ml regular beer 
- 2 small scoops ice cream 
These foods are not essential to 
provide nutrients the body 
needs and many contain too 
much fat, salt and sugar. 
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SAMPLE MEAL PLAN  
1400 kcal/day eating plan 
BREAKFAST 2 slices of toast with a thin scrape of margarine or jam 
Plus low fat yoghurt (125g) and 1 small banana 
 
Bowl of cereal and ½ cup of semi-skimmed milk with ½ banana or ½ 
grated apple  
 
Rolled oats with ½ cup milk (+ water), 1 tablespoon raisins, 1 
tablespoon seeds and ½ grated apple 
 
2 eggs (scrambled/omelette/poached) + beans & tomatoes + 1 slice 
toast  
LUNCH Toasted cheese and tomato sandwich 
 
Salad with tuna (80g), egg, tomato, cucumber, green beans, olives with 
low calorie salad dressing 
 
Sandwich/ bread roll/ pita bread with 60g lean 
ham/tuna/chicken/turkey/beef/egg with salad (add mustard, cranberry 
sauce or low fat mayo)  
 
Tuna or salmon pasta or couscous salad with peppers and sweet corn 
with low fat mayo or oil free dressing  
 
Jacket potato with reduced fat spread and baked beans  
 
100g ham/prawns/salmon with greek salad (tomato, feta cheese, 
cucumber, spring onion, olives, 2 teaspoons olive oil/vinegar) with 4 rye 
or wheat crackers 
 
PLUS apple/pear/2 satsumas/12 grapes 
DINNER 200g lean meat/ chicken/ fish/ lamb/ pork with 1 cup boiled vegetables 
 
Omelette (2 eggs, with 40g cheese, peppers and spring onions)  
 
150g meat/fish/lentil and vegetable curry with low fat yogurt or light 
coconut milk, with 2/3 cup cooked rice 
 
1 cup meat/veg stew with 2 small pieces of plantain, yam or sweet 
potato 
 
PLUS 125g low fat yoghurt, 2 small scoops reduced fat ice cream or 
frozen yogurt or 200g reduced fat rice pudding 
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Keeping track of your meals and activity 
 




Use this checklist to keep 
track of your physical activity 
and how many serves you 
have from each food group 
each day. 
 
Record activity in blocks of 
10 minutes and 30 minutes 
each day is the minimum 
recommended for adults 
 
Breads, cereals, rice  pasta, 
noodles 
        
 
Vegetables, legumes 





Milk, yoghurt, cheese 
    
 
Meat, fish, poultry, eggs, 
nuts, legumes 
        
 
Water 





Physical activity (per 10 
mins) 
         
Breakfast 
 
 
 
 
 
Mid-morning 
 
 
 
Lunch 
 
 
 
 
 
 
Mid-afternoon 
 
 
 
Dinner 
 
 
 
 
 
 
Extras 
 
 
 
 
 
 
 
Notes 
 
 
	  
